Lens ID,Title,Date Published,Publication Year,Publication Type,Source Title,ISSNs,Publisher,Source Country,Author/s,Abstract,Volume,Issue Number,Start Page,End Page,Fields of Study,Keywords,MeSH Terms,Chemicals,Funding,Source URLs,External URL,PMID,DOI,Microsoft Academic ID,PMCID,Citing Patents Count,References,Citing Works Count
000-463-679-101-319,The Value of Radiologic Interventions and 18 F-DOPA PET in Diagnosing and Localizing Focal Congenital Hyperinsulinism: Systematic Review and Meta-Analysis,2012-07-03,2012,journal article,Molecular imaging and biology,18602002; 15361632,Springer New York,Netherlands,Björn A. Blomberg; Mateen Moghbel; Babak Saboury; Charles A. Stanley; Abass Alavi,"This systematic review and meta-analysis aimed to quantify the diagnostic performance of pancreatic venous sampling (PVS), selective pancreatic arterial calcium stimulation with hepatic venous sampling (ASVS), and 18F-DOPA positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI). This systematic review and meta-analysis was conducted according to the PRISMA statement. PubMed, EMBASE, SCOPUS and Web of Science electronic databases were systematically searched from their inception to November 1, 2011. Using predefined inclusion and exclusion criteria, two blinded reviewers selected articles. Critical appraisal ranked the retrieved articles according to relevance and validity by means of the QUADAS-2 criteria. Pooled data of homogeneous study results estimated the sensitivity, specificity, likelihood ratios and diagnostic odds ratio (DOR). 18F-DOPA PET was superior in distinguishing focal from diffuse CHI (summary DOR, 73.2) compared to PVS (summary DOR, 23.5) and ASVS (summary DOR, 4.3). Furthermore, it localized focal CHI in the pancreas more accurately than PVS and ASVS (pooled accuracy, 0.82 vs. 0.76, and 0.64, respectively). Important limitations comprised the inclusion of studies with small sample sizes, high probability of bias and heterogeneity among their results. Studies with small sample sizes and high probability of bias tended to overestimate the diagnostic accuracy. This systematic review and meta-analysis found evidence for the superiority of 18F-DOPA PET in diagnosing and localizing focal CHI in patients requiring surgery for this disease.",15,1,97,105,Radiology; Critical appraisal; Diagnostic odds ratio; Positron emission tomography; Inclusion and exclusion criteria; Congenital hyperinsulinism; MEDLINE; Nuclear medicine; Text mining; Medicine; Meta-analysis,,Congenital Hyperinsulinism/diagnosis; Dihydroxyphenylalanine/analogs & derivatives; Fluorine Radioisotopes; Humans; Pancreas/blood supply; Positron-Emission Tomography/methods; Radiopharmaceuticals,Fluorine Radioisotopes; Radiopharmaceuticals; fluorodopa F 18; Dihydroxyphenylalanine,NIDDK NIH HHS (R37 DK056268) United States,https://paperity.org/p/8646823/the-value-of-radiologic-interventions-and-18f-dopa-pet-in-diagnosing-and-localizing-focal https://link.springer.com/article/10.1007/s11307-012-0572-0/fulltext.html https://core.ac.uk/display/81100392 https://link.springer.com/content/pdf/10.1007%2Fs11307-012-0572-0.pdf https://europepmc.org/article/MED/22752652 https://pubmed.ncbi.nlm.nih.gov/22752652/ https://rd.springer.com/article/10.1007/s11307-012-0572-0 http://www.ncbi.nlm.nih.gov/pubmed/22752652 https://link.springer.com/article/10.1007/s11307-012-0572-0,http://dx.doi.org/10.1007/s11307-012-0572-0,22752652,10.1007/s11307-012-0572-0,2362251916,PMC3553406,0,001-292-833-536-007; 003-518-132-806-678; 003-810-931-772-556; 009-777-396-716-216; 014-337-119-130-585; 017-279-246-193-497; 017-300-737-144-757; 021-946-710-618-059; 023-408-596-160-770; 024-811-031-123-549; 029-363-405-972-285; 032-342-898-180-264; 033-153-246-862-888; 035-611-011-835-509; 035-671-548-800-343; 036-587-467-305-310; 036-843-697-231-759; 038-092-892-151-680; 038-323-102-572-559; 038-386-027-612-183; 041-564-314-455-341; 041-627-500-093-845; 044-433-736-077-44X; 045-201-107-411-584; 045-341-195-177-955; 045-395-687-546-239; 045-416-413-742-937; 049-868-095-642-414; 050-633-858-179-798; 057-075-056-237-870; 057-777-010-890-82X; 058-966-553-020-002; 064-836-521-114-997; 071-463-161-593-799; 072-054-595-215-006; 073-237-415-977-053; 074-416-523-067-698; 076-600-963-476-13X; 080-729-512-647-720; 082-775-316-205-888; 083-275-795-865-394; 089-316-834-012-818; 089-466-066-160-722; 089-853-056-956-225; 094-674-342-520-868; 098-576-929-847-882; 109-158-143-270-511; 109-960-855-239-692; 122-572-406-956-166; 131-809-945-662-748; 141-410-018-273-555; 161-156-386-041-285; 163-717-011-358-104; 183-321-613-637-164,50
001-955-724-285-100,Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review.,2021-03-12,2021,journal article,Cancers,20726694,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Primož Strojan; Aleš Grošelj; Gregor Sersa; Christina Caroline Plaschke; Jan B. Vermorken; Sandra Nuyts; Remco de Bree; Avraham Eisbruch; William M. Mendenhall; Robert Smee; Alfio Ferlito,"Electrochemotherapy (ECT) is a local ablative treatment that is based on the reversible electroporation and intracellular accumulation of hydrophilic drug molecules, which greatly increases their cytotoxicity. In mucosal head and neck cancer (HNC), experience with ECT is limited due to the poor accessibility of tumors. In order to review the experience with ECT in mucosal HNC, we undertook a systematic review of the literature. In 22 articles, published between 1998 and 2020, 16 studies with 164 patients were described. Curative and palliative intent treatment were given to 36 (22%) and 128 patients (78%), respectively. The majority of tumors were squamous cell carcinomas (79.3%) and located in the oral cavity (62.8%). In the curative intent group, complete response after one ECT treatment was achieved in 80.5% of the patients, and in the palliative intent group, the objective (complete and partial) response rate was 73.1% (31.2% and 41.9%). No serious adverse events were reported during or soon after ECT and late effects were rare (19 events in 17 patients). The quality-of-life assessments did not show a significant deterioration at 12 months post-ECT. Provided these preliminary data are confirmed in randomized controlled trials, ECT may be an interesting treatment option in selected patients with HNC not amenable to standard local treatment.",13,6,1254,,Quality of life; Cancer; Internal medicine; Oncology; Randomized controlled trial; Adverse effect; Head and neck cancer; Electrochemotherapy; Response rate (survey); Head and neck; Medicine,electrochemotherapy; head and neck cancer; quality of life; systematic review,,,Javna Agencija za Raziskovalno Dejavnost RS (P3-03037); Javna Agencija za Raziskovalno Dejavnost RS (P3-0003),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999968 https://europepmc.org/article/PMC/PMC7999968 https://www.mdpi.com/2072-6694/13/6/1254/pdf https://www.mdpi.com/2072-6694/13/6/1254,http://dx.doi.org/10.3390/cancers13061254,33809141,10.3390/cancers13061254,3138785917,PMC7999968,0,000-281-211-491-027; 001-163-024-267-176; 001-167-587-025-697; 001-812-784-095-36X; 004-191-440-401-896; 005-757-391-459-86X; 006-589-099-134-079; 006-719-400-985-829; 009-595-226-572-144; 010-300-024-821-557; 012-796-583-594-818; 016-888-060-668-965; 018-524-455-870-944; 019-399-548-222-950; 019-809-038-936-223; 021-116-483-895-271; 021-421-730-042-139; 022-659-400-894-503; 024-968-040-949-188; 026-603-336-355-750; 026-963-871-436-180; 030-411-505-523-988; 037-370-906-246-850; 037-995-952-522-908; 038-361-948-397-448; 039-004-649-900-825; 039-993-239-328-062; 042-267-960-754-835; 042-348-882-770-235; 042-553-746-627-621; 042-716-068-512-836; 043-639-255-566-24X; 046-547-165-419-562; 046-851-862-189-383; 047-984-161-194-556; 050-376-317-789-441; 053-068-595-371-058; 053-614-256-349-556; 060-900-609-864-483; 064-051-202-715-322; 066-049-429-803-319; 073-366-714-129-215; 075-676-540-182-484; 076-575-792-792-581; 077-252-883-785-600; 085-259-432-448-340; 085-969-419-633-185; 088-484-245-477-576; 088-987-948-434-067; 097-914-994-442-614; 100-785-213-145-659; 106-382-204-764-740; 106-469-348-552-634; 114-790-192-858-717; 120-153-523-442-472; 122-861-028-783-341; 128-689-760-280-303; 141-911-873-206-885; 145-335-652-096-128; 154-399-282-361-201; 160-354-493-577-131; 169-905-750-128-720; 188-192-050-451-967,1
002-042-026-423-65X,A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care.,2021-03-16,2021,journal article,Frontiers in endocrinology,16642392,Frontiers Media S.A.,Switzerland,Maria Kamusheva; Konstantin Tachkov; Maria Dimitrova; Zornitsa Mitkova; Gema García-Sáez; M. Elena Hernando; Wim G. Goettsch; Guenka Petrova,"Introduction Diabetes monitoring systems (DMS) are a possible approach for regular control of glucose levels in patients with Type 1 or 2 diabetes in order to improve therapeutic outcomes or to identify and modify inappropriate patient behaviors in a timely manner. Despite the significant number of studies observing the DMS, no collective evidence is available about the effect of all devices. Goal To review and consolidate evidences from multiple systematic reviews on the diabetes monitoring systems and the outcomes achieved. Materials and methods Internet-based search in PubMed, EMBASE, and Cochrane was performed to identify all studies relevant to the research question. The data regarding type of intervention, type of diabetes mellitus, type of study, change in clinical parameter(s), or another relevant outcome were extracted and summarized. Results Thirty-three out of 1,495 initially identified studies, involving more than 44,100 patients with Type 1, Type 2, or gestational diabetes for real-time or retrospective Continuous Glucose Monitoring (CGMS), Sensor Augmented Pump Therapy (SAPT), Self-monitoring Blood Glucose (SMBG), Continuous subcutaneous insulin infusion (CSII), Flash Glucose Monitoring (FGM), Closed-loop systems and telemonitoring, were included. Most of the studies observed small nominal effectiveness of DMS. In total 11 systematic reviews and 15 meta-analyses, with most focusing on patients with Type 1 diabetes (10 and 6, respectively), reported a reduction in glycated hemoglobin (HbA1c) levels from 0.17 to 0.70% after use of DMS. Conclusion Current systematic review of already published systematic reviews and meta-analyses suggests that no statistically significant difference exists between the values of HbA1c as a result of application of any type of DMS. The changes in HbA1c values, number and frequency of hypoglycemic episodes, and time in glucose range are the most valuable for assessing the appropriateness and effectiveness of DMS. Future more comprehensive studies assessing the effectiveness, cost-effectiveness, and comparative effectiveness of DMS are needed to stratify them for the most suitable diabetes patients' subgroups.",12,,636959,636959,Health care; Intensive care medicine; Systematic review; Glycated hemoglobin; Gestational diabetes; Type 1 diabetes; Diabetes monitoring; Significant difference; Diabetes mellitus; Medicine,diabetes; diabetes monitoring systems; glucose control; personalized approach; systematic review,,,Horizon 2020 Framework Programme,https://pubmed.ncbi.nlm.nih.gov/33796074/ https://europepmc.org/article/PMC/PMC8008960 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008960 https://www.frontiersin.org/articles/10.3389/fendo.2021.636959/full https://www.ncbi.nlm.nih.gov/pubmed/33796074,http://dx.doi.org/10.3389/fendo.2021.636959,33796074,10.3389/fendo.2021.636959,3137753213,PMC8008960,0,000-590-159-353-020; 001-111-124-026-244; 002-893-839-670-67X; 004-637-889-189-606; 004-812-308-080-668; 005-353-568-891-56X; 007-474-454-309-272; 008-048-686-746-572; 010-027-254-707-675; 010-089-331-702-75X; 010-851-119-007-735; 011-018-369-458-121; 011-254-627-414-530; 011-363-006-724-563; 011-636-587-009-082; 014-100-031-967-510; 015-255-598-062-635; 015-500-789-522-557; 015-700-925-828-195; 015-951-483-467-375; 017-818-548-821-065; 018-857-333-572-469; 019-221-426-538-828; 021-056-855-071-993; 023-957-545-328-264; 026-725-257-045-493; 028-314-737-510-581; 029-927-122-023-400; 033-995-493-957-818; 034-040-175-084-702; 034-814-923-296-409; 037-076-168-397-931; 038-260-317-265-227; 039-025-428-766-098; 039-076-276-085-102; 040-334-314-593-947; 041-476-688-680-236; 045-072-606-715-058; 049-738-477-890-581; 050-326-804-070-658; 056-712-601-624-44X; 057-327-907-090-191; 058-104-655-298-188; 061-291-942-426-335; 066-291-169-027-821; 068-273-944-235-474; 070-035-714-698-025; 070-667-641-635-335; 073-008-449-589-228; 075-268-475-945-330; 077-733-282-945-645; 084-259-682-341-857; 084-675-520-903-143; 091-292-687-789-026; 093-619-546-622-50X; 095-267-457-586-267; 095-474-868-872-542; 095-535-288-696-171; 106-627-739-649-24X; 109-836-398-052-145; 112-935-875-458-415; 113-409-725-546-360; 129-578-011-864-891; 146-628-738-222-485; 167-375-012-148-06X; 171-685-228-774-690,2
002-582-554-884-860,Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials.,2020-08-12,2020,journal article,The Journal of infection,15322742; 01634453,W.B. Saunders Ltd,United Kingdom,T. ten Doesschate; T.W. van der Vaart; Johanna A A G Damen; Marc J. M. Bonten; C.H. van Werkhoven,,81,4,499,509,Internal medicine; Randomized controlled trial; Carbapenem; Intraabdominal infection; MEDLINE; Medicine; Urinary system,,Anti-Bacterial Agents/therapeutic use; Carbapenems/therapeutic use; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Urinary Tract Infections/drug therapy,Anti-Bacterial Agents; Carbapenems,,https://www.ncbi.nlm.nih.gov/pubmed/32795483 https://pubmed.ncbi.nlm.nih.gov/32795483/ https://www.sciencedirect.com/science/article/pii/S0163445320305417,http://dx.doi.org/10.1016/j.jinf.2020.08.008,32795483,10.1016/j.jinf.2020.08.008,3048794793,,0,002-365-984-994-241; 003-137-102-405-559; 004-389-532-970-651; 008-930-960-542-491; 009-501-706-677-21X; 009-603-792-637-755; 009-632-740-472-234; 009-943-700-416-324; 010-377-458-719-803; 016-346-945-313-348; 019-403-589-767-307; 024-163-531-056-386; 026-643-642-391-457; 028-026-262-983-986; 028-083-071-971-457; 029-027-490-695-717; 029-609-835-252-242; 031-606-568-919-687; 031-789-823-601-76X; 032-469-694-660-686; 032-918-242-766-421; 034-154-129-746-491; 034-177-487-154-973; 035-238-991-282-07X; 036-351-787-393-582; 036-757-954-173-756; 037-159-524-452-014; 037-560-802-391-84X; 045-503-651-272-294; 045-973-821-494-655; 054-949-612-755-00X; 055-954-544-267-292; 056-398-147-033-822; 062-068-775-801-04X; 064-420-170-451-318; 064-790-904-257-521; 066-097-102-595-323; 072-516-841-671-300; 081-065-590-705-145; 082-003-367-884-26X; 086-803-962-382-601; 088-056-054-586-701; 088-870-016-236-088; 089-448-895-406-823; 090-491-856-617-141; 097-912-411-932-787; 100-312-890-370-677; 103-538-872-660-786; 119-195-883-299-024; 120-529-529-340-453; 126-289-436-167-426,4
004-848-996-111-636,Sex Disparities in Cardiovascular Risk Factor Assessment and Screening for Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review.,2021-03-30,2021,journal article,Frontiers in endocrinology,16642392,Frontiers Media S.A.,Switzerland,Marit de Jong; Sanne A.E. Peters; Rianneke de Ritter; Carla J. H. van der Kallen; Simone J. S. Sep; Mark Woodward; Coen D.A. Stehouwer; Michiel L. Bots; Rimke C. Vos,"Background Insight in sex disparities in the detection of cardiovascular risk factors and diabetes-related complications may improve diabetes care. The aim of this systematic review is to study whether sex disparities exist in the assessment of cardiovascular risk factors and screening for diabetes-related complications. Methods PubMed was systematically searched up to April 2020, followed by manual reference screening and citations checks (snowballing) using Google Scholar. Observational studies were included if they reported on the assessment of cardiovascular risk factors (HbA1c, lipids, blood pressure, smoking status, or BMI) and/or screening for nephropathy, retinopathy, or performance of feet examinations, in men and women with diabetes separately. Studies adjusting their analyses for at least age, or when age was considered as a covariable but left out from the final analyses for various reasons (i.e. backward selection), were included for qualitative analyses. No meta-analyses were planned because substantial heterogeneity between studies was expected. A modified Newcastle-Ottawa Quality Assessment Scale for cohort studies was used to assess risk of bias. Results Overall, 81 studies were included. The majority of the included studies were from Europe or North America (84%).The number of individuals per study ranged from 200 to 3,135,019 and data were extracted from various data sources in a variety of settings. Screening rates varied considerably across studies. For example, screening rates for retinopathy ranged from 13% to 90%, with half the studies reporting screening rates less than 50%. Mixed findings were found regarding the presence, magnitude, and direction of sex disparities with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications, with some evidence suggesting that women, compared with men, may be more likely to receive retinopathy screening and less likely to receive foot exams. Conclusion Overall, no consistent pattern favoring men or women was found with regard to the assessment of cardiovascular risk factors and screening for diabetes-related complications, and screening rates can be improved for both sexes.",12,,617902,617902,Demography; Cohort study; Observational study; Retinopathy; Disease; Nephropathy; Risk factor; Diabetes mellitus; Medicine; Blood pressure,diabetes; diabetes-related complications; healthcare provision; risk factors; screening; sex disparities; systematic review,,,ZonMw,https://pubmed.ncbi.nlm.nih.gov/33859615/ https://europepmc.org/article/MED/33859615 https://www.ncbi.nlm.nih.gov/pubmed/33859615 https://cris.maastrichtuniversity.nl/en/publications/sex-disparities-in-cardiovascular-risk-factor-assessment-and-scre https://www.frontiersin.org/articles/10.3389/fendo.2021.617902/full,http://dx.doi.org/10.3389/fendo.2021.617902,33859615,10.3389/fendo.2021.617902,3145765905,PMC8043152,0,000-229-755-619-625; 000-389-760-951-326; 001-494-692-947-966; 001-807-149-350-177; 003-157-072-975-988; 004-178-252-611-179; 004-701-952-432-386; 004-803-106-318-004; 008-003-105-824-36X; 009-621-597-401-420; 009-885-286-588-311; 011-218-084-233-064; 011-671-611-321-636; 011-843-466-350-032; 012-202-737-290-77X; 013-289-837-408-385; 014-188-637-133-368; 016-061-319-159-866; 016-185-425-430-079; 017-300-737-144-757; 017-372-076-422-723; 017-832-337-585-286; 018-214-304-796-608; 018-278-559-338-265; 019-434-923-835-603; 019-481-590-147-088; 020-033-827-755-61X; 020-234-725-895-516; 020-399-071-708-640; 020-432-757-803-855; 020-436-133-640-240; 020-622-238-177-861; 020-950-578-554-259; 021-661-202-302-550; 022-552-934-264-266; 023-211-492-115-44X; 023-293-991-832-250; 023-753-591-305-747; 024-499-626-529-130; 025-687-290-704-066; 027-230-903-381-70X; 028-265-046-912-620; 028-314-049-250-835; 028-852-504-298-08X; 029-236-512-036-888; 029-494-565-413-546; 029-677-122-103-567; 029-762-598-259-512; 033-075-858-453-486; 033-527-222-914-632; 033-636-764-306-52X; 033-825-045-475-602; 034-485-625-885-729; 034-824-471-744-838; 036-463-843-409-654; 036-714-226-780-398; 037-717-574-125-576; 040-086-458-709-216; 040-371-826-117-824; 040-449-192-541-953; 040-600-676-409-931; 042-898-327-004-722; 043-148-320-236-102; 051-450-519-476-821; 052-502-644-119-952; 053-320-076-705-302; 054-055-054-538-760; 054-434-069-981-861; 057-183-111-895-111; 060-967-791-728-854; 062-622-283-634-981; 065-129-746-268-069; 068-504-590-026-813; 076-317-934-859-664; 079-988-432-393-522; 082-762-313-207-05X; 083-364-833-174-530; 084-355-364-750-225; 084-728-636-450-840; 084-867-953-877-979; 085-104-898-706-130; 086-119-450-156-589; 090-124-675-364-259; 090-662-125-121-277; 092-104-902-721-864; 093-023-912-730-432; 093-600-665-610-827; 093-826-760-039-78X; 094-993-066-688-40X; 094-994-960-945-823; 095-067-478-056-605; 096-318-217-504-422; 106-962-997-510-812; 107-778-377-898-971; 109-263-625-333-073; 112-385-543-242-972; 120-350-188-279-454; 126-392-418-326-898; 142-549-212-960-685; 150-307-383-644-765; 156-707-508-394-79X; 157-862-256-200-755; 174-330-653-918-647,1
004-868-562-022-693,Apparent diffusion coefficient measurements in the differentiation between benign and malignant lesions: a systematic review.,2012-06-07,2012,journal article,Insights into imaging,18694101,Springer Science and Business Media Deutschland GmbH,Germany,M. A. Vermoolen; Thomas C. Kwee; R. A. J. Nievelstein,"To systematically review the value of apparent diffusion coefficient (ADC) measurement in the differentiation between benign and malignant lesions. A systematic search of the Medline/Pubmed and Embase databases revealed 109 relevant studies. Quality of these articles was assessed using the Quality Assessment of the Studies of Diagnostic Accuracy Included in Systematic Reviews (QUADAS) criteria. Reported ADC values of benign and malignant lesions were compared per organ. The mean quality score of the reviewed articles was 50%. Comparison of ADC values showed marked variation among studies and between benign and malignant lesions in various organs. In several organs, such as breast, liver, and uterus, ADC values discriminated well between benign and malignant lesions. In other organs, such as the salivary glands, thyroid, and pancreas, ADCs were not significantly different between benign and malignant lesions. The potential utility of ADC measurement for the characterisation of tumours differs per organ. Future well-designed studies are required before ADC measurements can be recommended for the differentiation of benign and malignant lesions. These future studies should use standardised acquisition protocols and provide complete reporting of study methods, to facilitate comparison of results and clinical implementation of ADC measurement for tumour characterisation.",3,4,395,409,Pathology; Ultrasound; Diffusion MRI; Systematic review; Pancreas; Neuroradiology; Interventional radiology; Thyroid; Effective diffusion coefficient; Medicine,,,,,https://insightsimaging.springeropen.com/articles/10.1007/s13244-012-0175-y https://europepmc.org/articles/PMC3481080 https://core.ac.uk/display/81710421 https://link.springer.com/content/pdf/10.1007%2Fs13244-012-0175-y.pdf https://link.springer.com/article/10.1007/s13244-012-0175-y https://www.ncbi.nlm.nih.gov/pubmed/22695951 https://www.deepdyve.com/lp/springer-journals/apparent-diffusion-coefficient-measurements-in-the-differentiation-4LSQ0JkRc6 https://paperity.org/p/4117806/apparent-diffusion-coefficient-measurements-in-the-differentiation-between-benign-and https://pubmed.ncbi.nlm.nih.gov/22695951/,http://dx.doi.org/10.1007/s13244-012-0175-y,22695951,10.1007/s13244-012-0175-y,2122896303,PMC3481080,0,000-459-091-626-18X; 001-445-876-537-477; 001-572-967-292-294; 002-838-889-904-532; 002-898-571-193-210; 003-320-869-233-313; 003-325-404-164-760; 004-113-618-261-533; 005-152-635-670-310; 005-635-173-340-777; 005-670-681-065-576; 006-271-338-116-08X; 006-620-132-770-695; 006-873-991-558-794; 007-589-273-073-723; 009-176-588-823-610; 010-100-258-660-796; 010-838-293-307-817; 011-424-609-913-087; 011-486-011-349-673; 012-330-649-390-953; 012-562-485-062-496; 012-710-168-184-205; 012-832-594-566-48X; 014-277-163-619-159; 014-617-187-652-314; 014-865-123-606-549; 015-020-864-918-920; 016-811-691-884-730; 017-832-065-699-326; 019-808-608-879-327; 020-071-271-226-874; 021-673-178-593-711; 022-910-524-098-602; 023-917-671-435-523; 024-115-743-364-632; 024-147-712-203-146; 025-288-712-395-200; 025-528-965-075-862; 026-096-995-801-714; 026-715-873-734-808; 027-365-361-792-384; 027-495-073-588-739; 027-785-448-364-009; 027-830-622-292-232; 029-022-126-444-134; 029-295-248-715-311; 030-627-028-916-780; 032-074-887-577-022; 033-174-086-002-952; 034-061-080-059-507; 034-698-014-627-463; 035-344-980-231-663; 035-568-836-147-54X; 036-147-747-875-554; 037-629-414-070-342; 038-150-048-786-35X; 038-372-669-857-214; 038-751-138-775-383; 039-241-282-247-194; 039-961-659-764-243; 040-758-360-033-800; 041-895-208-398-394; 042-070-200-740-319; 044-691-756-899-354; 046-774-346-903-433; 046-794-266-946-490; 048-221-134-813-682; 048-478-405-947-740; 050-494-909-293-949; 051-688-641-966-883; 051-751-127-593-26X; 052-140-288-132-505; 052-151-810-666-715; 055-148-114-216-747; 055-192-919-950-103; 055-950-872-398-277; 056-140-348-541-77X; 056-409-890-659-70X; 058-184-282-111-984; 059-487-511-364-438; 060-497-133-956-691; 060-691-772-464-035; 061-689-184-277-464; 062-528-106-571-253; 062-636-160-583-640; 062-888-542-969-574; 064-115-062-883-761; 065-158-733-434-26X; 071-481-665-722-987; 071-483-364-473-592; 072-574-737-747-593; 072-946-972-703-480; 073-163-627-786-452; 073-237-296-759-669; 077-271-610-981-861; 078-650-809-189-499; 080-462-311-680-292; 080-909-106-279-625; 083-366-641-191-853; 084-886-681-260-599; 085-580-887-977-362; 085-606-713-095-493; 090-850-822-079-826; 091-229-892-356-068; 092-629-938-401-565; 095-460-469-571-630; 095-701-356-770-013; 096-857-464-124-091; 098-044-772-769-689; 101-368-349-158-765; 109-677-311-904-662; 109-733-497-706-552; 113-422-888-410-229; 114-246-641-162-880; 115-348-299-826-402; 117-895-823-786-562; 118-674-318-437-190; 121-714-562-752-055; 121-750-135-513-269; 123-821-926-906-913; 126-716-665-494-352; 128-210-948-384-561; 129-747-386-624-688; 138-532-573-301-479; 140-337-843-579-162; 141-791-478-320-668; 144-564-087-583-312; 144-867-583-820-012; 154-067-680-221-545; 154-166-483-243-087; 168-493-728-556-476,49
005-657-406-851-39X,The Effect of Physical Activity Interventions Comprising Wearables and Smartphone Applications on Physical Activity: a Systematic Review and Meta-analysis,2018-09-03,2018,journal article,Sports medicine - open,21991170; 21989761,Springer Science and Business Media LLC,Switzerland,Roxanne Gal; Anne M. May; Elon J. van Overmeeren; Monique Simons; Evelyn M. Monninkhof,"Worldwide physical activity levels of adults are declining, which is associated with increased chronic disease risk. Wearables and smartphone applications offer new opportunities to change physical activity behaviour. This systematic review summarizes the evidence regarding the effect of wearables and smartphone applications on promoting physical activity. PubMed, EMBASE and Cochrane databases were searched for RCTs, published since January 2008, on wearables and smartphone applications to promote physical activity. Studies were excluded when the study population consisted of children or adolescents, the intervention did not promote physical activity or comprised a minor part of the intervention, or the intervention was Internet-based and not accessible by smartphone. Risk of bias was assessed by the Cochrane collaboration tool. The primary outcome was changed in physical activity level. Meta-analyses were performed to assess the pooled effect on (moderate-to-vigorous) physical activity in minutes per day and daily step count. Eighteen RCTs were included. Use of wearables and smartphone applications led to a small to moderate increase in physical activity in minutes per day (SMD = 0.43, 95% CI = 0.03 to 0.82; I2 = 85%) and a moderate increase in daily step count (SMD = 0.51, 95% CI = 0.12 to 0.91; I2 = 90%). When removing studies with an unclear or high risk of bias, intervention effects improved and statistical heterogeneity was removed. This meta-analysis showed a small to moderate effect of physical activity interventions comprising wearables and smartphone applications on physical activity. Hence, wearables and smartphone applications are likely to bring new opportunities in delivering tailored interventions to increase levels of physical activity.",4,1,42,42,Wearable computer; Physical therapy; Physical activity level; Intervention (counseling); Physical activity interventions; Smartphone application; Physical activity; Sports medicine; Medicine; Meta-analysis,Physical activity; Smartphone applications; Wearables,,,ZonMw (NL) (016.156.050),https://europepmc.org/article/MED/30178072 https://www.narcis.nl/publication/RecordID/oai%3Ascholarlypublications.universiteitleiden.nl%3Aitem_2971586 https://pubmed.ncbi.nlm.nih.gov/30178072/ https://sportsmedicine-open.springeropen.com/articles/10.1186/s40798-018-0157-9 http://dspace.library.uu.nl/handle/1874/371715 https://link.springer.com/content/pdf/10.1186/s40798-018-0157-9.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120856 https://link.springer.com/article/10.1186/s40798-018-0157-9 http://www.ncbi.nlm.nih.gov/pubmed/30178072 https://link.springer.com/article/10.1186/s40798-018-0157-9/figures/5,http://dx.doi.org/10.1186/s40798-018-0157-9,30178072,10.1186/s40798-018-0157-9,2889406366,PMC6120856,0,000-397-269-838-26X; 001-026-807-669-648; 001-365-492-729-701; 004-599-818-381-305; 005-415-807-534-027; 007-537-154-290-480; 009-842-356-731-508; 010-542-077-263-108; 011-322-723-263-818; 014-539-831-490-360; 015-248-651-184-725; 017-300-737-144-757; 017-506-996-611-501; 017-638-544-546-600; 018-244-212-118-639; 018-394-624-986-882; 020-078-413-649-947; 021-479-201-085-493; 022-797-818-982-610; 022-991-965-257-637; 023-158-569-424-022; 027-696-624-412-977; 032-466-122-845-526; 032-904-647-057-044; 033-421-855-612-997; 036-332-131-771-217; 041-408-950-798-80X; 044-290-434-486-875; 045-416-413-742-937; 048-563-657-692-04X; 048-663-856-713-729; 053-909-009-519-755; 055-070-227-533-936; 057-447-287-172-669; 057-623-671-275-590; 059-255-052-976-159; 060-609-646-882-396; 061-442-173-260-603; 066-396-564-909-390; 067-715-519-706-692; 068-374-197-648-883; 072-729-915-131-93X; 072-917-880-005-631; 074-790-755-091-486; 076-887-884-467-359; 083-275-795-865-394; 085-078-538-816-364; 091-853-196-730-684; 094-991-077-385-149; 098-812-348-744-182; 103-741-577-259-344; 109-708-850-128-550; 111-065-202-861-389; 119-141-315-413-112; 120-423-737-816-473; 149-846-473-935-950,88
006-338-538-001-600,Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.,2018-01-29,2018,journal article,Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,14363305; 14363291,Springer Japan,Germany,Emil ter Veer; Jessy Joy van Kleef; Mirjam A. G. Sprangers; Nadia Haj Mohammad; Martijn G.H. van Oijen; Hanneke W. M. van Laarhoven,"Health-related quality of life (HRQoL) assessments are increasingly incorporated into oncological randomized controlled trials (RCTs). The quality of HRQoL reporting in RCTs concerning palliative systemic treatment for advanced esophagogastric cancer is currently unknown. Therefore, we conducted a systematic review to investigate the quality of HRQoL reporting over time. PubMed, CENTRAL and EMBASE were searched for RCTs concerning systemic treatment for advanced esophagogastric cancer up to February 2017. The Minimum Standard Checklist for Evaluating HRQoL Outcomes in Cancer Clinical Trials was used to rate the quality of HRQoL reporting. Univariate and multivariate generalized linear regression analysis was used to investigate factors affecting the quality of reporting over time. In total, 37 original RCTs (N = 10,887 patients) were included. The quality of reporting was classified as ‘very limited’ in 4 studies (11%), ‘limited’ in 24 studies (65%), and ‘probably robust’ in 9 studies (24%). HRQoL reporting did not improve over time, and it did not improve following the publication of the CONSORT-PRO statement in 2013. The publication of HRQoL findings in a separate article and second-line treatment were associated with better reporting. HRQoL reporting in RCTs concerning palliative systemic therapy for advanced esophagogastric cancer is limited and has not improved over time. This systematic review provides specific recommendations for authors to improve HRQoL reporting: formulate hypotheses a priori, clearly describe instrument administration, and handle missing data and interpret findings appropriately.",21,2,183,195,Quality of life; Randomized controlled trial; Intensive care medicine; Systemic therapy; Checklist; Esophageal cancer; Cancer clinical trial; Esophagogastric cancer; Health related quality of life; Medicine,Esophageal cancer; Gastric cancer; Quality of life; Randomized controlled trial; Systemic therapy,Antineoplastic Agents/therapeutic use; Esophageal Neoplasms/drug therapy; Esophagogastric Junction; Humans; Medical Oncology/standards; Palliative Care/methods; Quality of Life; Randomized Controlled Trials as Topic/standards; Research Design/standards; Salvage Therapy/methods; Stomach Neoplasms/drug therapy,Antineoplastic Agents,KWF Kankerbestrijding (2014-7000),https://core.ac.uk/display/153324547 https://pubmed.ncbi.nlm.nih.gov/29380191/ https://paperity.org/p/86173729/reporting-of-health-related-quality-of-life-in-randomized-controlled-trials-involving https://link.springer.com/article/10.1007/s10120-018-0792-3 https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2Fee58081a-37ac-4e21-a6a2-f3c7fc13a68e https://link.springer.com/content/pdf/10.1007%2Fs10120-018-0792-3.pdf https://www.ncbi.nlm.nih.gov/pubmed/29380191 https://europepmc.org/abstract/MED/29380191,http://dx.doi.org/10.1007/s10120-018-0792-3,29380191,10.1007/s10120-018-0792-3,2787831475,PMC5846827,0,001-356-499-457-011; 003-415-704-045-340; 003-698-253-263-930; 004-247-657-381-494; 005-476-831-967-139; 007-993-297-190-638; 009-125-767-520-236; 010-693-809-465-396; 012-180-892-296-704; 012-521-792-661-762; 012-644-404-136-043; 013-964-194-905-56X; 015-291-168-984-996; 015-767-931-570-158; 017-299-927-233-528; 017-328-624-464-951; 017-531-490-213-543; 018-530-026-930-022; 023-921-420-298-968; 028-503-960-341-517; 031-607-288-639-204; 031-611-348-715-507; 031-616-994-298-819; 032-750-178-008-83X; 033-159-617-221-594; 033-696-697-955-873; 034-264-196-239-737; 035-361-415-799-664; 038-079-005-828-151; 038-673-618-696-050; 038-760-933-428-844; 038-982-078-618-690; 039-308-434-149-512; 043-242-047-242-19X; 043-560-723-924-350; 044-512-630-880-985; 045-549-896-620-844; 050-746-623-155-936; 052-672-603-037-936; 052-931-272-177-398; 054-057-518-617-037; 058-114-622-097-784; 062-541-597-531-665; 063-614-501-138-481; 063-790-646-042-133; 067-682-652-114-700; 069-640-545-862-874; 071-050-991-088-657; 075-846-735-843-894; 076-634-821-716-981; 078-545-070-988-705; 078-753-329-947-627; 081-066-482-333-609; 091-702-842-104-541; 092-568-705-115-545; 097-685-748-912-266; 100-247-432-531-877; 105-258-058-964-263; 111-790-217-852-954; 130-478-946-149-815; 135-713-821-034-626; 149-288-645-475-599,9
007-189-812-368-705,Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review,2015-11-18,2015,journal article,Annals of hematology,14320584; 09395555,Springer Verlag,Germany,Hugo J. A. Adams; Rutger A.J. Nievelstein; Thomas C. Kwee,"This study aimed to systematically review the prognostic value of interim and end-of-treatment 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in follicular lymphoma during and after first-line therapy. The PubMed/MEDLINE database was searched for relevant original studies. Included studies were methodologically assessed, and their results were extracted and descriptively analyzed. Three studies on the prognostic value of interim FDG-PET and eight studies on the prognostic value of end-of-treatment FDG-PET were included. Overall, studies were of poor methodological quality. In addition, there was incomplete reporting of progression-free survival (PFS) and overall survival (OS) data by several studies, and none of the studies incorporated the Follicular Lymphoma International Prognostic Index (FLIPI) in the OS analyses. Two studies reported no significant difference in PFS between interim FDG-PET positive and negative patients, whereas one study reported a significant difference in PFS between the two groups. Two studies reported no significant difference in OS between interim FDG-PET positive and negative patients. Five studies reported end-of-treatment FDG-PET positive patients to have a significantly worse PFS than end-of-treatment FDG-PET negative patients, and one study reported a non-significant trend towards a worse PFS for end-of-treatment FDG-PET positive patients. Three studies reported end-of-treatment FDG-PET positive patients to have a significantly worse OS than end-of-treatment FDG-PET negative patients. In conclusion, the available evidence does not support the use of interim FDG-PET in follicular lymphoma. Although published studies suggest end-of-treatment FDG-PET to be predictive of PFS and OS, they suffer from numerous biases and failure to correct OS prediction for the FLIPI.",95,1,11,18,Internal medicine; Surgery; Oncology; Retrospective cohort study; Prospective cohort study; Hematology; Positron emission tomography; Interim; Follicular lymphoma; International Prognostic Index; Medline database; Medicine,End-of-treatment; FDG-PET; Follicular lymphoma; Interim; Systematic review,"Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular/diagnostic imaging; Positron-Emission Tomography; Prognosis; Prospective Studies; Retrospective Studies",Fluorodeoxyglucose F18,KWF Kankerbestrijding,https://rd.springer.com/article/10.1007/s00277-015-2553-2 https://core.ac.uk/display/81265768 http://dspace.library.uu.nl/handle/1874/332413 https://www.ncbi.nlm.nih.gov/pubmed/26576560 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F332413 https://link.springer.com/content/pdf/10.1007%2Fs00277-015-2553-2.pdf https://dspace.library.uu.nl/bitstream/1874/332413/1/2.pdf https://link.springer.com/article/10.1007/s00277-015-2553-2/fulltext.html https://link.springer.com/article/10.1007/s00277-015-2553-2 https://pubmed.ncbi.nlm.nih.gov/26576560/ https://europepmc.org/article/MED/26576560,http://dx.doi.org/10.1007/s00277-015-2553-2,26576560,10.1007/s00277-015-2553-2,2244337915,PMC4700102,0,002-270-190-310-723; 011-454-897-960-546; 012-102-362-847-018; 015-212-281-019-17X; 015-261-699-715-640; 027-396-342-382-939; 030-880-317-913-219; 032-901-221-129-086; 033-263-987-362-300; 042-509-022-390-966; 044-481-493-275-113; 045-154-205-506-000; 062-844-995-691-531; 063-232-343-564-165; 066-114-588-037-955; 080-755-394-202-761; 114-170-327-330-921; 161-364-111-800-736; 167-615-343-468-295; 177-026-035-201-983,28
007-825-786-971-176,Poor compliance of clinical trial registration among trials included in systematic reviews: a cohort study.,2020-12-14,2020,journal article,Journal of clinical epidemiology,18785921; 08954356,Elsevier USA,Netherlands,Kristina Lindsley; Nicole Fusco; Hannah Teeuw; Eva Mooij; Rob J.P.M. Scholten; Lotty Hooft,"Abstract Objectives The objective of the study was to examine whether clinical trials that have been included in systematic reviews have been registered in clinical trial registers and, when they have, whether results of the trials were included in the clinical trial register. Study Design and Setting This study used a sample of 100 systematic reviews published by the Cochrane Musculoskeletal, Oral, Skin and Sensory Network between 2014 and 2019. Results We identified 2,000 trials (369,778 participants) from a sample of 100 systematic reviews. The median year of trial publication was 2007. Of 1,177 trials published in 2005 or later, a clinical trial registration record was identified for 368 (31%). Of these registered trials, 135 (37%) were registered prospectively and results were posted for 114 (31%); most registered trials evaluated pharmaceutical interventions (62%). Of trials published in the last 10 years, the proportion of registered trials increased to 38% (261 of 682). Conclusion Although some improvement in clinical trial registration has been observed in recent years, the proportion of registered clinical trials included in recently published systematic reviews remains less than desirable. Prospective clinical trial registration provides an essential role in assessing the risk of bias and judging the quality of evidence in systematic reviews of intervention safety and effectiveness.",132,,79,87,Randomized controlled trial; Physical therapy; Systematic review; Cohort study; Psychological intervention; Trial registration; Poor compliance; Quality of evidence; Clinical trial; Medicine,Evidence synthesis; Randomized controlled trial; Systematic review; Trial registration,Clinical Trials as Topic/methods; Cohort Studies; Humans; Registries/statistics & numerical data; Systematic Reviews as Topic/methods,,,https://pubmed.ncbi.nlm.nih.gov/33333165/ https://www.sciencedirect.com/science/article/abs/pii/S0895435620312208 https://www.sciencedirect.com/science/article/pii/S0895435620312208,http://dx.doi.org/10.1016/j.jclinepi.2020.12.016,33333165,10.1016/j.jclinepi.2020.12.016,3111647988,,0,008-280-735-680-861; 017-300-737-144-757; 017-411-526-645-895; 021-908-662-512-585; 025-703-051-309-875; 029-257-830-371-473; 032-554-945-593-93X; 034-380-997-033-243; 048-040-376-772-729; 053-796-744-544-246; 056-620-029-085-175; 057-130-551-638-128; 058-975-253-349-994; 059-062-187-516-749; 069-079-536-752-576; 083-275-795-865-394; 093-715-434-142-421,1
007-914-278-171-898,Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic overview of systematic reviews,2017-08-08,2017,journal article,Clinical and translational allergy,20457022,BioMed Central,United Kingdom,Ulugbek Nurmatov; Sangeeta Dhami; Stefania Arasi; Graham Roberts; Oliver Pfaar; Antonella Muraro; Ignacio J. Ansotegui; Moises A. Calderon; Cemal Cingi; Stephen R. Durham; Roy Gerth van Wijk; Susanne Halken; Eckard Hamelmann; Peter Hellings; Lars Jacobsen; Edward F. Knol; Désirée Larenas-Linnemann; Sandra Y. Lin; Vivian Maggina; Hanneke Oude-Elberink; Giovanni Battista Pajno; Ruby Panwankar; Elideanna Pastorello; Constantinos Pitsios; Giuseppina Rotiroti; Frans Timmermans; Olympia Tsilochristou; Eva M. Varga; Jamie Wilkinson; Andrew Williams; Margitta Worm; Luo Zhang; Aziz Sheikh,"Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen; Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we; sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for; ARC.; Methods: We undertook a systematic overview, which involved searching nine international biomedical databases; from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility; criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist; for systematic reviews. Data were descriptively synthesized.; Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met; our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews; suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in; significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both; SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT; and SLIT.; Conclusions: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients,; reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does; however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and; protocols studied . There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT.; We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated; into the published systematic reviews.",7,1,24,24,Critical appraisal; Intensive care medicine; Systematic review; Immunology; Alternative medicine; Asthma; Hay fever; Checklist; Allergen immunotherapy; In patient; Medicine,Allergen immunotherapy; Allergic rhinitis; Allergic rhinoconjuctivitis; Allergy; Hay fever; Rhinitis,,,Medical Research Council (G1000758) United Kingdom,https://pure.rug.nl/ws/files/46989412/Allergen_immunotherapy_for_allergic_rhinoconjunctivitis_a_systematic_overview_of_systematic_reviews.pdf http://dspace.library.uu.nl/handle/1874/356415 https://pubmed.ncbi.nlm.nih.gov/28794855/ https://link.springer.com/article/10.1186/s13601-017-0159-6 https://lirias.kuleuven.be/1187608 https://research.rug.nl/en/publications/allergen-immunotherapy-for-allergic-rhinoconjunctivitis-a-systema https://www.ncbi.nlm.nih.gov/pubmed/28794855 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547534 https://link.springer.com/content/pdf/10.1186/s13601-017-0159-6.pdf https://orca.cardiff.ac.uk/103898/ https://www.research.ed.ac.uk/portal/en/publications/allergen-immunotherapy-for-allergic-rhinoconjunctivitis(aca296e6-92f6-4077-8db7-9137cc887809).html https://www.rug.nl/research/portal/files/46989412/Allergen_immunotherapy_for_allergic_rhinoconjunctivitis_a_systematic_overview_of_systematic_reviews.pdf https://jhu.pure.elsevier.com/en/publications/allergen-immunotherapy-for-allergic-rhinoconjunctivitis-a-systema-2 http://www.ncbi.nlm.nih.gov/pubmed/28794855 https://europepmc.org/article/MED/28794855 https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A101320 https://core.ac.uk/display/154412648 https://dspace.library.uu.nl/bitstream/1874/356415/1/s13601_017_0159_6.pdf http://orca.cf.ac.uk/103898/ https://ctajournal.biomedcentral.com/articles/10.1186/s13601-017-0159-6 https://repub.eur.nl/pub/101320 https://repub.eur.nl/pub/101320/REPUB_101320-OA.pdf https://core.ac.uk/download/97016012.pdf,http://dx.doi.org/10.1186/s13601-017-0159-6,28794855,10.1186/s13601-017-0159-6,2732964511,PMC5547534,0,000-228-309-831-170; 002-322-976-446-050; 002-674-674-433-229; 006-831-231-350-477; 009-541-908-244-419; 010-303-195-560-164; 014-384-494-585-532; 017-162-150-446-788; 019-258-512-336-72X; 019-400-196-317-029; 026-741-478-633-918; 031-417-473-078-341; 033-075-195-527-009; 034-924-860-551-405; 037-902-844-799-920; 040-599-109-232-265; 047-831-443-828-986; 049-883-282-843-997; 052-110-952-892-477; 053-673-884-590-914; 055-323-973-233-276; 062-241-096-230-413; 063-370-360-647-937; 075-567-609-141-670; 077-349-900-958-894; 080-482-436-820-525; 083-347-742-485-718; 090-917-761-977-14X; 092-811-210-866-045; 095-544-084-225-612; 095-644-626-287-614; 100-454-686-030-214; 102-103-661-485-229; 102-568-725-946-195; 103-381-789-668-565; 103-876-959-402-853; 107-431-300-071-893; 107-786-473-361-699; 121-285-110-769-523; 124-576-739-358-085; 168-625-437-747-573,39
008-800-308-683-976,"Diagnostic value of signs, symptoms and diagnostic tests for diagnosing pneumonia in ambulant children in developed countries: a systematic review.",2018-10-26,2018,journal article,NPJ primary care respiratory medicine,20551010,Nature Publishing Group,United Kingdom,Marjolein J C Schot; Anne R J Dekker; Wesley G. Giorgi; Rogier M. Hopstaken; Niek J. de Wit; Theo J M Verheij; Jochen W L Cals,"Identifying a child with pneumonia in the large group of children with acute respiratory tract infections can be challenging for primary care physicians. Knowledge on the diagnostic value of specific signs and symptoms may guide future decision rules and guidelines for clinicians. We aimed to identify and systematically review available evidence for the diagnostic value of signs, symptoms, and additional tests to diagnose pneumonia in children in an ambulatory setting in developed countries. We conducted a systematic review, searching in the electronic databases of PubMed and Embase. Quality assessment of studies was done using the QUADAS-2 criteria. After data extraction from selected studies, we calculated and summarized test characteristics (sensitivity, specificity, negative and positive predictive values) of all available signs, symptoms, additional laboratory tests, and chest ultrasonography. The original search yielded 4665 records, of which 17 articles were eligible for analysis: 12 studies on signs and symptoms, 4 on additional laboratory tests, and 6 on ultrasonography. All included studies were performed in a secondary care setting. Risk of bias was present in the majority of studies in the domain of patient selection. Prevalence of pneumonia varied from 3.4% to 71.7%. The diagnostic value of the available 27 individual signs and symptoms to identify pneumonia was low. In a low prevalence setting, (4 studies, pneumonia prevalence 10%), additional diagnostic tests such as oxygen saturation, C-reactive protein, and white blood cell count are more promising. Chest ultrasonography showed high diagnostic value in settings with higher prevalence of pneumonia. Single signs and symptoms from medical history and physical examination or individual additional diagnostic tests are insufficient to diagnose pneumonia in ambulant children. Very few diagnostic studies are conducted in settings with low prevalence of pneumonia. Future research in low prevalence settings should focus on the diagnostic value of the combination of clinical features and additional testing possibly using meta-analysis of individual data.",28,1,40,40,Ambulatory care; Pediatrics; Medical history; Respiratory tract infections; Community-acquired pneumonia; Pneumonia; Emergency department; Sign/symptom; Physical examination; Medicine,,"Ambulatory Care; Child; Developed Countries; Diagnostic Tests, Routine; Humans; Pneumonia/diagnosis; Symptom Assessment",,ZonMW; ZonMw Veni,https://www.narcis.nl/publication/RecordID/oai%3Acris.maastrichtuniversity.nl%3Apublications%2Fca058201-014d-4d84-b308-59e03c197393 https://www.nature.com/articles/s41533-018-0104-8.pdf http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203790 https://dspace.library.uu.nl/bitstream/1874/372984/1/s41533_018_0104_8.pdf http://dspace.library.uu.nl/handle/1874/372984 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203790 http://europepmc.org/articles/PMC6203790 https://www.nature.com/articles/s41533-018-0104-8/ https://pubmed.ncbi.nlm.nih.gov/30367067/,http://dx.doi.org/10.1038/s41533-018-0104-8,30367067,10.1038/s41533-018-0104-8,2897383970,PMC6203790,0,001-391-983-836-201; 003-613-236-397-800; 004-283-790-175-938; 004-891-320-975-630; 007-798-470-444-977; 010-480-739-728-517; 010-909-259-996-861; 014-162-296-441-059; 015-895-916-244-406; 019-303-602-294-076; 020-068-163-685-136; 021-090-295-607-815; 023-338-061-587-611; 024-232-495-635-52X; 025-074-616-835-663; 028-065-311-760-28X; 031-527-002-201-654; 032-352-101-330-528; 038-135-404-377-160; 044-064-329-005-130; 044-386-172-867-542; 044-726-683-340-409; 044-925-072-208-857; 046-250-802-112-487; 047-785-631-889-773; 048-779-736-983-964; 052-753-934-966-822; 057-075-056-237-870; 057-179-922-376-815; 057-388-755-234-617; 061-106-925-080-478; 065-519-990-008-975; 074-442-740-894-680; 077-685-127-734-553; 077-934-427-806-584; 083-203-534-087-608; 083-968-434-545-653; 093-689-340-278-161; 093-971-082-754-741; 100-623-207-877-253; 101-196-098-667-03X; 111-245-580-079-894; 111-370-926-662-829; 114-231-397-821-810; 114-486-007-850-945; 122-171-772-238-773; 125-585-100-254-868; 127-844-308-219-320; 129-369-828-030-831; 131-823-514-829-148; 133-598-017-015-092; 137-075-958-232-155; 138-602-524-725-129,7
009-720-475-545-024,Cochlear implant performance in children deafened by congenital cytomegalovirus-A systematic review.,2018-06-19,2018,journal article,Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery,17494486; 17494478,Wiley-Blackwell,United Kingdom,Véronique J. C. Kraaijenga; F. van Houwelingen; S. van der Horst; J. Visscher; J.M.L. Huisman; E.J. Hollman; Inge Stegeman; Adriana L. Smit,"Background Congenital cytomegalovirus (cCMV) infection is a major cause of sensorineural hearing loss in children. Objective of review The objective of this systematic review was to compare performance in paediatric cochlear implant users with SNHL caused by cCMV compared to non-cCMV implantees. Type of review Systematic review SEARCH STRATEGY: PubMed, EMBASE and the Cochrane databases were searched from inception up to 15 May 2017 for children, cochlear implant, performance and their synonyms. Evaluation methods Titles, abstracts and full texts were screened for eligibility. Directness of evidence and risk of bias were assessed. From the included studies, study characteristics and outcome data (speech perception, speech production, receptive language and auditory performance of cCMV groups and non-cCMV groups) were extracted. Results A total of 5280 unique articles were screened of which 28 were eligible for critical appraisal. After critical appraisal, 12 studies remained for data extraction. Seven of 12 studies showed worse performance after cochlear implantation in cCMV children compared to non-cCMV children. Worse performance in cCMV children was attributed to cCMV-related comorbidities in six of these studies. Available data on asymptomatic cCMV children compared to non-cCMV children did not reveal an unfavourable effect on cochlear implant performance. Conclusions The available evidence reveals that cCMV children often have worse cochlear implant performance compared to non-cCMV children, which can be attributed to cCMV related comorbidities. We urge physicians to take into account the cCMV related comorbidities in the counselling of paediatric CI users deafened by cCMV.",43,5,1283,1295,Critical appraisal; Systematic review; Congenital cytomegalovirus infection; Cochlear implant; Prelingual deafness; Sensorineural hearing loss; Cochlear implantation; Audiology; Medicine; Speech perception,children; cochlear implantation; comorbidities; congenital cytomegalovirus; performance; prelingual deafness; sensorineural hearing loss; systematic review,"Child; Cochlear Implantation; Cochlear Implants; Cytomegalovirus Infections/complications; Deafness/microbiology; Hearing Loss, Sensorineural/microbiology; Humans; Treatment Outcome",,,https://www.ncbi.nlm.nih.gov/pubmed/29768731 http://www.ncbi.nlm.nih.gov/pubmed/29768731 https://onlinelibrary.wiley.com/doi/pdf/10.1111/coa.13142 https://onlinelibrary.wiley.com/doi/full/10.1111/coa.13142 https://pubmed.ncbi.nlm.nih.gov/29768731/,http://dx.doi.org/10.1111/coa.13142,29768731,10.1111/coa.13142,2803546693,,0,002-797-261-044-946; 003-314-367-271-36X; 003-827-985-928-588; 004-405-089-614-843; 006-318-354-968-229; 006-859-741-016-043; 009-739-188-572-10X; 011-324-426-092-433; 012-310-663-575-032; 014-631-989-030-040; 020-721-236-778-165; 023-324-554-472-954; 026-916-423-560-143; 029-284-706-000-804; 030-129-761-543-84X; 031-440-052-738-298; 032-281-901-937-832; 032-734-586-957-321; 034-107-495-260-393; 036-231-083-953-901; 038-168-749-358-505; 040-205-972-777-173; 045-369-053-412-395; 052-981-709-704-732; 057-150-108-253-475; 059-430-728-911-263; 064-694-641-059-055; 065-692-441-823-239; 067-611-060-958-952; 067-694-599-273-03X; 069-609-289-678-764; 076-823-068-829-048; 077-653-754-465-034; 082-565-728-501-899; 083-670-535-652-077; 090-229-286-895-110; 109-575-751-706-902; 111-405-756-210-586; 115-418-816-723-382; 121-098-232-510-129; 129-650-970-094-865; 135-939-598-449-117; 144-287-370-265-333; 165-894-997-077-391; 195-191-093-780-794,5
012-124-483-362-604,Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review,2018-10-30,2018,journal article,Journal of neuro-oncology,15737373; 0167594x,Kluwer Academic Publishers,Netherlands,Margriet IJzerman-Korevaar; Tom J. Snijders; Alexander de Graeff; Saskia C.C.M. Teunissen; Filip de Vos,"Glioma patients suffer from a wide range of symptoms which influence quality of life negatively. The aim of this review is to give an overview of symptoms most prevalent in glioma patients throughout the total disease trajectory, to be used as a basis for the development of a specific glioma Patient Reported Outcome Measure (PROM) for early assessment and monitoring of symptoms in glioma patients. A systematic review focused on symptom prevalence in glioma patients in different phases of disease and treatment was performed in MEDLINE, CINAHL and EMBASE according to PRISMA recommendations. We calculated weighted means for prevalence rates per symptom. The search identified 2.074 unique papers, of which 32 were included in this review. In total 25 symptoms were identified. The ten most prevalent symptoms were: seizures (37%), cognitive deficits (36%), drowsiness (35%), dysphagia (30%), headache (27%), confusion (27%), aphasia (24%), motor deficits (21%), fatigue (20%) and dyspnea (20%). Eight out of ten of the most prevalent symptoms in glioma patients are related to the central nervous system and therefore specific for glioma. Our findings emphasize the importance of tailored symptom care for glioma patients and may aid in the development of specific PROMs for glioma patients in different phases of the disease.",140,3,485,496,Quality of life; Internal medicine; Neurology; Prevalence; Adverse effect; Glioma; Disease; Patient-reported outcome; Dysphagia; Medicine,Adverse events; Glioblastoma; Glioma; PROM; Patient reported outcomes; Symptoms; Toxicity,Brain Neoplasms/diagnosis; Disease Progression; Glioma/diagnosis; Humans; Prevalence; Quality of Life; Symptom Assessment,,University Medical Center Utrecht,https://europepmc.org/article/MED/30377935 https://link.springer.com/article/10.1007/s11060-018-03015-9 https://www.ncbi.nlm.nih.gov/pubmed/30377935 https://link.springer.com/content/pdf/10.1007/s11060-018-03015-9.pdf http://dspace.library.uu.nl/handle/1874/377077 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267240/ http://www.ncbi.nlm.nih.gov/pubmed/30377935 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F377077,http://dx.doi.org/10.1007/s11060-018-03015-9,30377935,10.1007/s11060-018-03015-9,2899363944,PMC6267240,0,001-203-569-039-45X; 001-511-300-450-769; 001-682-347-463-416; 004-588-044-295-425; 005-346-893-859-103; 012-787-338-379-079; 016-601-278-953-303; 017-729-874-759-813; 018-339-234-926-014; 020-409-353-248-458; 022-690-571-413-626; 023-249-959-801-923; 026-463-726-387-238; 026-500-687-393-108; 026-620-897-751-395; 026-687-548-323-25X; 027-148-678-571-546; 027-506-700-996-477; 030-930-037-441-192; 032-527-755-107-925; 032-871-901-844-214; 033-630-903-471-596; 034-600-684-728-898; 038-948-385-532-732; 039-454-748-313-050; 040-242-335-045-634; 044-220-530-345-542; 044-239-940-661-871; 045-082-118-149-383; 045-501-737-797-551; 046-424-555-884-507; 046-883-719-660-765; 047-610-287-633-546; 049-543-014-103-545; 051-213-405-683-874; 051-734-113-712-702; 053-519-573-710-610; 058-495-377-810-487; 058-863-054-299-561; 059-561-870-802-850; 061-037-190-160-218; 061-583-932-514-029; 063-173-405-820-738; 063-606-507-912-685; 063-609-490-080-248; 071-426-263-540-070; 072-112-939-485-054; 091-916-194-147-28X; 092-804-699-111-207; 092-864-235-322-940; 106-511-756-106-154; 110-761-107-164-57X; 110-829-758-655-194; 112-586-313-844-733; 116-849-353-758-001; 123-413-304-007-97X; 123-766-168-904-927; 124-448-033-288-584; 127-525-191-167-978; 133-399-727-082-319; 147-163-073-946-305; 153-808-253-589-512; 171-288-147-881-196,26
012-151-107-325-934,Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review.,2020-02-12,2020,journal article,Brain sciences,20763425,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Sanne J van der Steur; Albert Batalla; Matthijs G. Bossong,"Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use or the genetic profile of cannabis users, appear to moderate this association. The present systematic review presents a detailed and up-to-date literature overview on factors that influence the relationship between cannabis use and psychosis risk. A systematic search was performed according to the PRISMA guidelines in MEDLINE and Embase, and 56 studies were included. The results show that, in particular, frequent cannabis use, especially daily use, and the consumption of high-potency cannabis are associated with a higher risk of developing psychosis. Moreover, several genotypes moderate the impact of cannabis use on psychosis risk, particularly those involved in the dopamine function, such as AKT1. Finally, cannabis use is associated with an earlier psychosis onset and increased risk of transition in individuals at a clinical high risk of psychosis. These findings indicate that changing cannabis use behavior could be a harm reduction strategy employed to lower the risk of developing psychosis. Future research should aim to further develop specific biomarkers and genetic profiles for psychosis, thereby contributing to the identification of individuals at the highest risk of developing a psychotic disorder.",10,2,97,,Psychiatry; Association (psychology); Cannabis; Age of onset; MEDLINE; Psychosis; Cannabis use; Psychosis risk; Harm reduction; Medicine,age of onset; cannabis use; clinical high risk; genetics; psychotic disorder,,,Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Veni 016.166.038),https://pubmed.ncbi.nlm.nih.gov/32059350/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071602 https://www.mdpi.com/2076-3425/10/2/97/htm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071602 https://www.mdpi.com/2076-3425/10/2/97/pdf,http://dx.doi.org/10.3390/brainsci10020097,32059350,10.3390/brainsci10020097,3006606082,PMC7071602,0,000-039-054-810-761; 000-271-942-978-120; 000-284-112-559-341; 002-143-013-830-689; 002-329-154-572-076; 003-903-137-356-486; 004-655-893-303-095; 005-665-006-973-03X; 005-835-998-142-966; 005-882-158-568-587; 005-968-762-880-662; 006-223-774-847-616; 007-010-665-621-500; 007-203-121-468-035; 007-385-599-375-92X; 008-046-958-860-127; 008-307-591-457-755; 008-830-878-944-805; 009-790-795-396-527; 009-926-365-273-797; 010-048-850-943-028; 013-953-716-076-751; 014-114-119-351-742; 016-089-441-710-281; 016-970-638-250-219; 017-300-737-144-757; 017-769-279-057-32X; 018-359-571-069-947; 019-489-235-428-519; 021-254-487-374-671; 021-380-019-499-876; 021-524-438-869-050; 022-346-567-279-468; 024-175-827-070-580; 024-513-157-375-420; 024-530-354-016-552; 024-754-901-381-296; 024-778-213-656-555; 026-444-282-032-167; 028-037-921-749-67X; 030-077-492-508-461; 030-704-596-155-074; 031-009-574-549-832; 031-157-208-857-178; 031-823-465-838-72X; 031-952-813-142-86X; 032-817-477-846-810; 033-104-743-096-976; 033-721-188-764-894; 034-019-644-139-598; 035-008-408-532-091; 036-826-836-384-137; 037-091-231-573-615; 037-300-280-686-26X; 037-661-700-794-210; 039-254-001-654-301; 039-299-553-502-41X; 040-668-888-074-88X; 041-359-819-169-129; 042-555-971-464-661; 042-724-407-749-02X; 044-001-723-940-532; 044-229-995-927-56X; 044-449-846-267-718; 044-953-840-837-479; 046-016-829-036-925; 046-504-095-632-690; 049-072-931-501-518; 049-227-369-852-735; 049-787-187-943-658; 051-755-362-208-85X; 051-958-970-838-775; 052-163-311-168-429; 054-669-732-932-086; 058-141-234-508-143; 060-120-988-066-547; 061-616-127-644-793; 061-987-348-013-525; 063-632-140-093-896; 064-834-388-214-913; 070-996-384-828-626; 071-131-601-808-204; 072-221-222-436-135; 075-366-447-003-96X; 076-730-620-273-344; 079-765-480-079-943; 080-179-919-082-457; 081-441-011-698-89X; 087-557-996-947-24X; 088-341-693-487-032; 088-807-346-699-964; 089-873-549-393-369; 091-069-634-492-091; 093-158-671-160-210; 094-861-079-170-859; 101-563-693-872-603; 102-120-023-791-517; 102-209-393-175-114; 102-682-899-154-277; 104-291-022-733-314; 104-448-800-417-063; 105-010-458-322-949; 105-602-281-155-557; 105-770-599-617-013; 106-585-689-350-596; 108-976-508-648-045; 110-814-467-369-794; 112-445-570-813-015; 112-526-655-317-824; 116-867-369-241-233; 117-106-845-261-703; 117-391-501-355-867; 118-587-877-301-040; 121-319-722-454-971; 122-433-988-577-755; 122-730-421-376-056; 123-822-187-372-915; 123-998-197-404-916; 124-546-379-652-207; 129-477-772-249-831; 136-172-586-881-741; 140-211-012-948-744; 142-308-528-679-171; 144-487-995-969-986; 150-463-316-017-547; 157-441-869-161-634; 158-474-787-612-777; 171-642-033-388-298; 186-701-233-961-37X; 188-393-864-474-405; 193-930-330-776-216,13
012-702-845-049-503,Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis,2016-03-02,2016,journal article,Annals of hematology,14320584; 09395555,Springer Verlag,Germany,Hugo J. A. Adams; Thomas C. Kwee,"This study aimed to systematically review the prognostic value of pretransplant 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation (SCT). MEDLINE was systematically searched for appropriate studies. Included studies were methodologically appraised. Results of individual studies were meta-analyzed, if possible. Eleven studies, comprising a total of 745 refractory/relapsed Hodgkin lymphoma patients who underwent FDG-PET before autologous SCT, were included. The overall methodological quality of these studies was moderate. The proportion of pretransplant FDG-PET positive patients ranged between 25 and 65.2 %. Progression-free survival ranged between 0 and 52 % in pretransplant FDG-PET positive patients, and between 55 and 85 % in pretransplant FDG-PET negative patients. Overall survival ranged between 17 and 77 % in pretransplant FDG-PET positive patients, and between 78 and 100 % in FDG-PET negative patients. Based on five studies that provided sufficient data for meta-analysis, pooled sensitivity and specificity of pretransplant FDG-PET in predicting treatment failure (i.e., either progressive, residual, or relapsed disease) were 67.2 % (95 % confidence interval [CI] 58.2–75.3 %) and 70.7 % (95 % CI 64.2–76.5 %), respectively. Based on two studies that provided sufficient data for meta-analysis, pooled sensitivity and specificity of pretransplant FDG-PET in predicting death during follow-up were 74.4 % (95 % CI 58.8–86.5 %) and 58.0 % (95 % CI 49.3–66.3 %), respectively. In conclusion, the moderate quality evidence suggests pretransplant FDG-PET to have value in predicting outcome in refractory/relapsed Hodgkin lymphoma patients treated with autologous SCT. Nevertheless, a considerable proportion of pretransplant FDG-PET positive patients remains disease free and a considerable proportion of pretransplant FDG-PET negative patients develops disease relapse after autologous SCT.",95,5,695,706,Survival analysis; Internal medicine; Surgery; Hematology; Cohort study; Autologous stem-cell transplantation; Salvage therapy; Confidence interval; Refractory; Medicine; Gastroenterology; Meta-analysis,Autologous stem cell transplantation; FDG-PET; Hodgkin lymphoma; Meta-analysis; Systematic review,"Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bone Marrow Transplantation; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hodgkin Disease/diagnostic imaging; Humans; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Salvage Therapy; Sensitivity and Specificity; Survival Analysis; Transplantation, Autologous; Treatment Outcome",Fluorine Radioisotopes; Radiopharmaceuticals; Fluorodeoxyglucose F18,KWF Kankerbestrijding,http://dspace.library.uu.nl/handle/1874/342747 https://core.ac.uk/display/81087861 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F342747 https://www.ncbi.nlm.nih.gov/pubmed/26931115 https://rd.springer.com/article/10.1007/s00277-016-2619-9 http://www.ncbi.nlm.nih.gov/pubmed/26931115 https://link.springer.com/content/pdf/10.1007%2Fs00277-016-2619-9.pdf https://pubmed.ncbi.nlm.nih.gov/26931115/ https://link.springer.com/article/10.1007/s00277-016-2619-9 http://europepmc.org/abstract/MED/26931115,http://dx.doi.org/10.1007/s00277-016-2619-9,26931115,10.1007/s00277-016-2619-9,2289250711,PMC4819743,0,003-231-805-403-155; 005-498-734-005-285; 006-683-787-713-286; 007-744-774-622-759; 008-673-243-897-64X; 009-659-686-885-176; 011-148-560-861-483; 011-916-398-722-387; 013-094-984-497-461; 015-261-699-715-640; 015-622-334-926-139; 016-281-427-402-442; 017-147-489-067-394; 017-256-866-749-984; 020-388-741-795-015; 020-938-268-751-95X; 022-111-790-100-102; 022-748-547-103-387; 025-000-812-547-085; 029-664-754-319-363; 034-655-902-261-340; 037-295-671-039-592; 039-347-314-652-799; 041-290-727-497-317; 042-416-481-357-687; 043-723-026-808-905; 045-416-413-742-937; 050-366-656-558-649; 055-171-554-628-96X; 058-186-098-199-743; 059-695-388-149-519; 061-894-080-796-078; 062-844-995-691-531; 063-232-343-564-165; 064-703-650-501-898; 067-601-645-854-500; 070-230-024-963-286; 074-505-047-106-442; 085-979-843-149-295,38
014-835-447-432-613,Intestinal Viral Loads and Inactivation Kinetics of Livestock Viruses Relevant for Natural Casing Production: a Systematic Review and Meta-Analysis.,2021-02-04,2021,journal article,"Pathogens (Basel, Switzerland)",20760817,MDPI AG,Switzerland,Tinka Jelsma; Joris J. Wijnker; Wim H.M. van der Poel; Henk J. Wisselink,"Animal intestines are the source of edible sausage casings, which are traded worldwide and may come from areas where notifiable infectious animal diseases are prevalent. To estimate the risks of virus contamination, knowledge about the quantity of virus and decimal reduction values of the standard preservation method by salting is of great importance. A literature search, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was performed in search engine CAB Abstracts to determine the viral load of 14 relevant animal viruses in natural casings or intestines. Only a very limited number of scientific publications per virus were found and viral loads in the intestines varied from high for ASFV (five publications), BVDV (3), CSFV (6), PPRV (3), RPV (2) and TGEV (3) to moderate for PEDV (2) and SVDV (3), low for HEV (2) and FMDV (5), very low for VESV (1) and negative for PrV (2) and VSV (1). PRRSV was found in intestines, however, viral titers were not published. Three viruses (BVDV, CSFV and PPRV) with high viral loads were selected to search for their inactivation kinetics. For casings, no inactivation data were found, however, thermal inactivation data of these viruses were available, but differed in quantity, quality and matrices. In conclusion, important data gaps still exist when it comes to the quantitative inactivation of viruses in sausage casings or livestock intestines.",10,2,173,,Livestock; Viral load; Virology; Virus; Inactivation kinetics; Titer; Biology; Meta-analysis,D-value; animal viruses; inactivation; intestines; natural casings; titers; viral loads,,,,https://europepmc.org/article/MED/33557372 https://pubmed.ncbi.nlm.nih.gov/33557372/ https://www.mdpi.com/2076-0817/10/2/173/pdf https://www.narcis.nl/publication/RecordID/oai%3Alibrary.wur.nl%3Awurpubs%2F578754 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915499/ https://www.mdpi.com/2076-0817/10/2/173,http://dx.doi.org/10.3390/pathogens10020173,33557372,10.3390/pathogens10020173,3128020033,PMC7915499,0,000-196-563-582-962; 000-449-804-690-060; 001-837-503-563-616; 002-223-590-561-546; 002-548-244-485-056; 002-656-802-661-498; 003-531-749-242-995; 004-589-474-873-234; 005-155-634-915-172; 005-590-981-126-537; 006-102-795-503-379; 007-151-213-727-311; 007-622-329-831-151; 009-437-008-138-143; 009-775-360-538-834; 009-870-135-426-532; 009-889-935-863-095; 009-911-386-238-374; 010-090-394-372-389; 011-568-361-214-559; 012-136-676-837-82X; 013-489-157-865-781; 013-538-542-289-66X; 016-154-899-754-647; 016-748-892-714-608; 016-953-491-653-421; 017-239-224-654-284; 017-300-737-144-757; 017-437-625-011-631; 017-844-070-864-689; 018-997-656-805-380; 019-336-965-580-611; 020-216-839-860-435; 020-966-745-992-368; 021-278-514-096-408; 021-586-020-263-135; 021-779-596-402-32X; 022-312-358-668-63X; 024-857-176-584-796; 025-289-073-293-201; 025-860-397-441-354; 026-136-861-277-404; 027-881-891-833-340; 028-266-290-303-848; 028-800-435-331-792; 029-296-328-968-92X; 031-820-382-858-393; 031-831-868-628-495; 032-129-488-221-630; 032-239-163-344-154; 032-541-731-935-33X; 033-412-220-080-961; 033-645-205-579-577; 034-380-594-189-489; 036-309-184-398-633; 036-587-083-070-735; 037-546-348-195-425; 037-678-918-744-17X; 038-107-385-118-201; 038-706-312-479-457; 039-181-129-265-298; 040-015-952-327-952; 040-019-749-582-817; 040-502-827-645-36X; 041-338-109-364-736; 041-958-815-440-860; 043-900-140-473-410; 044-098-040-613-675; 044-178-654-577-891; 044-698-760-007-576; 049-629-064-637-454; 050-325-704-593-051; 050-331-208-969-831; 050-545-341-074-870; 050-745-938-612-412; 051-266-926-328-586; 051-578-266-238-00X; 051-594-296-253-999; 052-677-596-595-501; 054-225-244-942-368; 056-085-340-243-39X; 056-276-482-425-289; 058-317-170-788-356; 059-291-588-134-230; 059-862-506-951-39X; 060-789-714-883-616; 060-806-050-430-850; 062-487-547-599-907; 063-073-761-581-990; 069-717-739-680-14X; 072-116-538-974-146; 072-863-854-199-072; 074-120-210-983-182; 074-952-221-235-27X; 076-188-213-659-488; 078-695-124-589-843; 079-543-229-231-948; 079-965-603-476-647; 080-163-240-012-528; 081-214-394-592-661; 081-232-821-397-895; 083-210-752-779-341; 083-865-853-911-783; 084-467-956-950-702; 086-277-607-294-124; 087-915-963-156-676; 091-129-253-735-901; 091-825-944-310-792; 092-623-848-186-171; 092-865-051-459-138; 093-183-896-444-622; 094-075-980-367-103; 096-233-334-709-344; 101-147-775-201-632; 101-211-489-558-837; 102-328-717-104-809; 108-621-201-886-812; 110-209-922-615-489; 112-514-371-767-614; 112-701-753-658-345; 114-441-693-812-148; 116-758-408-005-389; 121-800-793-754-702; 126-765-413-574-963; 127-314-620-748-632; 127-352-979-098-506; 133-076-488-501-97X; 139-156-875-267-173; 139-200-735-526-167; 143-714-678-115-03X; 149-569-884-280-335; 158-545-721-452-817; 164-507-691-911-292; 168-152-638-998-486; 168-716-639-745-078; 170-561-832-168-573; 174-606-220-653-238; 178-931-772-634-152; 179-867-888-934-600; 181-392-774-755-829; 194-767-191-387-032,1
015-430-936-175-938,Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015 : A systematic review and meta-analysis,2017-04-20,2017,journal article,PloS one,19326203,Public Library of Science,United States,Min Zhao; Kerstin Klipstein-Grobusch; Xin Wang; Johannes B. Reitsma; Dong Zhao; Diederick E. Grobbee; Ian Graham; Ilonca Vaartjes,"Background ; Myocardial Infarction (MI) has become a major cause of morbidity and mortality in China, but little is known about the prevalence of guideline-recommended cardiovascular medications after MI events over the last two decades. This systematic review and meta-analysis aims to summarize cardiovascular medication use between 1995–2015 and to assess factors in associated with the trends in cardiovascular medications.; ; ; Method ; A systematic search was conducted in four databases (Pubmed, Embase, CENTRAL, and CNKI) to obtain observational studies published between 1995 and 2015, reporting on the use of cardiovascular medications in China. Risk of bias of individual studies was appraised and selected studies were pooled for estimated prevalence of cardiovascular medication. Prevalence of cardiovascular medication use for 1995 and 2015 was estimated by random effects meta-regression model.; ; ; Results ; From 13,940 identified publications, 35 studies, comprising 28,000 patients, were included. The pooled prevalence for aspirin, beta-blockers, statins, ACE-Inhibitors, ACE-Inhibitor/ARBs and nitrates was 92% [95% confidence interval (CI): 0.89–0.95], 63% (95% CI: 0.57–0.69), 72% (95% CI: 0.60–0.82), 49% (95% CI: 0.41–0.57), 59% (95% CI: 0.48–0.69) and 79% (95% CI: 0.74–0.91), respectively. A significant increase in beta-blocker and statin use and a decrease of nitrate use was observed over time. The estimated prevalence of beta-blockers, statins, and nitrates was 78%, 91.1%, and 59.3% in 2015, compared to 32%, 17% and 96% in 1995, respectively.; ; ; Conclusion ; Cardiovascular medication use after MI is far from optimal in Chinese patients, even though the prevalence of use increased over the period 1995–2015. With a rapidly increasing number of MI patients in China, a comprehensive strategy on secondary prevention is warranted.; ; ; Systematic review registration ; PROSPERO (CRD42015025246)",12,4,e0175947,,Pediatrics; Systematic review; Observational study; Chinese people; Aspirin; MEDLINE; Confidence interval; Myocardial infarction; Medicine; Meta-analysis,,"Cardiovascular Agents/therapeutic use; China/epidemiology; History, 20th Century; History, 21st Century; Humans; Myocardial Infarction/drug therapy; Prevalence; Secondary Prevention",Cardiovascular Agents,Netherlands Organisation for Scientific Research (NWO); Dutch heart foundation,https://doaj.org/article/76334272aedf498aa966cc45ff620054 https://dspace.library.uu.nl/handle/1874/348907 https://dx.plos.org/10.1371/journal.pone.0175947 https://ui.adsabs.harvard.edu/abs/2017PLoSO..1275947Z/abstract https://europepmc.org/abstract/MED/28426793 https://pubmed.ncbi.nlm.nih.gov/28426793/ https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F7e46eb18-fdcb-4ca3-971f-98cb15cebc67 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175947 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398555,http://dx.doi.org/10.1371/journal.pone.0175947,28426793,10.1371/journal.pone.0175947,2606711897,PMC5398555,0,002-509-225-949-52X; 003-350-127-063-72X; 005-317-584-200-791; 006-477-473-775-612; 006-513-524-081-924; 006-600-599-044-939; 007-702-738-778-101; 008-245-822-029-459; 009-469-511-075-14X; 011-448-669-954-709; 015-959-135-730-030; 019-690-094-396-617; 023-251-779-540-319; 026-459-673-819-989; 027-449-476-127-657; 027-931-743-878-574; 029-184-440-027-349; 032-603-204-079-448; 033-328-347-403-447; 036-668-761-047-396; 037-516-638-466-61X; 037-771-005-851-145; 043-539-003-869-393; 046-150-142-203-050; 050-667-158-227-221; 053-259-817-247-303; 053-801-363-411-099; 057-234-139-342-09X; 058-234-747-692-25X; 058-456-375-269-074; 059-736-252-968-898; 060-358-163-563-813; 060-456-503-513-29X; 063-323-736-458-850; 065-352-581-124-578; 075-126-414-471-625; 077-333-185-038-59X; 077-445-828-051-584; 081-526-298-164-547; 085-615-632-237-474; 086-438-007-125-559; 087-959-021-346-139; 089-375-424-002-756; 089-668-754-145-863; 095-889-372-020-607; 097-621-017-872-333; 100-471-801-116-043; 118-395-660-280-270; 122-204-125-369-812; 124-912-944-569-498; 137-866-913-220-661; 172-281-626-485-160; 183-564-336-098-823; 199-721-795-638-822,12
015-720-710-260-350,Long-term outcomes of survivors of neonatal insults: A systematic review and meta-analysis,2020-04-24,2020,journal article,PloS one,19326203,Public Library of Science,United States,Dorcas N. Magai; Eirini Karyotaki; Agnes M. Mutua; Esther Chongwo; Carophine Nasambu; Derrick Ssewanyana; Charles R. Newton; Hans M. Koot; Amina Abubakar,"Background The Millennium Developmental Goals ensured a significant reduction in childhood mortality. However, this reduction simultaneously raised concerns about the long-term outcomes of survivors of early childhood insults. This systematic review focuses on the long-term neurocognitive and mental health outcomes of neonatal insults (NNI) survivors who are six years or older. Methods Two independent reviewers conducted a comprehensive search for empirical literature by combining index and free terms from the inception of the databases until 10th October 2019. We also searched for additional relevant literature from grey literature and using reference tracking. Studies were included if they: were empirical studies conducted in humans; the study participants were followed at six years of age or longer; have an explicit diagnosis of NNI, and explicitly define the outcome and impairment. Medians and interquartile range (IQR) of the proportions of survivors of the different NNI with any impairment were calculated. A random-effect model was used to explore the estimates accounted for by each impairment domain. Results Fifty-two studies with 94,978 participants who survived NNI were included in this systematic review. The overall prevalence of impairment in the survivors of NNI was 10.0% (95% CI 9.8–10.2). The highest prevalence of impairment was accounted for by congenital rubella (38.8%: 95% CI 18.8–60.9), congenital cytomegalovirus (23.6%: 95% CI 9.5–41.5), and hypoxic-ischemic encephalopathy (23.3%: 95% CI 14.7–33.1) while neonatal jaundice has the lowest proportion (8.6%: 95% CI 2.7–17.3). The most affected domain was the neurodevelopmental domain (16.6%: 95% CI 13.6–19.8). The frequency of impairment was highest for neurodevelopmental impairment [22.0% (IQR = 9.2–24.8)] and least for school problems [0.0% (IQR = 0.0–0.00)] in any of the conditions. Conclusion The long-term impact of NNI is also experienced in survivors of NNI who are 6 years or older, with impairments mostly experienced in the neurodevelopmental domain. However, there are limited studies on long-term outcomes of NNI in sub-Saharan Africa despite the high burden of NNI in the region. Trial registration Registration number: CRD42018082119.",15,4,1,16,Interquartile range; Mental health; Neurocognitive; Pediatrics; Systematic review; Early childhood; Rubella; MEDLINE; Medicine; Meta-analysis,,"Humans; Infant, Newborn; Survivors/statistics & numerical data; Wounds and Injuries/epidemiology",,Wellcome Trust (107769/Z/10/Z) United Kingdom,https://www.narcis.nl/publication/RecordID/oai%3Aresearch.vu.nl%3Apublications%2F3d7597db-8b59-45e9-b007-5769ae184076 https://www.tropicalmedicine.ox.ac.uk/publications/1103232 https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0231947&type=printable https://works.bepress.com/amina_abubakar/31/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182387 https://ecommons.aku.edu/eastafrica_ihd/56/ https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231947 https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1055&context=eastafrica_ihd http://www.ncbi.nlm.nih.gov/pubmed/32330163 https://pubmed.ncbi.nlm.nih.gov/32330163/ https://www.psych.ox.ac.uk/publications/1103232 https://research.vu.nl/en/publications/long-term-outcomes-of-survivors-of-neonatal-insults-a-systematic- http://ui.adsabs.harvard.edu/abs/2020PLoSO..1531947M/abstract https://dx.plos.org/10.1371/journal.pone.0231947 https://plos.figshare.com/collections/Long-term_outcomes_of_survivors_of_neonatal_insults_A_systematic_review_and_meta-analysis/4952631,http://dx.doi.org/10.1371/journal.pone.0231947,32330163,10.1371/journal.pone.0231947,3018515414,PMC7182387,0,000-218-288-391-903; 000-886-989-019-681; 001-097-319-691-30X; 002-345-782-535-700; 003-427-304-555-235; 004-020-867-860-550; 004-113-618-574-003; 004-376-200-438-084; 004-729-720-365-799; 005-736-858-430-751; 006-579-930-807-411; 007-112-273-092-619; 009-473-203-900-146; 011-155-049-992-756; 011-241-082-581-888; 012-976-177-300-00X; 013-248-034-937-880; 015-676-312-520-051; 018-334-109-548-429; 018-846-424-864-914; 019-945-818-467-09X; 020-591-759-636-665; 020-673-405-216-742; 022-428-495-778-047; 023-074-148-661-363; 023-748-185-998-799; 024-217-191-444-251; 027-963-977-319-667; 029-043-002-236-299; 029-863-270-644-436; 030-799-554-128-187; 031-485-759-507-484; 034-195-126-622-187; 036-191-311-207-166; 036-219-257-462-052; 037-972-350-952-888; 039-366-386-271-753; 040-313-021-390-684; 041-124-523-670-495; 041-425-390-246-306; 041-811-933-285-009; 044-835-414-510-839; 049-693-575-342-224; 050-667-952-139-202; 050-979-152-331-004; 051-891-521-956-975; 052-831-040-301-259; 056-475-346-224-61X; 060-977-729-358-150; 061-130-031-506-353; 063-016-206-092-425; 063-020-483-479-726; 064-745-979-133-23X; 067-292-000-919-34X; 067-713-222-125-425; 074-869-013-661-971; 075-040-085-849-043; 076-478-016-848-031; 077-194-634-396-177; 083-277-961-257-386; 088-298-066-209-059; 093-190-379-509-85X; 094-011-469-773-937; 095-313-539-832-892; 096-132-407-563-727; 096-678-727-677-015; 096-983-857-815-587; 100-924-190-569-623; 101-396-202-872-452; 102-727-603-651-546; 103-417-728-538-021; 104-267-394-988-537; 105-091-341-667-078; 106-251-535-999-413; 107-166-766-248-81X; 109-477-124-901-937; 112-257-090-672-681; 123-186-076-532-862; 126-134-064-142-829; 140-122-043-195-55X; 142-112-154-141-363; 150-682-759-971-962; 160-950-839-229-320; 165-024-984-029-316; 181-666-014-650-616,2
016-598-600-357-16X,The study of institutional entrepreneurship and its implications for transition studies,,2020,journal article,Environmental Innovation and Societal Transitions,22104224,Elsevier BV,Netherlands,Marjolein J. Hoogstraaten; Koen Frenken; Wouter Boon,"Abstract Innovations accompanying transitions often prompt institutional change if they do not match with existing institutions. Transition studies started to incorporate institutional dynamics into their research, but efforts hitherto remain underdeveloped. In this paper, we systematically review the institutional entrepreneurship literature. Based on a reading of 153 empirical cases, we identify trends and biases in the literature and we distil a number of insights for transition studies to engage with.",36,,114,136,Positive economics; Political science; Transition (fiction); Institutional change; Institutional entrepreneurship; Reading (process),,,,NWO Vici programme,https://www.sciencedirect.com/science/article/abs/pii/S221042242030085X https://www.sciencedirect.com/science/article/pii/S221042242030085X,http://dx.doi.org/10.1016/j.eist.2020.05.004,,10.1016/j.eist.2020.05.004,3036018084,,0,000-328-340-053-328; 000-465-780-824-211; 001-320-563-566-69X; 002-342-495-551-237; 002-364-939-308-21X; 004-048-495-317-411; 007-270-189-300-511; 007-992-334-266-167; 008-112-394-395-874; 008-955-759-789-223; 011-199-026-370-617; 011-614-638-618-922; 012-831-679-884-394; 013-326-997-518-006; 015-271-876-692-523; 017-667-836-978-520; 018-329-600-843-843; 019-071-923-404-723; 019-130-183-390-983; 019-296-033-505-079; 019-976-409-408-648; 020-223-980-520-232; 020-955-929-008-907; 021-484-587-106-854; 021-682-525-378-640; 021-920-320-996-075; 021-962-494-509-48X; 022-512-643-506-628; 023-816-058-843-198; 024-436-210-528-646; 025-713-634-964-694; 026-562-998-167-910; 026-689-839-653-135; 031-259-317-935-208; 031-315-873-822-160; 034-369-893-576-254; 034-863-562-969-751; 035-420-083-809-746; 035-704-001-449-05X; 035-708-589-006-492; 036-710-174-141-966; 040-117-023-931-503; 042-654-900-327-92X; 044-861-777-637-635; 045-208-395-386-425; 046-426-535-214-177; 046-714-111-439-221; 047-545-845-603-280; 049-672-349-289-493; 049-690-346-541-656; 051-821-509-638-284; 054-733-622-133-834; 054-832-675-717-837; 056-256-742-618-514; 056-683-219-436-173; 057-734-908-951-561; 058-727-268-213-886; 058-915-584-946-625; 059-304-582-212-779; 059-354-276-889-146; 061-178-949-347-862; 062-065-250-177-033; 064-886-413-583-046; 066-552-063-508-398; 066-796-775-584-015; 070-048-400-986-369; 070-725-036-848-255; 070-918-727-528-227; 070-937-693-897-246; 071-237-537-299-980; 072-108-180-474-63X; 072-184-888-183-066; 074-029-940-370-938; 075-360-971-486-50X; 075-636-596-178-023; 075-743-770-289-057; 078-141-172-518-826; 079-084-970-607-557; 079-877-967-594-740; 080-009-469-215-125; 080-737-325-680-402; 081-069-471-541-887; 085-908-208-288-861; 086-133-242-674-622; 087-066-904-150-131; 087-785-915-857-15X; 089-139-642-815-099; 089-779-162-179-260; 090-180-088-401-699; 091-094-910-756-837; 092-163-899-683-456; 093-203-637-527-381; 095-088-408-219-846; 095-449-933-020-30X; 096-150-888-610-596; 099-715-180-361-939; 101-019-389-626-02X; 101-230-028-229-380; 102-082-995-943-197; 104-286-041-491-051; 106-182-100-214-684; 106-920-839-646-292; 109-204-687-980-153; 113-078-996-526-835; 115-287-136-422-693; 115-482-499-323-938; 116-216-753-391-384; 118-561-638-482-889; 118-664-672-714-809; 118-716-466-075-980; 120-320-816-469-383; 121-340-017-801-647; 122-961-857-357-786; 123-694-573-650-975; 123-910-495-659-571; 129-373-092-757-713; 131-161-136-561-016; 132-456-560-601-093; 132-595-924-469-282; 133-869-596-234-08X; 134-713-265-917-084; 135-734-344-285-694; 135-800-958-786-357; 136-146-846-490-36X; 137-740-262-623-307; 137-845-509-744-030; 140-152-638-698-68X; 140-370-299-650-360; 142-618-373-268-856; 143-783-928-051-876; 145-324-871-486-034; 145-890-476-463-402; 147-286-239-982-796; 147-354-983-349-261; 149-910-587-643-589; 150-005-284-621-599; 151-097-054-357-603; 151-622-443-987-302; 153-346-851-031-427; 155-638-239-602-462; 161-858-228-065-368; 163-637-734-144-951; 168-036-345-097-619; 181-947-160-357-734,8
017-249-029-664-064,A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance.,2018-08-30,2018,journal article,"Addiction (Abingdon, England)",13600443; 09652140,Wiley-Blackwell,United Kingdom,Craig Gunn; Marlou Mackus; Christopher T. Griffin; Marcus R. Munafò; Sally Adams,"BACKGROUND AND AIMS Studies examining the next-day cognitive effects of heavy alcohol consumption have produced mixed findings, which may reflect inconsistencies in definitions of 'hangover'. Recent consensus has defined hangover as 'mental and physical symptoms, experienced the day after a single episode of heavy drinking, starting when blood alcohol concentration (BAC) approaches zero'. In light of this, we aimed to review the literature systematically to evaluate and estimate mean effect sizes of the next-day effects of heavy alcohol consumption on cognition. METHODS Embase, PubMed and PsycNET databases were searched between December 2016 and May 2018 using terms based on 'alcohol' and 'hangover'. Studies of experimental designs which reported the next-day cognitive effects of heavy alcohol consumption in a 'hangover' group with BAC < 0.02% were reviewed. A total of 805 articles were identified. Thirty-nine full-text articles were screened by two independent reviewers and 19 included in the systematic review; 11 articles provided sufficient data to be included in the meta-analysis; 1163 participants across 19 studies conducted since 1970 were included in the analysis. Data for study design, hangover severity, BAC at testing and cognitive performance were extracted and effect estimates calculated. RESULTS The systematic review suggested that sustained attention and driving abilities were impaired during hangover. Mixed results were observed for: psychomotor skills, short- (STM) and long-term memory (LTM) and divided attention. The meta-analysis revealed evidence of impairments in STM [g = 0.64, 95% confidence interval (CI) = 0.15-1.13], LTM (Hedges' g = 0.59, 95% CI = 0.01-1.17) sustained attention (g = 0.47, 95% CI = 0.07-0.87) and psychomotor speed (Hedges' g = 0.66, 95% CI = 0.31-1.00) during alcohol hangover. CONCLUSION The research literature suggests that alcohol hangovers may involve impaired cognitive functions and performance of everyday tasks such as driving.",113,12,2182,2193,Psychology; Psychomotor learning; Cognition; Effects of sleep deprivation on cognitive performance; Hangovers; Everyday tasks; Heavy drinking; Alcohol consumption; Confidence interval; Clinical psychology,Alcohol; cognition; driving; hangover; memory; psychomotor; sustained attention,"Attention; Binge Drinking/psychology; Cognition; Humans; Memory, Long-Term; Memory, Short-Term; Psychomotor Performance",,Medical Research Council (MC_UU_00011/7) United Kingdom; Medical Research Council (MR/K023195/1) United Kingdom; Economic and Social Research Council International; National Institute for Health Research International; Cancer Research UK United Kingdom; British Heart Foundation United Kingdom; United Kingdom Clinical Research Collaboration International; University of Bath (Research Studentship) International,https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.14404 https://research-information.bristol.ac.uk/en/publications/a-systematic-review-of-the-nextday-effects-of-heavy-alcohol-consumption-on-cognitive-performance(c60e3742-e8d5-4087-a586-c9788ad31b79).html https://researchportal.bath.ac.uk/en/publications/a-systematic-review-of-the-next-day-effects-of-heavy-alcohol-cons https://onlinelibrary.wiley.com/doi/full/10.1111/add.14404 https://research-information.bris.ac.uk/files/168632323/Gunn_et_al_2018_Addiction.pdf https://europepmc.org/article/MED/30144191 https://pubmed.ncbi.nlm.nih.gov/30144191/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282576 https://research-information.bris.ac.uk/en/publications/a-systematic-review-of-the-next-day-effects-of-heavy-alcohol-cons https://www.ncbi.nlm.nih.gov/pubmed/30144191 https://research-information.bris.ac.uk/en/publications/a-systematic-review-of-the-nextday-effects-of-heavy-alcohol-consumption-on-cognitive-performance(c60e3742-e8d5-4087-a586-c9788ad31b79).html https://core.ac.uk/download/161257769.pdf,http://dx.doi.org/10.1111/add.14404,30144191,10.1111/add.14404,2888543336,PMC6282576,0,002-173-379-145-245; 003-707-257-032-269; 003-937-091-681-317; 004-723-245-051-397; 004-819-630-686-619; 005-628-309-225-319; 007-660-539-879-388; 008-405-099-135-673; 009-333-763-518-442; 009-883-912-063-549; 010-157-441-631-034; 015-285-316-118-651; 015-538-235-548-783; 017-249-029-664-064; 017-607-259-312-117; 019-849-386-789-887; 021-646-280-540-794; 021-927-108-893-417; 023-421-643-638-180; 025-142-507-817-732; 025-422-922-855-310; 027-031-796-233-602; 027-176-456-472-68X; 027-949-554-566-93X; 028-887-226-471-347; 029-641-992-522-189; 030-425-337-421-604; 030-523-797-410-77X; 031-595-067-730-674; 031-679-847-128-260; 032-495-583-839-033; 033-038-415-022-115; 033-480-641-539-085; 034-684-327-264-694; 039-313-693-278-032; 040-161-262-438-028; 040-222-874-729-009; 041-262-508-335-635; 042-115-916-591-159; 044-864-697-492-898; 044-884-888-181-951; 052-189-543-995-824; 053-349-500-755-114; 053-832-882-255-472; 054-047-015-062-683; 057-053-020-945-608; 057-354-239-780-173; 058-276-964-132-326; 059-974-420-485-224; 061-217-837-432-471; 062-120-895-775-574; 062-904-552-996-995; 064-952-574-886-075; 069-720-717-438-704; 070-728-588-840-909; 071-297-378-312-694; 072-476-068-915-908; 075-884-395-855-131; 079-471-724-863-387; 081-170-162-273-467; 082-645-504-861-588; 084-268-085-429-337; 085-281-414-960-050; 088-966-625-129-321; 089-124-656-393-710; 090-657-770-189-593; 091-004-717-687-903; 092-982-274-589-450; 096-483-994-043-869; 099-598-059-858-898; 100-607-293-075-459; 100-829-046-115-525; 101-507-364-241-046; 103-704-284-863-553; 105-503-021-503-048; 112-109-425-814-422; 113-654-298-325-350; 115-233-552-934-889; 115-362-077-317-195; 124-670-429-927-44X; 127-734-166-638-521; 148-580-710-007-110; 154-464-650-152-648; 155-585-029-908-109; 163-094-748-806-583; 167-479-509-197-795; 168-156-108-468-865; 186-086-643-200-846; 191-359-425-296-781,47
017-805-104-132-741,Accuracy of Tissue and Sonication Fluid Sampling for the Diagnosis of Fracture-Related Infection: A Systematic Review and Critical Appraisal.,2018-08-10,2018,journal article,Journal of bone and joint infection,22063552,Copernicus GmbH,Germany,Jolien Onsea; Melissa Depypere; Geertje A M Govaert; Richard Kuehl; Thomas Vandendriessche; Mario Morgenstern; Martin A. McNally; Andrej Trampuz; Willem-Jan Metsemakers,"Introduction: Intraoperatively obtained peri-implant tissue cultures remain the standard for diagnosis of fracture-related infection (FRI), although culture-negative cases may complicate treatment decisions. This paper reviews the evidence on sonication fluid and tissue sampling for the diagnosis of FRI. Methods: A comprehensive search in Pubmed, Embase and Web-of-Science was carried out on April 5, 2018, to identify diagnostic validation studies regarding sonication fluid and tissue sampling for FRI. Results: Out of 2624 studies, nine fulfilled the predefined inclusion criteria. Five studies focused on sonication fluid culture, two on PCR and two on histopathology. One additional histopathology study was found after screening of reference lists. There is limited evidence that sonication fluid culture may be a useful adjunct to conventional tissue culture, but no strong evidence that it is superior or can replace tissue culture. Regarding molecular techniques and histopathology the evidence is even less clear. Overall, studies had variable 'gold standard' criteria for comparison and poorly reported culture methods. Conclusions: Scientific evidence on sonication fluid and tissue sampling, including culture, molecular techniques and histopathology for the diagnosis of FRI is scarce. It is imperative that laboratory protocols become standardized and uniform diagnostic criteria, as recently published in a consensus definition, be implemented.",3,4,173,181,Sonication; Radiology; Critical appraisal; Sampling (medicine); Tissue sampling; Limited evidence; Gold standard (test); Histopathology; Medicine; Tissue culture,Fracture-related infection; diagnosis; histopathology; sonication; systematic review; tissue sampling,,,,https://jbji.copernicus.org/articles/3/173/2018/jbji-3-173-2018.pdf https://europepmc.org/article/MED/30155402 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098816 https://pubmed.ncbi.nlm.nih.gov/30155402/ https://lirias.kuleuven.be/retrieve/575505 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098816 https://jbji.copernicus.org/articles/3/173/2018/,http://dx.doi.org/10.7150/jbji.27840,30155402,10.7150/jbji.27840,2888785474,PMC6098816,0,002-444-642-067-136; 002-699-039-985-826; 002-983-948-922-548; 003-501-657-731-858; 006-140-589-532-416; 010-858-399-308-453; 011-400-873-371-399; 013-720-071-133-685; 019-665-391-461-513; 024-525-955-633-760; 027-893-644-704-726; 034-302-325-247-851; 042-420-295-455-736; 047-238-560-598-852; 054-086-824-933-161; 054-170-793-294-222; 059-556-850-742-09X; 060-516-675-876-873; 060-631-336-219-83X; 083-103-067-235-027; 083-396-812-791-800; 084-906-951-717-102; 088-588-329-105-303; 101-741-963-996-833; 102-893-086-669-919; 108-537-726-910-764; 114-755-145-398-654; 119-334-454-557-424; 122-030-424-498-094; 139-859-818-221-612; 143-770-681-046-81X; 188-255-248-084-379,19
017-900-945-434-221,Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review,2015-08-07,2015,journal article,PloS one,19326203,Public Library of Science,United States,Alberto Maino; Frits R. Rosendaal; Ale Algra; Flora Peyvandi; Bob Siegerink,"Background and Purpose: Hypercoagulability increases the risk of arterial thrombosis; however, this effect may differ between various manifestations of arterial disease. Methods: In this study, we compared the effect of coagulation factors asmeasures of hypercoagulability on the risk of ischaemic stroke (IS) and myocardial infarction (MI) by performing a systematic review of the literature. The effect of a risk factor on IS (relative risk for IS, RR IS ) was compared with the effect on MI (RR MI ) by calculating their ratio (RRR = RR IS /RR MI ). A relevant differential effect was considered when RRR was >1+ its own standard error (SE) or 1+1SE) was found in 49/343 (14%) markers. Of these, 18/49 (37%) had an RRR greater than 1+2SE. On the opposite side, a larger effect on MI risk (RRR<1-1SE) was found in only 17/343 (5%) markers. Conclusions: These results suggest that hypercoagulability has a more pronounced effect on the risk of IS than that of MI.",10,8,1,12,Internal medicine; Surgery; Cardiology; Brain ischemia; Thrombophilia; Thrombosis; Myocardial infarction; Risk factor; Stroke; Medicine; Relative risk; Meta-analysis,,Biomarkers/metabolism; Brain Ischemia/etiology; Humans; Myocardial Infarction/etiology; Risk Factors; Stroke/etiology; Thrombophilia/complications; Thrombosis/complications,Biomarkers,,https://paperity.org/p/73825602/hypercoagulability-is-a-stronger-risk-factor-for-ischaemic-stroke-than-for-myocardial https://doaj.org/article/610b49d828a248959939a179d92cdc0a https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F332037 https://air.unimi.it/handle/2434/429876 http://ui.adsabs.harvard.edu/abs/2015PLoSO..1033523M/abstract https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133523 http://www.ncbi.nlm.nih.gov/pubmed/26252207 https://moh-it.pure.elsevier.com/en/publications/hypercoagulability-is-a-stronger-risk-factor-for-ischaemic-stroke https://dx.plos.org/10.1371/journal.pone.0133523 http://dspace.library.uu.nl/handle/1874/332037 https://pubmed.ncbi.nlm.nih.gov/26252207/ https://europepmc.org/articles/PMC4529149 https://core.ac.uk/display/39823679,http://dx.doi.org/10.1371/journal.pone.0133523,26252207,10.1371/journal.pone.0133523,1895839389,PMC4529149,0,002-233-086-433-472; 004-206-092-832-524; 005-315-904-087-670; 010-015-439-704-456; 012-485-419-272-894; 017-300-737-144-757; 017-397-833-762-727; 032-702-052-201-734; 034-283-281-639-077; 037-877-279-379-664; 048-873-934-069-111; 050-608-773-596-459; 052-299-539-937-709; 054-503-956-988-740; 060-741-001-149-515; 060-910-632-783-525; 070-972-987-296-642; 075-791-318-553-76X; 097-079-061-756-834; 103-111-346-572-644; 108-660-847-199-001; 125-297-092-810-572; 133-089-408-887-124; 169-520-852-042-285,46
020-206-392-856-827,The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis.,2018-01-10,2018,journal article,NPJ schizophrenia,2334265x,Springer Science and Business Media LLC,United States,Janna de Boer; Merel Prikken; Wan U. Lei; Marieke J.H. Begemann; Iris E. C. Sommer,"Recognizing the robust sex differences in schizophrenia prevalence, the selective estrogen receptor modulator (SERM) raloxifene is a likely candidate for augmentation therapy in this disorder. Therefore, a systematic search was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Randomized controlled trials investigating the effect of raloxifene in schizophrenia spectrum disorders were included in the quantitative analyses. Outcome measures were psychotic symptom severity, depression, and cognition. Meta-analyses were performed using Comprehensive Meta-Analysis software. A random-effects model was used to compute overall weighted effect sizes in Hedges’ g. Nine studies were included, investigating 561 patients with a schizophrenia spectrum disorder. Raloxifene was superior to placebo in improving total symptom severity (N = 482; Hedge’s g = .57, p = 0.009), as well as positive (N = 561; Hedge’s g = 0.32, p = 0.02), negative (N = 561; Hedge’s g = 0.40, p = 0.02), and general (N = 526; Hedge’s g = 0.46, p = 0.01) subscales, as measured by the Positive and Negative Syndrome Scale. No significant effects were found for comorbid depression and cognitive functioning. Altogether, these results confirm the potential of raloxifene augmentation in the treatment of schizophrenia.",4,1,1,6,Internal medicine; Randomized controlled trial; Systematic review; Placebo-controlled study; Raloxifene; Positive and Negative Syndrome Scale; Sex differences in schizophrenia; Medicine; Schizophrenia; Meta-analysis,,,,,https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F705141e1-03fc-48db-8415-40c79e4de8d4 https://europepmc.org/articles/PMC5762671 https://www.nature.com/articles/s41537-017-0043-3 https://www.ncbi.nlm.nih.gov/pubmed/29321530 https://www.nature.com/articles/s41537-017-0043-3.pdf https://pubmed.ncbi.nlm.nih.gov/29321530/ https://www.rug.nl/research/portal/files/71240608/s41537_017_0043_3.pdf,http://dx.doi.org/10.1038/s41537-017-0043-3,29321530,10.1038/s41537-017-0043-3,2782018768,PMC5762671,0,000-671-138-341-367; 000-924-183-805-215; 003-584-581-932-499; 005-108-855-637-645; 007-029-154-980-982; 008-249-741-002-72X; 009-277-168-214-862; 010-551-630-294-562; 014-008-294-109-452; 014-060-517-338-948; 016-614-816-658-292; 020-597-504-143-92X; 024-175-418-528-888; 025-794-418-998-985; 030-439-908-802-900; 034-600-684-728-898; 035-774-740-028-80X; 037-357-016-440-970; 039-618-939-561-434; 040-531-955-988-810; 041-846-172-431-218; 042-436-490-010-595; 042-895-126-343-062; 047-260-716-087-452; 047-476-598-163-364; 054-083-401-298-625; 060-535-902-413-363; 067-715-519-706-692; 069-186-391-806-839; 070-734-451-127-257; 074-268-727-018-028; 079-179-376-032-916; 080-336-295-340-812; 092-424-805-324-931; 100-747-195-482-24X; 106-956-198-838-204; 120-754-396-770-484; 129-505-832-031-881; 131-423-542-523-282; 137-910-793-895-079; 138-937-665-177-503; 154-160-285-426-117; 163-255-475-344-807; 173-390-710-223-111,33
020-544-765-969-94X,(In)comparability of Carotid Artery Stent Characteristics: A Systematic Review on Assessment and Comparison with Manufacturer Data,2020-05-14,2020,journal article,Cardiovascular and interventional radiology,1432086x; 01741551; 74155101,Springer Verlag,Germany,Evelien E. de Vries; Mert Kök; Astrid M. Hoving; Cornelis H. Slump; Raechel J. Toorop; Gert J. de Borst,"Carotid stent (CS) characteristics, such as radial force, scaffolding and flexibility, are continuously modified by stent manufacturers aiming to improve stent performance. Since manufacturers’ definitions and assessment methods are not disclosed, it is unknown how characteristics of different CSs relate to each other or to published literature. We examined in vitro methodological techniques used to measure CS characteristics and assessed comparability between published papers and outcomes as provided by the manufacturers. A systematic review was conducted in MEDLINE, Embase, Cochrane, and Scopus databases. Studies reporting on in vitro investigations of predefined characteristics of CS used in current everyday clinical practice were included. The predefined characteristics were radial force, scaffolding, flexibility, foreshortening, side-branch preservation and visibility. Eight manufacturers of 10 currently used CS were contacted and data on the predefined device characteristics was requested. 12 published articles were included and six stent manufacturers provided data on six stents (two refused to share data). Used methodologies to measure stent characteristics in published literature and manufacturer data varied greatly for all included characteristics except foreshortening. The number of different units of measurement to express outcomes ranged from two for foreshortening to six for radial force. A variety of methodologies and outcome measures is used to quantify CS characteristics, which hampers comparisons between published studies and manufacturer data. Future studies are encouraged to synchronize methodologies and outcome measures. Manufacturers are encouraged up to increase transparency of applied testing methodologies and outcomes.",43,10,1430,1437,Medical physics; Comparability; Radial Force Variation; Stent; MEDLINE; Carotid arteries; Future studies; Assessment methods; Outcome measures; Medicine,Carotid artery stent; Carotid stenosis; In vitro testing; Mechanical behavior; Systematic review,"Carotid Arteries; Carotid Stenosis/surgery; Commerce; Humans; In Vitro Techniques; Prosthesis Design; Stents; Technology Assessment, Biomedical; Treatment Outcome",,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524852 https://link.springer.com/article/10.1007/s00270-020-02499-1 https://www.narcis.nl/publication/RecordID/oai%3Aris.utwente.nl%3Apublications%2F8c5752c3-369d-4179-b092-4b5008c4436d https://pubmed.ncbi.nlm.nih.gov/32409999/ https://research.utwente.nl/en/publications/incomparability-of-carotid-artery-stent-characteristics-a-systema https://link.springer.com/content/pdf/10.1007/s00270-020-02499-1.pdf,http://dx.doi.org/10.1007/s00270-020-02499-1,32409999,10.1007/s00270-020-02499-1,3024521840,PMC7524852,0,001-180-986-338-929; 001-829-020-418-692; 012-539-842-497-557; 014-431-593-249-189; 016-755-788-794-295; 016-962-741-229-645; 028-058-613-721-58X; 036-676-496-518-432; 042-206-346-227-964; 047-573-726-498-180; 055-138-757-369-588; 057-435-622-999-092; 064-456-411-926-834; 069-680-262-027-285; 089-324-002-434-911; 102-045-611-710-368; 114-664-321-574-060; 126-141-954-363-127; 155-431-995-017-594,2
021-366-327-335-290,Anti‐platelet antibody immunoassays in childhood immune thrombocytopenia: a systematic review,2020-02-20,2020,journal article,Vox sanguinis,14230410; 00429007,Wiley-Blackwell,United Kingdom,David E. Schmidt; Anke J. Lakerveld; Katja M. J. Heitink-Pollé; Marrie C. A. Bruin; Gestur Vidarsson; Leendert Porcelijn; Masja de Haas,"Background In adult immune thrombocytopenia (ITP), an acquired autoimmune bleeding disorder, anti-platelet autoantibody testing may be useful as a rule-in test. Childhood ITP has different disease characteristics, and the diagnostic and prognostic value of anti-platelet antibody testing remains uncertain. Objective To systematically review the diagnostic accuracy of anti-platelet autoantibody testing in childhood ITP. Methods PubMed and EMBASE were searched for studies evaluating immunoassays in childhood ITP. Study quality was assessed (QUADAS2), and evidence was synthesized descriptively. Results In total, 40 studies (1606 patients) were identified. Nine studies reported sufficient data to determine diagnostic accuracy measures. Anti-platelet IgG antibody testing showed a moderate sensitivity (0·36-0·80 platelet-associated IgG [direct test]; 0·19-0·39 circulating IgG [indirect test]). In studies that reported control data, including patients with non-immune thrombocytopenia, specificity was very good (0·80-1·00). Glycoprotein-specific immunoassays showed comparable sensitivity (three studies) and predominantly identified IgG anti-GP IIb/IIIa antibodies, with few IgG anti-GP Ib/IX antibodies. Anti-platelet IgM antibodies were identified in a substantial proportion of children (sensitivity 0·62-0·64 for direct and indirect tests). Conclusion The diagnostic evaluation of IgG and IgM anti-platelet antibodies may be useful as a rule-in test for ITP. In children with insufficient platelets for a direct test, indirect tests may be performed instead. A negative test does not rule out the diagnosis of ITP. Future studies should evaluate the value of anti-platelet antibody tests in thrombocytopenic children with suspected ITP.",115,4,323,333,Antibody; Autoantibody; Immunology; Anti-platelet antibody; Future studies; Immune thrombocytopenia; Igm antibody; Control data; Medicine; Platelet,autoantibodies; clinical laboratory techniques; immune thrombocytopenia; paediatrics; systematic review,"Autoantibodies/immunology; Child; Humans; Immunoassay/methods; Platelet Glycoprotein GPIIb-IIIa Complex/immunology; Platelet Glycoprotein GPIb-IX Complex/immunology; Purpura, Thrombocytopenic, Idiopathic/blood; Sensitivity and Specificity; Serologic Tests/methods",Autoantibodies; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Glycoprotein GPIb-IX Complex,Landsteiner Foundation for Blood Transfusion Research; Studienstiftung des Deutschen Volkes,https://onlinelibrary.wiley.com/doi/10.1111/vox.12894 https://pubmed.ncbi.nlm.nih.gov/32080872/ https://europepmc.org/article/MED/32080872 https://www.ncbi.nlm.nih.gov/pubmed/32080872 https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F3f723d08-6de0-47db-a39a-7bc880eb50b0,http://dx.doi.org/10.1111/vox.12894,32080872,10.1111/vox.12894,3006996166,PMC7317748,0,001-022-126-684-895; 002-405-617-585-829; 002-568-796-008-774; 003-155-679-189-706; 005-028-919-140-807; 006-819-352-535-441; 007-823-620-448-386; 008-580-435-109-166; 008-947-574-153-130; 009-408-127-206-61X; 012-656-152-996-44X; 013-227-884-988-235; 013-303-182-007-131; 013-327-503-673-87X; 013-353-959-799-832; 017-591-757-924-470; 022-807-292-561-008; 024-831-682-371-050; 026-193-108-885-603; 026-933-121-508-571; 027-411-155-574-719; 027-597-363-111-805; 029-770-402-669-588; 034-932-150-094-393; 040-859-940-580-838; 044-055-655-737-121; 044-121-101-160-749; 044-140-343-247-744; 045-684-372-531-228; 047-099-838-258-215; 047-463-614-725-986; 050-056-264-222-480; 052-732-633-973-129; 057-075-056-237-870; 059-768-794-254-423; 059-849-592-282-770; 061-617-601-642-045; 071-086-122-068-608; 072-789-186-145-606; 075-568-583-305-626; 075-685-480-979-241; 094-477-701-400-460; 104-431-533-479-137; 109-147-322-463-446; 109-276-777-078-887; 116-551-473-751-515; 121-981-670-804-322; 124-227-964-539-768; 124-995-344-436-604; 127-441-767-426-664; 139-160-208-284-641; 147-189-191-237-142; 149-256-199-990-85X; 149-421-907-474-87X; 189-902-822-466-019,5
023-029-695-165-796,Biochemical marker research in hemophilic arthropathy: A systematic review.,2020-11-22,2020,journal article,Blood reviews,15321681; 0268960x,Churchill Livingstone,United States,E.D.P. van Bergen; L. F. D. van Vulpen; Roger E. G. Schutgens; Simon C. Mastbergen; F.P.J.G. Lafeber,"Abstract Hemophilic arthropathy (HA) causes major morbidity. Breakthrough therapies reduce the bleeding frequency tremendously, but well-defined joint outcome assessments with a focus on early changes and subclinical damage are lacking. Biomarkers reflecting joint tissue turnover/inflammation might be useful to predict invalidating arthropathy. This systematic review summarized and categorized publications on blood/urinary biomarkers in HA to provide leads for implementation. A PubMed/EMBASE search was performed on September 9, 2019. All publications were assessed and allocated to one or several BIPED-categories, based on the utility of biomarkers. Of the initial 1307 publications found, 27 were eligible for inclusion. The majority (81%, n = 32/42) was cross-sectional in design, including relatively small numbers of patients (median 44, interquartile range 35–78). Fourteen percent (n = 6/42) investigated dynamic changes around a bleeding or treatment. Only two studies investigated the prognostic value of biomarkers. Most promising biomarkers were serum Coll2-1, COL-18N, COMP, C1,2C, C2M, CS846, MIF, plasma sVCAM-1 and urinary CTX-II. Comparing performances and pooling data was not possible due to heterogeneity. Currently, biomarker research in HA is still in an explorative stage and not yet sufficient for translation into daily practice. Clearly, larger homogeneous longitudinal studies in well-defined populations should be performed for further development.",47,,100781,,Subclinical infection; Interquartile range; Internal medicine; Stage (cooking); Arthropathy; Hemophilic arthropathy; Homogeneous; Medicine; Biomarker (medicine); Urinary system,BIPED - Hemophilic arthropathy; Biochemical markers; Inflammation; Joint tissue turnover,Biomarkers/blood; Blood Proteins/metabolism; Hemarthrosis/blood; Humans,Biomarkers; Blood Proteins,,https://www.ncbi.nlm.nih.gov/pubmed/33277057 https://www.sciencedirect.com/science/article/pii/S0268960X20301314 https://pubmed.ncbi.nlm.nih.gov/33277057/ https://www.sciencedirect.com/science/article/abs/pii/S0268960X20301314,http://dx.doi.org/10.1016/j.blre.2020.100781,33277057,10.1016/j.blre.2020.100781,3109071383,,0,002-856-769-185-763; 002-871-743-035-762; 005-811-901-443-134; 008-123-638-421-439; 009-206-441-063-885; 013-743-222-582-835; 013-958-300-203-764; 014-039-862-689-064; 016-018-366-079-793; 016-745-912-711-380; 016-989-320-255-132; 018-550-370-475-813; 018-778-275-423-389; 022-781-848-473-343; 023-257-022-682-46X; 023-307-247-617-629; 026-004-240-733-062; 026-622-557-656-323; 028-873-466-936-994; 030-708-226-957-457; 038-191-942-005-205; 039-114-893-226-083; 039-446-526-274-164; 039-682-436-747-735; 040-785-616-280-121; 046-560-073-334-031; 048-716-793-816-603; 052-728-441-298-366; 054-558-733-119-968; 055-959-359-711-665; 062-173-690-051-600; 063-407-529-614-513; 063-993-607-829-910; 075-560-942-810-637; 077-199-078-808-400; 086-782-576-973-796; 091-580-368-734-868; 096-683-881-449-754; 098-102-335-659-118; 102-012-204-461-498; 112-756-772-125-980; 116-170-384-825-966; 121-123-556-316-332; 133-333-349-844-109; 141-184-654-199-402; 147-893-007-987-904; 152-809-386-877-532; 160-592-968-724-398,2
023-346-555-303-850,A Systematic Review Comparing Experimental Design of Animal and Human Methotrexate Efficacy Studies for Rheumatoid Arthritis: Lessons for the Translational Value of Animal Studies,2020-06-17,2020,journal article,Animals : an open access journal from MDPI,20762615,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Cathalijn H. C. Leenaars; F.R. Stafleu; David de Jong; Maikel van Berlo; Tijmen Geurts; Tineke Coenen-de Roo; Jan-Bas Prins; Rosalie W. M. Kempkes; Janneke Elzinga; André Bleich; Rob B. M. de Vries; Franck L. B. Meijboom; Merel Ritskes-Hoitinga,"Increased awareness and understanding of current practices in translational research is required for informed decision making in drug development. This paper describes a systematic review of methotrexate for rheumatoid arthritis, comparing trial design between 147 animal and 512 human studies. Animal studies generally included fewer subjects than human studies, and less frequently reported randomisation and blinding. In relation to life span, study duration was comparable for animals and humans, but included animals were younger than included humans. Animal studies often comprised males only (61%), human studies always included females (98% included both sexes). Power calculations were poorly reported in both samples. Analyses of human studies more frequently comprised Chi-square tests, those of animal studies more frequently reported analyses of variance. Administration route was more variable, and more frequently reported in animal than human studies. Erythrocyte sedimentation rate and c-reactive protein were analysed more frequently in human than in animal studies. To conclude, experimental designs for animal and human studies are not optimally aligned. However, methotrexate is effective in treating rheumatoid arthritis in animal models and humans. Further evaluation of the available evidence in other research fields is needed to increase the understanding of translational success before we can optimise translational strategies.",10,6,1047,,Translational research; Animal studies; Blinding; Rheumatoid arthritis; Erythrocyte sedimentation rate; Methotrexate; Human studies; Bioinformatics; Drug development; Medicine,Systematic review; animal-to-human translation; experimental design; methotrexate; rheumatoid arthritis,,,Nederlandse Organisatie voor Wetenschappelijk Onderzoek (313-99-310); Federal State of Lower Saxony (R2N),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341304 https://repository.ubn.ru.nl/handle/2066/220843 https://www.mdpi.com/2076-2615/10/6/1047 https://www.mdpi.com/2076-2615/10/6/1047/pdf https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F220843,http://dx.doi.org/10.3390/ani10061047,32560528,10.3390/ani10061047,3036575216,PMC7341304,0,001-984-709-374-597; 002-098-852-663-228; 003-156-019-488-019; 004-031-466-608-366; 004-109-467-438-116; 004-571-965-869-525; 005-018-521-019-389; 005-253-811-731-710; 006-092-151-215-412; 008-611-134-048-549; 008-726-002-406-172; 008-964-323-115-812; 008-977-966-730-782; 010-050-479-637-079; 010-769-484-112-477; 014-926-048-063-527; 016-212-404-270-441; 016-873-527-323-417; 018-013-701-887-617; 020-186-539-743-398; 020-651-208-809-728; 020-711-986-306-395; 022-963-195-141-137; 023-346-555-303-850; 025-220-627-825-105; 035-887-149-853-336; 036-118-520-988-72X; 039-596-636-704-771; 039-886-986-885-168; 044-621-724-293-725; 045-228-776-565-003; 046-290-794-593-810; 047-650-818-647-709; 048-243-484-131-638; 049-577-686-527-75X; 051-626-737-252-988; 052-454-818-621-413; 068-432-516-040-836; 068-604-495-023-41X; 070-121-700-043-854; 075-260-855-445-622; 080-722-110-339-037; 081-292-385-055-198; 081-584-656-480-255; 086-114-066-855-809; 099-967-212-076-472; 099-997-936-336-708; 101-967-882-508-625; 114-251-883-659-335; 118-100-189-980-847; 141-901-370-557-086; 146-347-761-669-727; 150-295-674-145-864; 194-125-668-811-271,5
023-813-846-175-975,The increasing need for systematic reviews of prognosis studies: strategies to facilitate review production and improve quality of primary research.,2019-01-23,2019,journal article,Diagnostic and prognostic research,23977523,Springer Science and Business Media LLC,England,Johanna A A G Damen; Lotty Hooft,"Personalized, precision, and risk-based medicine are becoming increasingly important in medicine. These involve the use of information about the prognosis of a patient, to make individualized treatment decisions. This has led to an accumulating amount of literature available on prognosis studies. To summarize and evaluate this information overload, high-quality systematic reviews are essential, additionally helping us to facilitate interpretation and usability of prognosis study findings and to identify gaps in literature. Four types of prognosis studies can be identified: overall prognosis, prognostic factors, prognostic models, and predictors of treatment effect. Methodologists have focussed on developing methods and tools for every step of a systematic review for reviews of all four types of prognosis studies, from formulating the review question and writing a protocol to searching for studies, assessing risk of bias, meta-analysing results, and interpretation of results. The growing attention for prognosis research has led to the introduction of the Cochrane Prognosis Methods Group (PMG). Since 2016, reviews of prognosis studies are formally implemented within Cochrane. With these recent methodological developments and tools, and the implementation within Cochrane, it becomes increasingly feasible to perform high-quality reviews of prognosis studies that will have an impact on clinical practice.",3,1,1,4,Usability; Intensive care medicine; Information overload; Systematic review; Primary research; Production (economics); Quality (business); Protocol (science); Medicine; Meta-analysis,Meta-analysis; Prediction; Prognosis; Systematic review,,,Cochrane Strategic Methods Fund,https://link.springer.com/article/10.1186/s41512-019-0049-6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460843/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460843/ https://link.springer.com/content/pdf/10.1186/s41512-019-0049-6.pdf https://diagnprognres.biomedcentral.com/articles/10.1186/s41512-019-0049-6,http://dx.doi.org/10.1186/s41512-019-0049-6,31093572,10.1186/s41512-019-0049-6,2924891771,PMC6460843,0,001-625-857-182-007; 002-213-086-253-545; 002-221-487-883-994; 006-394-448-836-758; 006-787-746-859-672; 007-333-620-793-196; 012-820-517-539-279; 018-290-903-850-789; 019-035-103-991-151; 020-101-512-404-323; 023-171-734-710-29X; 025-241-633-097-960; 038-801-679-789-406; 039-117-718-377-945; 050-049-805-753-343; 062-740-099-067-478; 063-232-343-564-165; 068-774-343-037-718; 070-514-004-433-856; 071-579-150-651-820; 072-926-089-016-851; 073-932-282-959-306; 076-847-308-034-516; 077-327-880-426-403; 077-705-059-309-250; 083-961-130-929-189; 093-722-753-317-247; 114-685-179-805-480; 122-407-567-198-707; 129-171-126-831-710,6
024-827-989-561-391,The Effect of Mindfulness-Based Interventions on Tinnitus Distress. A Systematic Review,2019-11-01,2019,journal article,Frontiers in neurology,16642295,Frontiers Media S.A.,Switzerland,Maaike M. Rademaker; Inge Stegeman; Krysten E. Ho-Kang-You; Robert J. Stokroos; Adriana L. Smit,"Objectives: With this systematic review we aim to provide an overview of the evidence of the effect of Mindfulness Based Interventions (MBIs) on (1) tinnitus distress and (2) anxiety and/or depression in tinnitus patients. Methods: We conducted a systematic search in PubMed Medline, EMBASE and PsycInfo combining the terms and synonyms of ""Tinnitus"" and ""Mindfulness."" The most recent search was performed on December 4th 2018. We wrote this systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two independent authors identified studies, assessed the risk of bias and extracted data. Studies were considered eligible if they included adults with tinnitus, performed a protocolled MBI and measured tinnitus distress with validated questionnaires. Studies were appraised with either the Cochrane Risk of Bias tool or the MINORS criteria, depending on their design. Results: The systematic search yielded seven articles (425 patients). Three randomized controlled trials (RCTs), three cohort studies and one comparative controlled trial. Different types of MBIs, including MBCT and MBSR, were assessed with various questionnaires. Two of three RCTs showed a statistically significant decrease in tinnitus distress scores directly after treatment in the mindfulness group compared to the control group. Six of seven studies showed statistically significant decrease in tinnitus distress scores directly after mindfulness therapy. One of three RCTs showed a statistically significant improvement of depression questionnaire scores after MBI compared to the control group directly post treatment. Conclusions: A decrease of tinnitus distress scores in MBIs can be observed directly post-therapy based on moderate to high quality studies. This was found regardless of the heterogeneity of patients, study design, type of MBI and outcome assessment. Two out of three RCTs found clinically relevant decreases in tinnitus distress scores. No effect of MBIs was observed for depression and anxiety in tinnitus patients. Long term effects remain uncertain. Mindfulness may have a place in tinnitus therapy, although the long term effects need to be studied.",10,,1135,1135,Distress; Randomized controlled trial; Physical therapy; Systematic review; Cohort study; Tinnitus; Mindfulness; Cognitive behavioral therapy; Anxiety; Medicine,MBCT; MBSR; anxiety; cognitive behavioral therapy; depression; mindfulness; tinnitus,,,,https://pubmed.ncbi.nlm.nih.gov/31736854/ https://www.frontiersin.org/articles/10.3389/fneur.2019.01135/full https://europepmc.org/article/MED/31736854 http://www.ncbi.nlm.nih.gov/pubmed/31736854 https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F3e972117-fd3d-4652-8430-3f51a9976fb1 https://www.frontiersin.org/article/10.3389/fneur.2019.01135/full http://dspace.library.uu.nl/handle/1874/391621 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838968/,http://dx.doi.org/10.3389/fneur.2019.01135,31736854,10.3389/fneur.2019.01135,2983223814,PMC6838968,0,000-124-011-821-045; 000-468-840-056-255; 003-881-345-726-790; 003-980-049-737-149; 006-963-705-660-659; 007-040-341-856-896; 008-641-346-803-865; 008-958-107-619-839; 010-367-729-210-840; 012-418-855-689-67X; 012-606-455-094-624; 012-755-130-604-146; 014-091-174-900-426; 017-257-367-182-092; 020-555-614-481-027; 022-468-187-442-804; 022-593-603-103-653; 024-176-663-256-446; 025-387-212-092-16X; 027-423-013-331-613; 028-726-698-945-494; 029-674-690-216-320; 032-817-299-114-528; 037-565-187-791-907; 038-728-607-589-394; 044-667-981-035-325; 048-532-922-828-357; 055-421-248-554-551; 059-029-632-199-880; 060-601-435-955-616; 060-606-599-347-361; 062-092-252-679-380; 067-125-677-552-393; 070-081-205-073-761; 077-777-794-414-172; 083-053-822-459-559; 089-628-065-749-657; 090-964-981-345-357; 093-864-197-011-24X; 098-141-236-570-806; 101-909-168-720-842; 103-195-793-648-138; 103-585-492-548-890; 104-176-558-915-016; 109-549-716-941-588; 115-581-954-561-940; 149-886-167-383-269; 154-216-318-305-152,11
025-077-119-523-734,"Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.",2021-03-29,2021,journal article,Frontiers in psychiatry,16640640,Frontiers Media S.A.,Switzerland,Marius H Sneller; Nini de Boer; Sophie Everaars; Max Schuurmans; Sinan Guloksuz; Wiepke Cahn; Jurjen J. Luykx,"Background: Individuals with severe mental illness experience increased morbidity and mortality compared to the general population. Adverse effects of antipsychotics, including weight gain, may contribute to the development of metabolic syndrome (MetS), which is associated with increased risks of all-cause and cardiovascular disease mortality. We aim to provide a comprehensive overview of clinical, biochemical and genetic factors associated with MetS among patients with schizophrenia spectrum disorders using second-generation antipsychotics (SGA). Methods: A literature search was performed in Pubmed and Embase to identify all cohort studies, cross-sectional studies and clinical trials investigating associations with MetS in patients with schizophrenia spectrum disorders using SGAs. We extracted and enumerated clinical, biochemical and genetic factors reported to be associated with MetS. We defined factors associated with MetS as factors being reported as associated with MetS in two or more studies. Results: 58 studies were included in this review (n = 12,123). In total, 62 factors were found to be associated with increased risk of MetS. Thirty one out of 58 studies investigated factors that were reported as associated with MetS in two or more studies. With regard to clinical factors, we found gender, higher age, concomitant use of mood stabilizers, higher baseline and current BMI, earlier SGA exposure, higher dose, longer duration of treatment, psychosis and tobacco smoking to be significantly associated with MetS. Furthermore, the biochemical factors hypo-adiponectinemia, elevated levels of C-reactive protein (CRP) and higher white blood cell (WBC) count were identified as factors associated with MetS. Among pharmacogenetic factors, the rs1414334 C-allele of the HTR2C-gene was associated with MetS in patients using SGA. Conclusion: In this systematic review investigating clinical, biochemical and genetic factors associated with MetS in patients using SGAs we found that higher age, higher baseline BMI, higher current BMI and male as well as female gender were positively associated with MetS across all antipsychotics. This study may set the stage for the application of clinical, biochemical and genetic factors to predict the risk of developing MetS in patients using SGAs. Future research is needed to determine which patients using SGAs are at risk to develop MetS in clinical practice.",12,,625935,625935,Internal medicine; Adverse effect; Cohort study; Psychosis; Metabolic syndrome; Population; Clinical trial; Pharmacogenetics; Medicine; Schizophrenia,antipsychotics; metabolic syndrome; psychotic spectrum disorder; schizophrenia; systematic review,,,,https://pubmed.ncbi.nlm.nih.gov/33868046/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044798 https://europepmc.org/article/PMC/PMC8044798 https://www.frontiersin.org/articles/10.3389/fpsyt.2021.625935/full,http://dx.doi.org/10.3389/fpsyt.2021.625935,33868046,10.3389/fpsyt.2021.625935,3147960047,PMC8044798,0,000-216-260-272-874; 000-663-148-160-439; 001-385-276-592-649; 001-595-167-857-535; 001-629-056-477-268; 001-657-703-069-219; 001-805-010-243-992; 004-524-034-781-726; 005-479-259-096-945; 005-695-441-785-620; 006-993-410-656-115; 010-339-961-017-502; 010-494-755-936-575; 010-908-919-680-64X; 011-488-768-084-856; 012-115-230-567-068; 012-156-177-943-837; 013-055-765-239-305; 013-675-756-928-835; 016-297-343-806-219; 016-303-357-971-782; 016-324-861-872-137; 017-974-202-387-227; 018-024-316-987-447; 019-984-953-420-165; 020-506-305-821-701; 021-136-518-742-506; 021-944-720-672-500; 022-565-910-227-922; 023-835-683-749-694; 025-631-041-529-903; 025-751-867-803-16X; 026-410-311-164-682; 026-995-610-170-106; 027-191-131-539-300; 027-289-657-987-963; 027-985-430-870-508; 027-993-149-567-013; 029-159-775-170-468; 029-164-123-471-683; 030-236-798-238-551; 030-593-186-464-369; 031-497-402-641-638; 031-825-056-909-805; 032-828-746-165-356; 035-480-923-234-442; 035-703-188-167-778; 036-173-553-979-637; 036-904-014-788-360; 037-182-191-062-688; 037-941-955-550-871; 038-499-353-688-125; 039-459-342-562-367; 039-620-865-099-031; 042-788-079-771-801; 044-321-509-630-86X; 044-482-294-618-78X; 044-994-670-926-575; 045-966-552-275-829; 048-310-550-318-36X; 049-088-218-611-574; 051-064-082-471-394; 051-815-566-037-839; 052-499-468-276-54X; 052-776-750-756-056; 053-380-315-912-38X; 053-481-170-561-955; 053-638-126-992-443; 054-077-659-255-71X; 054-389-889-339-428; 055-634-719-268-877; 057-746-560-039-130; 057-922-596-388-850; 058-923-723-287-157; 059-744-410-736-313; 060-838-068-528-529; 061-148-843-206-474; 061-149-748-966-234; 062-169-027-021-059; 062-381-659-310-068; 062-729-553-023-620; 064-694-327-849-147; 066-908-191-951-102; 070-296-545-990-88X; 073-769-097-904-39X; 078-563-973-457-20X; 078-794-508-273-913; 078-854-664-170-838; 081-923-165-710-152; 082-111-716-369-126; 083-176-213-625-718; 083-282-252-183-19X; 083-872-324-574-852; 084-230-550-506-091; 085-032-066-524-254; 087-720-013-810-70X; 089-458-285-543-299; 090-009-283-057-272; 092-992-482-277-055; 093-141-573-654-435; 093-905-712-292-583; 096-273-407-609-237; 096-714-809-509-184; 097-860-136-440-304; 098-135-070-983-449; 099-883-114-833-005; 100-217-669-863-418; 104-070-416-159-977; 107-626-322-903-160; 114-323-453-259-120; 114-919-663-533-13X; 120-094-346-045-443; 121-798-746-560-657; 125-307-761-936-647; 126-864-443-697-706; 129-918-296-757-325; 133-148-937-286-911; 134-392-579-099-331; 142-145-914-812-950; 159-874-158-457-291; 161-101-075-403-64X; 164-474-659-842-241; 182-071-680-683-202; 190-460-621-071-336; 195-667-539-335-515,0
026-083-025-635-660,A systematic review of indicators to assess the sustainability of road infrastructure projects,2020-04-03,2020,journal article,European Transport Research Review,18670717; 18668887,Springer Science and Business Media LLC,Germany,Gede B. Suprayoga; Martha M. Bakker; Patrick Witte; Tejo Spit,"This study aims to examine to what extent sustainability has been incorporated into assessments of road infrastructure projects. It identifies promising approaches that include indicators reflecting core sustainability criteria, determines criteria that were insufficiently covered as indicators, and develops an integrated indicator set covering all criteria. A systematic review was performed to obtain all related papers/reports in two academic databases: Scopus and Web of Sciences. The indicators extracted from papers/reports were first coded, then evaluated by using quantitative and qualitative content analysis. The project appraisal methods for decision-making is found to be a promising approach, covering more extensive criteria than others. Two criteria – namely adaptation and precaution and intergenerational equity – were hardly ever adopted as indicators. Ten main groups of indicators were extracted to construct an integrated set incorporating all core criteria. Some criteria appear to have become mainstream, while others deserve attention. The safest choice is to combine methods/tools or to adopt the integrated set developed for exhaustive criteria inclusion.",12,1,1,15,Impact assessment; Cost–benefit analysis; Construct (philosophy); Process management; Project appraisal; Intergenerational equity; Computer science; Sustainable development; Sustainability; Scopus,,,,LPDP,"https://link.springer.com/content/pdf/10.1186/s12544-020-0400-6.pdf https://link.springer.com/article/10.1186/s12544-020-0400-6 https://trid.trb.org/view/1720877 https://www.narcis.nl/publication/RecordID/oai%3Alibrary.wur.nl%3Awurpubs%2F563953 https://www.scipedia.com/public/238,295pz http://dspace.library.uu.nl/handle/1874/395440 https://etrr.springeropen.com/articles/10.1186/s12544-020-0400-6",http://dx.doi.org/10.1186/s12544-020-0400-6,,10.1186/s12544-020-0400-6,3021519647,,0,001-609-758-858-075; 005-937-669-125-898; 006-367-037-732-010; 008-183-380-850-432; 009-457-260-370-049; 011-373-031-579-256; 015-138-795-538-257; 018-022-558-357-975; 022-679-308-814-097; 027-357-197-982-804; 029-797-675-744-280; 030-199-967-838-751; 031-295-533-084-151; 032-002-493-678-952; 033-439-230-183-649; 034-706-800-429-322; 035-224-373-229-733; 035-430-250-884-727; 035-554-675-303-099; 038-273-147-382-959; 038-830-868-730-713; 040-647-057-989-007; 043-665-475-401-93X; 044-927-867-325-650; 046-313-731-760-174; 046-566-477-507-75X; 046-689-482-865-607; 051-771-592-165-533; 052-146-649-973-105; 053-173-089-429-661; 053-390-059-406-304; 056-188-393-870-751; 057-273-822-849-401; 059-448-491-073-788; 061-772-268-782-596; 066-490-603-630-28X; 067-668-705-235-370; 069-338-448-146-553; 072-312-913-401-605; 072-572-080-201-422; 073-146-923-910-679; 075-199-342-918-375; 076-662-925-675-414; 077-595-604-904-422; 078-187-218-256-539; 080-113-482-532-344; 080-310-933-125-071; 080-632-540-667-47X; 081-341-154-831-215; 081-564-878-637-571; 083-154-166-953-438; 084-559-890-333-389; 085-271-281-941-323; 090-419-331-743-974; 091-090-897-760-162; 092-344-415-277-922; 093-264-888-461-435; 094-362-181-525-306; 095-068-585-153-421; 095-698-513-696-706; 096-553-441-648-199; 097-914-336-326-46X; 097-996-890-076-746; 098-846-133-393-165; 100-070-975-384-286; 100-643-408-134-155; 102-073-134-181-042; 106-401-108-561-653; 106-550-084-099-52X; 107-233-917-707-946; 107-601-770-966-324; 109-120-948-156-499; 110-660-867-208-819; 111-551-219-969-808; 121-164-909-676-60X; 121-664-191-239-769; 122-301-365-700-548; 125-164-095-207-040; 126-770-000-750-929; 136-301-163-586-781; 138-388-386-689-312; 140-164-034-277-399; 144-062-137-699-699; 144-623-006-194-786; 145-914-070-042-185; 146-845-903-724-122; 150-108-555-121-417; 150-164-690-206-911; 162-735-017-899-473; 166-684-667-502-165; 167-481-718-311-278; 173-620-441-623-483; 187-954-577-604-554; 197-609-607-915-544,6
027-010-831-810-602,The Reporting Quality of Systematic Reviews and Meta-Analyses in Industrial and Organizational Psychology: A Systematic Review.,2017-08-22,2017,journal article,Frontiers in psychology,16641078,Frontiers Media S.A.,Switzerland,Naomi Schalken; Charlotte Rietbergen,"Objective: The goal of this systematic review was to examine the reporting quality of the method section of quantitative systematic reviews and meta-analyses from 2009-2016 in the field of industrial and organizational psychology with the help of the Meta-Analysis Reporting Standards (MARS), and to update previous research, such as the study of Aytug et al. (2012) and Dieckmann et al. (2009). Methods: A systematic search for quantitative systematic reviews and meta-analyses was conducted in the top 10 journals in the field of industrial and organizational psychology between January 2009 and April 2016. Data were extracted on study characteristics and items of the method section of MARS. A cross-classified multilevel model was analyzed, to test whether publication year and journal impact factor (JIF) were associated with the reporting quality scores of articles. Results: Compliance with MARS in the method section was generally inadequate in the random sample of 120 articles. Variation existed in the reporting of items. There were no significant effects of publication year and journal impact factor (JIF) on the reporting quality scores of articles. Conclusions: The reporting quality in the method section of systematic reviews and meta-analyses was still insufficient, therefore we recommend researchers to improve the reporting in their articles by using reporting standards like MARS.",8,,1395,1395,Industrial and organizational psychology; Psychology; Systematic review; Test (assessment); Impact factor; Quality (business); Study Characteristics; Systematic search; Multilevel model; Management science; Applied psychology,MARS; industrial and organizational psychology; replicability; reporting quality; systematic review; transparency,,,,https://core.ac.uk/display/87636104 https://www.frontiersin.org/articles/10.3389/fpsyg.2017.01395/pdf http://journal.frontiersin.org/article/10.3389/fpsyg.2017.01395/full https://europepmc.org/articles/PMC5572251 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572251 https://www.frontiersin.org/articles/10.3389/fpsyg.2017.01395/full http://dspace.library.uu.nl/handle/1874/339163 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572251,http://dx.doi.org/10.3389/fpsyg.2017.01395,28878704,10.3389/fpsyg.2017.01395,2572176498,PMC5572251,0,000-560-798-097-126; 001-256-195-854-36X; 013-541-969-076-695; 017-551-929-085-866; 017-669-609-381-205; 019-459-021-342-157; 020-264-821-523-517; 026-279-711-533-618; 032-032-395-882-906; 037-508-767-907-960; 049-207-420-494-294; 051-826-428-280-252; 052-470-367-657-627; 052-634-448-864-642; 053-927-938-312-176; 060-793-666-892-949; 066-498-442-099-913; 067-596-345-808-496; 083-275-795-865-394; 108-831-924-899-305; 108-834-055-387-087; 111-820-603-331-254; 115-418-816-723-382; 135-136-677-180-161; 140-388-040-487-985; 145-644-577-808-138; 152-859-059-396-390; 184-399-089-718-30X,12
028-428-468-331-846,Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis,2021-08-02,2021,journal article,The Journal of infectious diseases,15376613; 00221899,Oxford University Press,United States,Silvia Bertagnolio; Lucas E Hermans; Michael R. Jordan; Santiago Ávila-Ríos; Collins Iwuji; Anne Derache; Eric Delaporte; Annemarie M. J. Wensing; Theresa Aves; A S M Borhan; Alvin Leenus; Neil Parkin; Meg Doherty; Seth C Inzaule; Lawrence Mbuagbaw,"Background Increased access to antiretroviral therapy (ART) has resulted in rising levels of pretreatment human immunodeficiency virus drug resistance (PDR). This is the first systematic review and meta-analysis to assess the impact of PDR on treatment outcomes among people initiating nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, including the combination of efavirenz (EFV), tenofovir (TDF), and lamivudine or emtricitabine (XTC). Methods We systematically reviewed studies and conference proceedings comparing treatment outcomes in populations initiating NNRTI-based ART with and without PDR. We conducted subgroup analyses by regimen: (1) NNRTIs + 2 nucleoside reverse transcriptase inhibitors (NRTIs), (2) EFV + 2 NRTIs, or (3) EFV/TDF/XTC; by population (children vs adults); and by definition of resistance (PDR vs NNRTI PDR). Results Among 6197 studies screened, 32 were analyzed (31 441 patients). We found that individuals with PDR initiating NNRTIs across all the subgroups had increased risk of virological failure compared to those without PDR. Risk of acquisition of new resistance mutations and ART switch was also higher in people with PDR. Conclusions This review shows poorer treatment outcomes in the presence of PDR, supporting the World Health Organization's recommendation to avoid using NNRTIs in countries where levels of PDR are high.",224,3,377,388,Drug resistance; Internal medicine; Oncology; Reverse-transcriptase inhibitor; Lamivudine; HIV drug resistance; Emtricitabine; Regimen; Efavirenz; Population; Medicine,ART; HIV drug resistance; NNRTIs; pretreatment HIV drug resistance; treatment failure; virological failure,,,World Health Organization (001) International,https://academic.oup.com/jid/article/224/3/377/5986606 https://pubmed.ncbi.nlm.nih.gov/33202025/ https://www.ncbi.nlm.nih.gov/pubmed/33202025 http://www.ncbi.nlm.nih.gov/pubmed/33202025 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328216,http://dx.doi.org/10.1093/infdis/jiaa683,33202025,10.1093/infdis/jiaa683,3100521696,PMC8328216,0,001-436-325-242-969; 001-750-954-345-034; 003-711-916-668-271; 005-919-480-521-169; 006-878-009-445-705; 007-138-659-078-647; 007-641-899-286-742; 008-172-762-570-678; 009-994-661-402-99X; 012-844-383-066-838; 014-784-010-992-223; 015-813-378-652-936; 016-365-640-480-560; 019-122-830-935-127; 024-832-068-880-853; 029-042-416-475-682; 031-586-370-564-192; 032-407-054-958-149; 033-914-620-978-797; 042-123-823-114-273; 044-244-781-865-784; 048-392-900-036-074; 050-289-525-078-526; 056-719-380-412-030; 057-390-348-117-715; 060-014-676-462-349; 061-864-920-353-679; 062-403-477-275-518; 064-514-791-578-183; 066-478-936-682-895; 068-002-228-555-042; 070-051-914-642-552; 071-562-575-223-273; 077-941-134-529-662; 081-843-497-029-355; 083-010-821-762-193; 091-546-917-115-738; 098-183-163-391-553; 111-918-528-609-310; 139-525-283-678-21X; 143-805-902-960-857,3
032-091-901-844-815,Reservoirs and transmission routes of leprosy; A systematic review,2020-04-27,2020,journal article,PLoS neglected tropical diseases,19352735; 19352727,Public Library of Science,United States,Thomas Ploemacher; William R. Faber; Henk Menke; Victor P.M.G. Rutten; Toine Pieters,"Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae) and the more recently discovered Mycobacterium lepromatosis (M. lepromatosis). The two leprosy bacilli cause similar pathologic conditions. They primarily target the skin and the peripheral nervous system. Currently it is considered a Neglected Tropical Disease, being endemic in specific locations within countries of the Americas, Asia, and Africa, while in Europe it is only rarely reported. The reason for a spatial inequality in the prevalence of leprosy in so-called endemic pockets within a country is still largely unexplained. A systematic review was conducted targeting leprosy transmission research data, using PubMed and Scopus as sources. Publications between January 1, 1945 and July 1, 2019 were included. The transmission pathways of M. leprae are not fully understood. Solid evidence exists of an increased risk for individuals living in close contact with leprosy patients, most likely through infectious aerosols, created by coughing and sneezing, but possibly also through direct contact. However, this systematic review underscores that human-to-human transmission is not the only way leprosy can be acquired. The transmission of this disease is probably much more complicated than was thought before. In the Americas, the nine-banded armadillo (Dasypus novemcinctus) has been established as another natural host and reservoir of M. leprae. Anthroponotic and zoonotic transmission have both been proposed as modes of contracting the disease, based on data showing identical M. leprae strains shared between humans and armadillos. More recently, in red squirrels (Sciurus vulgaris) with leprosy-like lesions in the British Isles M. leprae and M. lepromatosis DNA was detected. This finding was unexpected, because leprosy is considered a disease of humans (with the exception of the armadillo), and because it was thought that leprosy (and M. leprae) had disappeared from the United Kingdom. Furthermore, animals can be affected by other leprosy-like diseases, caused by pathogens phylogenetically closely related to M. leprae. These mycobacteria have been proposed to be grouped as a M. leprae-complex. We argue that insights from the transmission and reservoirs of members of the M. leprae-complex might be relevant for leprosy research. A better understanding of possible animal or environmental reservoirs is needed, because transmission from such reservoirs may partly explain the steady global incidence of leprosy despite effective and widespread multidrug therapy. A reduction in transmission cannot be expected to be accomplished by actions or interventions from the human healthcare domain alone, as the mechanisms involved are complex. Therefore, to increase our understanding of the intricate picture of leprosy transmission, we propose a One Health transdisciplinary research approach.",14,4,e0008276,,Immunology; Transmission (medicine); Tropical disease; Disease; Mycobacterium leprae; Mycobacterium; Leprosy; Mycobacterium lepromatosis; Disease reservoir; Biology,,"Animals; Armadillos/microbiology; Disease Reservoirs; Disease Transmission, Infectious; Global Health; Humans; Incidence; Leprosy/epidemiology; Mycobacterium/isolation & purification; Mycobacterium leprae/isolation & purification; Prevalence; Sciuridae/microbiology",,,https://dx.plos.org/10.1371/journal.pntd.0008276 https://journals.plos.org/plosntds/article?id=10.1371%2Fjournal.pntd.0008276 https://pubmed.ncbi.nlm.nih.gov/32339201/ https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0008276&type=printable https://www.scilit.net/article/18a9d24ce077bd70ec7f967691b0147b http://europepmc.org/article/MED/32339201 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205316,http://dx.doi.org/10.1371/journal.pntd.0008276,32339201,10.1371/journal.pntd.0008276,3020684566,PMC7205316,0,000-090-396-884-22X; 000-528-443-543-270; 002-125-053-903-038; 003-036-477-599-000; 003-086-830-220-651; 004-071-498-229-279; 004-631-102-710-342; 004-910-355-529-447; 005-452-632-069-997; 006-696-314-147-803; 007-503-707-966-802; 007-535-000-761-850; 008-034-553-369-18X; 008-101-589-045-387; 008-425-528-615-949; 009-621-312-306-164; 010-235-385-876-950; 011-358-021-785-915; 011-776-539-249-094; 013-522-548-791-558; 014-729-750-188-159; 015-205-413-102-819; 016-027-437-634-112; 016-174-982-568-608; 016-316-841-861-481; 017-150-815-414-847; 017-332-130-486-773; 018-400-442-529-662; 018-526-904-779-919; 019-505-813-026-894; 019-590-392-882-383; 020-134-685-522-556; 021-576-334-933-868; 022-766-238-318-121; 023-919-270-335-686; 024-061-217-668-002; 024-312-329-836-078; 025-186-523-623-641; 025-472-894-208-751; 025-963-994-967-460; 026-421-297-840-376; 026-737-701-286-68X; 027-647-344-385-846; 027-719-792-880-365; 028-711-491-976-515; 028-888-191-459-27X; 029-262-691-797-031; 029-717-149-516-728; 030-319-692-152-673; 032-833-472-382-113; 034-283-845-049-188; 034-495-535-512-40X; 034-613-539-065-752; 035-757-787-460-89X; 037-622-988-418-393; 037-724-511-938-620; 037-818-085-332-454; 042-119-211-067-048; 042-539-841-915-014; 042-558-210-428-926; 042-755-565-416-863; 043-067-231-954-407; 044-291-083-535-608; 044-371-614-972-55X; 045-334-561-607-973; 046-601-206-742-222; 048-050-650-760-202; 049-072-064-651-613; 049-138-714-749-321; 050-034-338-453-883; 050-512-658-324-857; 051-767-530-491-665; 052-060-303-216-417; 053-207-641-452-789; 053-311-879-359-920; 053-900-912-870-794; 054-225-389-357-194; 054-472-194-383-710; 054-928-282-608-062; 056-232-690-995-548; 057-047-646-071-999; 057-638-564-378-123; 057-988-303-042-04X; 058-890-006-758-026; 059-069-155-786-033; 061-563-019-325-959; 061-787-059-586-451; 062-792-016-104-902; 062-871-767-612-153; 063-007-503-709-140; 063-046-359-294-682; 065-814-910-731-752; 069-252-136-508-933; 069-751-254-806-874; 072-577-168-557-805; 074-487-491-140-659; 074-727-561-614-566; 076-077-805-187-240; 078-251-799-126-655; 079-762-790-383-445; 081-101-156-037-127; 081-432-754-918-625; 082-802-829-407-654; 083-976-416-812-009; 084-061-821-559-503; 087-335-539-398-077; 089-441-416-606-827; 093-628-687-260-690; 096-038-665-048-663; 099-500-774-714-588; 100-007-249-332-156; 103-023-066-573-028; 105-173-119-097-237; 105-259-637-607-548; 106-457-351-506-358; 109-025-350-425-230; 117-398-384-924-865; 118-973-815-199-146; 126-248-173-698-856; 127-367-548-258-215; 131-806-679-537-00X; 134-651-073-645-095; 135-035-261-932-662; 135-513-363-110-321; 135-562-576-807-879; 139-421-712-702-876; 139-618-115-759-910; 141-103-330-471-396; 146-275-964-550-419; 156-647-871-352-445; 165-092-927-083-564; 165-310-705-204-888; 168-189-835-678-122; 179-246-978-710-123; 182-749-354-881-55X; 191-003-951-167-86X,24
032-427-489-727-612,Childhood aggression : A synthesis of reviews and meta-analyses to reveal patterns and opportunities for prevention and intervention strategies,2018-03-24,2018,journal article,Neuroscience and biobehavioral reviews,18737528; 01497634,Elsevier Limited,United Kingdom,Anne M. Hendriks; Meike Bartels; Olivier F. Colins; Catrin Finkenauer,"This study provides a synthesis of meta-analyses and systematic reviews on non-pharmacological treatments for childhood aggression. Treatments referred to universal prevention, selective prevention, indicated prevention, or intervention (Mrazek and Haggerty, 1994). Seventy-two meta-analyses and systematic reviews met the inclusion criteria. We describe their characteristics, effect sizes across types of treatments, and the effects of various moderators. For universal and selective prevention, effects were mostly absent or small; for indicated prevention and interventions, effects were mostly small or medium. Only two moderators had a positive effect on treatment effectiveness, namely pre-test levels of aggression and parental involvement. These results identified similarities between indicated prevention and intervention treatments, on the one hand, and universal prevention and selective prevention, on the other. Our findings suggest that research distinguishing between targets of treatments (i.e., factors associated with childhood aggression vs. present aggressive behaviors) would be promising. Moreover, to further increase effectiveness of treatments for childhood aggression, individual differences warrant scientific attention.",91,,278,291,Systematic review; Injury prevention; Psychological intervention; Aggression; Conduct disorder; Poison control; Suicide prevention; Clinical psychology; Medicine; Meta-analysis,Childhood aggression; Intervention; Meta-analysis; Prevention; Systematic review,Aggression/psychology; Child; Child Behavior Disorders/psychology; Humans; Primary Prevention/methods; Psychotherapy/methods; Systematic Reviews as Topic,,European Union Seventh Framework Program,https://biblio.ugent.be/publication/8588067 http://dspace.library.uu.nl/handle/1874/373310 https://www.ncbi.nlm.nih.gov/pubmed/29580961 https://www.safetylit.org/citations/index.php?fuseaction=citations.viewdetails&citationIds[]=citjournalarticle_577952_23 https://core.ac.uk/display/155021845 https://www.sciencedirect.com/science/article/abs/pii/S0149763417309454 https://dspace.library.uu.nl/bitstream/1874/373310/1/hendriks.pdf https://europepmc.org/abstract/MED/29580961 https://research.vu.nl/en/publications/childhood-aggression-a-synthesis-of-reviews-and-meta-analyses-to- https://www.sciencedirect.com/science/article/pii/S0149763417309454#! https://www.narcis.nl/publication/RecordID/oai%3Aresearch.vu.nl%3Apublications%2Ffe72b16f-0d85-4bb6-8d77-079a3960953d https://www.sciencedirect.com/science/article/pii/S0149763417309454,http://dx.doi.org/10.1016/j.neubiorev.2018.03.021,29580961,10.1016/j.neubiorev.2018.03.021,2789584557,,0,000-271-005-440-588; 000-512-123-460-453; 000-859-484-297-754; 002-885-713-608-897; 003-679-114-690-234; 005-951-652-452-404; 006-578-059-801-566; 007-274-127-752-553; 010-633-894-110-201; 010-898-171-795-183; 013-541-969-076-695; 018-370-930-836-384; 018-719-089-788-675; 019-765-476-041-321; 020-088-674-393-096; 020-483-142-231-088; 020-975-910-865-536; 021-218-970-301-458; 021-372-839-631-350; 021-393-960-002-153; 021-457-286-367-133; 022-863-094-234-352; 023-027-431-806-87X; 023-842-958-219-365; 024-911-613-461-095; 025-067-697-218-644; 026-351-800-779-365; 026-766-556-399-997; 026-983-906-432-20X; 027-575-646-981-504; 027-935-371-143-558; 029-367-064-359-762; 029-999-165-659-145; 030-298-923-036-566; 030-688-994-689-138; 030-788-542-158-211; 031-447-325-262-769; 031-577-729-668-912; 031-797-907-332-202; 032-643-929-981-531; 033-592-374-521-492; 034-489-086-839-413; 034-782-905-507-467; 035-455-044-415-891; 037-998-518-501-104; 038-578-501-676-560; 039-296-083-013-844; 043-201-804-797-117; 044-208-192-537-688; 044-861-159-954-692; 045-081-638-449-30X; 045-289-497-663-590; 046-536-406-682-780; 046-624-737-033-072; 047-087-285-101-104; 047-182-091-172-305; 047-393-662-631-262; 048-693-129-005-539; 049-293-612-940-678; 050-862-123-460-828; 052-092-267-035-42X; 052-377-014-855-154; 052-660-672-913-41X; 054-925-936-236-154; 054-973-866-502-344; 055-805-972-913-562; 061-612-495-216-057; 062-007-843-643-006; 063-203-630-969-840; 064-586-459-377-665; 065-024-335-366-333; 066-307-825-891-815; 066-624-237-545-237; 067-145-455-053-116; 067-307-840-828-108; 067-496-878-744-642; 069-041-544-229-36X; 069-744-432-509-093; 070-832-609-560-851; 071-587-296-533-982; 072-307-715-588-310; 074-887-208-950-262; 075-212-327-304-395; 078-205-355-685-90X; 079-186-631-498-074; 079-533-794-638-91X; 081-701-963-890-115; 083-275-795-865-394; 084-360-165-546-260; 084-636-266-814-986; 085-178-760-244-203; 085-202-456-732-47X; 085-806-732-125-009; 087-700-457-686-721; 088-335-328-086-707; 088-520-432-321-767; 089-529-650-152-129; 089-963-305-925-129; 091-010-820-906-343; 091-084-629-830-354; 092-754-085-713-171; 096-957-274-801-782; 097-917-991-200-306; 101-151-357-860-055; 105-579-594-604-189; 105-956-639-346-576; 106-171-885-266-850; 106-398-071-894-82X; 106-443-420-881-833; 108-213-327-865-002; 109-086-490-363-042; 111-953-270-252-88X; 112-403-034-900-670; 113-257-166-363-778; 113-655-127-733-258; 114-705-256-087-597; 115-242-897-056-668; 116-749-618-016-989; 118-597-834-700-083; 122-428-895-813-142; 123-423-905-399-613; 123-728-845-019-902; 126-143-118-135-873; 129-683-711-957-460; 130-606-229-246-157; 131-137-415-306-966; 139-497-176-940-539; 146-039-186-012-045; 166-582-338-671-315; 172-239-584-952-824; 182-514-741-554-579; 193-129-485-925-075,13
032-853-776-626-090,The development of offspring from mothers with systemic lupus erythematosus. A systematic review.,2017-05-04,2017,journal article,Autoimmunity reviews,18730183; 15689972,Elsevier,Netherlands,Fjodor A. Yousef Yengej; Annet van Royen-Kerkhof; Ronald H. W. M. Derksen; Ruth D E Fritsch-Stork,"Abstract Objective To analyze published data on the influence of maternal systemic lupus erythematosus (SLE) on different aspects of child development. Methods A systematic review was conducted using PubMed and Embase searches for SLE or SLE-related antibodies and physical, neurocognitive, psychiatric or motor development outcomes in children. Results In total 24 cohort and 4 case-control studies were included after initial screening of 1853 hits. Learning disorders (LD) were reported in 21.4–26% of SLE offspring, exceeding the prevalence in the general population. Four studies reported that dyslexia and reading problems were present in 14.3–21.6% of lupus offspring with a clear male predominance. Furthermore, a twofold increased rate of autism spectrum disorders (ASD) (n = 1 study) and a two- to threefold increased risk for speech disorders (n = 3 studies) were reported in lupus offspring compared to controls, although the latter was not statistically significant. More divergent results were found for attention deficit (n = 5 studies) and behavior disorders (n = 3 studies). In two large controlled studies attention disorders were more prevalent and a trend towards more behavior disorders was reported in 2 of 3 studies analyzing this subject. Finally, IQ and motor skills were not affected in respectively 7 and 5 studies. Cardiopulmonary functioning and mood disorders were scarcely investigated (both n = 1). Maternal anti-SSA antibodies were associated with LD in offspring in one study. Other SLE-related antibodies were rarely studied. Conclusion This systematic review suggests that maternal SLE is associated with LD (specifically dyslexia), ASD, attention deficit and probably speech problems in offspring. However, over half of the studies were assigned a low or moderate evidence level. Therefore, further research is necessary to substantiate the found evidence and expand the scope to lesser researched areas such as cardiopulmonary functioning.",16,7,701,711,Offspring; Neurocognitive; Pediatrics; Immunology; Autism; Systemic lupus erythematosus; Mood disorders; Autism spectrum disorder; Population; Dyslexia; Medicine,Antibodies; Development; Offspring; Pregnancy; Systemic lupus erythematosus,"Animals; Attention Deficit Disorder with Hyperactivity/epidemiology; Autism Spectrum Disorder/epidemiology; Female; Humans; Learning Disabilities/epidemiology; Lupus Erythematosus, Systemic/complications; Mothers; Speech Disorders/epidemiology",,,https://pubmed.ncbi.nlm.nih.gov/28479488/ https://core.ac.uk/display/153349121 http://dspace.library.uu.nl/handle/1874/358413 https://www.sciencedirect.com/science/article/pii/S1568997217301258 http://europepmc.org/abstract/MED/28479488 https://www.ncbi.nlm.nih.gov/pubmed/28479488 https://www.sciencedirect.com/science/article/abs/pii/S1568997217301258,http://dx.doi.org/10.1016/j.autrev.2017.05.005,28479488,10.1016/j.autrev.2017.05.005,2610905437,,0,001-267-777-311-49X; 002-980-924-742-645; 003-772-072-990-373; 008-023-375-706-505; 011-427-668-084-796; 013-572-640-727-685; 014-281-602-340-638; 014-853-222-644-948; 015-738-570-143-317; 016-045-080-474-943; 017-142-765-456-669; 017-377-595-815-767; 017-649-610-706-283; 019-110-103-434-512; 020-286-423-711-982; 021-403-707-573-215; 022-057-261-993-289; 022-978-276-493-363; 023-937-179-661-615; 026-937-622-683-480; 030-566-004-402-56X; 031-104-790-125-044; 033-413-532-133-123; 034-030-394-923-351; 034-047-185-177-55X; 035-563-916-007-86X; 039-474-857-883-333; 039-615-693-695-059; 046-649-969-349-544; 046-932-737-188-28X; 048-685-627-848-192; 049-369-246-071-270; 051-399-909-582-282; 052-240-511-744-853; 052-548-309-843-939; 053-539-783-303-544; 056-667-373-374-484; 057-574-949-296-364; 058-634-354-463-010; 059-327-641-767-136; 061-423-445-574-152; 066-112-358-517-823; 069-912-542-715-883; 072-036-173-882-731; 077-887-086-282-591; 079-532-805-924-707; 082-343-275-797-274; 085-246-533-829-318; 088-607-261-767-642; 091-983-056-499-615; 093-025-429-948-65X; 094-467-003-595-572; 096-145-949-399-493; 102-752-998-957-340; 104-344-714-919-079; 105-551-455-687-653; 107-562-931-874-06X; 109-310-098-543-835; 110-089-259-471-613; 118-962-374-154-431; 121-449-872-368-863; 129-384-859-362-21X; 138-197-792-666-122; 143-766-731-454-933; 160-312-318-032-219,27
033-951-582-891-852,Neighbourhood deprivation effects on young people's mental health and well-being: A systematic review of the literature.,2020-11-24,2020,journal article,Social science & medicine (1982),18735347; 02779536,Elsevier Limited,United Kingdom,Kirsten Visser; Gideon Bolt; Catrin Finkenauer; Merel Jonker; Dominic Weinberg; Gonneke W. J. M. Stevens,"Abstract Since the growth of research into neighbourhood effects on young people's health in the 1980s, there have been major societal changes and scientific methodological advancements. In this systematic review we will, therefore, discuss the recent (>2009) literature on the association between neighbourhood deprivation and young people's (0–19 years old) mental health and well-being. We focus on whether neighbourhood deprivation effects exist, and how and for whom the neighbourhood matters. Together, the thirty studies included in the review indicate that overall there are neighbourhood effects on young people's mental health and well-being. The comparison of results from these studies suggests that such associations were more commonly found for well-being and externalising problem behaviour rather than internalising problem behaviour. Also, mental health and well-being seemed to be more often associated with the neighbourhood social environment than neighbourhood socio-economic status and neighbourhood disorder. Studies investigating mediating processes between the linkage between neighbourhood deprivation and mental health and well-being were rare although there was some evidence that processes within the family and peer context are important mechanisms in this linkage. Inconsistent evidence was found regarding the moderating role of age, gender, and ethnicity. There are ongoing challenges of researching the how and for whom neighbourhoods are important. We should work towards rigorous theory and evidence on how different features of residential contexts matter and on differential exposure and vulnerability to these contexts.",270,,113542,,Social environment; Mental health; Ethnic group; Developmental psychology; Association (psychology); Psychology; Neighbourhood (mathematics); Vulnerability; Well-being; Context (language use),Mental health and well-being; Neighbourhood deprivation effects; Systematic review; Young people,"Adolescent; Adult; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Longitudinal Studies; Mental Health; Residence Characteristics; Social Class; Social Environment; Socioeconomic Factors; Young Adult",,Universiteit Utrecht,https://www.ncbi.nlm.nih.gov/pubmed/33495056 https://www.sciencedirect.com/science/article/pii/S0277953620307619,http://dx.doi.org/10.1016/j.socscimed.2020.113542,33495056,10.1016/j.socscimed.2020.113542,3110289926,,0,002-002-276-680-214; 004-185-125-380-625; 007-126-376-894-961; 007-371-430-678-880; 007-592-502-612-637; 009-060-214-653-966; 010-137-288-202-808; 010-818-377-757-710; 012-263-413-033-805; 012-573-911-765-850; 012-581-845-374-316; 015-865-290-228-609; 018-706-182-985-304; 019-714-207-979-557; 020-677-903-042-966; 021-680-559-398-608; 021-944-720-672-500; 023-958-844-810-725; 026-837-407-051-626; 028-863-203-761-193; 029-006-120-103-187; 030-210-245-211-628; 031-650-476-412-991; 036-533-065-067-82X; 039-585-734-167-080; 042-319-298-204-418; 048-052-035-962-135; 053-638-402-764-106; 057-394-069-857-524; 058-727-575-480-159; 059-709-864-831-944; 062-655-231-178-831; 063-583-600-345-612; 066-370-167-239-172; 068-118-236-258-528; 069-141-735-725-591; 073-020-741-850-237; 076-630-168-023-374; 078-582-503-706-981; 078-720-113-667-609; 080-380-320-666-792; 084-520-720-549-349; 085-247-986-711-720; 086-103-896-061-350; 090-935-735-931-681; 095-257-559-383-402; 095-670-007-693-831; 097-726-610-957-777; 103-231-352-100-762; 105-753-821-558-399; 106-444-558-554-442; 116-506-165-447-279; 117-953-602-934-173; 118-778-064-624-549; 129-456-351-560-83X; 130-316-958-596-32X; 133-709-464-809-715; 135-216-882-081-963; 141-901-271-337-774; 143-535-863-260-569; 154-792-077-166-547; 176-939-933-828-569,5
034-353-267-255-350,Ischaemic heart disease during pregnancy or post-partum: systematic review and case series,2015-04-14,2015,journal article,Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation,15685888; 18766250,Bohn Stafleu van Loghum,Netherlands,Heleen Lameijer; M. A. M. Kampman; Martijn A. Oudijk; Petronella G. Pieper,"The risk of manifestations of ischaemic heart disease (IHD) in fertile women is elevated during pregnancy and the post-partum period. With increasing maternal age and a higher prevalence of cardiac risk factors, the incidence of IHD during pregnancy is rising. However, information in the literature is scarce. We therefore performed a retrospective cohort study and systematically reviewed the overall (1975-2013) and contemporary (2005-2013) literature concerning IHD presenting during pregnancy or in the post-partum period. We report two cases of IHD with atypical presentation during pregnancy or post-partum. In our review, we describe 146 pregnancies, including 57 contemporary cases (2005-2013). Risk factors for IHD were present in 80 %. Of the cases of IHD, 71 % manifested in the third trimester or the post-partum period, and 95 % presented with chest pain. The main cause was coronary dissection (35 %), or thrombus/emboli (35 %) in the more contemporary group. Maternal mortality was 8 % (6 % in the contemporary group), and the main cardiac complication was ventricular tachycardia (n = 17). Premature delivery rate was 56 %, and caesarean section was performed in 57 %. Perinatal mortality was 4 %. In conclusion, IHD during pregnancy or in the post-partum period has high maternal mortality and morbidity rates. Also, premature delivery and perinatal mortality rates are high.",23,5,249,257,Epidemiology; Retrospective cohort study; Pediatrics; Caesarean section; Ventricular tachycardia; Chest pain; Pregnancy; Incidence (epidemiology); Myocardial infarction; Medicine,,,,,https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F152401 https://research.rug.nl/en/publications/ischaemic-heart-disease-during-pregnancy-or-post-partum-systemati https://paperity.org/p/61532661/ischaemic-heart-disease-during-pregnancy-or-post-partum-systematic-review-and-case-series https://link.springer.com/content/pdf/10.1007%2Fs12471-015-0677-6.pdf http://europepmc.org/articles/PMC4409591 https://link.springer.com/article/10.1007/s12471-015-0677-6 https://pubmed.ncbi.nlm.nih.gov/25911007/ https://www.ncbi.nlm.nih.gov/pubmed/25911007 https://repository.ubn.ru.nl/handle/2066/152401 https://www.rug.nl/research/portal/publications/ischaemic-heart-disease-during-pregnancy-or-postpartum(6129f9f4-fa89-4495-8826-321cede39804).html https://core.ac.uk/display/92533646 https://core.ac.uk/download/43599873.pdf,http://dx.doi.org/10.1007/s12471-015-0677-6,25911007,10.1007/s12471-015-0677-6,1973831175,PMC4409591,0,000-015-554-404-165; 000-580-203-815-343; 000-615-764-146-837; 002-604-331-245-767; 004-940-930-258-784; 005-356-493-571-791; 007-320-402-347-945; 011-667-563-757-723; 011-678-252-231-904; 012-634-448-845-811; 012-795-869-086-654; 013-819-241-339-812; 017-300-737-144-757; 018-754-954-982-522; 025-432-555-560-471; 029-543-423-357-735; 030-209-188-405-136; 035-467-156-233-687; 035-515-994-141-486; 035-537-662-045-356; 036-555-910-815-627; 040-475-848-867-809; 043-881-938-392-504; 045-341-195-177-955; 045-691-934-536-625; 045-980-976-959-344; 048-002-614-059-180; 049-542-752-309-276; 056-330-532-974-96X; 058-923-618-930-227; 061-086-453-985-192; 063-766-306-803-688; 069-410-907-341-301; 073-781-019-316-113; 077-577-682-256-556; 081-871-872-926-41X; 083-338-402-693-540; 086-739-222-272-817; 088-887-327-414-196; 094-288-575-824-429; 100-258-095-348-708; 106-270-452-875-224; 111-087-311-471-90X; 117-045-085-825-054; 126-037-538-534-484; 173-205-246-504-747; 186-416-304-413-387,24
035-192-389-389-527,Publications on Clinical Research in Otolaryngology–A Systematic Analysis of Leading Journals in 2010,2019-04-09,2019,journal article,Frontiers in surgery,2296875x,Frontiers Media SA,Switzerland,Nina M. Kaper; Geerte G. J. Ramakers; Mark C. J. Aarts; Geert J. M. G. van der Heijden,"Background: We wanted to asses and characterize the volume of Otolaryngology publications on clinical research, published in major journals. Methods and Material: To assess volume and study type of clinical research in Otolaryngology we performed a literature search in high impact factor journals. We included 10 high impact factor Otolaryngology journals and 20 high impact factor medical journals outside this field (2011). We extracted original publications and systematic reviews from 2010. Publications were classified according to their research question, that is therapy, diagnosis, prognosis or etiology. Results: From Otolaryngology journals (impact factor 1.8 to 2.8) we identified 694 (46%) publications on original observations and 27 (2%) systematic reviews. From selected medical journals (impact factor 6.0 to 101.8) 122 (2%) publications related to Otolaryngology, 102 (83%) were on original observations and 2 (0.04%) systematic reviews. The most common category was therapy (40%). Conclusion: Half of publications in Otolaryngology concerns clinical research, which is higher than other specialties. In medical journals outside the field of Otolaryngology, a small proportion (2%) of publications is related to Otolaryngology. Striking is that systematic reviews, which are considered high level evidence, make up for only 2% of publications. We must ensure an increase of clinical research for optimizing medical practice.",6,,18,,Otorhinolaryngology; Evidence-based practice; Systematic review; Evidence-based medicine; Research question; Impact factor; Medical practice; Clinical research; Family medicine; Medicine,diagnosis; etiology; evidence-based medicine; evidence-based practice; impact factor; otolaryngology; prognosis; therapy,,,,https://www.ncbi.nlm.nih.gov/pubmed/31024926 https://pubmed.ncbi.nlm.nih.gov/31024926/ https://www.frontiersin.org/article/10.3389/fsurg.2019.00018/full https://www.frontiersin.org/articles/10.3389/fsurg.2019.00018/full,http://dx.doi.org/10.3389/fsurg.2019.00018,31024926,10.3389/fsurg.2019.00018,2937555059,PMC6467099,0,000-182-484-526-391; 003-571-248-442-40X; 014-999-350-794-715; 018-106-924-294-504; 023-761-853-925-12X; 035-924-517-674-084; 040-496-238-794-676; 048-200-160-837-976; 059-089-582-631-042; 063-123-144-836-508; 071-014-167-303-699; 086-546-955-250-091; 095-657-287-769-389; 149-422-599-028-134,0
037-341-694-571-21X,Patient delay in TIA: a systematic review,2018-07-19,2018,journal article,Journal of neurology,14321459; 03405354,D. Steinkopff-Verlag,Germany,L. Servaas Dolmans; Arno W. Hoes; Marie Louise E.L. Bartelink; Niels C.T. Koenen; L. Jaap Kappelle; Frans H. Rutten,"Patients who suffer a transient ischemic attack (TIA) have a high short-term risk of developing ischemic stroke, notably within the first 48 h. Timely diagnosis and urgent preventive treatment substantially reduce this risk. We conducted a systemic review to quantify patient delay in patients with (suspected) TIA, and assess determinants related to such delay. A systematic review using MEDLINE and EMBASE databases up to March 2017 to identify studies reporting the time from onset of TIA symptoms to seeking medical help. We identified nine studies providing data on patient delay, published between 2006 and 2016, with 7/9 studies originating from the United Kingdom (UK). In total 1103 time-defined TIA patients (no remaining symptoms > 24 h), and 896 patients with a minor stroke (i.e., mild remaining symptoms > 24 h) were included (49.1% men, mean age 72.2 years). Patient’s delay of more than 24 h was reported in 33.1–44.4% of TIA patients, with comparable proportions for minor stroke patients. Delays were on average shorter in patients interviewed at the emergency department than among patients seen at TIA outpatient clinics. Univariably associated with a shorter delay were (1) a longer duration of symptoms, (2) motor symptoms, (3) a higher ABCD2 score, and (4) correct patient’s recognition as possible ischemic cerebrovascular event. More than a third of patients experiencing a TIA delays medical attention for more than a day, thus critically extending the initiation of stroke preventive treatment. There still seems to be insufficient awareness among lay people that symptoms suggestive of TIA should be considered as an emergency. Additional data and multivariable analyses are needed to define main determinants of patient delay.",266,5,1051,1058,Neurology; Emergency medicine; ABCD2; MEDLINE; Neuroradiology; Emergency department; Patient delay; Outpatient clinic; Stroke; Medicine,Minor stroke; Patient delay; Systematic review; TIA,"Databases, Bibliographic/statistics & numerical data; Humans; Ischemic Attack, Transient/complications; Stroke/etiology; Time Factors; Time-to-Treatment",,,https://link.springer.com/content/pdf/10.1007/s00415-018-8977-6.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469675 http://dspace.library.uu.nl/bitstream/1874/386390/1/dolmans.pdf https://pubmed.ncbi.nlm.nih.gov/30027321/ https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F386390 http://dspace.library.uu.nl/handle/1874/386390 https://europepmc.org/article/PMC/PMC6469675 https://link.springer.com/article/10.1007/s00415-018-8977-6,http://dx.doi.org/10.1007/s00415-018-8977-6,30027321,10.1007/s00415-018-8977-6,2883045669,PMC6469675,0,000-744-442-690-70X; 003-063-587-682-917; 012-195-882-759-56X; 014-300-843-679-211; 014-961-697-672-924; 017-165-304-765-778; 017-272-702-300-523; 021-513-003-958-19X; 021-944-720-672-500; 022-446-867-509-550; 039-933-581-879-64X; 056-029-593-089-072; 063-064-587-644-356; 066-855-117-411-590; 088-166-622-639-208; 099-309-632-060-827; 135-176-625-907-273; 156-998-648-892-881,8
038-096-249-755-096,Comparability of PD‐L1 immunohistochemistry assays for non‐small cell lung cancer: a systematic review,2020-03-24,2020,journal article,Histopathology,13652559; 03090167,Wiley-Blackwell,United Kingdom,Bregje M Koomen; Sushil K Badrising; Michel M. van den Heuvel; Stefan M. Willems,"Programmed cell death ligand 1 (PD-L1) immunohistochemistry is used to determine which patients with advanced non-small-cell lung cancer (NSCLC) respond best to treatment with PD-L1 inhibitors. For each inhibitor, a unique immunohistochemical assay was developed. This systematic review gives an up-to-date insight into the comparability of standardised immunohistochemical assays and laboratory-developed tests (LDTs), focusing specifically on tumour cell (TC) staining and scoring. A systematic search was performed identifying publications that assessed interassay, interobserver and/or interlaboratory concordance of PD-L1 assays and LDTs in tissue of NSCLC patients. Of 4294 publications identified through the systematic search, 27 fulfilled the inclusion criteria and were of sufficient methodological quality. Studies assessing interassay concordance found high agreement between assays 22C3, 28-8 and SP263 and properly validated LDTs, and lower concordance for comparisons involving SP142. A decrease in concordance, however, is seen with use of cut-offs, which hampers interchangeability of PD-L1 immunohistochemistry assays and LDTs. Studies assessing interobserver concordance found high agreement for all assays and LDTs, but lower agreement with use of a 1% cut-off. This may be problematic in clinical practice, as discordance between pathologists at this cut-off may result in some patients being denied valuable treatment options. Finally, five studies assessed interlaboratory concordance and found moderate to high agreement levels for various assays and LDTs. However, to assess the actual existence of interlaboratory variation in PD-L1 testing and PD-L1 positivity in clinical practice, studies using real-world clinical pathology data are needed.",76,6,793,802,Internal medicine; Oncology; Concordance; Comparability; Immunohistochemistry; Lung cancer; PD-L1; Programmed cell death ligand 1; Non small cell; Clinical pathology; Medicine,immunohistochemistry; immunotherapy; non-small-cell lung cancer; predictive biomarker; programmed cell death-ligand 1; systematic review,"B7-H1 Antigen/analysis; Biomarkers, Tumor/analysis; Carcinoma, Non-Small-Cell Lung/diagnosis; Humans; Immunohistochemistry/methods; Lung Neoplasms/diagnosis","B7-H1 Antigen; Biomarkers, Tumor; CD274 protein, human",,https://www.ncbi.nlm.nih.gov/pubmed/31793055 https://onlinelibrary.wiley.com/doi/epdf/10.1111/his.14040 https://onlinelibrary.wiley.com/doi/full/10.1111/his.14040 https://europepmc.org/article/PMC/PMC7318295 https://pubmed.ncbi.nlm.nih.gov/31793055/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318295,http://dx.doi.org/10.1111/his.14040,31793055,10.1111/his.14040,2992200227,PMC7318295,0,000-238-921-435-827; 000-558-445-206-451; 002-352-047-448-69X; 002-909-373-285-270; 004-957-677-907-605; 005-226-295-867-414; 006-212-036-298-260; 006-628-506-521-308; 006-866-668-984-616; 008-139-697-129-848; 011-849-623-043-712; 014-267-523-518-716; 014-990-705-047-292; 015-304-913-223-485; 015-429-365-066-464; 016-034-270-220-115; 020-984-003-473-648; 022-306-250-888-47X; 022-594-389-839-233; 029-801-383-782-057; 030-643-926-955-503; 031-450-012-935-501; 031-891-578-287-877; 032-051-797-598-67X; 036-593-583-309-109; 037-088-519-625-763; 038-096-249-755-096; 040-960-548-267-632; 043-108-415-574-706; 045-911-376-256-566; 049-440-817-169-319; 052-758-464-207-743; 055-707-862-562-985; 057-075-056-237-870; 057-260-652-135-47X; 057-645-010-359-073; 058-960-804-221-136; 059-611-687-517-333; 060-832-909-661-336; 063-232-343-564-165; 064-111-670-585-575; 065-886-124-789-44X; 068-416-071-545-291; 075-765-671-176-097; 076-707-698-301-08X; 078-024-193-251-259; 083-070-402-708-090; 083-431-907-921-277; 084-371-970-078-504; 084-929-120-631-553; 089-426-760-561-343; 092-043-289-392-823; 095-315-872-748-335; 097-165-902-274-794; 098-247-449-371-873; 107-009-334-693-881; 109-459-824-413-804; 112-706-706-408-91X; 118-312-289-853-401; 130-671-398-925-75X; 148-730-364-862-456; 154-852-835-837-63X; 189-370-616-749-101,21
039-084-889-876-767,Computer-Based Interventions for Problematic Alcohol Use: a Review of Systematic Reviews,2016-10-18,2016,journal article,International journal of behavioral medicine,15327558; 10705503,Routledge,United States,Christopher Sundström; Matthijs Blankers; Zarnie Khadjesari,"The aim of this review is to provide an overview of knowledge and knowledge gaps in the field of computer-based alcohol interventions by (1) collating evidence on the effectiveness of computer-based alcohol interventions in different populations and (2) exploring the impact of four specified moderators of effectiveness: therapeutic orientation, length of intervention, guidance and trial engagement. A review of systematic reviews of randomized trials reporting on effectiveness of computer-based alcohol interventions published between 2005 and 2015. Fourteen reviews met the inclusion criteria. Across the included reviews, it was generally reported that computer-based alcohol interventions were effective in reducing alcohol consumption, with mostly small effect sizes. There were indications that longer, multisession interventions are more effective than shorter or single session interventions. Evidence on the association between therapeutic orientation of an intervention, guidance or trial engagement and reductions in alcohol consumption is limited, as the number of reviews addressing these themes is low. None of the included reviews addressed the association between therapeutic orientation, length of intervention or guidance and trial engagement. This review of systematic reviews highlights the mostly positive evidence supporting computer-based alcohol interventions as well as reveals a number of knowledge gaps that could guide future research in this field.",24,5,646,658,Inclusion (education); Health psychology; Randomized controlled trial; Systematic review; Psychological intervention; Intervention (counseling); Computer based interventions; Clinical psychology; Medicine; Meta-analysis,Alcohol; Computer-based intervention; E-health; Internet intervention; Meta-analysis; Systematic review,"Alcohol Drinking/prevention & control; Humans; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Therapy, Computer-Assisted/methods",,Karolinska Institute,https://ueaeprints.uea.ac.uk/66724/ https://link.springer.com/article/10.1007/s12529-016-9601-8 https://core.ac.uk/display/77064950 https://pubmed.ncbi.nlm.nih.gov/27757844/ https://research-portal.uea.ac.uk/en/publications/computer-based-interventions-for-problematic-alcohol-use-a-review https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F8dd3d366-3541-486a-8f40-0c10bb926956 https://europepmc.org/abstract/MED/27757844 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608865 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608865 https://link.springer.com/content/pdf/10.1007%2Fs12529-016-9601-8.pdf https://core.ac.uk/download/154425551.pdf,http://dx.doi.org/10.1007/s12529-016-9601-8,27757844,10.1007/s12529-016-9601-8,2536805816,PMC5608865,0,001-325-381-294-323; 001-500-726-342-008; 003-045-669-196-104; 005-594-447-804-893; 007-967-261-942-165; 012-345-776-116-916; 012-799-499-501-934; 013-721-016-924-876; 014-863-055-748-596; 016-199-167-029-713; 020-660-568-574-349; 021-382-849-192-231; 022-369-265-534-728; 022-959-736-904-618; 023-224-796-320-111; 026-220-975-487-436; 027-830-138-626-683; 029-853-496-215-491; 035-238-416-516-01X; 035-855-078-766-481; 036-740-128-013-530; 038-838-571-327-508; 041-327-435-728-685; 041-461-239-726-487; 042-063-789-021-441; 042-976-806-691-09X; 043-879-011-070-021; 048-003-902-873-536; 050-917-339-973-417; 053-768-739-908-385; 059-262-303-102-41X; 071-736-295-472-766; 076-536-840-663-29X; 079-825-115-022-182; 086-698-882-912-99X; 088-131-166-254-792; 096-972-159-395-673; 103-741-577-259-344; 105-905-761-344-910; 106-804-273-663-705; 128-565-523-061-743; 137-181-277-299-011; 158-708-543-019-116; 169-779-147-281-46X; 171-810-831-484-268; 196-392-349-856-500,66
041-105-929-120-473,Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis,2020-09-14,2020,journal article,International journal of molecular sciences,14220067; 16616596,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Merle M. Krebber; Christian G. M. van Dijk; Robin W.M. Vernooij; Maarten M. Brandt; Craig A. Emter; Christoph Rau; Joost O. Fledderus; Dirk J. Duncker; Marianne C. Verhaar; Caroline Cheng; Jaap A. Joles,"Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are pivotal regulators of extracellular matrix (ECM) composition and could, due to their dynamic activity, function as prognostic tools for fibrosis and cardiac function in left ventricular diastolic dysfunction (LVDD) and heart failure with preserved ejection fraction (HFpEF). We conducted a systematic review on experimental animal models of LVDD and HFpEF published in MEDLINE or Embase. Twenty-three studies were included with a total of 36 comparisons that reported established LVDD, quantification of cardiac fibrosis and cardiac MMP or TIMP expression or activity. LVDD/HFpEF models were divided based on underlying pathology: hemodynamic overload (17 comparisons), metabolic alteration (16 comparisons) or ageing (3 comparisons). Meta-analysis showed that echocardiographic parameters were not consistently altered in LVDD/HFpEF with invasive hemodynamic measurements better representing LVDD. Increased myocardial fibrotic area indicated comparable characteristics between hemodynamic and metabolic models. Regarding MMPs and TIMPs; MMP2 and MMP9 activity and protein and TIMP1 protein levels were mainly enhanced in hemodynamic models. In most cases only mRNA was assessed and there were no correlations between cardiac tissue and plasma levels. Female gender, a known risk factor for LVDD and HFpEF, was underrepresented. Novel studies should detail relevant model characteristics and focus on MMP and TIMP protein expression and activity to identify predictive circulating markers in cardiac ECM remodeling.",21,18,1,22,Matrix metalloproteinase; Cardiac function curve; Internal medicine; Cardiology; Hemodynamics; Tissue inhibitor of metalloproteinase; Heart failure with preserved ejection fraction; Cardiac fibrosis; Fibrosis; TIMP1; Medicine,animal models; extracellular matrix; fibrosis; heart failure with preserved ejection fraction; left ventricular diastolic dysfunction; matrix metalloproteinase; systematic review; tissue inhibitor of metalloproteinase,"Animals; Extracellular Matrix/metabolism; Heart Failure/metabolism; Humans; Matrix Metalloproteinases/metabolism; Tissue Inhibitor of Metalloproteinases/metabolism; Ventricular Dysfunction, Left/metabolism; Ventricular Function, Left/physiology; Ventricular Remodeling/physiology",Tissue Inhibitor of Metalloproteinases; Matrix Metalloproteinases,,https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A130402 https://www.mdpi.com/1422-0067/21/18/6742 https://repub.eur.nl/pub/130402/Repub_130402_O-A.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555240 https://repub.eur.nl/pub/130402 https://pubmed.ncbi.nlm.nih.gov/32937927/ https://www.ncbi.nlm.nih.gov/pubmed/32937927 https://www.mdpi.com/1422-0067/21/18/6742/pdf https://core.ac.uk/download/334430427.pdf,http://dx.doi.org/10.3390/ijms21186742,32937927,10.3390/ijms21186742,3086647289,PMC7555240,0,000-145-700-512-785; 000-595-151-344-894; 002-314-515-216-367; 002-552-454-257-344; 002-667-480-908-024; 003-431-155-240-249; 004-617-405-243-525; 005-326-451-228-007; 007-561-180-693-179; 009-659-686-885-176; 010-321-205-112-197; 010-775-932-792-033; 014-049-131-461-743; 016-214-595-924-004; 017-027-155-449-724; 018-243-124-379-375; 021-175-719-493-560; 021-255-764-391-037; 021-827-455-600-369; 021-870-886-780-203; 022-576-081-510-336; 024-482-951-669-881; 024-783-451-171-074; 026-695-010-515-305; 028-320-949-834-730; 028-499-854-560-194; 028-720-279-404-67X; 028-957-353-938-940; 029-050-036-334-298; 029-408-370-196-437; 029-851-595-594-571; 030-364-997-441-567; 031-503-802-868-880; 031-586-485-557-013; 033-368-225-884-39X; 033-566-789-987-72X; 033-875-636-970-168; 033-972-843-526-603; 034-224-384-079-404; 034-912-586-487-309; 036-648-536-658-74X; 036-906-171-815-712; 037-168-496-292-731; 038-660-869-625-203; 040-422-015-457-101; 041-356-596-962-600; 041-866-995-527-737; 042-718-259-809-148; 043-098-511-456-084; 044-794-680-364-266; 044-921-041-854-954; 047-960-548-265-068; 050-410-769-929-966; 050-433-846-289-336; 052-778-289-464-547; 053-321-510-344-98X; 056-369-953-772-82X; 056-931-726-843-320; 057-016-426-471-657; 057-444-917-922-337; 057-495-499-750-818; 057-838-477-964-518; 058-114-607-921-114; 058-793-675-505-793; 058-865-973-504-852; 059-580-862-427-855; 061-075-851-478-336; 068-502-241-491-267; 071-828-989-975-040; 072-487-399-973-460; 074-257-757-075-994; 074-434-003-622-351; 074-667-083-783-549; 080-603-931-372-430; 081-075-371-060-673; 085-844-133-582-395; 091-353-887-660-100; 092-031-877-117-168; 092-264-962-609-199; 096-192-207-601-623; 101-496-604-223-963; 103-457-080-047-129; 105-910-815-125-403; 111-462-654-913-396; 111-746-613-972-01X; 114-311-921-076-23X; 117-253-761-149-466; 117-832-994-506-416; 119-988-638-501-188; 121-606-160-826-519; 128-023-277-816-20X; 129-742-813-805-30X; 136-734-589-704-582; 152-440-994-336-070; 155-820-880-234-782; 171-932-853-241-211; 173-311-717-548-738; 174-162-047-682-777,18
041-778-570-427-167,Poor methodological detail precludes experimental repeatability and hampers synthesis in ecology.,2015-09-23,2015,journal article,Ecology and evolution,20457758,John Wiley and Sons Ltd,United Kingdom,Neal R. Haddaway; Jos T. A. Verhoeven,"Despite the scientific method's central tenets of reproducibility (the ability to obtain similar results when repeated) and repeatability (the ability to replicate an experiment based on methods described), published ecological research continues to fail to provide sufficient methodological detail to allow either repeatability of verification. Recent systematic reviews highlight the problem, with one example demonstrating that an average of 13% of studies per year (±8.0 [SD]) failed to report sample sizes. The problem affects the ability to verify the accuracy of any analysis, to repeat methods used, and to assimilate the study findings into powerful and useful meta-analyses. The problem is common in a variety of ecological topics examined to date, and despite previous calls for improved reporting and metadata archiving, which could indirectly alleviate the problem, there is no indication of an improvement in reporting standards over time. Here, we call on authors, editors, and peer reviewers to consider repeatability as a top priority when evaluating research manuscripts, bearing in mind that legacy and integration into the evidence base can drastically improve the impact of individual research reports.",5,19,4451,4454,Sample size determination; Variety (cybernetics); Repeatability; Ecology; Systematic review; Data science; Replicate; Computer science; Reliability (statistics); Metadata; Meta-analysis,Evidence synthesis; experimental design; meta‐analysis; reliability; research legacy; susceptibility to bias; systematic review; transparency,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667817/ https://onlinelibrary.wiley.com/doi/10.1002/ece3.1722 https://www.onlinelibrary.wiley.com/doi/pdf/10.1002/ece3.1722 http://europepmc.org/articles/PMC4667817,http://dx.doi.org/10.1002/ece3.1722,26664691,10.1002/ece3.1722,1917545934,PMC4667817,0,004-854-468-958-906; 010-480-883-726-372; 013-978-706-184-637; 015-904-383-621-126; 017-688-092-345-781; 023-776-095-270-655; 026-804-614-916-185; 029-017-792-436-455; 030-351-850-804-017; 033-291-734-724-084; 036-620-266-622-506; 041-778-570-427-167; 050-453-067-972-281; 053-976-909-068-013; 057-880-055-016-031; 061-401-711-406-024; 075-343-668-177-259; 088-912-976-386-561; 110-295-949-866-863; 114-539-697-740-140; 118-095-468-952-757; 118-554-425-200-088; 134-054-548-444-794; 164-747-020-249-405; 195-595-429-573-31X,30
042-398-480-593-809,Correlates of prenatal and postnatal mother-to-infant bonding quality: A systematic review,2019-09-24,2019,journal article,PloS one,19326203,Public Library of Science,United States,Elke Tichelman; Myrte Westerneng; Anke B. Witteveen; Anneloes L. van Baar; Henriëtte E. van der Horst; Ank de Jonge; Marjolein Y. Berger; François G. Schellevis; Huibert Burger; Lilian L. Peters,"Background Mother-to-infant bonding is defined as the emotional tie experienced by a mother towards her child, which is considered to be important for the socio-emotional development of the child. Numerous studies on the correlates of both prenatal and postnatal mother-to-infant bonding quality have been published over the last decades. An up-to-date systematic review of these correlates is lacking, however. Objective To systematically review correlates of prenatal and postnatal mother-to-infant bonding quality in the general population, in order to enable targeted interventions. Methods MEDLINE, Embase, CINAHL, and PsychINFO were searched through May 2018. Reference checks were performed. Case-control, cross-sectional or longitudinal cohort studies written in English, German, Swedish, Spanish, Norwegian, French or Dutch defining mother-to-infant bonding quality as stipulated in the protocol (PROSPERO CRD42016040183) were included. Two investigators independently reviewed abstracts, full-text articles and extracted data. Methodological quality was assessed using the National Institute of Health Quality Assessment Tool for Observational Cohort and Cross-sectional studies and was rated accordingly as poor, fair or good. Clinical and methodological heterogeneity were examined. Main results 131 studies were included. Quality was fair for 20 studies, and poor for 111 studies. Among 123 correlates identified, 3 were consistently associated with mother-to-infant bonding quality: 1) duration of gestation at assessment was positively associated with prenatal bonding quality, 2) depressive symptoms were negatively associated with postnatal mother-to-infant bonding quality, and 3) mother-to-infant bonding quality earlier in pregnancy or postpartum was positively associated with mother-to-infant bonding quality later in time. Conclusion Our review suggests that professionals involved in maternal health care should consider monitoring mother-to-infant bonding already during pregnancy. Future research should evaluate whether interventions aimed at depressive symptoms help to promote mother-to-infant bonding quality. More high-quality research on correlates for which inconsistent results were found is needed.",14,9,e0222998,,Child development; Systematic review; Observational study; Psychological intervention; MEDLINE; CINAHL; Population; Clinical psychology; Medicine; Cohort,,"Child Development; Depression, Postpartum/prevention & control; Female; Humans; Infant; Mother-Child Relations/psychology; Mothers/psychology; Postpartum Period/psychology; Pregnancy; Prenatal Care/methods",,,https://europepmc.org/article/MED/31550274 https://research.vumc.nl/en/publications/correlates-of-prenatal-and-postnatal-mother-to-infant-bonding-qua http://dspace.library.uu.nl/handle/1874/387539 https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Ffcc171df-f24c-468d-a35f-fb4687cd74dd http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759162 https://www.ncbi.nlm.nih.gov/pubmed/31550274 https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0222998&type=printable https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0222998 https://www.rug.nl/research/portal/files/97728207/Correlates_of_prenatal_and_postnatal_mother_to_infant_bonding_qualit_A_systematic_review.pdf http://ui.adsabs.harvard.edu/abs/2019PLoSO..1422998T/abstract https://www.rug.nl/research/portal/publications/ecorrelates-of-prenatal-and-postnatal-mothertoinfant-bonding-quality(fcc171df-f24c-468d-a35f-fb4687cd74dd).html https://dx.plos.org/10.1371/journal.pone.0222998 https://pubmed.ncbi.nlm.nih.gov/31550274/,http://dx.doi.org/10.1371/journal.pone.0222998,31550274,10.1371/journal.pone.0222998,2975920003,PMC6759162,0,003-325-192-090-13X; 005-675-165-888-851; 005-911-001-086-520; 006-900-257-505-701; 007-215-358-062-859; 007-371-490-704-77X; 008-231-561-383-03X; 008-484-960-377-281; 009-758-509-606-90X; 010-367-729-210-840; 010-693-647-602-713; 014-397-121-263-840; 014-931-462-179-396; 015-595-159-873-541; 015-637-299-917-545; 017-300-737-144-757; 018-282-517-882-424; 020-517-570-510-561; 024-136-121-453-844; 027-588-140-490-305; 028-910-513-358-702; 031-876-581-129-524; 033-198-907-383-93X; 033-252-224-622-393; 037-944-164-755-030; 040-172-850-296-699; 043-402-963-968-21X; 044-644-791-906-714; 044-788-967-907-810; 045-201-107-411-584; 045-208-766-867-456; 048-031-660-899-028; 050-210-638-821-000; 051-869-229-585-125; 053-533-637-937-277; 055-536-114-115-756; 056-254-821-224-258; 056-476-360-821-829; 067-163-843-912-09X; 067-839-473-322-603; 075-364-010-684-708; 075-369-068-784-560; 079-852-808-041-806; 081-880-379-022-673; 083-275-795-865-394; 083-561-544-611-020; 083-718-184-171-473; 093-399-427-104-775; 098-475-449-798-716; 107-727-928-901-242; 109-317-852-624-576; 129-102-911-921-384; 134-648-902-338-256; 135-150-655-798-375; 141-040-975-662-610; 141-946-089-021-609; 160-649-340-320-368,40
043-077-059-046-202,The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis,2020-04-25,2020,journal article,Heart failure reviews,15737322; 13824147,Springer Netherlands,Netherlands,Lena Bosch; Judith J. de Haan; Marissa Bastemeijer; Jennifer J. van der Burg; Erik van der Worp; Marian Wesseling; Margarida Viola; Clémene Odille; Hamid el Azzouzi; Gerard Pasterkamp; Joost P.G. Sluijter; Kimberley E. Wever; Saskia C.A. de Jager,"The transverse aortic constriction (TAC) model is frequently used to study adverse cardiac remodeling upon pressure overload. We set out to define the most important characteristics that define the degree of cardiac remodeling in this model. A systematic review and meta-analyses were performed on studies using the TAC mouse/rat model and reporting echocardiographic outcome parameters. We included all animal studies in which a constriction around the transverse aorta and at least one of the predefined echocardiography or MRI outcome parameters were assessed. A total of 502 articles and > 3000 wild-type, untreated animals undergoing TAC were included in this study and referenced to a control group. The duration of aortic constriction correlated to the degree of adverse remodeling. However, the mouse data is strongly biased by the preferential use of male C57Bl/6 mice (66% of studies). Furthermore, mostly ketamine/xylazine anesthetics, 27G needle constriction, and silk sutures are used. Nonetheless, despite the homogeneity in experimental design, the model contained a substantial degree of heterogeneity in the functional outcome measures. When looking at study quality, only 12% reported randomization, 23% mentioned any sort of blinding, 25% adequately addressed the outcomes, and an amazingly low percentage (2%) showed sample size calculation. Meta-analyses did not detect specific study characteristics that explained the heterogeneity in the reported outcome measures, however this might be related to the strong bias towards the use of specific mouse lines, sex as well as age or to poor reporting of characteristics of study quality.",26,6,1515,1524,Internal medicine; Sample size determination; Cardiology; Animal studies; Constriction; Randomization; Blinding; Heart failure; Pressure overload; Medicine; Meta-analysis,Animal model; Hear failure; Meta-analysis; Systematic review; Transverse aortic constriction,,,ZonMw (114024108),https://repub.eur.nl/pub/126699/Repub_126699_O-A.pdf https://pubmed.ncbi.nlm.nih.gov/32335789/ https://link.springer.com/article/10.1007/s10741-020-09960-w https://repub.eur.nl/pub/126699 https://link.springer.com/content/pdf/10.1007/s10741-020-09960-w.pdf https://www.narcis.nl/publication/RecordID/oai%3Arepub.eur.nl%3A126699 https://www.ncbi.nlm.nih.gov/pubmed/32335789 https://core.ac.uk/download/322667963.pdf,http://dx.doi.org/10.1007/s10741-020-09960-w,32335789,10.1007/s10741-020-09960-w,3017883389,PMC8510918,0,007-614-764-466-152; 008-278-706-913-686; 009-605-153-787-318; 013-407-177-353-722; 014-240-508-364-990; 015-113-034-458-622; 016-733-271-037-278; 018-013-701-887-617; 025-179-747-295-274; 029-335-179-051-091; 032-878-599-009-542; 035-434-138-239-312; 038-480-375-379-075; 048-040-140-426-459; 052-734-780-539-938; 061-580-860-715-476; 078-503-353-437-123; 085-839-283-036-019; 097-597-701-117-88X; 132-305-583-974-791; 180-343-637-230-973,11
044-478-307-765-120,"Effects of the application of a checklist during trauma resuscitations on ATLS adherence, team performance, and patient-related outcomes: a systematic review.",2019-08-07,2019,journal article,European journal of trauma and emergency surgery : official publication of the European Trauma Society,18639941; 18639933,Urban und Vogel,Germany,Oscar E. C. van Maarseveen; Wietske H. W. Ham; Nils L.M. van de Ven; Tim F F Saris; Luke P. H. Leenen,"In this systematic literature review, the effects of the application of a checklist during in hospital resuscitation of trauma patients on adherence to the ATLS guidelines, trauma team performance, and patient-related outcomes were integrated. A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses checklist. The search was performed in Pubmed, Embase, CINAHL, and Cochrane inception till January 2019. Randomized controlled- or controlled before-and-after study design were included. All other forms of observational study designs, reviews, case series or case reports, animal studies, and simulation studies were excluded. The Effective Public Health Practice Project Quality Assessment Tool was applied to assess the methodological quality of the included studies. Three of the 625 identified articles were included, which all used a before-and-after study design. Two studies showed that Advanced Trauma Life Support (ATLS)-related tasks are significantly more frequently performed when a checklist was applied during resuscitation. [14 of 30 tasks (p   25, aOR 0.51, 95% CI 0.30–0.89). The application of a checklist may improve ATLS adherence and workflow during trauma resuscitation. Current literature is insufficient to truly define the effect of the application of a checklist during trauma resuscitation on patient-related outcomes, although one study showed promising results as an improved chance of survival for the most severely injured patients was found.",46,1,65,72,Public health; Systematic review; Emergency medicine; Observational study; Resuscitation; Checklist; Advanced trauma life support; CINAHL; Sports medicine; Medicine,Adherence; Checklist; Process- and patient related outcome; Trauma resuscitation,Advanced Trauma Life Support Care/standards; Checklist; Guideline Adherence; Hospital Mortality; Humans; Patient Care Team; Patient Outcome Assessment; Pneumonia; Resuscitation/standards; Task Performance and Analysis; Trauma Centers; Video Recording; Workflow,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026213 http://www.ncbi.nlm.nih.gov/pubmed/31392359 https://link.springer.com/content/pdf/10.1007/s00068-019-01181-7.pdf https://link.springer.com/article/10.1007/s00068-019-01181-7 https://pubmed.ncbi.nlm.nih.gov/31392359/,http://dx.doi.org/10.1007/s00068-019-01181-7,31392359,10.1007/s00068-019-01181-7,2964428410,PMC7026213,0,001-288-260-891-279; 002-437-968-676-083; 003-267-396-140-837; 007-251-065-982-035; 008-540-378-141-330; 009-285-113-953-553; 009-478-469-196-064; 012-646-389-602-219; 015-629-757-153-619; 015-827-479-087-494; 016-576-895-355-657; 018-235-376-058-922; 019-412-636-020-797; 021-039-961-480-067; 023-914-331-286-206; 025-415-725-538-599; 027-449-476-127-657; 027-723-925-900-238; 031-823-864-435-362; 032-761-523-976-879; 035-954-914-571-334; 038-209-367-866-932; 040-599-166-192-108; 046-178-786-591-217; 050-311-660-499-807; 053-064-662-672-275; 053-505-316-078-645; 054-900-543-939-333; 060-744-615-491-175; 068-578-402-235-223; 069-473-846-733-704; 080-431-369-653-973; 082-800-306-158-856; 089-273-305-006-570; 097-962-479-442-077; 101-336-047-938-807; 102-373-603-775-631; 105-238-670-687-161; 109-683-412-547-052; 111-697-719-291-468; 112-448-179-848-403; 116-045-562-159-108; 119-554-287-876-368; 123-308-718-004-205; 138-612-114-846-20X; 169-522-611-850-061,6
048-169-592-858-25X,Cue-reminders to prevent health-risk behaviors: A systematic review,2019-04-30,2019,journal article,Frontiers in public health,22962565,Frontiers Media SA,Switzerland,Lonneke van Leeuwen; Simone Onrust; Bas van den Putte; Marloes Kleinjan; Lex Lemmers; Rutger C. M. E. Engels; Roel C.J. Hermans,"Introduction: It has been proposed that the use of cue-reminders may increase the effectiveness of interventions that aim to prevent health-risk behaviors (i.e., having unsafe sex, unhealthy dietary intake, lack of physical activity, and substance use). The aim of this systematic review was to explore whether there is evidence supporting this proposition, and to explore how cue-reminders are applied in health-risk behavior interventions to date. Method: We systemically reviewed (non-) randomized trials that examine differences in health-risk behaviors between an experimental group receiving an intervention with exposure to a cue-reminder and a control group receiving the intervention without such cue. Results: Six studies were eligible for inclusion. The studies differed in sample and research design, and how the cue-reminder was applied. One study demonstrated a positive and small effect, and one study found a negative medium effect of the cue-reminder. In the remaining studies, the effect sizes were positive but non-significant. Discussion: It is unclear whether complementing health-risk behavior interventions with cue-reminders increases the effectiveness of these interventions. Further investigation and experimentation into the efficiency and effectiveness of cue-reminders is needed before health-risk behavior interventions are complemented with cue-reminders.",7,,97,97,Randomized controlled trial; Health promotion; Psychological intervention; Research design; Intervention (counseling); Unsafe Sex; Health risk; Substance use; Clinical psychology; Medicine,cue-reminder; health promotion; health-risk behaviors; intervention programs; reminder cue,,,ZonMw,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524686/ https://pubmed.ncbi.nlm.nih.gov/31134173/ https://europepmc.org/article/PMC/PMC6524686 http://dspace.library.uu.nl/handle/1874/390441 https://www.frontiersin.org/articles/10.3389/fpubh.2019.00097/pdf https://www.frontiersin.org/articles/10.3389/fpubh.2019.00097/full https://repository.ubn.ru.nl/handle/2066/203412 https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F203412,http://dx.doi.org/10.3389/fpubh.2019.00097,31134173,10.3389/fpubh.2019.00097,2942532181,PMC6524686,0,013-934-837-047-718; 017-300-737-144-757; 034-672-199-602-477; 039-566-201-075-585; 046-103-544-340-427; 046-168-705-567-76X; 047-192-755-452-924; 049-554-571-992-924; 051-448-747-432-799; 064-311-311-371-336; 070-172-317-354-537; 073-361-869-835-98X; 078-561-857-629-298; 096-809-647-161-841; 118-399-068-886-95X; 153-278-939-356-523,1
049-235-985-072-660,Health related quality of life in adults after burn injuries: A systematic review.,2018-05-24,2018,journal article,PloS one,19326203,Public Library of Science,United States,Inge Spronk; C.M. Legemate; I.M.M.H. Oen; Nancy E. E. Van Loey; Suzanne Polinder; Margriet E. van Baar,"Objectives Measurement of health-related quality of life (HRQL) is essential to qualify the subjective burden of burns in survivors. We performed a systematic review of HRQL studies in adult burn patients to evaluate study design, instruments used, methodological quality, and recovery patterns. Methods A systematic review was performed. Relevant databases were searched from the earliest record until October 2016. Studies examining HRQL in adults after burn injuries were included. Risk of bias was scored using the Quality in Prognostic Studies tool. Results Twenty different HRQL instruments were used among the 94 included studies. The Burn Specific Health Scale–Brief (BSHS-B) (46%), the Short Form–36 (SF-36) (42%) and the EuroQol questionnaire (EQ-5D) (9%) were most often applied. Most domains, both mentally and physically orientated, were affected shortly after burns but improved over time. The lowest scores were reported for the domains ‘work’ and ‘heat sensitivity’ (BSHS-B), ‘bodily pain’, ‘physical role limitations’ (SF-36), and ‘pain/discomfort’ (EQ-5D) in the short-term and for ‘work’ and ‘heat sensitivity’, ‘emotional functioning’ (SF-36), ‘physical functioning’ and ‘pain/discomfort’ in the long-term. Risk of bias was generally low in outcome measurement and high in study attrition. Conclusion Consensus on preferred validated methodologies of HRQL measurement in burn patients would facilitate comparability across studies, resulting in improved insights in recovery patterns and better estimates of HRQL after burns. We recommend to develop a guideline on the measurement of HRQL in burns. Five domains representing a variety of topics had low scores in the long-term and require special attention in the aftermath of burns.",13,5,1,21,Quality of life; Physical therapy; Systematic review; MEDLINE; Guideline; Publication bias; Bodily pain; Health related quality of life; Medicine; Meta-analysis,,Adult; Age Factors; Burns/epidemiology; Health Surveys; Humans; Publication Bias; Quality of Life; Surveys and Questionnaires,,The Dutch Burn Foundation,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197507 https://www.ncbi.nlm.nih.gov/pubmed/29795616 https://repub.eur.nl/pub/107150 https://www.narcis.nl/publication/RecordID/oai%3Apure.atira.dk%3Apublications%2F4f773b1e-bfaa-4cba-ad6a-462e7d5c0752 https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0197507&type=printable https://research.vumc.nl/en/publications/health-related-quality-of-life-in-adults-after-burn-injuries-a-sy https://doaj.org/article/157308ff5b7a4cf0925dc9d1fef30a8e https://dx.plos.org/10.1371/journal.pone.0197507 https://repub.eur.nl/pub/107150/REPUB_107150-OA.pdf http://dspace.library.uu.nl/handle/1874/369836 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967732/ https://europepmc.org/article/MED/29795616 http://ui.adsabs.harvard.edu/abs/2018PLoSO..1397507S/abstract https://pubmed.ncbi.nlm.nih.gov/29795616/ https://core.ac.uk/download/158600741.pdf,http://dx.doi.org/10.1371/journal.pone.0197507,29795616,10.1371/journal.pone.0197507,2804212020,PMC5967732,0,000-095-418-219-654; 000-476-376-436-27X; 001-988-286-976-462; 002-517-356-598-133; 005-676-320-924-619; 006-062-331-782-185; 006-599-030-957-56X; 006-723-710-020-952; 006-792-858-101-328; 007-413-146-957-156; 009-558-679-892-447; 010-215-142-120-253; 010-823-176-942-983; 013-571-073-707-500; 013-573-490-516-077; 015-155-985-695-610; 015-890-594-520-654; 017-300-737-144-757; 017-328-424-448-615; 017-951-672-196-191; 017-997-047-947-301; 018-383-448-380-369; 018-920-128-076-617; 020-177-985-800-28X; 021-252-163-460-574; 021-382-858-924-166; 021-536-952-159-72X; 021-676-528-864-053; 021-845-710-078-774; 022-096-101-358-069; 027-043-142-957-490; 027-528-378-332-521; 028-282-496-609-244; 028-563-171-787-852; 028-576-437-862-729; 028-581-807-913-260; 029-134-341-176-765; 030-311-277-357-835; 030-388-525-660-290; 030-638-685-241-035; 032-234-465-372-000; 032-653-034-065-726; 034-322-772-308-642; 034-658-976-439-950; 034-976-140-122-922; 035-099-621-109-459; 036-143-298-915-048; 036-316-407-640-964; 037-675-016-101-550; 037-858-857-213-057; 039-652-393-026-008; 039-880-465-208-578; 040-421-501-086-815; 041-364-822-425-417; 042-139-277-979-718; 042-585-201-912-349; 043-509-255-624-651; 043-675-623-963-299; 043-917-347-802-462; 043-972-189-442-300; 045-003-476-406-396; 045-852-113-448-243; 048-987-162-011-846; 049-498-163-875-936; 050-161-763-471-611; 051-720-242-590-978; 052-075-779-686-192; 053-082-644-810-506; 055-145-568-139-455; 056-483-465-366-557; 057-001-127-196-286; 057-571-706-320-24X; 060-417-084-663-186; 060-467-397-818-957; 060-924-342-336-943; 060-934-377-125-926; 063-232-343-564-165; 064-526-107-399-559; 065-565-118-459-201; 066-444-904-368-898; 068-526-338-360-657; 068-743-054-120-994; 068-760-067-498-536; 070-873-434-063-917; 073-837-227-794-160; 075-461-759-418-801; 075-903-212-158-802; 075-908-813-993-697; 078-027-790-184-967; 079-064-816-679-757; 079-781-202-630-15X; 080-251-278-964-364; 081-828-421-361-241; 082-061-594-261-578; 083-275-795-865-394; 084-688-251-773-039; 087-692-009-311-582; 088-064-242-267-628; 090-266-453-798-776; 090-382-478-416-955; 092-197-600-348-780; 093-706-799-228-979; 100-660-177-576-507; 100-720-025-833-06X; 101-716-855-120-16X; 107-855-731-321-814; 109-162-523-739-635; 117-669-300-092-662; 118-848-696-147-219; 122-995-180-856-684; 123-062-237-619-949; 123-270-618-727-229; 124-728-861-114-885; 126-347-918-902-852; 127-332-497-697-938; 137-130-922-340-997; 140-400-104-366-525; 157-910-716-293-029; 167-133-622-793-064; 171-167-831-321-434; 171-651-696-595-495; 180-985-382-338-820,49
049-286-329-480-789,Wernicke encephalopathy in patients with depression: A systematic review,2020-08-06,2020,journal article,Psychiatry and clinical neurosciences,14401819; 13231316,Wiley-Blackwell,United Kingdom,Erik Oudman,,74,10,569,572,Pediatrics; Depression (differential diagnoses); MEDLINE; Wernicke Encephalopathy; In patient; Medicine,,Adult; Aged; Depressive Disorder/complications; Female; Humans; Male; Middle Aged; Wernicke Encephalopathy/etiology; Young Adult,,,https://onlinelibrary.wiley.com/doi/10.1111/pcn.13113 https://pubmed.ncbi.nlm.nih.gov/32657502/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590192,http://dx.doi.org/10.1111/pcn.13113,32657502,10.1111/pcn.13113,3042988616,PMC7590192,0,002-681-489-110-933; 007-216-411-594-526; 020-886-444-066-133; 023-280-348-827-441; 032-525-651-502-622; 040-238-965-621-761; 044-985-305-640-494; 060-654-694-241-81X; 148-381-284-833-61X,1
049-379-768-446-606,The relationship between preterm birth and sleep in children at school age: A systematic review,2021-01-26,2021,journal article,Sleep medicine reviews,15322955; 10870792,W.B. Saunders Ltd,United Kingdom,Simone S.M. Visser; Willemijn J.M. van Diemen; Laura Kervezee; Agnes van den Hoogen; Olaf Verschuren; Sigrid Pillen; Manon J.N.L. Benders; Jeroen Dudink,"Premature birth (before 37 weeks of gestation) has been linked to a variety of adverse neurological outcomes. Sleep problems are associated with decreased neurocognitive functioning, which is especially common in children born preterm. The exact relationship between prematurity and sleep at school age is unknown. A systematic review is performed with the aim to assess the relationship between prematurity and sleep at school age (5th to 18th year of life), in comparison to sleep of their peers born full-term. Of 347 possibly eligible studies, nine were included. The overall conclusion is that prematurity is associated with earlier bedtimes and a lower sleep quality, in particular more nocturnal awakenings and more non-rapid eye movement stage 2 sleep. Interpretations and limitations of the review are discussed. Moreover, suggestions for future research are brought forward, including the need for a systematic approach with consistent outcome measures in this field of research. A better understanding of the mechanisms that influence sleep in the vulnerable group of children born preterm could help optimize these children's behavioral and intellectual development.",57,,101447,,Sleep in non-human animals; Eye movement; Neurocognitive; Premature birth; Sleep quality; Intellectual development; School age child; Gestation; Clinical psychology; Medicine,Preterm birth; School-aged children; Sleep characteristics; Sleep problems; Systematic review,"Child; Cognition; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Schools; Sleep",,,https://www.narcis.nl/publication/RecordID/oai%3Ascholarlypublications.universiteitleiden.nl%3Aitem_3209336 https://pubmed.ncbi.nlm.nih.gov/33611088/ https://www.ncbi.nlm.nih.gov/pubmed/33611088 https://www.sciencedirect.com/science/article/pii/S1087079221000320 http://pubmed.ncbi.nlm.nih.gov/33611088/,http://dx.doi.org/10.1016/j.smrv.2021.101447,33611088,10.1016/j.smrv.2021.101447,3125865816,,0,000-946-161-036-125; 003-479-757-976-491; 006-579-930-807-411; 007-447-193-002-040; 010-214-846-378-143; 010-530-829-570-146; 014-065-988-264-896; 015-195-171-804-976; 016-613-020-315-361; 017-300-737-144-757; 017-563-935-608-22X; 018-239-243-391-260; 018-360-945-236-024; 018-747-454-333-096; 019-710-914-138-02X; 021-575-553-735-381; 023-378-702-973-704; 031-425-563-558-058; 031-697-861-886-841; 032-004-305-998-588; 033-765-409-692-99X; 035-393-276-265-166; 039-108-286-020-701; 041-408-950-798-80X; 042-005-185-807-309; 044-169-771-923-20X; 044-479-681-468-542; 045-827-147-714-744; 050-311-031-296-601; 052-788-941-812-258; 052-803-275-201-852; 054-150-678-978-794; 056-019-760-491-634; 057-047-609-116-369; 057-965-539-486-868; 061-073-617-928-248; 062-504-715-588-484; 062-605-538-889-640; 072-519-784-697-486; 075-442-899-294-800; 077-100-966-109-883; 083-275-795-865-394; 085-068-031-096-725; 085-682-433-026-076; 097-988-286-476-970; 100-149-515-115-749; 101-573-238-172-735; 107-510-318-648-078; 112-656-577-990-284; 115-618-909-483-476; 125-776-868-053-432; 130-510-814-709-38X; 131-346-217-513-631; 137-419-905-340-941; 150-682-759-971-962; 192-371-000-655-126,1
050-664-124-893-900,Return to Sport in Athletes with Midportion Achilles Tendinopathy: A Qualitative Systematic Review Regarding Definitions and Criteria,2017-12-16,2017,journal article,"Sports medicine (Auckland, N.Z.)",11792035; 01121642,Springer International Publishing AG,United Kingdom,Bas Habets; Anke G. van den Broek; Bionka M. A. Huisstede; Frank J G Backx; Robert van Cingel,"Midportion Achilles tendinopathy (AT) can cause long-term absence from sports participation, and shows high recurrence rates. It is important that the decision to return to sport (RTS) is made carefully, based on sharply delimited criteria. Lack of a well-defined definition and criteria hampers the decision to RTS among athletes with AT, and impedes comparison of RTS rates between different studies. The aim of this study was to systematically review the literature for definitions of, and criteria for, RTS in AT research. Qualitative systematic review. The PubMed, EMBASE, Cochrane, CINAHL, PEDro, and Scopus electronic databases were searched for articles that reported on the effect of a physiotherapeutic intervention for midportion AT. Article selection was independently performed by two researchers. Qualitative content analysis was used to analyze the included studies and extract definitions of, and criteria for, RTS. Thirty-five studies were included in the content analysis, showing large variety in both the definitions and criteria. Thirty-two studies reported a definition of RTS, but only 19 studies described the criteria for RTS. The content analysis revealed that ‘reaching pre-injury activity/sports level, with the ability to perform training and matches without limitations’, ‘absence of pain’, and ‘recovery’ were the main content categories used to define RTS. Regarding the criteria for RTS, eight different content categories were defined: (1) ‘level of pain’; (2) ‘level of functional recovery’; (3) ‘recovery of muscle strength’; (4) ‘recovery of range of motion’; (5) ‘level of endurance of the involved limb’; (6) ‘medical advice’; (7) ‘psychosocial factors’; and (8) ‘anatomical/physiological properties of the musculotendinous complex’. Many criteria were not clearly operationalized and lacked specific information. This systematic review shows that RTS may be defined according to the pre-injury level of sports (including both training and matches), but also with terms related to the absence of pain and recovery. Multiple criteria for RTS were found, which were all related to level of pain, level of functional recovery, muscular strength, range of motion, endurance, medical advice, psychosocial factors, or anatomical/physiological properties of the Achilles tendon. For most of the criteria we identified, no clear operationalization was given, which limits their validity and practical usability. Further research on how RTS after midportion AT should be defined, and which criteria should be used, is warranted. CRD42017062518.",48,3,705,723,Psychosocial; Psychology; Medical advice; Tendinopathy; MEDLINE; Athletes; CINAHL; Sports medicine; Operationalization; Physical medicine and rehabilitation,,Achilles Tendon/injuries; Athletes; Athletic Injuries/physiopathology; Humans; Muscle Strength/physiology; Recovery of Function; Return to Sport; Tendinopathy/surgery; Tenotomy/methods; Time Factors; Treatment Outcome,,,https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F364358 https://www.ncbi.nlm.nih.gov/pubmed/29249084 https://pubmed.ncbi.nlm.nih.gov/29249084/ https://link.springer.com/article/10.1007/s40279-017-0833-9 https://europepmc.org/article/MED/29249084 https://paperity.org/p/85695882/return-to-sport-in-athletes-with-midportion-achilles-tendinopathy-a-qualitative https://link.springer.com/article/10.1007/s40279-017-0833-9/fulltext.html http://dspace.library.uu.nl/handle/1874/364358 https://link.springer.com/content/pdf/10.1007%2Fs40279-017-0833-9.pdf,http://dx.doi.org/10.1007/s40279-017-0833-9,29249084,10.1007/s40279-017-0833-9,2771299360,PMC5808052,0,000-394-621-237-33X; 004-834-713-849-909; 005-579-031-711-655; 006-038-098-632-331; 007-563-753-588-915; 008-408-032-315-964; 009-663-220-046-655; 010-087-024-199-817; 010-665-588-778-509; 010-871-162-503-177; 011-140-185-083-643; 012-095-711-803-599; 012-964-336-918-424; 014-573-258-791-687; 018-882-656-445-426; 021-224-055-647-317; 021-862-840-020-92X; 025-257-405-959-641; 025-609-621-601-325; 031-056-855-501-837; 032-335-221-877-267; 034-753-484-918-643; 035-652-852-687-097; 041-669-116-670-527; 046-733-694-695-086; 048-814-100-489-873; 050-051-254-783-660; 052-602-479-187-334; 056-672-567-840-363; 058-468-154-085-341; 060-805-762-660-107; 061-330-234-974-268; 061-507-436-468-647; 061-536-627-779-600; 065-055-544-806-376; 067-181-817-917-646; 069-769-426-615-368; 072-651-914-245-890; 073-440-266-937-78X; 086-706-166-103-494; 094-213-099-107-472; 096-519-418-572-246; 098-603-954-565-255; 099-409-484-390-944; 100-200-307-156-635; 102-288-651-492-621; 108-247-504-907-10X; 112-894-847-206-343; 113-484-406-638-129; 128-027-811-235-746; 128-228-414-547-27X; 142-283-443-689-655; 175-289-007-026-921; 180-373-229-924-527,14
054-207-309-797-175,Flare-Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]-NaF PET/CT Study and a Systematic Review.,2017-07-05,2017,journal article,JBMR plus,24734039,Wiley,England,E. Marelise W. Eekhoff; J. Coen Netelenbos; Pim de Graaf; Max Hoebink; Nathalie Bravenboer; Dimitra Micha; Gerard Pals; Teun J. de Vries; Adriaan A. Lammertsma; Pieter G. Raijmakers; Robert J.J. van Es,"Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder leading to progressive heterotopic ossifications (HO) of muscles, tendons, and ligaments, which can be induced by trauma or by surgery. Despite strong medical advice to the contrary, an FOP patient insisted on surgery to alleviate her complete trismus, which caused an unbearable impact on her quality of life (QOL). The entire trismus history of this FOP patient is presented. [18F]-NaF position emission tomography/computed tomography (PET/CT) scans were introduced as an imaging method for heterotopic bone formation activity. To place our findings into context, a systematic review on jaw surgery in FOP was performed. After falling down the stairs, a 9-year-old patient developed mobility impairment of her left-sided jaw. During the following 13 years bone scintigraphy showed persistent activity of the disease leading to progressive left-sided zygomatico-mandibular fusion by HO, resulting in complete trismus. Within 1 month after HO removal on the left side and a matching right coronoidectomy, [18F]-NaF PET/CT demonstrated a substantial flare-up activity followed by new HO in both masseter and temporalis muscles. Despite recurrent HO and trismus her QOL increased due to a stable increased interincisal opening of 5.5 mm. Although systematic review reveals a 100% risk of HO recurrence after jaw surgery, information on improved QOL is scarce. In conclusion, surgery in FOP may be beneficial for QOL despite new HO formation. Assessment of disease activity using [18F]-NaF PET/CT is possible before HO is evident on CT and may serve as a new and quantitative marker of the disease. © 2017 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.",2,1,55,58,Quality of life; PET-CT; Surgery; Bone scintigraphy; Fibrodysplasia ossificans progressiva; Trismus; Context (language use); Heterotopic ossification; Jaw Surgery; Medicine,FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FLARE‐UP; FOP; HETEROTOPIC OSSIFICATION; HO; MAXILLOFACIAL SURGERY; SYSTEMATIC REVIEW; TRISMUS; [18F]‐NAF PET/CT,,,,https://asbmr.onlinelibrary.wiley.com/doi/pdf/10.1002/jbm4.10008 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124206/ https://onlinelibrary.wiley.com/doi/full/10.1002/jbm4.10008 https://www.narcis.nl/publication/RecordID/oai%3Adare.uva.nl%3Apublications%2Ff8d1ab1a-57e0-47aa-b819-e73cf89e6292 https://pure.uva.nl/ws/files/32346732/Eekhoff_et_al_2018_JBMR_Plus.pdf https://europepmc.org/abstract/MED/30283890 https://research.vumc.nl/en/publications/flare-up-after-maxillofacial-surgery-in-a-patient-with-fibrodyspl https://onlinelibrary.wiley.com/doi/abs/10.1002/jbm4.10008 https://asbmr.onlinelibrary.wiley.com/doi/full/10.1002/jbm4.10008,http://dx.doi.org/10.1002/jbm4.10008,30283890,10.1002/jbm4.10008,2620142672,PMC6124206,2,000-650-911-042-821; 001-039-677-648-453; 018-247-229-564-364; 021-156-914-619-84X; 045-084-740-087-628; 056-072-774-372-719; 072-810-977-478-996; 116-010-529-862-002; 131-664-323-818-694; 135-479-240-187-015; 146-451-072-000-980; 152-967-299-258-091; 175-596-911-075-094; 176-706-981-515-447; 185-872-581-871-696; 194-604-687-784-334,16
054-913-007-421-533,Tackling Missing Heritability by Use of an Optimum Curve: A Systematic Review and Meta-Analysis,2019-10-15,2019,journal article,International journal of molecular sciences,14220067; 16616596,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Anneke Wegener Sleeswijk; Reinout Heijungs; Sarah Durston,"Missing heritability is a common problem in psychiatry that impedes precision medicine approaches to autism and other heritable complex disorders. This proof-of-concept study uses a systematic review and meta-analysis of the association between variants of the serotonin transporter promoter (5-HTTLPR) and autism to explore the hypothesis that some missing heritability can be explained using an optimum curve. A systematic literature search was performed to identify transmission disequilibrium tests on the short/long (S/L) 5-HTTLPR polymorphism in relation to autism. We analysed five American, seven European, four Asian and two American/European samples. We found no transmission preference in the joint samples and in Europe, preferential transmission of S in America and preferential transmission of L in Asia. Heritability will be underestimated or missed in genetic association studies if two alternative genetic variants are associated with the same disorder in different subsets of a sample. An optimum curve, relating a multifactorial biological variable that incorporates genes and environment to a score for a human trait, such as social competence, can explain this. We suggest that variants of functionally related genes will sometimes appear in fixed combinations at both sides of an optimum curve and propose that future association studies should account for such combinations.",20,20,5104,,Trait; Missing heritability problem; Heritability; Genetic association; Autism; Disequilibrium; Sample (statistics); Evolutionary biology; Biology; Meta-analysis,5-HTTLPR polymorphism; autism; context-dependent risk variants; genetic association; inverted U; meta-analysis; missing heritability; multifactorial variable; optimum curve; systematic review,"Autism Spectrum Disorder/diagnosis; Genetic Predisposition to Disease; Humans; Odds Ratio; Polymorphism, Single Nucleotide; Risk Assessment; Serotonin Plasma Membrane Transport Proteins/genetics","SLC6A4 protein, human; Serotonin Plasma Membrane Transport Proteins",,https://www.mdpi.com/1422-0067/20/20/5104/pdf https://research.vu.nl/en/publications/tackling-missing-heritability-by-use-of-an-optimum-curve-a-system https://www.narcis.nl/publication/RecordID/oai%3Ascholarlypublications.universiteitleiden.nl%3Aitem_2914931 http://dspace.library.uu.nl/handle/1874/392000 https://europepmc.org/abstract/MED/31618836 https://pubmed.ncbi.nlm.nih.gov/31618836/ https://www.mdpi.com/1422-0067/20/20/5104/htm https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829377,http://dx.doi.org/10.3390/ijms20205104,31618836,10.3390/ijms20205104,2979869960,PMC6829377,0,001-598-980-698-008; 004-694-153-472-039; 005-001-563-181-658; 005-549-290-968-060; 008-911-386-657-679; 013-868-990-792-666; 014-987-237-674-270; 017-300-737-144-757; 018-266-559-066-134; 019-362-221-557-952; 024-551-419-875-140; 026-186-769-115-627; 027-793-233-871-724; 032-490-269-378-07X; 033-584-852-511-409; 045-416-413-742-937; 046-778-113-015-660; 049-009-799-345-156; 052-506-760-597-888; 058-301-807-577-905; 058-349-855-284-691; 059-923-199-605-572; 065-386-062-844-923; 073-143-602-796-488; 077-139-663-027-31X; 078-744-037-121-562; 079-596-679-986-677; 080-051-072-096-26X; 080-729-512-647-720; 081-514-422-183-414; 090-747-524-416-85X; 095-715-382-558-208; 099-239-103-248-858; 100-251-899-808-878; 103-427-212-049-250; 108-151-510-475-204; 112-428-677-812-763; 112-892-937-942-708; 121-551-458-084-997; 126-100-430-890-099; 140-193-251-536-679; 144-720-592-370-440; 148-119-655-468-356; 149-038-784-397-437; 171-581-005-552-875; 191-244-620-290-713,2
055-332-017-875-628,Postoperative care in microvascular free flap reconstruction of the lower extremity: A systematic review,,2020,journal article,Orthoplastic Surgery,2666769x,Elsevier BV,,David D. Krijgh; Milou M.E. van Straeten; Marc A.M. Mureau; Antonius J.M. Luijsterburg; Pascal P. A. Schellekens; Wiesje Maarse; J. Henk Coert,"Abstract Background Free tissue transfer is a commonly used procedure to reconstruct defects of the lower extremity. However, measures of postoperative care to promote flap maturity vary greatly. Dangling protocols tend to be highly divergent regarding the start, duration, schedules and monitoring of dangling, as well as the additional use of compression stockings or bandaging. The aim of this systematic review to review and evaluate current literature and to provide recommendations. Methods A systematic literature review was performed in accordance with PRISMA guidelines. Literature databases were searched for relevant articles about early ambulation following lower leg reconstruction. Results A total of 10 articles met the inclusion criteria: 2 randomized controlled trials and 7 case-series and one cohort study. The optimal start, duration and frequency of the dangling and compression procedures remain unclear, and so does the necessity of dangling and compression in general. An early and aggressive dangling procedure can be safely introduced on postoperative day (POD) 3, taking possible comorbidities into consideration. Early initiation might help shorten hospital stay, thereby reducing associated medical costs. Furthermore, compressive wrapping applied to the dangled leg seems to have a positive effect on flap perfusion and patient comfort. Conclusion Based on the current literature, it is suggested that an early and aggressive dangling procedure can safely be started on POD 3. Compression therapy during dangling increases perfusion and venous return of the free flap and increases the comfort of the patient.",1-2,,21,26,Surgery; Randomized controlled trial; Systematic review; Cohort study; Compression stockings; Free flap; Free flap reconstruction; Early initiation; Venous return curve; Medicine,,,,,https://www.sciencedirect.com/science/article/pii/S2666769X20300038,http://dx.doi.org/10.1016/j.orthop.2020.10.003,,10.1016/j.orthop.2020.10.003,3099757865,,0,003-249-061-852-18X; 003-909-086-446-154; 004-683-264-845-033; 010-768-771-452-816; 017-881-808-671-983; 019-055-521-833-365; 020-711-392-557-787; 021-831-138-917-831; 023-368-757-030-384; 023-970-724-621-358; 028-325-952-133-778; 029-922-110-576-021; 030-347-242-238-689; 032-884-849-042-291; 035-707-051-905-707; 040-569-156-385-187; 045-749-985-767-959; 048-767-010-501-69X; 056-098-747-567-196; 058-636-477-973-781; 068-400-939-902-77X; 078-886-174-321-732; 079-749-515-244-292; 080-341-574-141-783; 080-889-191-712-28X; 083-275-795-865-394; 084-302-894-390-74X; 098-319-077-438-87X; 110-745-593-518-029; 115-238-510-142-499; 129-271-862-382-843; 140-981-043-678-08X; 156-661-388-483-155; 163-223-987-448-910,0
058-895-823-408-950,Anti-inflammatory compounds to reduce infarct size in large-animal models of myocardial infarction: A meta-analysis,,2014,journal article,Evidence-based Preclinical Medicine,2054703x,Wiley,,G. P. J. van Hout; Kimberley E. Wever; Emily S. Sena; W. W. van Solinge; P. A. F. M. Doevendans; Gerard Pasterkamp; Steven A. J. Chamuleau; Imo E. Hoefer,"Targeting the inflammatory response after myocardial infarction (MI) could potentially prevent infarct expansion, resulting in a preservation of cardiac function. Despite extensive testing in large-animal models of MI, anti-inflammatory therapeutics are not incorporated in daily clinical practice. Methodological review of the literature describing the effects of anti-inflammatory compounds in large-animal models of MI may provide useful insights into the reasons for the translational failure from preclinical to clinical studies. Moreover, systematic review of these preclinical studies may allow us to determine which anti-inflammatory agents have the greatest potential to successfully treat MI in the clinic and guide which preclinical setting appears most appropriate to test these future treatment strategies in. The current systematic review protocol provides a detailed description of the design of this systematic review of studies investigating the effects of anti-inflammatory compounds in large-animal models of MI.",1,1,4,10,Intensive care medicine; Physical therapy; Clinical Practice; Treatment strategy; Infarct size; Large animal; Inflammatory response; Myocardial infarction; Medicine; Meta-analysis,,,,,http://www.dcn.ed.ac.uk/camarades/files/van%20Hout%20et%20al.%20-%202014%20-%20Evidence-based%20Preclinical%20Medicine.pdf https://onlinelibrary.wiley.com/doi/full/10.1002/ebm2.4 http://onlinelibrary.wiley.com/doi/10.1002/ebm2.4/full,http://dx.doi.org/10.1002/ebm2.4,,10.1002/ebm2.4,1554641031,,0,005-470-147-782-982; 006-200-591-206-654; 011-394-022-782-706; 012-144-855-592-741; 020-498-444-069-532; 021-312-284-450-85X; 022-724-457-993-391; 023-692-494-882-394; 028-399-061-858-056; 030-491-636-368-810; 036-118-520-988-72X; 040-577-952-309-134; 049-586-358-683-408; 054-505-107-864-064; 059-276-745-883-10X; 069-713-764-127-76X; 085-021-301-691-375; 090-326-252-759-609; 097-597-701-117-88X; 110-276-917-575-531; 115-199-787-228-982,2
059-276-745-883-10X,Publication bias in reports of animal stroke studies leads to major overstatement of efficacy.,2010-03-30,2010,journal article,PLoS biology,15457885; 15449173,Public Library of Science,United States,Emily S. Sena; H. Bart van der Worp; Philip M.W. Bath; David W. Howells; Malcolm R. Macleod,"The consolidation of scientific knowledge proceeds through the interpretation and then distillation of data presented in research reports, first in review articles and then in textbooks and undergraduate courses, until truths become accepted as such both amongst “experts” and in the public understanding. Where data are collected but remain unpublished, they cannot contribute to this distillation of knowledge. If these unpublished data differ substantially from published work, conclusions may not reflect adequately the underlying biological effects being described. The existence and any impact of such “publication bias” in the laboratory sciences have not been described. Using the CAMARADES (Collaborative Approach to Meta-analysis and Review of Animal Data in Experimental Studies) database we identified 16 systematic reviews of interventions tested in animal studies of acute ischaemic stroke involving 525 unique publications. Only ten publications (2%) reported no significant effects on infarct volume and only six (1.2%) did not report at least one significant finding. Egger regression and trim-and-fill analysis suggested that publication bias was highly prevalent (present in the literature for 16 and ten interventions, respectively) in animal studies modelling stroke. Trim-and-fill analysis suggested that publication bias might account for around one-third of the efficacy reported in systematic reviews, with reported efficacy falling from 31.3% to 23.8% after adjustment for publication bias. We estimate that a further 214 experiments (in addition to the 1,359 identified through rigorous systematic review; non publication rate 14%) have been conducted but not reported. It is probable that publication bias has an important impact in other animal disease models, and more broadly in the life sciences.",8,3,1,8,Bibliometrics; Systematic review; MEDLINE; Publication bias; Meta-Analysis as Topic; Animal data; Clinical trial; Clinical psychology; Biology; Meta-analysis,,"Animals; Disease Models, Animal; Humans; Meta-Analysis as Topic; Models, Statistical; Publication Bias; Review Literature as Topic; Stroke/pathology; Treatment Outcome",,Chief Scientist Office (CZB/4/531) United Kingdom; Medical Research Council (G0800803) United Kingdom,http://www.ncbi.nlm.nih.gov/pubmed/20361022 https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1000344 http://www.dcn.ed.ac.uk/camarades//files/PLOS_Biology_PubBias.pdf https://www.rug.nl/research/portal/en/publications/publication-bias-in-reports-of-animal-stroke-studies-leads-to-major-overstatement-of-efficacy(243d757a-b23e-4b13-82a0-a0a85e2af0c3).html https://core.ac.uk/display/28969820 https://www.pure.ed.ac.uk/ws/files/8225089/Sena_et_al_2010.pdf https://ideas.repec.org/a/plo/pbio00/1000344.html https://www.research.ed.ac.uk/portal/files/8225089/Sena_et_al_2010.pdf https://pubmed.ncbi.nlm.nih.gov/20361022/ https://www.research.ed.ac.uk/en/publications/publication-bias-in-reports-of-animal-stroke-studies-leads-to-maj https://europepmc.org/articles/PMC2846857 https://www.wellbeingintlstudiesrepository.org/valaexp/17 https://www.wellbeingintlstudiesrepository.org/cgi/viewcontent.cgi?article=1017&context=valaexp https://animalstudiesrepository.org/valaexp/17/ https://dx.plos.org/10.1371/journal.pbio.1000344 https://minerva-access.unimelb.edu.au/handle/11343/263896 https://core.ac.uk/download/28969820.pdf,http://dx.doi.org/10.1371/journal.pbio.1000344,20361022,10.1371/journal.pbio.1000344,2164759539,PMC2846857,0,005-008-052-242-959; 005-286-066-747-157; 006-849-612-392-422; 006-992-219-658-88X; 007-606-121-101-256; 007-613-048-008-228; 010-964-451-032-757; 012-404-394-963-535; 013-136-026-952-654; 017-888-735-669-015; 022-012-691-457-014; 024-164-067-962-303; 024-263-634-091-625; 025-966-430-685-541; 026-929-334-244-264; 028-014-193-840-798; 036-118-520-988-72X; 042-301-020-915-711; 043-237-361-283-356; 047-608-782-925-287; 049-898-881-273-510; 050-192-652-879-00X; 050-293-888-300-466; 053-957-820-706-580; 060-040-141-390-579; 061-739-744-044-304; 076-937-571-051-048; 080-729-512-647-720; 085-839-283-036-019; 092-328-357-527-427; 098-399-104-101-58X; 098-466-838-538-139; 103-135-884-755-639; 105-315-616-673-910; 110-325-964-227-642; 120-091-125-432-93X; 136-017-968-222-135; 136-097-438-815-665; 145-059-605-089-437; 164-582-488-045-616; 173-289-307-414-536,443
065-377-632-328-388,"The effect of the CONSORT statement on the amount of ""unclear"" Risk of Bias reporting in Cochrane Systematic Reviews.",2020-07-10,2020,journal article,PloS one,19326203,Public Library of Science,United States,Maaike M. Rademaker; Geerte G. J. Ramakers; Adriana L. Smit; Lotty Hooft; Inge Stegeman,"Background ; The Consolidated Standards of Reporting Trials (CONSORT) statement aims to improve clarity and consistency of transparency of reporting in Randomized Controlled Trials (RCTs). The Cochrane Risk of Bias (RoB) tool for RCTs helps authors to judge the RoB. as ‘‘low”, “high” or “unclear”.; ; ; Objective ; In this study we aimed to assess whether the implementation and updates of the CONSORT statement influenced the trend of “unclear” RoB scores of RCTs included in Cochrane systematic reviews.; ; ; Methods ; All Cochrane reviews published in December to October 2016 were retrieved. The publication year of RCTS included in the reviews were sorted into time frames (≤1995, 1996–2000, 2001–2009 and ≥2010) based on the release- and updates of the CONSORT statement (1996, 2001 and 2010). The association between “unclear” RoB versus “low or high” RoB and the year of publication in different time frames were calculated using a binary logistic regression.; ; ; Results ; Data was extracted from 64 Cochrane reviews, with 989 RCTS (6471 items). The logistic regression showed that the odds of RCTs published ≥2010, compared to ≤1995 were more likely not to report an “unclear” RoB for the total data (Odds Ratio (OR) 0.69 (95% Confidence interval: 0.59–0.80)), random sequence generation (OR 0.32 (0.22–0.47), allocation concealment (0.64 (0.43–0.95)) and incomplete outcome data (OR 0.60 (0.39–0.91)).; ; ; Conclusion ; A slight decrease of “unclear” RoB reporting over time was found. To improve quality of reporting authors are encouraged to adhere to reporting guidelines.",15,7,1,9,Odds; Logistic regression; Odds ratio; Randomized controlled trial; Systematic review; MEDLINE; Confidence interval; Consolidated Standards of Reporting Trials; Family medicine; Medicine,,Bias; Randomized Controlled Trials as Topic; Reference Standards; Research Design/standards; Systematic Reviews as Topic,,,https://europepmc.org/article/PMC/PMC7351499 https://EconPapers.repec.org/RePEc:plo:pone00:0235535 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235535 https://plos.figshare.com/collections/The_effect_of_the_CONSORT_statement_on_the_amount_of_unclear_Risk_of_Bias_reporting_in_Cochrane_Systematic_Reviews/5056499 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351499 https://figshare.com/collections/The_effect_of_the_CONSORT_statement_on_the_amount_of_unclear_Risk_of_Bias_reporting_in_Cochrane_Systematic_Reviews/5056499 https://ui.adsabs.harvard.edu/abs/2020PLoSO..1535535R/abstract https://ideas.repec.org/a/plo/pone00/0235535.html https://dx.plos.org/10.1371/journal.pone.0235535 https://pubmed.ncbi.nlm.nih.gov/32650340/,http://dx.doi.org/10.1371/journal.pone.0235535,32650340,10.1371/journal.pone.0235535,3042042782,PMC7351499,0,000-182-484-526-391; 005-225-291-076-135; 005-634-009-454-524; 005-952-018-461-711; 007-611-448-549-681; 007-791-359-336-183; 010-088-663-461-556; 010-392-731-710-697; 010-396-081-524-929; 014-020-855-899-848; 014-771-012-282-134; 018-779-174-157-231; 018-879-462-801-27X; 020-055-834-926-285; 022-244-422-100-028; 022-791-770-842-995; 022-907-589-526-017; 027-778-489-979-557; 031-409-796-613-468; 032-422-028-158-880; 034-205-279-765-222; 036-392-470-270-171; 045-376-144-884-940; 047-358-448-526-61X; 048-382-477-690-730; 050-051-661-305-252; 055-597-044-553-732; 064-595-458-351-687; 066-823-239-717-858; 072-605-612-383-748; 075-259-496-264-353; 076-969-601-781-452; 085-174-383-485-66X; 087-250-328-220-313; 087-500-482-297-780; 092-373-511-812-625; 094-984-159-164-766; 099-001-109-017-145; 124-347-546-936-804; 125-953-390-163-804; 144-520-000-403-477; 150-275-239-465-179,3
065-711-248-562-429,Genetic underpinnings of schizophrenia-related electroencephalographical intermediate phenotypes: A systematic review and meta-analysis.,2020-06-07,2020,journal article,Progress in neuro-psychopharmacology & biological psychiatry,18784216; 02785846,Elsevier Inc.,Netherlands,Jure Hederih; Jasper O. Nuninga; Kristel R. van Eijk; Edwin van Dellen; Dirk J.A. Smit; Bob Oranje; Jurjen J. Luykx,"Although substantial research into genetics of psychotic disorders has been conducted, a large proportion of their genetic architecture has remained unresolved. Electroencephalographical intermediate phenotypes (EIP) have the potential to constitute a valuable tool when studying genetic risk loci for schizophrenia, in particular P3b amplitude, P50 suppression, mismatch negativity (MMN) and resting state power spectra of the electroencephalogram (EEG). Here, we systematically reviewed studies investigating the association of single nucleotide polymorphisms (SNPs) with these EIPs and meta-analysed them when appropriate. We retrieved 45 studies (N = 34,971 study participants). Four SNPs investigated in more than one study were genome-wide significant for an association with schizophrenia and three were genome-wide suggestive, based on a lookup in the influential 2014 GWAS (Ripke et al., 2014). However, in our meta-analyses, rs1625579 failed to reach a statistically significant association with p3b amplitude decrease and rs4680 risk allele carrier status was not associated with p3b amplitude decrease or with impaired p50 suppression. In conclusion, evidence for SNP associations with EIPs remains limited to individual studies. Careful selection of EIPs and SNPs, combined with consistent reporting of effect sizes, directions of effect and p-values would aid future meta-analyses.",104,,110001,,Genome-wide association study; SNP; Single-nucleotide polymorphism; Mismatch negativity; rs4680; Bioinformatics; Schizophrenia; Biology; Genetic architecture; Meta-analysis,ERP; Electroencephalography (EEG); Electrophysiology; Intermediate phenotypes; SNP; Schizophrenia,,,,https://www.sciencedirect.com/science/article/abs/pii/S0278584620303171 https://www.sciencedirect.com/science/article/pii/S0278584620303171 https://pubmed.ncbi.nlm.nih.gov/32525059/ http://pubmed.ncbi.nlm.nih.gov/32525059/ https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F0502655b-cba4-4b85-8805-c24fd8e56ac0 https://www.ncbi.nlm.nih.gov/pubmed/32525059,http://dx.doi.org/10.1016/j.pnpbp.2020.110001,32525059,10.1016/j.pnpbp.2020.110001,3033974797,,0,000-020-954-303-423; 000-406-475-294-04X; 001-648-139-432-915; 001-748-424-380-85X; 004-472-202-288-737; 006-178-053-331-249; 006-467-647-359-805; 008-127-236-461-364; 008-649-964-239-612; 011-854-625-626-387; 012-114-099-385-394; 013-016-247-179-638; 014-019-468-224-690; 014-691-983-440-035; 014-758-247-996-258; 016-583-087-352-98X; 017-017-934-916-003; 017-888-213-176-037; 018-450-211-843-414; 019-456-069-756-339; 020-984-899-924-084; 022-143-480-122-724; 022-810-150-562-846; 024-210-623-401-078; 024-512-539-631-392; 026-300-410-761-864; 026-804-904-392-770; 028-015-594-590-667; 030-412-971-540-077; 030-944-916-716-532; 035-317-068-355-824; 035-394-128-765-34X; 036-424-479-138-955; 036-826-836-384-137; 037-440-716-298-773; 037-656-218-245-639; 038-805-814-849-802; 040-477-748-452-453; 040-691-739-411-366; 041-095-884-378-596; 041-114-106-669-208; 042-477-570-051-734; 043-100-387-821-40X; 043-142-436-729-286; 043-447-520-808-005; 044-963-957-837-543; 047-012-734-011-416; 047-851-075-853-78X; 047-861-142-419-385; 048-070-489-927-237; 051-068-813-773-66X; 054-953-586-427-660; 056-536-762-505-660; 057-021-745-943-216; 057-378-085-265-844; 058-540-498-045-566; 061-293-941-887-833; 062-914-448-599-542; 064-492-116-065-718; 064-663-345-418-998; 067-121-551-105-370; 067-327-280-990-972; 067-988-875-988-159; 069-462-436-290-716; 070-085-100-188-835; 071-501-755-748-81X; 072-301-931-515-805; 072-907-324-979-989; 074-021-228-397-786; 075-365-857-815-464; 075-817-199-085-360; 076-961-062-718-027; 082-374-116-388-205; 089-712-662-302-994; 090-665-940-081-658; 090-792-041-585-141; 092-996-073-117-884; 093-790-916-573-208; 094-969-873-206-059; 095-630-580-962-735; 097-609-801-752-990; 101-117-782-919-805; 102-089-222-983-56X; 102-204-175-982-628; 102-632-361-814-813; 103-081-737-277-146; 113-294-595-474-436; 124-986-846-288-686; 130-097-069-293-807; 131-773-892-672-966; 141-419-439-630-777; 142-444-795-681-942; 143-588-631-393-070; 148-877-113-112-243; 153-092-788-969-799; 160-885-031-889-889; 166-268-524-352-590; 175-893-540-120-466; 180-754-449-873-564; 183-967-085-653-402; 185-165-225-800-776; 194-132-928-787-745,0
066-331-861-049-318,A systematic review and meta-analysis of the evidence for unaware fear conditioning,2019-11-17,2019,journal article,Neuroscience and biobehavioral reviews,18737528; 01497634,Elsevier Limited,United Kingdom,Gaëtan Mertens; Iris M. Engelhard,"Whether fear conditioning can take place without contingency awareness is a topic of continuing debate and conflicting findings have been reported in the literature. This systematic review provides a critical assessment of the available evidence. Specifically, a search was conducted to identify articles reporting fear conditioning studies in which the contingency between conditioned stimuli (CS) and the unconditioned stimulus (US) was masked, and in which CS-US contingency awareness was assessed. A systematic assessment of the methodological quality of the included studies (k = 41) indicated that most studies suffered from methodological limitations (i.e., poor masking procedures, poor awareness measures, researcher degrees of freedom, and trial-order effects), and that higher quality predicted lower odds of studies concluding in favor of contingency unaware fear conditioning. Furthermore, meta-analytic moderation analyses indicated no evidence for a specific set of conditions under which contingency unaware fear conditioning can be observed. Finally, funnel plot asymmetry and p-curve analysis indicated evidence for publication bias. We conclude that there is no convincing evidence for contingency unaware fear conditioning.",108,,254,268,Extinction (psychology); Psychology; Set (psychology); Fear conditioning; Publication bias; Clinical psychology; Funnel plot; Moderation; Meta-analysis; Contingency,Awareness; Fear conditioning; Meta-analysis; P-curve,"Awareness/physiology; Cognitive Neuroscience/methods; Conditioning, Classical/physiology; Fear/physiology; Humans; Perceptual Masking/physiology; Research Design/standards",,Netherlands Organization for Scientific Research,https://www.sciencedirect.com/science/article/abs/pii/S0149763419303100 https://pubmed.ncbi.nlm.nih.gov/31747553/ https://www.ncbi.nlm.nih.gov/pubmed/31747553 https://europepmc.org/article/MED/31747553 https://www.sciencedirect.com/science/article/pii/S0149763419303100 https://osf.io/dy4ac/#! https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=202002237651316847 https://www.narcis.nl/publication/RecordID/oai%3Atilburguniversity.edu%3Apublications%2Fa4685f04-38b4-4794-964b-a2ec33a067e7 https://research.tilburguniversity.edu/en/publications/a-systematic-review-and-meta-analysis-of-the-evidence-for-unaware https://pure.uvt.nl/ws/files/32799881/MCP_Mertens_a_systematic_review_and_meta_analysis_NaBR_2020.pdf,http://dx.doi.org/10.1016/j.neubiorev.2019.11.012,31747553,10.1016/j.neubiorev.2019.11.012,2987251308,,0,001-783-528-734-775; 001-989-736-869-053; 002-798-866-294-643; 003-274-605-397-408; 003-464-255-191-262; 003-945-248-615-247; 004-097-456-917-052; 004-693-705-492-456; 004-943-161-990-738; 006-316-833-087-016; 006-476-111-201-000; 007-800-716-556-160; 008-245-822-029-459; 008-298-659-160-148; 010-397-760-304-244; 010-445-667-468-336; 010-904-714-697-941; 012-168-181-787-046; 012-170-316-625-881; 012-604-759-168-080; 013-286-930-373-419; 013-315-478-550-780; 013-702-161-895-027; 014-055-043-430-972; 014-627-164-941-876; 014-648-686-091-197; 015-280-090-947-218; 016-368-457-792-359; 016-838-882-305-72X; 017-959-401-082-439; 018-078-583-998-849; 018-658-066-225-195; 018-854-898-239-993; 019-526-561-393-745; 019-642-502-653-461; 020-639-378-620-782; 021-263-944-606-496; 021-674-499-744-810; 022-567-679-857-524; 023-442-434-747-228; 023-551-959-330-241; 023-704-804-526-834; 024-092-640-376-789; 025-067-813-111-917; 025-175-705-986-917; 025-847-909-788-866; 027-068-496-300-622; 028-591-300-236-95X; 029-403-361-487-176; 029-603-408-772-908; 030-296-451-744-097; 030-425-337-421-604; 031-841-602-974-058; 032-495-583-839-033; 032-804-094-246-735; 032-863-667-185-387; 034-600-684-728-898; 035-947-026-072-89X; 038-595-384-127-179; 042-545-263-646-860; 042-768-858-757-592; 042-964-817-909-308; 043-642-542-693-396; 044-558-145-241-542; 045-201-107-411-584; 045-246-322-159-122; 045-416-413-742-937; 046-485-503-053-188; 047-688-124-590-756; 048-096-250-560-168; 048-233-128-292-444; 048-837-620-019-973; 048-896-699-512-292; 049-898-881-273-510; 051-697-990-093-106; 053-017-456-556-685; 053-161-958-510-27X; 053-490-431-155-133; 053-523-547-896-927; 054-437-057-724-079; 054-447-512-631-798; 054-859-201-831-494; 055-982-095-825-938; 056-760-571-619-581; 057-090-999-783-012; 058-519-371-981-22X; 058-685-733-735-207; 058-795-771-979-373; 059-246-706-507-147; 060-418-049-020-040; 060-799-867-750-223; 060-840-197-843-608; 060-905-981-244-929; 062-091-530-460-748; 063-081-058-826-669; 063-403-123-775-757; 064-263-496-122-85X; 064-671-559-529-466; 065-478-090-590-228; 065-622-789-589-638; 068-110-402-278-086; 068-844-305-620-209; 069-039-831-717-224; 070-119-266-513-063; 070-643-749-136-021; 071-938-138-913-439; 072-135-412-308-416; 073-287-782-529-717; 074-386-912-464-596; 074-635-896-479-839; 074-708-660-902-279; 076-937-571-051-048; 077-449-026-364-587; 078-684-856-123-930; 078-854-137-172-946; 079-486-928-947-517; 080-729-512-647-720; 081-453-556-778-900; 081-984-678-010-740; 083-745-572-183-509; 084-780-176-030-391; 087-346-451-202-934; 088-277-640-302-23X; 090-512-457-032-891; 090-749-656-107-302; 094-275-419-934-818; 096-206-229-132-375; 097-840-637-516-292; 098-816-932-291-643; 100-636-298-548-449; 100-788-054-447-054; 102-927-519-605-754; 107-332-867-551-077; 108-665-173-332-496; 112-778-487-656-640; 113-192-693-884-001; 115-200-963-993-241; 124-709-685-964-94X; 128-026-865-129-434; 132-861-120-659-75X; 133-763-572-045-30X; 137-487-692-692-971; 142-529-785-434-174; 142-537-870-893-658; 151-416-865-192-211; 154-589-699-813-178; 158-484-759-120-555; 164-494-557-574-213; 172-872-559-508-311; 185-138-433-723-804; 194-382-788-265-620,19
066-596-552-897-827,Welfare Impact of Carbon Dioxide Euthanasia on Laboratory Mice and Rats: A Systematic Review,2020-07-22,2020,journal article,Frontiers in veterinary science,22971769,Frontiers Media SA,Switzerland,Patricia V. Turner; Debra L. Hickman; Judith van Luijk; Merel Ritskes-Hoitinga; Jan M. Sargeant; T. Miki Kurosawa; Takashi Agui; Vera Baumans; Woo Sung Choi; Yang Kyu Choi; Paul A. Flecknell; Byeong Han Lee; Pedro J. Otaegui; Kathleen R. Pritchett-Corning; Keisuke Shimada,"Background: There has been increased concern about the suitability of CO2 as a method for euthanasia of laboratory mice and rats, including the potential discomfort, pain or distress that animals may experience prior to loss of consciousness; time to loss of consciousness; best methods for use of CO2; and the availability of better alternatives. These discussions have been useful in providing new information, but have resulted in significant confusion regarding the acceptability of CO2 for rodent euthanasia. In some cases, researchers and veterinarians have become uncertain as to which techniques to recommend or use for euthanasia of laboratory mice and rats. Methods: The International Association of Colleges of Laboratory Animal Medicine (IACLAM) convened a taskforce to examine the evidence for adverse welfare indicators in laboratory rats and mice undergoing CO2 euthanasia using a SYRCLE-registered systematic review protocol. Of 3,772 papers identified through a database search (PubMed, Web of Science, CAB Direct, Agricola, and grey literature) from 1900 to 2017, 37 studies were identified for detailed review (some including more than one species or age group), including 15 in adult mice, 21 in adult rats, and 5 in neonates of both species. Experiments or reports were excluded if they only assessed parameters other than those directly affecting animal welfare during CO2 induction and/or euthanasia. Results: Study design and outcome measures were highly variable and there was an unclear to high risk of bias in many of the published studies. Changes in the outcome measures evaluated were inconsistent or poorly differentiated. It is likely that repeated exposures to carbon dioxide inhalation are aversive to adult rats and mice, based on avoidance behavior studies; however, this effect is largely indistinguishable from aversion induced by repeated exposures to other inhalant anesthetic gasses. Conclusion: There is insufficient evidence to permit an unbiased assessment of the effect of CO2 inhalation during euthanasia on welfare indicators in laboratory mice and rats. Additional well-designed, unbiased, and adequately powered studies are needed to accurately assess the welfare of laboratory mice and rats undergoing euthanasia via CO2 gas.",7,,411,,Welfare; Intoxicative inhalant; Distress; Intensive care medicine; Protocol (science); Laboratory Animal Medicine; Carbon Dioxide Euthanasia; Co2 inhalation; Animal welfare; Medicine,animal welfare; carbon dioxide; distress; euthanasia; mouse; pain; rat; systematic review,,,,https://www.ncbi.nlm.nih.gov/pubmed/32793645 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387666 https://www.frontiersin.org/articles/10.3389/fvets.2020.00411/full https://pubmed.ncbi.nlm.nih.gov/32793645/ https://www.frontiersin.org/article/10.3389/fvets.2020.00411/full https://repository.ubn.ru.nl/handle/2066/225409 https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F225409,http://dx.doi.org/10.3389/fvets.2020.00411,32793645,10.3389/fvets.2020.00411,3044452432,PMC7387666,0,000-657-030-242-024; 000-912-940-250-205; 003-295-792-853-255; 004-593-385-511-663; 005-032-344-456-887; 005-253-811-731-710; 005-531-218-698-419; 006-856-744-599-746; 006-902-801-861-232; 007-378-335-273-166; 007-653-467-023-306; 011-601-800-856-29X; 015-460-452-228-615; 017-300-737-144-757; 018-013-701-887-617; 023-690-754-503-014; 026-903-881-208-97X; 030-452-865-490-594; 035-094-607-644-321; 035-434-138-239-312; 037-108-090-055-715; 039-009-329-571-674; 041-181-574-690-518; 042-764-483-417-488; 046-461-843-089-076; 047-385-488-005-556; 048-850-394-316-166; 051-249-390-670-281; 056-826-498-426-386; 060-403-070-118-649; 060-798-281-362-747; 063-158-545-376-258; 064-766-099-102-956; 069-208-373-891-94X; 070-221-081-389-87X; 071-280-695-324-399; 072-297-753-998-71X; 073-829-769-464-545; 074-569-795-381-311; 074-979-172-644-543; 075-265-627-883-041; 077-632-290-254-059; 080-219-667-904-12X; 086-039-278-827-749; 086-771-795-131-448; 088-143-304-758-170; 089-356-546-450-529; 089-703-734-074-464; 091-680-299-773-967; 092-137-201-872-513; 093-850-622-771-294; 097-549-082-625-781; 120-939-271-535-625; 126-138-121-466-343; 126-647-293-802-871; 135-193-210-049-814; 138-233-739-100-854; 165-710-586-812-540; 189-813-764-935-707; 199-282-975-185-718,1
067-223-181-022-638,Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care setting.,2020-04-03,2020,journal article,Diabetologia,14320428; 0012186x,Springer Verlag,Germany,Amber A. van der Heijden; Giel Nijpels; Fariza Badloe; Heidi L Lovejoy; Linda M. Peelen; Talitha L Feenstra; Karel G.M. Moons; Roderick C. Slieker; Ron M C Herings; Petra J M Elders; Joline W.J. Beulens,"The aims of this study were to identify all published prognostic models predicting retinopathy risk applicable to people with type 2 diabetes, to assess their quality and accuracy, and to validate their predictive accuracy in a head-to-head comparison using an independent type 2 diabetes cohort. A systematic search was performed in PubMed and Embase in December 2019. Studies that met the following criteria were included: (1) the model was applicable in type 2 diabetes; (2) the outcome was retinopathy; and (3) follow-up was more than 1 year. Screening, data extraction (using the checklist for critical appraisal and data extraction for systemic reviews of prediction modelling studies [CHARMS]) and risk of bias assessment (by prediction model risk of bias assessment tool [PROBAST]) were performed independently by two reviewers. Selected models were externally validated in the large Hoorn Diabetes Care System (DCS) cohort in the Netherlands. Retinopathy risk was calculated using baseline data and compared with retinopathy incidence over 5 years. Calibration after intercept adjustment and discrimination (Harrell’s C statistic) were assessed. Twelve studies were included in the systematic review, reporting on 16 models. Outcomes ranged from referable retinopathy to blindness. Discrimination was reported in seven studies with C statistics ranging from 0.55 (95% CI 0.54, 0.56) to 0.84 (95% CI 0.78, 0.88). Five studies reported on calibration. Eight models could be compared head-to-head in the DCS cohort (N = 10,715). Most of the models underestimated retinopathy risk. Validating the models against different severities of retinopathy, C statistics ranged from 0.51 (95% CI 0.49, 0.53) to 0.89 (95% CI 0.88, 0.91). Several prognostic models can accurately predict retinopathy risk in a population-based type 2 diabetes cohort. Most of the models include easy-to-measure predictors enhancing their applicability. Tailoring retinopathy screening frequency based on accurate risk predictions may increase the efficiency and cost-effectiveness of diabetic retinopathy care. PROSPERO registration ID CRD42018089122",63,6,1110,1119,Risk assessment; Critical appraisal; Pediatrics; Type 2 diabetes; Retinopathy; Checklist; Diabetic retinopathy; Population; Medicine; Cohort,External validation; Prediction models; Retinal screening; Retinopathy; Systematic review; Type 2 diabetes,"Animals; Diabetes Mellitus, Type 2/complications; Diabetic Retinopathy/epidemiology; Humans; Netherlands/epidemiology; Primary Health Care/statistics & numerical data; Prognosis; Risk Assessment/methods",,Diabetes Fonds (Grant no. 2014.00.1753) International,https://pure.rug.nl/ws/files/121783111/Prediction_models_for_development_of_retinopathy_in_people_with_type_2_diabetes_systematic_review_and_external_validation_in_a_Dutch_primary_care_setting.pdf https://pubmed.ncbi.nlm.nih.gov/32246157/ https://research.vumc.nl/en/publications/prediction-models-for-development-of-retinopathy-in-people-with-t https://research.rug.nl/en/publications/prediction-models-for-development-of-retinopathy-in-people-with-t https://researchportal.vub.be/en/publications/prediction-models-for-development-of-retinopathy-in-people-with-t https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228897 https://cris.vub.be/ws/files/64195658/Heijden2020_Article_PredictionModelsForDevelopment.pdf https://rivm.openrepository.com/handle/10029/624326 https://europepmc.org/article/MED/32246157 https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F52d8c99a-7171-4d1d-882a-2db9d152df8f https://link.springer.com/article/10.1007/s00125-020-05134-3 https://www.rug.nl/research/portal/files/121783111/Prediction_models_for_development_of_retinopathy_in_people_with_type_2_diabetes_systematic_review_and_external_validation_in_a_Dutch_primary_care_setting.pdf https://link.springer.com/content/pdf/10.1007/s00125-020-05134-3.pdf,http://dx.doi.org/10.1007/s00125-020-05134-3,32246157,10.1007/s00125-020-05134-3,3015119658,PMC7228897,0,001-923-454-827-507; 002-221-487-883-994; 003-486-143-962-648; 014-380-017-812-925; 016-167-335-649-334; 017-157-215-645-707; 022-069-713-838-991; 022-279-029-709-785; 023-171-734-710-29X; 024-436-115-943-104; 039-061-893-433-334; 040-226-310-980-845; 041-560-563-938-514; 044-157-806-625-782; 045-183-959-586-396; 048-058-701-733-623; 049-962-368-320-13X; 050-049-805-753-343; 057-471-842-224-422; 058-607-660-306-837; 072-516-841-671-300; 077-603-193-688-020; 078-306-509-671-395; 080-460-436-198-134; 080-796-419-663-830; 087-709-118-692-124; 093-661-529-358-443; 108-271-144-819-121; 112-433-086-571-757; 112-496-112-944-114; 120-529-529-340-453; 120-912-258-418-088; 125-787-939-449-332; 126-051-178-655-901; 129-171-126-831-710; 130-731-094-625-370; 137-526-759-545-650; 141-956-450-304-239; 156-909-982-162-799,9
067-553-619-700-643,Mode of delivery in non-cephalic presenting twins: a systematic review.,2012-04-01,2012,journal article,Archives of gynecology and obstetrics,14320711; 09320067,Springer Verlag,Germany,Charlotte N. Steins Bisschop; Tatjana E. Vogelvang; Anne M. May; Nico W.E. Schuitemaker,"Purpose; This systematic review aims to determine if there are evidence-based recommendations for the optimal mode of delivery for non-cephalic presenting first- and/or second twins. We investigated the impact of the mode of delivery on neonatal outcome for twin deliveries with (1) the first twin (twin A) in non-cephalic presentation, (2) the second (twin B) in non-cephalic presentation and (3) both twins in non-cephalic presentation.",286,1,237,247,Obstetrics; Presentation (obstetrics); Twin Pregnancy; Mode of delivery; Breech presentation; Medicine,,"Apgar Score; Breech Presentation/therapy; Cesarean Section; Delivery, Obstetric/methods; Female; Humans; Pregnancy; Pregnancy, Twin",,,https://link.springer.com/content/pdf/10.1007%2Fs00404-012-2294-6.pdf http://europepmc.org/articles/PMC3374120 https://link.springer.com/article/10.1007/s00404-012-2294-6/fulltext.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374120/ https://paperity.org/p/29879020/mode-of-delivery-in-non-cephalic-presenting-twins-a-systematic-review https://pubmed.ncbi.nlm.nih.gov/22465994/ https://rd.springer.com/article/10.1007/s00404-012-2294-6 https://link.springer.com/article/10.1007/s00404-012-2294-6 https://core.ac.uk/display/81727933,http://dx.doi.org/10.1007/s00404-012-2294-6,22465994,10.1007/s00404-012-2294-6,1965935384,PMC3374120,0,000-042-700-001-270; 003-027-520-145-940; 003-933-434-651-905; 005-679-293-692-659; 006-973-282-486-239; 007-089-487-475-428; 008-410-419-422-839; 010-145-940-599-675; 010-350-117-699-453; 012-917-509-928-232; 012-929-151-359-749; 022-512-593-978-765; 023-864-423-746-051; 028-607-217-778-196; 028-974-792-305-605; 030-225-797-548-634; 038-888-524-080-069; 041-521-536-824-560; 046-491-310-549-145; 047-018-679-496-613; 047-197-264-496-511; 048-027-029-229-434; 048-453-451-534-399; 048-953-464-071-208; 054-121-125-378-227; 054-946-742-422-306; 057-023-043-849-89X; 062-545-183-806-145; 062-555-848-824-268; 063-151-046-240-303; 067-930-007-855-426; 068-425-126-261-46X; 070-733-725-044-711; 076-976-482-600-123; 083-135-910-351-619; 083-260-296-046-229; 084-836-009-702-381; 090-911-225-098-03X; 107-949-494-562-725; 109-432-417-826-329; 117-367-536-369-708; 127-358-808-904-777; 130-498-318-563-626,24
068-762-010-097-028,Cerebrospinal fluid leakage after cranial surgery in the pediatric population—a systematic review and meta-analysis,2021-02-04,2021,journal article,Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,14330350; 02567040,Springer Verlag,Germany,Emma M.H. Slot; Kirsten van Baarsen; Eelco W. Hoving; Nicolaas P.A. Zuithoff; Tristan P.C. van Doormaal,"Cerebrospinal fluid (CSF) leakage is a common complication after neurosurgical intervention. It is associated with substantial morbidity and increased healthcare costs. The current systematic review and meta-analysis aim to quantify the incidence of cerebrospinal fluid leakage in the pediatric population and identify its risk factors. The authors followed the PRISMA guidelines. The Embase, PubMed, and Cochrane database were searched for studies reporting CSF leakage after intradural cranial surgery in patients up to 18 years old. Meta-analysis of incidences was performed using a generalized linear mixed model. Twenty-six articles were included in this systematic review. Data were retrieved of 2929 patients who underwent a total of 3034 intradural cranial surgeries. Surprisingly, only four of the included articles reported their definition of CSF leakage. The overall CSF leakage rate was 4.4% (95% CI 2.6 to 7.3%). The odds of CSF leakage were significantly greater for craniectomy as opposed to craniotomy (OR 4.7, 95% CI 1.7 to 13.4) and infratentorial as opposed to supratentorial surgery (OR 5.9, 95% CI 1.7 to 20.6). The odds of CSF leakage were significantly lower for duraplasty use versus no duraplasty (OR 0.41 95% CI 0.2 to 0.9). The overall CSF leakage rate after intradural cranial surgery in the pediatric population is 4.4%. Risk factors are craniectomy and infratentorial surgery. Duraplasty use is negatively associated with CSF leak. We suggest defining a CSF leak as “leakage of CSF through the skin,” as an unambiguous definition is fundamental for future research.",37,5,1439,1447,Neurosurgery; Surgery; Craniotomy; Cerebrospinal fluid; Leak; Cerebrospinal Fluid Leakage; Incidence (epidemiology); Medicine; Complication; Meta-analysis,Cerebrospinal fluid leakage; Craniectomy; Craniotomy; Pediatrics; Posterior fossa surgery,Cerebrospinal Fluid Leak/epidemiology; Child; Craniotomy/adverse effects; Humans; Neurosurgical Procedures/adverse effects; Postoperative Complications/epidemiology; Reconstructive Surgical Procedures; Retrospective Studies,,Polyganics b.v.,https://www.zora.uzh.ch/id/eprint/199454/ https://pubmed.ncbi.nlm.nih.gov/33538867/ https://link.springer.com/content/pdf/10.1007/s00381-021-05036-8.pdf https://europepmc.org/article/PMC/PMC8084768 http://www.ncbi.nlm.nih.gov/pubmed/33538867 https://www.ncbi.nlm.nih.gov/pubmed/33538867 https://link.springer.com/article/10.1007/s00381-021-05036-8,http://dx.doi.org/10.1007/s00381-021-05036-8,33538867,10.1007/s00381-021-05036-8,3128263497,PMC8084768,0,001-185-726-631-670; 001-989-140-021-051; 003-169-565-287-460; 003-790-670-622-326; 004-504-235-940-238; 006-262-990-013-212; 007-916-263-424-804; 008-135-580-069-353; 009-648-111-573-303; 010-022-083-107-866; 010-196-609-253-797; 011-245-662-671-415; 017-300-737-144-757; 019-250-196-266-291; 022-627-638-386-166; 023-144-641-982-540; 035-346-697-464-700; 036-772-344-571-541; 040-422-400-153-85X; 041-185-931-272-583; 042-734-980-518-493; 047-427-023-798-472; 050-527-229-511-285; 064-624-030-035-069; 065-715-563-255-97X; 066-075-705-665-012; 068-348-960-523-189; 069-282-692-206-159; 069-773-249-254-419; 071-137-500-372-795; 080-310-531-849-245; 083-275-795-865-394; 090-816-627-342-482; 104-326-493-247-889; 118-154-114-334-73X; 126-637-839-134-221; 137-292-093-607-018; 148-757-885-802-766; 188-548-715-661-067,0
069-167-374-620-000,"Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review",2017-12-21,2017,journal article,PloS one,19326203,Public Library of Science,United States,M. Safy; M. J. H. de Hair; J. W. G. Jacobs; Frank Buttgereit; M. C. Kraan; J.M. van Laar,"BACKGROUND Long-term treatment with glucocorticoids (GCs) plays an important role in the management of arthritis patients, although the efficacy/safety balance is unfavorable. Alternatives with less (severe) adverse effects but with good efficacy are needed. Selective GC receptor modulators (SGRMs) are designed to engage the GC receptor with dissociative characteristics: transactivation of genes, which is mainly responsible for unwanted effects, is less strong while trans-repression of genes, reducing inflammation, is maintained. It is expected that SGRMs thus have a better efficacy/safety balance than GCs. A systematic review providing an overview of the evidence in arthritis is lacking. OBJECTIVE To systematically review the current literature on efficacy and safety of oral SGRMs in comparison to GCs in arthritis. METHODS A search was performed in Medline, Embase and the Cochrane Library, from inception dates of databases until May 2017. Experimental studies involving animal arthritis models or human material of arthritis patients, as well as clinical studies in arthritis patients were included, provided they reported original data. All types of arthritis were included. Data was extracted on the SGRM studied and on the GC used as reference standard; the design or setting of the study was extracted as well as the efficacy and safety results. RESULTS A total of 207 articles was retrieved of which 17 articles were eligible for our analysis. Two studies concerned randomized controlled trials (RCT), five studies were pre-clinical studies using human material, and 10 studies involved pre-clinical animal models (acute and/or chronic arthritis induced in mice or rats). PF-04171327, the only compound investigated in a clinical trial setting, had a better efficacy/safety balance compared to GCs: better clinical anti-inflammatory efficacy and similar safety. CONCLUSION Studies assessing both efficacy and safety of SGRMs are scarce. There is limited evidence for dissociation of anti-inflammatory and metabolic effects of the SGRMs studied. Development of many SGRMs is haltered in a preclinical phase. One SGRM showed a better clinical efficacy/safety balance.",12,12,e0188810,,Randomized controlled trial; Adverse effect; Cochrane Library; Arthritis; MEDLINE; Clinical efficacy; Clinical trial; Glucocorticoid receptor; Bioinformatics; Medicine,,"Arthritis/drug therapy; Glucocorticoids/administration & dosage; Humans; Randomized Controlled Trials as Topic; Receptors, Glucocorticoid/drug effects","Glucocorticoids; Receptors, Glucocorticoid",,https://dx.plos.org/10.1371/journal.pone.0188810 https://core.ac.uk/display/149319261 https://www.ncbi.nlm.nih.gov/pubmed/29267302 http://ui.adsabs.harvard.edu/abs/2017PLoSO..1288810S/abstract http://europepmc.org/abstract/MED/29267302,http://dx.doi.org/10.1371/journal.pone.0188810,29267302,10.1371/journal.pone.0188810,2777500966,PMC5739390,0,000-155-311-136-797; 000-924-183-805-215; 002-341-463-718-245; 003-924-446-721-064; 004-190-576-851-015; 004-336-521-610-256; 004-772-135-559-393; 006-200-671-966-012; 006-396-950-282-155; 009-007-248-916-215; 014-496-864-768-886; 015-047-222-211-376; 017-300-737-144-757; 020-023-690-463-827; 021-007-964-933-07X; 024-975-678-350-620; 025-132-504-449-533; 026-266-690-561-253; 026-749-605-500-381; 027-056-620-041-982; 028-188-107-137-829; 029-808-128-984-18X; 032-372-571-188-309; 035-320-841-806-395; 041-859-233-752-30X; 046-980-839-765-11X; 047-919-316-199-650; 048-885-792-413-658; 049-016-971-597-976; 053-662-299-657-379; 054-525-759-200-640; 055-806-176-412-93X; 056-152-397-819-713; 056-184-041-278-350; 059-451-988-565-873; 060-022-491-115-148; 064-738-019-511-832; 067-563-190-402-975; 070-555-968-200-804; 071-287-575-219-537; 076-347-249-011-363; 078-404-958-319-281; 091-924-697-884-345; 095-415-470-906-271; 102-284-984-285-876; 107-138-764-235-128; 122-644-248-115-248; 147-603-163-320-257; 148-179-708-675-987; 159-610-381-491-311,14
069-473-238-404-915,Comparison of analgesic interventions for traumatic rib fractures: a systematic review and meta-analysis.,2018-02-06,2018,journal article,European journal of trauma and emergency surgery : official publication of the European Trauma Society,18639941; 18639933,Urban und Vogel,Germany,Jesse Peek; Diederik P.J. Smeeing; Falco Hietbrink; Roderick M. Houwert; Marije Marsman; Mirjam B. de Jong,"Many studies report on outcomes of analgesic therapy for (suspected) traumatic rib fractures. However, the literature is inconclusive and diverse regarding the management of pain and its effect on pain relief and associated complications. This systematic review and meta-analysis summarizes and compares reduction of pain for the different treatment modalities and as secondary outcome mortality during hospitalization, length of mechanical ventilation, length of hospital stay, length of intensive care unit stay (ICU) and complications such as respiratory, cardiovascular, and/or analgesia-related complications, for four different types of analgesic therapy: epidural analgesia, intravenous analgesia, paravertebral blocks and intercostal blocks. PubMed, EMBASE and CENTRAL databases were searched to identify comparative studies investigating epidural, intravenous, paravertebral and intercostal interventions for traumatic rib fractures, without restriction for study type. The search strategy included keywords and MeSH or Emtree terms relating blunt chest trauma (including rib fractures), analgesic interventions, pain management and complications. A total of 19 papers met our inclusion criteria and were finally included in this systematic review. Significant differences were found in favor of epidural analgesia for the reduction of pain. No significant differences were observed between epidural analgesia, intravenous analgesia, paravertebral blocks and intercostal blocks, for the secondary outcomes. Results of this study show that epidural analgesia provides better pain relief than the other modalities. No differences were observed for secondary endpoints like length of ICU stay, length of mechanical ventilation or pulmonary complications. However, the quality of the available evidence is low, and therefore, preclude strong recommendations.",45,4,597,622,Blunt; Psychological intervention; Intensive care unit; Mechanical ventilation; Modalities; Analgesic; Anesthesia; Sports medicine; Medicine; Meta-analysis,Analgesia; Anesthesia; Hospitalization; Mortality; Pain Management; Rib Fractures,"Administration, Intravenous; Adolescent; Adult; Aged; Analgesia, Epidural/statistics & numerical data; Analgesics/therapeutic use; Critical Care/statistics & numerical data; Epidemiologic Methods; Humans; Length of Stay/statistics & numerical data; Middle Aged; Musculoskeletal Pain/prevention & control; Nerve Block/statistics & numerical data; Pain Measurement; Rib Fractures/complications; Young Adult",Analgesics,,https://pubmed.ncbi.nlm.nih.gov/29411048/ https://europepmc.org/article/MED/29411048 https://link.springer.com/content/pdf/10.1007%2Fs00068-018-0918-7.pdf https://www.ncbi.nlm.nih.gov/pubmed/29411048 https://link.springer.com/article/10.1007/s00068-018-0918-7 https://paperity.org/p/86051428/comparison-of-analgesic-interventions-for-traumatic-rib-fractures-a-systematic-review-and,http://dx.doi.org/10.1007/s00068-018-0918-7,29411048,10.1007/s00068-018-0918-7,2791905011,PMC6689037,0,000-308-135-380-17X; 005-350-126-938-523; 009-358-419-771-554; 009-501-036-253-820; 010-774-210-557-037; 010-907-148-741-314; 014-413-613-572-698; 014-470-201-118-043; 014-770-508-188-868; 015-396-006-862-137; 015-894-470-655-491; 017-081-027-120-315; 017-300-737-144-757; 018-123-857-460-924; 021-022-082-229-166; 022-240-549-808-068; 023-775-738-510-444; 024-661-133-932-469; 025-328-313-984-298; 025-740-442-472-867; 027-401-606-554-129; 027-668-521-171-586; 031-777-532-709-406; 040-496-131-095-525; 041-203-349-844-327; 044-319-689-509-65X; 045-013-522-077-562; 045-204-309-556-574; 045-600-110-980-946; 046-185-881-664-109; 046-425-110-173-715; 048-002-941-337-379; 052-332-474-973-363; 052-930-474-304-186; 053-364-714-625-61X; 063-748-600-501-323; 067-049-315-158-127; 070-032-865-496-507; 071-386-624-176-857; 077-598-763-596-651; 077-777-794-414-172; 078-144-870-124-684; 081-359-078-897-831; 081-554-411-421-823; 083-275-795-865-394; 083-391-239-454-541; 083-968-046-512-534; 095-340-234-517-06X; 118-247-236-500-233; 123-831-306-158-802; 124-828-752-144-696; 126-956-330-914-565; 160-629-692-622-425; 172-828-823-142-34X,31
073-018-833-913-423,Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.,2018-08-23,2018,journal article,European journal of nuclear medicine and molecular imaging,16197089; 16197070,Springer Verlag,Germany,Coreline N. Burggraaff; Antoinette de Jong; Otto S. Hoekstra; Nikie J. Hoetjes; Rutger A.J. Nievelstein; Elise P. Jansma; Martijn W. Heymans; Henrica C.W. de Vet; Josée M. Zijlstra,"Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma. Most relapses occur in the first 2 years after diagnosis. Early response assessment with 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) may facilitate early change of treatment, thereby preventing ineffective treatment and unnecessary side effects. We aimed to assess the predictive value of visually-assessed interim 18F-FDG PET on progression-free survival (PFS) or event-free survival (EFS) in DLBCL patients treated with first-line immuno-chemotherapy regimens. For this systematic review and meta-analysis Pubmed, Embase, and the Cochrane Library were searched until July 11, 2017. Prospective and retrospective studies investigating qualitative interim PET response assessment without treatment adaptation based on the interim PET result were eligible. The primary outcome was two-year PFS or EFS. Prognostic and diagnostic measures were extracted and analysed with pooled hazard ratios and Hierarchical Summary Receiver Operator Characteristic Curves, respectively. Meta-regression was used to study covariate effects. The pooled hazard ratio for 18 studies comprising 2,255 patients was 3.13 (95%CI 2.52–3.89) with a 95% prediction interval of 1.68–5.83. In 19 studies with 2,366 patients, the negative predictive value for progression generally exceeded 80% (64–95), but sensitivity (33–87), specificity (49–94), and positive predictive values (20–74) ranged widely. These findings showed that interim 18F-FDG PET has predictive value in DLBCL patients. However, (subgroup) analyses were limited by lack of information and small sample sizes. Some diagnostic test characteristics were not satisfactory, especially the positive predictive value should be improved, before a successful risk stratified treatment approach can be implemented in clinical practice.",46,1,65,79,Internal medicine; Oncology; Retrospective cohort study; Predictive value of tests; Hazard ratio; Positron emission tomography; Cochrane Library; Interim; Diffuse large B-cell lymphoma; Medicine; Meta-analysis,Aggressive non-Hodgkin’s lymphoma; Diffuse large B-cell lymphoma; Meta-analysis; Positron-emission tomography; Systematic review,"Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse/diagnostic imaging; Positron-Emission Tomography/methods; Predictive Value of Tests; Radiopharmaceuticals",Radiopharmaceuticals; Fluorodeoxyglucose F18,KWF Kankerbestrijding,https://dspace.library.uu.nl/bitstream/1874/378307/1/burggraaff.pdf http://dspace.library.uu.nl/handle/1874/378307 https://link.springer.com/article/10.1007/s00259-018-4103-3 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F378307 http://www.ncbi.nlm.nih.gov/pubmed/30141066 https://www.ncbi.nlm.nih.gov/pubmed/30141066 https://link.springer.com/article/10.1007/s00259-018-4103-3/fulltext.html https://link.springer.com/content/pdf/10.1007/s00259-018-4103-3.pdf https://pubmed.ncbi.nlm.nih.gov/30141066/ https://europepmc.org/article/MED/30141066 https://research.vumc.nl/en/publications/predictive-value-of-interim-positron-emission-tomography-in-diffu,http://dx.doi.org/10.1007/s00259-018-4103-3,30141066,10.1007/s00259-018-4103-3,2888322511,PMC6267696,0,000-217-560-481-760; 000-305-427-961-781; 000-414-536-956-052; 003-465-280-765-461; 006-943-996-606-768; 007-813-698-902-201; 008-344-606-406-356; 009-132-780-206-853; 011-469-980-859-58X; 011-698-791-705-134; 012-022-366-552-268; 015-261-699-715-640; 016-303-894-868-393; 017-147-489-067-394; 017-977-948-667-405; 018-724-352-494-727; 019-627-086-562-118; 020-388-741-795-015; 021-104-159-501-594; 024-452-293-996-76X; 028-534-688-219-222; 032-183-164-368-860; 032-718-797-132-581; 042-221-905-416-661; 045-416-413-742-937; 055-831-640-840-407; 057-075-056-237-870; 057-574-762-086-308; 059-666-799-176-818; 062-844-995-691-531; 063-232-343-564-165; 064-216-660-096-795; 065-467-105-837-614; 066-012-750-913-611; 067-075-387-301-104; 067-713-222-125-425; 069-372-169-042-398; 069-755-283-970-057; 072-247-302-945-314; 074-638-736-358-687; 076-479-068-280-606; 078-207-731-555-404; 080-729-512-647-720; 080-854-100-071-342; 083-919-105-260-154; 086-010-392-985-979; 091-783-562-070-233; 092-379-702-947-175; 093-023-516-175-748; 094-962-691-579-573; 100-317-600-725-517; 102-231-638-361-267; 104-118-450-417-108; 105-561-264-607-867; 116-785-727-819-949; 125-902-941-547-979; 127-180-859-518-344; 130-332-163-796-133; 150-325-162-873-23X; 156-063-129-491-230; 165-437-650-575-603,35
074-175-352-902-825,Deformation imaging to assess global and regional effects of cardiac regenerative therapy in ischaemic heart disease : A systematic review,2019-09-01,2019,journal article,Journal of tissue engineering and regenerative medicine,19327005; 19326254,John Wiley and Sons Ltd,United Kingdom,Bas R van Klarenbosch; Steven A. J. Chamuleau; Arco J. Teske,"Currently, left ventricular ejection fraction (LVEF) is the most common endpoint in cardiovascular stem cell therapy research. However, this global measure of cardiac function might not be suitable to detect the regional effects sorted by this therapy and is hampered by high operator variability and loading dependency. Deformation imaging might be more accurate in detecting potential regional functional improvements by cardiac regenerative therapy. The aim of this systematic review is to provide a comprehensive overview of current literature on the value of deformation imaging in cardiac regenerative therapy. A systematic review of current literature available on PubMed, Embase, and Cochrane databases was performed regarding both animal and patient studies in which deformation imaging was used to study cardiac cell therapy. After critical appraisal, outcomes regarding study design, type of cell therapy, procedural characteristics, outcome measure, method for measuring strain, and efficacy on both LVEF and deformation parameters were depicted. A total of 30 studies, 15 preclinical and 15 clinical, were included for analysis. Deformation outcomes improved significantly in 14 out of 15 preclinical studies and in 10 out of 15 clinical studies, whereas LVEF improved in 12 and 4 articles, respectively. Study designs and used deformation outcomes varied significantly among the included papers. Six studies found a positive effect on deformation outcomes without LVEF improvement. Hence, deformation imaging seems at least equal, and perhaps superior, to LVEF measurement in the assessment of cardiac regenerative therapy. However, strategies varied substantially and call for a standardized approach.",13,10,1872,1882,Cell therapy; Cardiac function curve; Internal medicine; Clinical study design; Critical appraisal; Cardiology; Coronary artery disease; MEDLINE; Myocardial infarction; Medicine; Ejection fraction,2D speckle tracking; coronary artery disease; deformation imaging; echocardiography; left ventricular ejection fraction; myocardial infarction; stem cells; strain,"Animals; Humans; Imaging, Three-Dimensional; Myocardial Ischemia/diagnostic imaging; Publication Bias; Regenerative Medicine; Risk; Stem Cell Transplantation",,,https://onlinelibrary.wiley.com/doi/full/10.1002/term.2937 http://dspace.library.uu.nl/handle/1874/390207 http://pubmed.ncbi.nlm.nih.gov/31314949/ https://www.ncbi.nlm.nih.gov/pubmed/31314949 https://pubmed.ncbi.nlm.nih.gov/31314949/ https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F390207 https://europepmc.org/abstract/MED/31314949 https://www.mendeley.com/catalogue/c79cb87b-78e1-3b37-a998-f9208b4b9091/,http://dx.doi.org/10.1002/term.2937,31314949,10.1002/term.2937,2960634833,PMC6852417,0,000-924-183-805-215; 000-926-526-975-400; 001-536-889-045-029; 002-694-449-624-107; 002-994-965-852-266; 003-585-162-702-239; 003-598-314-556-609; 006-433-121-338-131; 008-204-113-934-906; 012-013-056-074-366; 014-385-304-900-664; 015-290-011-631-098; 018-880-824-886-150; 019-381-166-486-197; 020-162-421-356-003; 020-304-112-968-517; 020-635-414-769-835; 021-438-838-614-566; 021-944-921-282-98X; 022-168-856-452-360; 022-562-575-340-261; 022-871-253-215-811; 026-222-142-885-412; 031-221-646-999-225; 032-633-044-346-590; 033-378-786-387-456; 036-248-703-880-784; 036-496-860-530-369; 038-042-502-949-713; 039-662-143-712-485; 039-959-169-014-412; 047-738-571-236-719; 053-282-752-253-82X; 053-938-929-081-832; 055-728-765-178-933; 056-302-429-006-954; 066-041-470-905-740; 069-205-367-457-852; 069-367-028-707-775; 072-190-616-997-69X; 074-175-352-902-825; 079-820-955-444-545; 081-572-252-150-42X; 086-153-411-033-067; 087-748-125-575-059; 088-051-770-961-83X; 089-906-383-935-874; 093-878-846-467-886; 109-404-738-754-794; 111-649-697-951-771; 121-016-818-112-580; 125-942-495-674-674; 144-827-215-464-716; 152-223-366-642-260; 158-662-263-582-325; 161-156-386-041-285,1
074-285-577-595-587,Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.,2021-04-15,2021,journal article,Frontiers in immunology,16643224,Frontiers Media S.A.,Switzerland,Olivia A. C. Lamers; Bas M. Smits; Helen L. Leavis; Godelieve J. de Bree; Charlotte Cunningham-Rundles; Virgil A. S. H. Dalm; Hsi-en Ho; John R. Hurst; Hanna IJspeert; Sabine M. P. J. Prevaes; Alex Robinson; Astrid C. van Stigt; Suzanne W.J. Terheggen-Lagro; Annick A. J. M. van de Ven; Klaus Warnatz; Janneke van de Wijgert; Joris M. van Montfrans,"Introduction Besides recurrent infections, a proportion of patients with Common Variable Immunodeficiency Disorders (CVID) may suffer from immune dysregulation such as granulomatous-lymphocytic interstitial lung disease (GLILD). The optimal treatment of this complication is currently unknown. Experienced-based expert opinions have been produced, but a systematic review of published treatment studies is lacking. Goals To summarize and synthesize the published literature on the efficacy of treatments for GLILD in CVID. Methods We performed a systematic review using the PRISMA guidelines. Papers describing treatment and outcomes in CVID patients with radiographic and/or histologic evidence of GLILD were included. Treatment regimens and outcomes of treatment were summarized. Results 6124 papers were identified and 42, reporting information about 233 patients in total, were included for review. These papers described case series or small, uncontrolled studies of monotherapy with glucocorticoids or other immunosuppressants, rituximab monotherapy or rituximab plus azathioprine, abatacept, or hematopoietic stem cell transplantation (HSCT). Treatment response rates varied widely. Cross-study comparisons were complicated because different treatment regimens, follow-up periods, and outcome measures were used. There was a trend towards more frequent GLILD relapses in patients treated with corticosteroid monotherapy when compared to rituximab-containing treatment regimens based on qualitative endpoints. HSCT is a promising alternative to pharmacological treatment of GLILD, because it has the potential to not only contain symptoms, but also to resolve the underlying pathology. However, mortality, especially among immunocompromised patients, is high. Conclusions We could not draw definitive conclusions regarding optimal pharmacological treatment for GLILD in CVID from the current literature since quantitative, well-controlled evidence was lacking. While HSCT might be considered a treatment option for GLILD in CVID, the risks related to the procedure are high. Our findings highlight the need for further research with uniform, objective and quantifiable endpoints. This should include international registries with standardized data collection including regular pulmonary function tests (with carbon monoxide-diffusion), uniform high-resolution chest CT radiographic scoring, and uniform treatment regimens, to facilitate comparison of treatment outcomes and ultimately randomized clinical trials.",12,,606099,606099,Randomized controlled trial; Intensive care medicine; Common variable immunodeficiency; Azathioprine; Hematopoietic stem cell transplantation; Immunodeficiency; Abatacept; Immune dysregulation; Rituximab; Medicine,CVID; GLILD; common variable immunodeficiency; granulomatous lymphocytic interstitial lung disease; immunodeficiency; systematic review; treatment,"Clinical Trials as Topic; Combined Modality Therapy/adverse effects; Common Variable Immunodeficiency/complications; Disease Management; Disease Susceptibility; Humans; Lung Diseases, Interstitial/diagnosis; Prognosis",,NIAID NIH HHS (P01 AI061093) United States; NIAID NIH HHS (U24 AI086037) United States,https://research.rug.nl/en/publications/treatment-strategies-for-glild-in-common-variable-immunodeficienc https://pubmed.ncbi.nlm.nih.gov/33936030/ https://europepmc.org/article/MED/33936030 https://www.narcis.nl/publication/RecordID/oai:pure.rug.nl:publications%2F68e5cab6-aa31-439a-bb25-f017f79a4b70 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086379/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086379/ https://www.frontiersin.org/articles/10.3389/fimmu.2021.606099/full,http://dx.doi.org/10.3389/fimmu.2021.606099,33936030,10.3389/fimmu.2021.606099,3155854102,PMC8086379,0,001-487-425-724-404; 001-956-005-194-530; 001-956-754-655-699; 002-001-387-637-943; 002-698-652-484-283; 002-882-737-612-598; 003-109-162-282-919; 004-860-413-427-535; 005-148-325-030-80X; 009-671-270-814-966; 011-845-712-054-757; 014-679-146-687-354; 015-238-364-625-824; 015-709-198-892-721; 016-053-939-778-57X; 016-102-073-856-28X; 017-354-931-947-119; 018-886-837-818-218; 019-111-414-133-201; 021-206-073-640-670; 021-944-720-672-500; 022-226-677-425-001; 023-545-839-287-76X; 023-614-511-974-079; 026-235-014-154-810; 027-324-567-282-813; 028-391-822-526-78X; 028-985-094-393-840; 029-624-575-923-294; 031-930-972-465-546; 032-573-731-419-323; 033-373-250-337-765; 033-997-136-772-646; 034-825-254-683-324; 035-490-029-731-777; 037-499-840-303-660; 039-256-756-792-656; 041-912-335-541-378; 042-425-453-290-774; 043-618-507-280-019; 047-716-171-515-172; 050-335-206-394-454; 050-381-217-770-547; 051-296-472-288-635; 051-713-180-954-266; 053-581-134-353-073; 055-267-442-050-16X; 055-663-286-641-631; 057-746-480-671-224; 059-342-956-698-572; 061-430-941-144-720; 062-230-661-981-313; 063-192-498-189-490; 063-310-178-015-517; 065-718-652-568-357; 066-979-055-195-320; 075-193-625-920-283; 075-849-360-365-905; 077-913-782-828-718; 081-085-463-110-358; 083-123-384-035-588; 083-267-844-985-158; 085-971-821-328-480; 088-353-182-641-008; 089-126-179-450-274; 096-400-692-711-60X; 098-625-368-387-385; 107-320-985-166-403; 110-263-808-615-917; 115-421-834-287-104; 116-709-082-643-194; 117-253-966-785-423; 117-411-309-203-826; 124-135-057-322-655; 125-977-035-821-186; 156-045-098-651-588,1
075-482-738-751-923,Prognostic gene expression profiling in esophageal cancer: a systematic review.,2016-11-12,2016,journal article,Oncotarget,19492553,Impact Journals,United States,E. Visser; Ingrid A. Franken; Lodewijk A.A. Brosens; Jelle P. Ruurda; Richard van Hillegersberg,"// Els Visser 1 , Ingrid A. Franken 1 , Lodewijk A.A. Brosens 2 , Jelle P. Ruurda 1 and Richard van Hillegersberg 1 1 Department of Surgery, University Medical Center Utrecht, The Netherlands 2 Department of Pathology, University Medical Center Utrecht, The Netherlands Correspondence to: Richard van Hillegersberg, email: // Keywords : esophageal cancer, gene expression profiling, response to chemo(radio)therapy, lymph node metastasis, survival, prognosis Received : July 06, 2016 Accepted : October 13, 2016 Published : November 12, 2016 Abstract Background: Individual variability in prognosis of esophageal cancer highlights the need for advances in personalized therapy. This systematic review aimed at elucidating the prognostic role of gene expression profiles and at identifying gene signatures to predict clinical outcome. Methods: A systematic search of the Medline, Embase and the Cochrane library databases (2000-2015) was performed. Articles associating gene expression profiles in patients with esophageal adenocarcinoma or squamous cell carcinoma to survival, response to chemo(radio)therapy and/or lymph node metastasis were identified. Differentially expressed genes and gene signatures were extracted from each study and combined to construct a list of prognostic genes per outcome and histological tumor type. Results: This review includes a total of 22 studies. Gene expression profiles were related to survival in 9 studies, to response to chemo(radio)therapy in 7 studies, and to lymph node metastasis in 9 studies. The studies proposed many differentially expressed genes. However, the findings were heterogeneous and only 12 (ALDH1A3, ATR, BIN1, CSPG2, DOK1, IFIT1, IFIT3, MAL, PCP4, PHB, SPP1) of the 1.112 reported genes were identified in more than 1 study. Overall, 16 studies reported a prognostic gene signature, which was externally validated in 10 studies. Conclusion: This systematic review shows heterogeneous findings in associating gene expression with clinical outcome in esophageal cancer. Larger validated studies employing RNA next-generation sequencing are required to establish gene expression profiles to predict clinical outcome and to select optimal personalized therapy.",8,3,5566,5577,Gene; Gene expression; Gene expression profiling; Cochrane Library; MEDLINE; Gene signature; Esophageal cancer; Lymph node metastasis; Bioinformatics; Medicine,esophageal cancer; gene expression profiling; lymph node metastasis; prognosis; response to chemo(radio)therapy; survival,"Adenocarcinoma/genetics; Carcinoma, Squamous Cell/genetics; Esophageal Neoplasms/genetics; Gene Expression Profiling; Humans; Prognosis; Transcriptome",,,http://www.ncbi.nlm.nih.gov/pubmed/27852047 https://dspace.library.uu.nl/bitstream/1874/350482/1/Prognostic.pdf https://www.oncotarget.com/fulltext/13328 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F350482 https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=13328 https://europepmc.org/articles/PMC5354930 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354930 https://pubmed.ncbi.nlm.nih.gov/27852047/ https://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=13328&path%5B%5D=42306 http://dspace.library.uu.nl/handle/1874/350482,http://dx.doi.org/10.18632/oncotarget.13328,27852047,10.18632/oncotarget.13328,2555053325,PMC5354930,0,002-034-999-768-97X; 003-691-947-996-192; 004-622-893-178-967; 005-657-093-851-339; 006-297-929-861-837; 010-151-282-951-702; 011-715-136-964-131; 012-347-246-911-604; 015-985-187-246-952; 018-257-137-573-510; 019-801-740-756-533; 019-828-857-652-228; 020-452-161-274-68X; 023-154-464-929-528; 025-327-672-443-632; 026-194-352-883-567; 026-929-763-499-628; 027-006-386-763-681; 027-985-735-139-96X; 028-788-760-917-851; 029-217-672-424-739; 032-338-399-442-547; 033-511-439-118-809; 034-981-849-573-401; 037-151-258-206-470; 040-427-840-096-003; 041-284-158-112-243; 042-932-633-853-411; 042-938-065-380-843; 045-816-348-564-507; 058-730-509-718-701; 062-028-222-808-27X; 063-232-343-564-165; 066-520-901-165-384; 067-766-525-517-863; 070-538-566-984-365; 071-951-894-169-277; 083-248-398-765-927; 083-444-386-831-50X; 085-918-555-059-35X; 086-658-166-396-908; 091-013-722-704-725; 092-455-595-685-49X; 093-847-410-363-398; 094-900-373-429-453; 100-430-859-207-545; 103-309-953-249-201; 105-848-805-818-180; 108-951-134-631-01X; 116-625-134-698-325; 145-011-518-970-434; 154-012-447-770-785; 154-777-639-664-295; 165-157-717-565-551; 165-946-128-525-721; 184-366-624-168-979,31
076-514-066-324-901,The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.,2018-08-16,2018,journal article,Vaccine,18732518; 0264410x; 13588745,Elsevier BV,Netherlands,Mariëlle van Aalst; Annefleur C. Langedijk; René Spijker; Godelieve J. de Bree; Martin P. Grobusch; Abraham Goorhuis,"Abstract Introduction Patients with a weakened immune system due to immunosuppressive treatment are at increased risk of infection with Streptococcus pneumoniae. Although pneumococcal vaccination is highly recommended for those patients, the effectiveness of pneumococcal vaccination in this population remains largely unknown. Therefore, the objective of this PROSPERO-registered systematic review and meta-analysis was to evaluate the effect of the most commonly prescribed immunosuppressive agents such as azathioprine, methotrexate, anti-Tumor Necrosis Factor α (TNFα), or rituximab, on the initial serologic response to pneumococcal vaccination in patients with auto-immune disease. Methods We included 22 articles comprising 2077 patients, of whom 1623 were treated with immunosuppressive agents, and 454 were controls. Results and discussion The findings of our systematic review indicate that, in patients treated with immunosuppressive medication and compared to controls, the initial serologic response to pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV) are impaired. Moreover, this impaired response was more profound after PCV than after PPSV. We hypothesize that the immunosuppressive medication mainly compromises the cellular immunity, explaining the more severely reduced response rate to PCV (which induces a T-cell dependent immune response), compared to PPSV. Treatment with TNFα blocking agents was associated with a more favorable response, compared to patients treated with other immunosuppressive medication. Targeted research applying uniform correlates of protection is needed to bridge the knowledge gap in vaccination immunology in this patient group. PROSPERO registration: CRD42017058364.",36,39,5832,5845,Immunology; Vaccination; Azathioprine; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; Rituximab; Population; Cellular immunity; Medicine; Immune system,Auto-immune disease; Immunogenicity; Immunosuppressive therapy; PCV; PPSV; Pneumococcal vaccination,"Antibodies, Bacterial/blood; Autoimmune Diseases/complications; Azathioprine/adverse effects; Heptavalent Pneumococcal Conjugate Vaccine/therapeutic use; Humans; Immunocompromised Host/drug effects; Immunogenicity, Vaccine; Immunosuppressive Agents/adverse effects; Pneumococcal Infections/prevention & control; Pneumococcal Vaccines/therapeutic use; Rituximab/adverse effects; Streptococcus pneumoniae","Antibodies, Bacterial; Heptavalent Pneumococcal Conjugate Vaccine; Immunosuppressive Agents; Pneumococcal Vaccines; Rituximab; Azathioprine",,https://europepmc.org/article/MED/30122649 https://pubmed.ncbi.nlm.nih.gov/30122649/ https://www.ncbi.nlm.nih.gov/pubmed/30122649 https://pubag.nal.usda.gov/catalog/6102459 https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2Feaf21b29-941f-4abf-a403-f9a49ff6732f https://www.sciencedirect.com/science/article/pii/S0264410X18310089 https://researchinformation.amsterdamumc.org/en/publications/the-effect-of-immunosuppressive-agents-on-immunogenicity-of-pneum,http://dx.doi.org/10.1016/j.vaccine.2018.07.039,30122649,10.1016/j.vaccine.2018.07.039,2885979605,,0,001-503-320-952-774; 001-923-330-535-430; 003-484-160-782-252; 003-969-868-130-677; 004-130-161-228-649; 004-496-839-875-943; 004-720-655-019-468; 005-685-955-631-048; 005-830-017-923-771; 005-845-021-264-061; 012-437-387-779-415; 013-920-556-912-333; 014-170-521-129-089; 019-403-495-474-204; 020-084-276-571-493; 023-171-039-368-146; 025-236-889-877-681; 026-417-576-106-500; 026-425-558-665-261; 027-094-626-596-361; 028-091-480-206-692; 031-466-243-432-879; 035-080-441-014-997; 035-149-537-583-281; 035-905-087-661-262; 040-343-126-931-296; 041-057-721-435-878; 041-572-942-669-519; 044-382-541-506-809; 048-182-068-205-62X; 052-260-686-036-646; 052-467-654-808-339; 058-870-470-456-373; 059-252-542-297-198; 059-969-706-422-185; 060-913-641-548-061; 068-683-471-203-772; 072-917-183-855-366; 075-972-846-039-038; 078-397-131-887-747; 081-416-421-373-858; 081-652-952-372-066; 091-508-191-719-016; 091-618-883-139-079; 105-175-539-572-70X; 112-476-557-927-490; 112-606-653-584-590; 113-243-636-254-959; 124-847-338-768-27X; 125-055-539-058-232; 125-569-261-633-818; 128-049-134-165-820; 129-063-585-094-600; 130-025-117-898-569,35
079-903-264-116-968,Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis,2019-04-26,2019,journal article,Cancers,20726694,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Madelaine G. van Mackelenbergh; Charlotte I. Stroes; René Spijker; Casper H.J. van Eijck; Johanna W. Wilmink; Maarten F. Bijlsma; Hanneke W. M. van Laarhoven,"The tumor microenvironment plays an important role in the initiation and progression of pancreatic adenocarcinoma (PDAC). In this systematic review, we provide an overview of clinical trials with stroma-targeting agents. We systematically searched MEDLINE/PubMed and the EMBASE database, using the PRISMA guidelines, for eligible clinical trials. In total, 2330 records were screened, from which we have included 106 articles. A meta-analysis could be performed on 51 articles which describe the targeting of the vascular endothelial growth factor (VEGF) pathway, and three articles which describe the targeting of hyaluronic acid. Anti-VEGF therapies did not show an increase in median overall survival (OS) with combined hazard ratios (HRs) of 1.01 (95% confidence interval (CI) 0.90–1.13). Treatment with hyaluronidase PEGPH20 showed promising results, but, thus far, only in combination with gemcitabine and nab-paclitaxel in selected patients with hyaluronic acid (HA)high tumors: An increase in median progression free survival (PFS) of 2.9 months, as well as a HR of 0.51 (95% CI 0.26–1.00). In conclusion, we found that anti-angiogenic therapies did not show an increased benefit in median OS or PFS in contrast to promising results with anti-hyaluronic acid treatment in combination with gemcitabine and nab-paclitaxel. The PEGPH20 clinical trials used patient selection to determine eligibility based on tumor biology, which underlines the importance to personalize treatment for pancreatic cancer patients.",11,5,588,,Internal medicine; Oncology; Hazard ratio; Pancreatic cancer; Gemcitabine; Progression-free survival; Adenocarcinoma; Targeted therapy; Clinical trial; Medicine; Meta-analysis,PDAC; clinical trial; stroma; systematic review; targeted therapy,,,Stichting Overleven met Alvleesklierkanker (OVIT17.02),https://europepmc.org/abstract/MED/31035512 https://www.narcis.nl/publication/RecordID/oai%3Apure.amc.nl%3Apublications%2F2c76af9f-c6b2-4d57-9aef-ac05545bacb2 https://www.ncbi.nlm.nih.gov/pubmed/31035512 https://pubmed.ncbi.nlm.nih.gov/31035512/ https://www.mdpi.com/2072-6694/11/5/588 https://repub.eur.nl/pub/117878/RePub-117878-OA.pdf https://repub.eur.nl/pub/117878 https://research.vumc.nl/en/publications/clinical-trials-targeting-the-stroma-in-pancreatic-cancer-a-syste https://www.mdpi.com/2072-6694/11/5/588/pdf https://core.ac.uk/download/224788101.pdf,http://dx.doi.org/10.3390/cancers11050588,31035512,10.3390/cancers11050588,2941560116,PMC6562438,0,000-524-949-489-63X; 000-562-622-997-939; 000-903-733-771-10X; 001-366-697-142-458; 001-937-873-552-971; 002-641-988-255-997; 003-933-541-188-24X; 004-195-725-853-501; 004-197-655-947-068; 006-002-091-859-758; 006-174-510-304-61X; 006-227-262-955-574; 010-224-556-607-218; 010-712-669-275-021; 011-728-937-975-925; 011-973-902-919-308; 012-538-837-405-027; 012-796-256-094-170; 013-956-089-888-083; 014-289-103-923-86X; 016-289-061-614-42X; 017-300-737-144-757; 017-345-003-640-38X; 018-010-333-718-559; 018-684-440-190-72X; 019-743-728-830-355; 021-212-316-601-221; 023-171-337-935-225; 023-189-721-729-624; 025-238-528-373-946; 025-265-403-681-172; 026-098-979-275-223; 026-745-876-167-017; 026-949-614-468-455; 027-439-710-000-437; 027-457-990-377-755; 027-579-695-930-39X; 027-806-335-463-158; 028-425-745-982-548; 028-720-041-147-984; 028-860-556-514-311; 029-848-679-835-793; 030-942-762-008-701; 031-974-470-160-536; 033-224-920-325-618; 033-484-012-922-274; 033-736-562-848-863; 035-388-268-012-808; 035-613-305-055-523; 036-024-440-132-887; 036-634-298-126-723; 036-723-918-845-935; 037-277-414-846-562; 038-533-452-072-840; 038-618-358-487-153; 038-822-458-605-792; 039-188-478-120-478; 040-499-561-917-553; 042-238-258-766-112; 042-301-298-043-831; 042-863-313-571-179; 043-593-416-278-716; 044-998-937-992-263; 046-275-909-851-344; 046-629-771-227-797; 046-722-419-911-932; 048-758-028-327-269; 049-992-897-287-352; 051-863-551-261-690; 052-198-975-261-650; 054-252-545-497-556; 055-017-968-565-924; 055-245-958-899-722; 055-606-187-504-817; 055-758-404-321-586; 056-713-058-990-249; 056-851-808-918-066; 057-034-340-947-836; 057-276-107-829-640; 058-424-844-370-604; 061-013-938-420-547; 061-119-497-841-180; 061-149-991-834-485; 061-224-851-769-586; 061-265-374-656-757; 061-509-528-039-814; 061-899-022-473-441; 062-007-698-040-54X; 062-035-984-421-667; 062-752-606-972-439; 062-926-222-316-878; 064-552-126-310-854; 065-100-429-361-041; 065-509-067-709-55X; 067-006-242-240-41X; 067-102-979-726-035; 067-123-855-556-815; 068-240-497-187-237; 069-785-693-151-14X; 070-634-880-696-679; 071-384-694-908-508; 072-317-403-437-248; 073-206-126-583-566; 074-422-952-605-512; 075-507-053-187-627; 075-664-055-859-81X; 076-071-820-264-550; 076-743-416-219-036; 076-828-291-234-007; 079-081-680-823-178; 081-025-535-096-643; 082-866-343-134-53X; 083-313-272-486-453; 086-036-056-821-276; 088-623-443-623-324; 089-104-388-418-062; 089-358-625-451-764; 091-379-211-573-803; 092-806-999-759-637; 093-458-176-019-564; 093-887-749-935-849; 095-410-102-593-977; 095-746-024-593-590; 096-378-773-522-394; 096-417-325-052-332; 096-493-004-018-47X; 097-378-437-578-125; 097-952-021-444-258; 098-048-962-624-155; 098-905-697-141-155; 099-143-397-972-545; 099-566-664-887-56X; 106-738-223-790-893; 107-891-446-464-371; 114-545-056-640-685; 122-312-072-263-085; 123-321-014-727-807; 127-323-700-381-599; 131-525-125-280-926; 138-430-882-891-815; 142-338-761-606-232; 144-635-079-215-910; 154-952-448-170-714; 160-061-411-835-565; 181-938-765-175-541; 184-027-996-935-765; 185-584-095-986-942,29
082-485-881-637-549,Brodie's Abscess: A Systematic Review of Reported Cases.,2019-01-24,2019,journal article,Journal of bone and joint infection,22063552,Copernicus GmbH,Germany,Niels van der Naald; Diederik P.J. Smeeing; Roderick M. Houwert; Falco Hietbrink; Geertje A M Govaert; Detlef van der Velde,"Introduction: Brodie's abscess is a form of osteomyelitis. Since its first appearance in the medical literature in 1832, numerous cases have been described. The aim of this article is to provide the first comprehensive overview of published cases of Brodie's abscess, and to describe diagnostic methods, therapeutic consequences and outcomes. Methods: According to PRISMA guidelines a systematic review of the literature was performed. All published data in English or Dutch were considered for inclusion with no limitations on publication date. Data was extracted on demography, duration of symptoms, signs of inflammation, diagnostic imaging, causative agent, treatment and follow-up. Results: A total of 70 articles were included, reporting on a total of 407 patients, mostly young (median age 17) males (male:female ratio 2.1:1). The median duration of symptoms before diagnosis was 12 weeks (SD 26). Mostly consisting of pain (98%) and/or swelling (53%). 84% of all patients were afebrile, and less than 50% had elevated serum inflammation markers. Diagnosis was made with a combination of imaging modalities: plain X-ray in 96%, MRI (16%) and CT-scan (8%). Treatment consisted of surgery in 94% of the cases, in conjunction with long term antibiotics in 77%. Staphylococcus aureus was the pathogen most often found in the culture (67,3%). Outcome was generally reported as favorable. Recurrence was reported in 15,6% of the cases requiring further intervention. Two cases developed permanent disability. Conclusion: Brodie's abscess has an insidious onset as systemic inflammatory signs and symptoms were often not found. Treatment consisted mostly of surgery followed by antibiotics (77%) or only surgery (17%) and outcomes were generally reported as favourable.",4,1,33,39,Pediatrics; Abscess; Medical literature; Osteomyelitis; Brodie's abscess; Permanent disability; Elevated serum; Signs and symptoms; Antibiotics; Medicine,Brodie's abscess; case report; osteomyelitis; systematic review,,,,https://pubmed.ncbi.nlm.nih.gov/30755846/ http://www.ncbi.nlm.nih.gov/pubmed/30755846 http://dspace.library.uu.nl/handle/1874/381392 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367194 https://europepmc.org/article/MED/30755846 https://jbji.copernicus.org/articles/4/33/2019/jbji-4-33-2019.pdf https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F381392 https://jbji.copernicus.org/articles/4/33/2019/,http://dx.doi.org/10.7150/jbji.31843,30755846,10.7150/jbji.31843,2913558384,PMC6367194,0,004-549-255-617-795; 007-286-851-789-515; 012-679-692-057-162; 014-522-855-501-457; 017-300-737-144-757; 020-059-035-165-801; 020-872-405-390-793; 021-635-445-451-463; 024-421-700-079-685; 034-147-752-740-512; 035-175-369-364-109; 037-834-766-394-853; 040-559-574-087-474; 043-278-285-962-509; 046-216-790-764-429; 047-818-757-906-91X; 056-455-484-951-147; 060-785-738-585-164; 065-554-135-518-310; 072-121-476-751-997; 082-693-559-590-443; 083-275-795-865-394; 084-906-951-717-102; 087-875-503-343-426; 096-540-563-074-311; 098-209-118-152-847; 099-035-696-382-758; 102-224-763-044-097; 106-014-657-704-522; 110-052-534-519-521; 111-216-450-496-97X; 112-557-800-918-952; 139-672-395-669-06X; 143-465-377-015-882; 150-511-085-263-356; 161-156-386-041-285; 168-250-737-406-73X,21
083-019-389-658-741,"Brain Microdialysate Monoamines in Relation to Circadian Rhythms, Sleep, and Sleep Deprivation – a Systematic Review, Network Meta-analysis, and New Primary Data",2019-01-14,2019,journal article,Journal of circadian rhythms,17403391,BioMed Central,United Kingdom,Julia M.L. Menon; Christ Nolten; E. J. Marijke Achterberg; Ruud N. J. M. A. Joosten; Maurice Dematteis; Matthijs G.P. Feenstra; Wilhelmus Drinkenburg; Cathalijn H. C. Leenaars,"Disruption of the monoaminergic system, e.g. by sleep deprivation (SD), seems to promote certain diseases. Assessment of monoamine levels over the circadian cycle, during different sleep stages and during SD is instrumental to understand the molecular dynamics during and after SD. To provide a complete overview of all available evidence, we performed a systematic review. A comprehensive search was performed for microdialysis and certain monoamines (dopamine, serotonin, noradrenaline, adrenaline), certain monoamine metabolites (3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindoleacetic acid (5-HIAA)) and a precursor (5-hydroxytryptophan (5-HTP)) in PubMed and EMBASE. After screening of the search results by two independent reviewers, 94 publications were included. All results were tabulated and described qualitatively. Network-meta analyses (NMAs) were performed to compare noradrenaline and serotonin concentrations between sleep stages. We further present experimental monoamine data from the medial prefrontal cortical (mPFC). Monoamine levels varied with brain region and circadian cycle. During sleep, monoamine levels generally decreased compared to wake. These qualitative observations were supported by the NMAs: noradrenaline and serotonin levels decreased from wakefulness to slow wave sleep and decreased further during Rapid Eye Movement sleep. In contrast, monoamine levels generally increased during SD, and sometimes remained high even during subsequent recovery. Decreases during or after SD were only reported for serotonin. In our experiment, SD did not affect any of the mPFC monoamine levels. Concluding, monoamine levels vary over the light-dark cycle and between sleep stages. SD modifies the patterns, with effects sometimes lasting beyond the SD period.",17,1,1,32,Slow-wave sleep; Circadian rhythm; Internal medicine; Endocrinology; Monoamine neurotransmitter; Serotonin; Sleep deprivation; Rapid eye movement sleep; Sleep Stages; Monoaminergic; Medicine,Systematic review; circadian rhythm; microdialysis; monoamines; network meta-analysis; sleep deprivation,,,,https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F377905 https://www.ncbi.nlm.nih.gov/pubmed/30671123 https://www.jcircadianrhythms.com/article/10.5334/jcr.174/ http://dspace.library.uu.nl/handle/1874/377905 https://dx.doi.org/10.5334/jcr.174,http://dx.doi.org/10.5334/jcr.174,30671123,10.5334/jcr.174,2908597151,PMC6337052,0,000-073-368-498-511; 000-082-973-145-815; 000-400-605-057-513; 000-839-937-806-091; 001-325-366-263-473; 001-344-413-105-19X; 001-512-112-311-491; 001-609-061-405-201; 002-175-354-757-850; 002-478-316-099-867; 002-824-063-259-402; 003-031-336-072-202; 003-816-241-441-407; 003-847-855-751-997; 004-311-599-323-387; 004-550-593-479-979; 004-763-820-285-736; 005-922-595-393-90X; 006-395-147-476-001; 006-550-262-546-586; 007-158-961-694-916; 007-414-847-463-487; 007-775-690-135-47X; 007-879-122-235-858; 009-312-282-881-029; 009-679-776-477-713; 009-890-984-354-738; 010-480-859-236-525; 010-708-752-906-611; 011-763-067-119-861; 011-768-815-663-612; 012-292-798-159-881; 012-654-077-759-25X; 013-145-615-630-965; 013-194-611-116-978; 013-255-307-689-583; 013-559-265-359-326; 014-537-407-787-406; 015-027-625-095-797; 015-672-370-194-09X; 015-711-996-891-187; 016-074-000-830-577; 016-193-335-489-261; 016-293-313-405-467; 017-165-328-595-777; 017-856-874-147-368; 018-013-701-887-617; 018-202-427-917-010; 019-259-132-055-410; 019-473-735-430-299; 019-584-017-780-560; 019-654-075-691-372; 020-912-703-236-456; 021-577-551-957-780; 021-960-278-574-878; 021-978-023-708-139; 022-259-181-490-791; 022-557-138-047-765; 022-868-327-450-199; 023-349-959-608-97X; 023-443-194-850-350; 024-100-842-869-618; 024-687-461-053-207; 024-827-360-322-81X; 025-120-778-951-186; 025-451-181-875-770; 025-454-254-727-079; 025-580-069-592-00X; 025-842-841-598-43X; 026-363-710-687-449; 026-744-343-154-454; 027-168-725-481-534; 027-246-230-652-750; 028-595-408-189-807; 028-738-215-168-220; 028-793-859-081-149; 029-289-144-146-66X; 029-600-987-598-276; 029-853-026-468-224; 030-206-852-246-054; 030-550-974-359-084; 030-739-942-166-797; 033-103-511-664-124; 033-748-691-375-087; 033-857-752-498-869; 034-430-583-628-928; 034-968-377-461-455; 035-040-093-607-801; 036-226-382-811-560; 038-854-500-755-353; 042-261-826-530-446; 042-299-091-598-717; 043-303-972-813-849; 043-333-865-605-54X; 043-998-268-183-963; 044-052-732-484-372; 044-570-739-364-146; 046-447-567-859-108; 048-168-490-476-555; 049-523-871-981-803; 050-766-051-326-709; 050-843-494-415-440; 051-634-923-844-282; 052-140-514-430-392; 052-152-079-679-019; 052-886-291-365-765; 053-001-757-336-305; 053-356-301-351-454; 053-854-470-063-228; 054-807-345-544-051; 055-503-473-511-207; 056-562-527-130-650; 057-081-022-043-374; 058-713-039-384-764; 060-685-613-420-763; 062-035-902-338-940; 062-743-917-398-222; 063-654-348-022-517; 064-686-640-011-447; 065-167-269-440-934; 067-693-077-757-251; 068-574-374-283-990; 068-719-558-359-042; 069-748-287-592-879; 071-463-647-941-730; 075-201-306-461-697; 076-186-798-190-582; 076-903-256-401-583; 077-305-636-749-166; 077-306-099-543-22X; 080-560-642-674-240; 082-829-971-040-718; 083-237-151-677-825; 083-775-527-303-804; 083-924-042-871-551; 085-423-322-559-498; 086-055-852-275-919; 087-755-756-257-263; 088-725-558-651-39X; 089-455-620-457-846; 090-315-219-944-032; 090-919-039-681-631; 093-521-213-569-207; 095-393-969-760-924; 095-683-390-717-498; 095-969-868-190-992; 096-298-725-037-28X; 097-075-857-957-73X; 097-980-927-192-382; 100-697-626-695-448; 102-890-932-988-377; 104-456-870-245-586; 108-580-717-395-362; 108-592-623-641-452; 111-230-792-144-043; 111-691-600-580-783; 120-717-660-523-86X; 121-787-173-710-369; 135-717-012-824-204; 136-250-558-811-026; 139-096-435-661-685; 145-277-191-997-544; 152-375-421-371-778; 154-656-542-124-89X; 154-781-685-052-582; 158-072-672-682-95X,19
084-036-012-777-223,Postoperative headache after surgical treatment of cerebellopontine angle tumors: a systematic review.,2021-02-01,2021,journal article,European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,14344726; 09374477,Springer Verlag,Germany,Louis Pogoda; Jelle S. Nijdam; Diederik P.J. Smeeing; Eduard H.J. Voormolen; Fuat Ziylan; Hans G X M Thomeer,"Postoperative headache (POH) is a complication that occurs after surgical resection of cerebellopontine angle (CPA) tumors. The two most common surgical approaches are the translabyrinthine (TL), and retrosigmoid (RS) approach. The objective of this systematic review was to investigate whether POH occurs more frequently after RS compared to TL approaches. A systematic search was conducted in Cochrane, Pubmed and Embase. Studies were included if POH after CPA tumor removal was reported and both surgical approaches were compared. The methodological quality of the studies was assessed using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool. In total, 3,942 unique articles were screened by title and abstract. After the initial screening process 63 articles were screened for relevance to the inquiry, of which seven studies were included. Three studies found no significant difference between both surgical approaches (p = 0.871, p = 0.120, p = 0.592). Three other studies found a lower rate of POH in the TL group compared to the RS group (p = 0.019, p < 0.001, p < 0.001). Another study showed a significantly lower POH rate in the TL group after one and six months (p = 0.006), but not after 1 year (p = 0.6). The results of this systematic review show some evidence of a lower rate of POH in favor of the TL approach versus the RS approach for CPA tumor resection. Prospective research studies are needed to further investigate this finding.",278,10,3643,3651,Otorhinolaryngology; Neurosurgery; Surgery; Translabyrinthine approach; Cerebellopontine angle tumors; Surgical approach; Surgical treatment; Medicine; Complication; Cerebellopontine angle,Cerebellopontine angle tumors; Postoperative headache; Retrosigmoid approach; Surgical techniques; Translabyrinthine approach; Vestibular schwannoma,"Cerebellopontine Angle/surgery; Headache; Humans; Neuroma, Acoustic/surgery; Neurosurgical Procedures/adverse effects; Postoperative Complications/diagnosis",,,http://europepmc.org/article/MED/33523284 https://www.scilit.net/article/470aacafcd1bf7035d5c014d08fbced3?action=show-references https://link.springer.com/content/pdf/10.1007/s00405-021-06627-6.pdf https://link.springer.com/article/10.1007/s00405-021-06627-6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382607,http://dx.doi.org/10.1007/s00405-021-06627-6,33523284,10.1007/s00405-021-06627-6,3127635756,PMC8382607,0,000-940-385-521-915; 002-166-425-652-470; 004-599-913-977-860; 004-669-660-488-487; 007-813-739-486-727; 008-978-753-942-583; 009-407-023-422-866; 009-710-071-814-065; 010-770-888-340-263; 011-706-476-855-631; 015-221-490-413-91X; 018-945-146-233-875; 021-658-550-478-897; 022-348-302-208-372; 023-703-600-744-202; 024-986-558-431-809; 027-000-955-763-159; 027-056-515-287-251; 029-373-689-033-472; 044-875-641-509-949; 045-678-222-371-352; 046-272-848-791-179; 048-005-818-320-970; 048-303-878-524-081; 069-725-837-685-729; 072-154-742-372-502; 081-563-957-891-936; 083-029-976-357-539; 083-275-795-865-394; 084-284-630-426-220; 086-823-725-189-275; 092-185-265-610-586; 095-724-922-941-49X; 102-162-212-198-697; 114-832-060-930-441; 161-156-386-041-285; 161-438-349-595-815; 181-401-131-946-252,2
090-459-861-665-279,Current treatment and outcomes of traumatic sternovertebral fractures: a systematic review,2020-10-01,2020,journal article,European journal of trauma and emergency surgery : official publication of the European Trauma Society,18639941; 18639933,Urban und Vogel,Germany,Dorine S Klei; F. Cumhur Oner; Luke P. H. Leenen; Karlijn J P van Wessem,"Combined sternal and spinal fractures are rare traumatic injuries with significant risk of spinal and thoracic wall instability. Controversy remains with regard to treatment strategies and the biomechanical need for sternal fixation to achieve spinal healing. The present study aimed to assess outcomes of sternovertebral fracture treatment. A systematic review of literature on the treatment of traumatic sternovertebral fractures was conducted. Original studies published after 1990, reporting sternal and spinal healing or stability were included. Studies not reporting treatment outcomes were excluded. Six studies were included in this review, with a total study population of 98 patients: 2 case series, 3 case reports, and 1 retrospective cohort study. 10 per cent of sternal fractures showed displacement. Most spinal fractures were located in the thoracic spine and were AOSpine type A (51%), type B (35%), or type C (14%). 14 per cent of sternal fractures and 49% of spinal fractures were surgically treated. Sternal treatment failure occurred in 5% of patients and biomechanical spinal failure in 8%. There were no differences in treatment failure between conservative and operative treatment. Literature on traumatic sternovertebral fracture treatment is sparse. Findings indicate that in most patients, sternal fixation is not required to achieve sternal and spinal stability. However, results of the current review should be cautiously interpreted, since most included studies were of poor quality.",47,4,991,1001,Surgery; Retrospective cohort study; Thoracic wall; Treatment failure; Thoracic spine; Significant risk; Treatment outcome; Poor quality; Sports medicine; Medicine,Outcomes; Sternovertebral fractures; Systematic review; Traumatic sternal and spinal fractures; Treatment,"Fractures, Bone; Humans; Retrospective Studies; Spinal Fractures/diagnostic imaging; Sternum/diagnostic imaging; Treatment Outcome",,University Medical Center Utrecht,https://link.springer.com/article/10.1007/s00068-020-01505-y https://www.ncbi.nlm.nih.gov/pubmed/33006034 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322016 https://pubmed.ncbi.nlm.nih.gov/33006034/ https://link.springer.com/content/pdf/10.1007/s00068-020-01505-y.pdf,http://dx.doi.org/10.1007/s00068-020-01505-y,33006034,10.1007/s00068-020-01505-y,3090254541,PMC8322016,0,000-262-728-618-55X; 000-439-699-858-060; 000-793-658-791-252; 001-067-629-682-196; 001-393-948-158-010; 002-443-652-131-053; 006-335-614-614-844; 006-667-728-684-85X; 007-079-160-028-299; 007-959-153-378-886; 008-528-480-982-097; 009-406-412-388-96X; 010-059-699-038-191; 017-753-055-720-472; 019-461-139-206-604; 019-796-968-981-805; 021-704-511-862-786; 023-010-611-104-057; 026-048-598-874-50X; 033-091-167-998-305; 033-268-174-860-727; 033-618-236-228-733; 037-774-541-918-52X; 040-916-818-205-274; 047-397-027-549-815; 061-814-999-823-315; 069-317-739-534-123; 070-087-913-372-962; 073-429-681-552-644; 076-135-626-779-964; 077-777-794-414-172; 082-946-237-573-782; 105-622-438-585-538; 107-793-485-896-362; 111-781-077-650-36X; 114-496-068-009-964; 121-339-293-229-423; 141-634-652-642-63X; 159-707-933-636-488,0
091-724-887-895-516,Reporting Quality of Systematic Reviews and Meta-Analyses of Otorhinolaryngologic Articles Based on the PRISMA Statement.,2015-08-28,2015,journal article,PloS one,19326203,Public Library of Science,United States,Jeroen P. M. Peters; Lotty Hooft; Wilko Grolman; Inge Stegeman,"BACKGROUND: Systematic reviews (SRs) and meta-analyses (MAs) provide the highest possible level of evidence. However, poor conduct or reporting of SRs and MAs may reduce their utility. The PRISMA Statement (Preferred Reporting Items for Systematic reviews and Meta-Analyses) was developed to help authors report their SRs and MAs adequately. OBJECTIVES: Our objectives were to (1) evaluate the quality of reporting of SRs and MAs and their abstracts in otorhinolaryngologic literature using the PRISMA and PRISMA for Abstracts checklists, respectively, (2) compare the quality of reporting of SRs and MAs published in Ear Nose Throat (ENT) journals to the quality of SRs and MAs published in the 'gold standard' Cochrane Database of Systematic Reviews (CDSR), and (3) formulate recommendations to improve reporting of SRs and MAs in ENT journals. METHODS: On September 3, 2014, we searched the Pubmed database using a combination of filters to retrieve SRs and MAs on otorhinolaryngologic topics published in 2012 and 2013 in the top 5 ENT journals (ISI Web of Knowledge 2013) or CDSR and relevant articles were selected. We assessed how many, and which, PRISMA (for Abstracts) items were reported adequately per journal type. RESULTS: We identified large differences in the reporting of individual items between the two journal types with room for improvement. In general, SRs and MAs published in ENT journals (n = 31) reported a median of 54.4% of the PRISMA items adequately, whereas the 49 articles published in the CDSR reported a median of 100.0 adequately (difference statistically significant, p < 0.001). For abstracts, medians of 41.7% for ENT journals and 75.0% for the CDSR were found (p < 0.001). CONCLUSION: The reporting of SRs and MAs in ENT journals leaves room for improvement and would benefit if the PRISMA Statement were endorsed by these journals.",10,8,e0136540,,Otorhinolaryngology; Systematic review; Medical physics; Evidence-based medicine; Meta-Analysis as Topic; Scientific publishing; Web of knowledge; Ear nose throat; Medicine; Meta-analysis,,Data Accuracy; Humans; Meta-Analysis as Topic; Otorhinolaryngologic Diseases; Periodicals as Topic; PubMed,,,http://dspace.library.uu.nl/handle/1874/332617 https://dx.plos.org/10.1371/journal.pone.0136540 http://ui.adsabs.harvard.edu/abs/2015PLoSO..1036540P/abstract https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F332617 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552785 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136540 https://paperity.org/p/73917981/reporting-quality-of-systematic-reviews-and-meta-analyses-of-otorhinolaryngologic http://europepmc.org/articles/PMC4552785 http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136540,http://dx.doi.org/10.1371/journal.pone.0136540,26317406,10.1371/journal.pone.0136540,1933605941,PMC4552785,0,005-408-253-373-210; 014-046-267-411-282; 017-300-737-144-757; 018-056-989-049-187; 018-945-146-233-875; 020-546-820-441-080; 027-684-341-720-517; 028-845-471-578-855; 034-600-684-728-898; 039-204-853-121-577; 044-802-610-299-451; 048-201-822-092-278; 053-927-938-312-176; 065-556-902-441-721; 065-899-161-405-313; 070-749-802-806-393; 072-516-841-671-300; 076-504-287-789-914; 080-796-419-663-830; 083-275-795-865-394; 120-529-529-340-453; 124-746-942-962-164,59
093-479-641-449-598,Effectiveness of mHealth Interventions Targeting Health Care Workers to Improve Pregnancy Outcomes in Low- and Middle-Income Countries : A Systematic Review,2016-08-19,2016,journal article,Journal of medical Internet research,14388871,Journal of medical Internet Research,Canada,Mary Amoakoh-Coleman; Alexander Berend Jan Borgstein; Stephanie Felicie Victoria Sondaal; Diederick E. Grobbee; Andrea Solnes Miltenburg; Mirjam Verwijs; Evelyn K. Ansah; Joyce L. Browne; Kerstin Klipstein-Grobusch,"Background: Low- and middle-income countries (LMICs) face the highest burden of maternal and neonatal deaths. Concurrently, they have the lowest number of physicians. Innovative methods such as the exchange of health-related information using mobile devices (mHealth) may support health care workers in the provision of antenatal, delivery, and postnatal care to improve maternal and neonatal outcomes in LMICs. Objective: We conducted a systematic review evaluating the effectiveness of mHealth interventions targeting health care workers to improve maternal and neonatal outcomes in LMIC. Methods: The Cochrane Library, PubMed, EMBASE, Global Health Library, and Popline were searched using predetermined search and indexing terms. Quality assessment was performed using an adapted Cochrane Risk of Bias Tool. A strength, weakness, opportunity, and threat analysis was performed for each included paper. Results: A total of 19 studies were included for this systematic review, 10 intervention and 9 descriptive studies. mHealth interventions were used as communication, data collection, or educational tool by health care providers primarily at the community level in the provision of antenatal, delivery, and postnatal care. Interventions were used to track pregnant women to improve antenatal and delivery care, as well as facilitate referrals. None of the studies directly assessed the effect of mHealth on maternal and neonatal mortality. Challenges of mHealth interventions to assist health care workers consisted mainly of technical problems, such as mobile network coverage, internet access, electricity access, and maintenance of mobile phones. Conclusions: mHealth interventions targeting health care workers have the potential to improve maternal and neonatal health services in LMICs. However, there is a gap in the knowledge whether mHealth interventions directly affect maternal and neonatal outcomes and future research should employ experimental designs with relevant outcome measures to address this gap. [J Med Internet Res 2016;18(8):e226]",18,8,e226,,Nursing; Health care; Poverty; Psychological intervention; Cochrane Library; mHealth; Telemedicine; Postnatal Care; Global health; Medicine,low- and middle-income countries; mHealth; maternal; neonatal; providers of care,Female; Health Personnel/education; Humans; Poverty; Pregnancy; Pregnancy Outcome; Social Class; Telemedicine/methods,,FIC NIH HHS (D43 TW009140) United States,https://www.jmir.org/2016/8/e226 https://pubmed.ncbi.nlm.nih.gov/27543152/ https://europepmc.org/article/MED/27543152 http://www.ncbi.nlm.nih.gov/pubmed/27543152 http://dspace.library.uu.nl/handle/1874/337816 https://dspace.library.uu.nl/bitstream/1874/337816/1/2.pdf https://www.ncbi.nlm.nih.gov/pubmed/27543152 https://www.mendeley.com/catalogue/140c60ee-255e-36d4-a726-d89b455203de/ https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F337816 https://core.ac.uk/display/46177327,http://dx.doi.org/10.2196/jmir.5533,27543152,10.2196/jmir.5533,2513375503,PMC5010646,0,002-026-665-696-902; 004-871-196-658-84X; 006-950-532-481-501; 013-040-369-207-588; 015-062-582-981-951; 017-016-524-048-229; 018-945-146-233-875; 019-747-403-234-051; 021-944-720-672-500; 024-389-386-594-744; 027-810-903-423-341; 029-206-714-096-419; 030-012-603-815-177; 031-878-412-231-818; 036-764-225-011-648; 037-536-290-735-652; 040-435-231-626-187; 040-599-109-232-265; 050-270-083-621-412; 055-180-434-629-962; 056-114-956-388-036; 058-976-071-689-482; 059-319-123-613-559; 069-760-558-746-449; 072-819-805-923-978; 090-561-645-581-354; 094-541-162-375-094; 106-002-754-902-151; 107-059-595-181-652; 118-083-604-024-333; 131-201-074-659-248; 139-527-026-195-953; 155-946-390-285-388,72
095-606-069-928-724,Reducing Inappropriate Proton Pump Inhibitors Use for Stress Ulcer Prophylaxis in Hospitalized Patients: Systematic Review of De-Implementation Studies,2021-02-02,2021,journal article,Journal of general internal medicine,15251497; 08848734,Springer Nature,Germany,Claudia C. Orelio; Pauline Heus; Judith J Kroese-van Dieren; René Spijker; Barbara C. van Munster; Lotty Hooft,"A large proportion of proton pump inhibitor (PPI) prescriptions, including those for stress ulcer prophylaxis (SUP), are inappropriate. Our study purpose was to systematically review the effectiveness of de-implementation strategies aimed at reducing inappropriate PPI use for SUP in hospitalized, non-intensive care unit (non-ICU) patients. We searched MEDLINE and Embase databases (from inception to January 2020). Two authors independently screened references, performed data extraction, and critical appraisal. Randomized trials and comparative observational studies were eligible for inclusion. Criteria developed by the Cochrane Effective Practice and Organisation of Care (EPOC) group were used for critical appraisal. Besides the primary outcome (inappropriate PPI prescription or use), secondary outcomes included (adverse) pharmaceutical effects and healthcare use. We included ten studies in this review. Most de-implementation strategies contained an educational component (meetings and/or materials), combined with either clinical guideline implementation (n = 5), audit feedback (n = 3), organizational culture (n = 4), or reminders (n = 1). One study evaluating the de-implementation strategy effectiveness showed a significant reduction (RR 0.14; 95% CI 0.03–0.55) of new inappropriate PPI prescriptions. Out of five studies evaluating the effectiveness of de-implementing inappropriate PPI use, four found a significant reduction (RR 0.21; 95% CI 0.18–0.26 to RR 0.76; 95% CI 0.68–0.86). No significant differences in the occurrence of pharmaceutical effects (n = 1) and in length of stay (n = 3) were observed. Adverse pharmaceutical effects were reported in two studies and five studies reported on PPI or total drug costs. No pooled effect estimates were calculated because of large statistical heterogeneity between studies. All identified studies reported mainly educational interventions in combination with one or multiple other intervention strategies and all interventions were targeted at providers. Most studies found a small to moderate reduction of (inappropriate) PPI prescriptions or use.",36,7,2065,2073,Study heterogeneity; Internal medicine; Critical appraisal; Randomized controlled trial; Observational study; Medical prescription; Psychological intervention; MEDLINE; Proton-pump inhibitor; Medicine,de-implementation; hospital; proton pump inhibitor (PPI); stress ulcer prophylaxis (SUP); systematic review,Acute Disease; Humans; Inappropriate Prescribing/prevention & control; Proton Pump Inhibitors; Ulcer,Proton Pump Inhibitors,,https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F7c743825-c56e-4512-ba41-b449079cf3bd https://link.springer.com/article/10.1007/s11606-020-06425-6 https://link.springer.com/content/pdf/10.1007/s11606-020-06425-6.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298652 https://europepmc.org/article/MED/33532958 https://research.rug.nl/en/publications/reducing-inappropriate-proton-pump-inhibitors-use-for-stress-ulce,http://dx.doi.org/10.1007/s11606-020-06425-6,33532958,10.1007/s11606-020-06425-6,3127555701,PMC8298652,0,000-366-608-770-967; 000-495-363-934-038; 001-170-196-424-882; 001-277-081-237-825; 002-096-348-038-790; 004-631-907-001-965; 005-397-116-785-373; 006-692-210-311-631; 006-725-427-298-659; 008-406-195-694-795; 009-112-629-780-352; 009-121-393-680-455; 009-207-034-896-921; 010-889-660-013-539; 013-850-030-670-658; 015-521-058-860-985; 016-586-746-737-917; 017-300-737-144-757; 018-661-195-990-018; 019-756-924-228-583; 022-992-302-746-792; 023-593-969-852-233; 030-309-041-519-292; 030-998-748-367-057; 031-539-006-411-008; 033-507-752-062-133; 035-240-423-556-266; 036-278-063-742-152; 041-064-764-692-220; 041-807-895-445-400; 042-487-100-041-83X; 043-721-749-907-107; 044-377-951-175-911; 050-763-383-069-880; 052-025-665-667-983; 052-401-662-709-080; 053-062-438-124-013; 057-538-213-752-664; 057-904-231-568-69X; 058-870-470-456-373; 069-885-117-128-716; 070-967-748-664-739; 072-286-572-699-899; 073-801-954-958-091; 074-924-455-505-457; 081-707-134-716-491; 083-275-795-865-394; 085-863-056-265-102; 105-536-751-735-394; 110-660-074-903-627; 113-124-246-264-770; 113-443-090-754-295; 137-071-286-430-096; 139-302-983-403-059; 146-757-712-199-978; 149-595-386-008-100; 154-423-612-925-119; 168-805-978-714-377,3
102-164-652-964-454,Use of PET tracers for parathyroid localization: a systematic review and meta-analysis,2016-04-16,2016,journal article,Langenbeck's archives of surgery,14352451; 14352443,Springer Verlag,Germany,Wouter P. Kluijfhout; Jesse D. Pasternak; Frederick Thurston Drake; Toni Beninato; Jessica E. Gosnell; Wen T. Shen; Quan-Yang Duh; Isabel E. Allen; Menno R. Vriens; Bart de Keizer; Miguel Hernandez Pampaloni; Insoo Suh,Purpose; The great spatial and temporal resolution of positron emission tomography might provide the answer for patients with primary hyperparathyroidism (pHPT) and non-localized parathyroid glands. We performed a systematic review of the evidence regarding all investigated tracers.,401,7,925,935,Radiology; PET-CT; Positron emission tomography; Parathyroidectomy; Primary hyperparathyroidism; 18F-fluorocholine; Nuclear medicine; Pet tracer; 11c methionine; Medicine; Meta-analysis,11C-Methionine; 18F-Fluorocholine; Minimal invasive parathyroidectomy; PET/CT; Primary hyperparathyroidism,"Carbon Radioisotopes; Humans; Hyperparathyroidism, Primary/diagnostic imaging; Methionine; Parathyroidectomy; Positron-Emission Tomography; Radiopharmaceuticals",Carbon Radioisotopes; Radiopharmaceuticals; Methionine,,https://paperity.org/p/75790130/use-of-pet-tracers-for-parathyroid-localization-a-systematic-review-and-meta-analysis https://europepmc.org/abstract/MED/27086309 https://escholarship.org/uc/item/3bs1h1z5 https://dspace.library.uu.nl/handle/1874/344897 https://link.springer.com/content/pdf/10.1007%2Fs00423-016-1425-0.pdf https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F344897 https://www.ncbi.nlm.nih.gov/pubmed/27086309 https://link.springer.com/article/10.1007/s00423-016-1425-0 https://pubmed.ncbi.nlm.nih.gov/27086309/,http://dx.doi.org/10.1007/s00423-016-1425-0,27086309,10.1007/s00423-016-1425-0,2337805229,PMC5086346,0,001-099-632-305-574; 002-697-347-573-525; 002-767-568-653-968; 003-118-910-314-387; 004-301-103-776-376; 009-659-686-885-176; 010-780-661-798-471; 010-788-042-481-340; 011-432-776-784-462; 011-567-369-398-335; 012-395-212-908-278; 014-156-202-575-224; 014-549-647-053-717; 016-253-354-981-368; 018-958-166-135-298; 025-980-796-340-397; 027-688-582-338-560; 029-451-096-005-610; 029-654-574-146-451; 035-288-981-843-270; 035-903-572-612-30X; 036-796-155-487-507; 038-121-175-229-211; 040-023-082-419-203; 040-100-697-793-61X; 045-416-413-742-937; 046-842-526-058-654; 046-886-706-111-357; 050-540-296-778-066; 054-396-489-281-170; 057-075-056-237-870; 057-533-018-201-936; 063-693-736-629-080; 069-624-379-457-880; 070-203-001-370-927; 080-252-653-829-944; 080-564-237-991-187; 087-629-815-318-111; 088-417-581-230-281; 090-456-269-181-095; 092-901-436-877-90X; 093-733-352-854-555; 095-417-260-178-869; 101-533-476-420-371; 104-453-454-389-771; 106-259-991-473-630; 109-567-934-895-910; 113-084-702-054-440; 113-263-627-206-582; 126-248-806-235-270; 127-520-530-846-332; 149-760-518-135-221; 193-752-364-153-86X,60
102-359-270-672-907,"Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges.",2020-10-16,2020,journal article,Frontiers in medicine,2296858x,Frontiers Media SA,Switzerland,Richard Ofori-Asenso; Christine E. Hallgreen; Marie L. De Bruin,"The need to optimize drug development and facilitate faster access for patients has ignited discussions around the importance of improving interactions between health technology assessment (HTA) bodies and regulatory agencies. In this study, we conducted a systematic review to examine processes, progress, outcomes, and challenges of harmonization/interaction initiatives between HTA bodies and regulatory agencies. MEDLINE, EMBASE, and the International Pharmaceutical Abstracts database were searched up to 21 October 2019. Searches for gray literature (working papers, commissioned reports, policy documents, etc.) were performed via Google scholar and several institutional websites. An online cross-sectional survey was also conducted among HTA (n = 22) and regulatory agencies (n = 6) across Europe to supplement the systematic review. Overall, we found that while there are areas of divergence, there has been progress over time in narrowing the gap in evidentiary requirements for HTA bodies and regulatory agencies. Most regulatory agencies (4/6; 67%) and half (11/22, 50%) of the HTA bodies reported having a formal link for ""collaborating"" with the other. Several mechanisms such as early tripartite dialogues, parallel submissions (reviews), adaptive licensing pathways, and postauthorization data generation have been explored as avenues for improving collaboration. A number of pilot initiatives have shown positive effects of these models to reduce the time between regulatory and HTA decisions, which may translate into faster access for patients to life-saving therapies. Thus, future approaches aimed at improving harmonization/interaction between HTA bodies and regulatory agencies should build on these existing models/mechanisms while examining their long-term impacts. Several barriers including legal, organizational, and resource-related factors were also identified, and these need to be addressed to achieve greater alignment in the current regulatory and reimbursement landscape.",7,,582634,582634,Cross-sectional study; Business; Health technology; MEDLINE; Reimbursement; Harmonization; Public relations; Grey literature; Drug development,HTA; collaboration synergy between HTA and regulatory agencies; harmonization; regulatory approval; synergy,,,,https://europepmc.org/article/MED/33178721 https://www.frontiersin.org/articles/10.3389/fmed.2020.582634/full https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596325 https://doaj.org/article/7babf9c46e814066a668254caacbc14b https://www.ncbi.nlm.nih.gov/pubmed/33178721,http://dx.doi.org/10.3389/fmed.2020.582634,33178721,10.3389/fmed.2020.582634,3093378950,PMC7596325,0,000-389-998-844-926; 004-029-266-916-038; 004-138-506-625-807; 006-194-069-429-654; 006-395-691-998-479; 007-345-527-337-944; 010-811-585-922-870; 012-282-829-264-491; 013-308-425-910-003; 013-949-177-966-234; 017-493-555-246-270; 018-136-442-053-019; 024-910-104-637-094; 032-001-808-296-701; 033-249-398-910-646; 033-628-615-737-705; 034-322-798-761-031; 040-985-186-260-986; 041-198-595-807-202; 042-154-783-624-333; 043-307-997-345-621; 044-814-041-482-368; 045-489-433-206-346; 049-115-261-470-974; 049-790-884-081-210; 051-814-198-598-725; 053-265-074-991-182; 057-648-310-784-964; 059-621-296-574-321; 060-029-020-457-389; 062-951-526-651-768; 064-602-382-225-176; 068-485-535-227-101; 079-908-119-389-508; 081-521-832-915-652; 082-973-698-585-309; 085-563-954-521-783; 086-716-177-033-910; 088-022-904-008-575; 092-735-910-817-680; 092-867-819-814-758; 094-619-718-309-04X; 099-466-166-787-779; 102-213-382-649-064; 108-162-965-476-979; 112-112-484-026-722; 133-237-954-517-878; 143-938-509-974-979,2
102-951-643-631-079,Escape education: A systematic review on escape rooms in education,,2020,journal article,Educational Research Review,1747938x,Elsevier BV,Netherlands,Alice Veldkamp; Liesbeth van de Grint; Marie-Christine P. J. Knippels; Wouter R. van Joolingen,"Abstract The global increase in recreational escape rooms has inspired teachers around the world to implement escape rooms in educational settings. As escape rooms are increasingly popular in education, there is a need to evaluate their use, and a need for guidelines to develop and implement escape rooms in the classroom. This systematic review synthesizes current practices and experiences, focussing on important educational and game design aspects. Subsequently, relations between the game design aspects and the educational aspects are studied. Finally, student outcomes are related to the intended goals. Educators in different disciplines appear to have different motives for using the game’s time constraints and teamwork. These educators make different choices for related game aspects such as the structuring of the puzzles. Unlike recreational escape rooms, in educational escape rooms players need to reach the game goal by achieving the educational goals. More alignment in game mechanics and pedagogical approaches is recommended. There is a discrepancy in perceived and actual learning of content knowledge in recreational escape rooms. Recommendations in the article for developing and implementing escape rooms in education will help educators in creating these new learning environments, and eventually help students to foster knowledge and skills more effectively.",31,,100364,,Recreation; Teamwork; Psychology; Game mechanics; Structuring; Content knowledge; Public relations; Game design,,,,IT; Utrecht University,https://www.sciencedirect.com/science/article/pii/S1747938X20300531 https://www.sciencedirect.com/science/article/abs/pii/S1747938X20300531 https://europepmc.org/article/PPR/PPR116978,http://dx.doi.org/10.1016/j.edurev.2020.100364,,10.1016/j.edurev.2020.100364,3011612309,,0,000-197-319-365-151; 001-177-219-022-168; 005-043-744-502-209; 007-139-387-089-16X; 008-942-678-346-524; 012-226-259-683-806; 012-462-264-494-385; 014-852-536-804-890; 017-525-428-522-256; 017-863-618-200-604; 021-442-250-115-936; 022-442-193-849-699; 022-643-881-567-67X; 025-212-498-386-272; 027-332-292-897-471; 029-238-628-492-729; 030-344-192-299-673; 030-813-523-714-667; 031-925-653-269-648; 035-563-980-194-583; 038-220-603-531-470; 039-925-317-983-800; 042-798-499-483-450; 046-453-323-232-481; 047-349-773-490-978; 047-572-380-852-343; 048-338-128-089-201; 051-733-343-516-93X; 051-938-898-271-533; 054-907-449-402-662; 057-418-339-678-512; 058-632-433-920-188; 059-223-674-745-199; 059-877-163-734-511; 060-218-243-473-020; 064-652-327-623-118; 074-516-814-773-515; 074-567-383-341-648; 079-029-968-819-436; 083-704-523-247-309; 086-680-018-311-889; 088-076-352-006-259; 088-371-840-782-89X; 089-546-099-896-613; 090-655-068-939-789; 095-932-811-369-677; 099-397-527-011-698; 099-645-258-011-058; 100-403-433-513-98X; 108-203-797-786-342; 110-015-766-301-449; 111-251-309-898-383; 116-849-265-867-144; 121-917-739-836-36X; 128-176-175-541-257; 132-515-875-570-444; 134-138-941-987-670; 135-135-556-462-23X; 143-245-590-598-111; 160-238-137-210-036; 170-243-948-162-292; 170-705-588-237-214; 175-876-964-503-722; 191-152-484-817-569,15
102-971-390-208-827,A Systematic Review of Field Experiments in Public Administration,2020-03-23,2020,journal article,Public Administration Review,00333352; 15406210,Wiley,United Kingdom,Jesper Asring Hansen; Lars Tummers,"Field experiments have become popular in public administration. By allowing for the identification of causal effects in realistic settings, field experiments may become central in several research agendas of relevance to the field. Conducting field experiments is difficult and problems often occur along the way. However, researchers new to the method have few resources in public administration to consider the problems that arise when conducting field experiments. This systematic review identifies 42 field experiments in public administration and serves as an introduction to field experiments in public administration. The article discusses how field experiments developed over time and highlights trends in field experimentation in public administration. It then discusses issues to consider when designing field experiments. Among these are costs, practicality, ethics, and validity. Finally, the authors suggest a future research agenda for public administration field experiments.",80,6,921,931,Field (Bourdieu); Causal effect; Public administration; Computer science; Identification (information); Relevance (information retrieval),,,,,https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F395234 https://onlinelibrary.wiley.com/doi/pdf/10.1111/puar.13181 http://dspace.library.uu.nl/handle/1874/395234 https://onlinelibrary.wiley.com/doi/10.1111/puar.13181,http://dx.doi.org/10.1111/puar.13181,,10.1111/puar.13181,3013482727,,0,005-021-448-758-763; 005-312-257-115-044; 006-040-072-789-448; 007-308-390-587-607; 008-087-838-626-193; 009-287-531-126-55X; 009-756-144-477-746; 010-175-218-556-878; 013-541-969-076-695; 013-870-259-076-233; 014-906-960-835-54X; 015-729-942-084-350; 018-658-066-225-195; 020-203-003-568-829; 021-249-691-817-664; 021-944-232-729-133; 023-442-434-747-228; 024-250-752-027-429; 024-268-019-618-387; 024-690-667-955-991; 024-877-648-614-075; 027-544-070-166-088; 028-334-930-275-649; 029-736-569-556-228; 031-151-033-734-717; 032-477-333-508-507; 033-976-209-596-59X; 035-832-861-489-875; 036-196-967-056-199; 046-096-840-120-952; 047-178-315-926-515; 048-371-488-723-434; 048-643-733-195-724; 048-693-534-546-347; 052-231-224-637-778; 056-199-654-804-327; 057-624-293-105-942; 058-172-185-623-277; 058-635-926-235-406; 059-906-464-158-933; 061-375-078-720-256; 061-705-290-226-254; 062-607-641-860-44X; 064-646-430-722-56X; 068-375-255-781-012; 070-015-728-751-909; 073-546-087-244-326; 077-130-646-730-192; 077-493-351-811-780; 078-520-863-981-326; 078-830-617-466-429; 079-661-121-499-712; 082-627-083-445-738; 083-496-686-508-792; 084-045-167-688-369; 085-964-245-468-040; 085-970-712-488-755; 089-015-720-781-011; 089-482-620-369-663; 092-029-740-836-521; 095-759-778-893-584; 100-291-963-966-106; 101-415-428-280-530; 101-436-136-435-468; 105-897-706-807-153; 106-108-074-809-792; 110-876-793-746-43X; 112-422-162-870-369; 127-487-761-653-472; 135-995-296-026-916; 143-826-092-328-130; 144-328-292-388-060; 146-147-589-589-912; 157-385-127-325-878; 158-639-024-013-760; 163-880-732-919-864; 164-905-071-172-074; 176-648-861-257-700; 181-967-000-946-239; 186-973-513-348-675,8
103-004-307-195-256,Prenatal Amino Acid Supplementation to Improve Fetal Growth: A Systematic Review and Meta-Analysis.,2020-08-21,2020,journal article,Nutrients,20726643,Multidisciplinary Digital Publishing Institute (MDPI),Switzerland,Fieke Terstappen; Angela J C Tol; Hendrik Gremmels; Kimberley E. Wever; Nina D Paauw; Jaap A. Joles; Eline M. van der Beek; A. Titia Lely,"Aberrant fetal growth remains a leading cause of perinatal morbidity and mortality and is associated with a risk of developing non-communicable diseases later in life. We performed a systematic review and meta-analysis combining human and animal studies to assess whether prenatal amino acid (AA) supplementation could be a promising approach to promote healthy fetal growth. PubMed, Embase and Cochrane libraries were searched to identify studies orally supplementing the following AA groups during gestation: (1) arginine family; (2) branched chain (BCAA); (3) methyl donors. Primary outcome was fetal/birth weight. 22 human and 89 animal studies were included in the systematic review. The arginine family, and especially arginine itself, was studied most. Our meta-analysis showed beneficial effects of arginine and (N-Carbamyl) glutamate (NCG), but not aspartic acid and citrulline on fetal/birth weight. However, no effects were reported when isonitrogenous control diet was included. BCAA and methyl donor supplementation did not affect fetal/birth weight. Arginine family supplementation, in particular arginine and NCG, improves fetal growth in complicated pregnancies. BCAA and methyl donor supplementation do not seem to be as promising to target fetal growth. Well controlled research in complicated pregnancies is needed before ruling out AA supplements or preferring arginine above other AAs.",12,9,1,55,Internal medicine; Endocrinology; Animal studies; Fetus; Arginine; Citrulline; Pregnancy; Branched-chain amino acid; Gestation; Birth weight; Medicine,amino acids; arginine; birth weight; branched chain amino acid; fetal growth restriction; meta-analysis; methyl donor; pregnancy,Amino Acids/administration & dosage; Animals; Arginine/administration & dosage; Birth Weight/drug effects; Dietary Supplements; Female; Fetal Development/drug effects; Fetal Growth Retardation/prevention & control; Glutamic Acid/administration & dosage; Humans; Maternal Nutritional Physiological Phenomena/physiology; Maternal-Fetal Exchange/physiology; Pregnancy; Prenatal Nutritional Physiological Phenomena/physiology,Amino Acids; Glutamic Acid; Arginine,ZonMw (114024115 and 114024131); Nierstichting (15O141),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551332 https://www.mdpi.com/2072-6643/12/9/2535/pdf https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F7032ffa8-bfca-451f-b4e8-4e340d8a371d https://www.ncbi.nlm.nih.gov/pubmed/32825593 https://repository.ubn.ru.nl/handle/2066/225492 https://www.mdpi.com/2072-6643/12/9/2535 https://research.rug.nl/en/publications/prenatal-amino-acid-supplementation-to-improve-fetal-growth-a-sys,http://dx.doi.org/10.3390/nu12092535,32825593,10.3390/nu12092535,3081303817,PMC7551332,0,000-245-668-915-311; 000-628-657-603-396; 001-083-811-500-854; 001-684-678-428-331; 001-721-642-721-739; 001-836-766-116-303; 002-007-669-787-920; 004-127-823-275-763; 004-435-085-513-364; 004-754-571-666-807; 004-840-040-991-169; 005-011-655-573-842; 005-109-159-167-584; 005-300-372-048-467; 005-349-679-216-67X; 006-632-124-730-595; 006-961-907-144-995; 007-174-387-543-936; 007-546-569-704-846; 007-774-881-457-055; 007-941-595-054-218; 008-245-822-029-459; 009-370-756-981-618; 009-563-476-696-661; 010-081-320-503-003; 010-428-653-771-495; 010-625-933-480-601; 011-939-542-591-273; 012-557-141-962-080; 013-098-763-518-554; 013-585-960-519-319; 014-298-934-704-689; 014-818-731-754-80X; 014-970-360-764-633; 015-046-571-755-991; 015-160-329-171-444; 015-162-275-994-654; 015-444-156-387-830; 015-895-718-739-774; 016-057-882-244-515; 016-194-712-725-325; 016-344-014-257-094; 017-110-926-046-884; 017-760-560-073-54X; 017-846-368-225-918; 018-013-701-887-617; 018-805-925-578-341; 018-823-313-495-683; 018-945-146-233-875; 019-016-858-514-448; 020-050-516-632-22X; 020-894-868-885-108; 021-088-575-864-127; 021-793-253-303-929; 021-808-661-425-537; 021-997-721-865-530; 022-495-452-190-50X; 022-522-012-273-337; 022-597-199-720-104; 023-523-966-818-829; 023-709-684-665-030; 024-188-813-731-029; 025-320-324-726-415; 026-856-425-612-97X; 027-279-704-423-02X; 028-101-371-963-172; 028-431-958-820-607; 028-744-945-910-686; 030-640-874-037-087; 031-304-473-006-224; 031-312-192-184-403; 031-969-419-815-836; 033-367-121-600-220; 035-112-480-495-352; 036-665-868-371-838; 037-083-290-686-855; 037-246-902-787-643; 037-743-172-827-347; 038-110-318-483-038; 038-930-972-067-120; 039-138-598-179-356; 039-824-631-279-042; 040-424-201-017-205; 041-413-980-892-983; 042-219-449-027-001; 043-121-525-995-399; 043-913-841-366-258; 045-575-953-326-406; 045-575-981-613-066; 047-150-666-911-900; 047-559-662-655-456; 047-711-710-230-57X; 048-223-239-637-143; 049-376-474-826-749; 050-732-224-208-503; 051-879-783-137-767; 052-354-409-420-823; 053-750-517-333-656; 053-918-866-507-032; 055-370-947-208-255; 056-055-185-695-523; 056-308-600-327-035; 057-927-261-880-029; 060-190-016-290-038; 060-533-496-497-397; 060-969-632-974-360; 061-638-744-843-170; 061-660-523-099-166; 064-381-377-542-656; 066-423-593-865-658; 066-870-764-830-05X; 067-267-799-641-355; 067-273-692-275-923; 069-139-550-965-561; 072-021-074-892-051; 072-802-873-512-176; 073-114-745-344-195; 073-273-032-265-583; 076-077-918-482-537; 076-470-419-044-605; 077-151-908-256-658; 079-117-428-261-283; 083-486-894-997-19X; 083-524-735-711-531; 088-246-201-727-349; 088-345-284-994-584; 089-175-024-798-437; 089-332-971-347-040; 089-343-778-508-651; 093-453-469-393-119; 095-185-755-865-847; 095-780-897-816-633; 102-942-758-139-864; 103-386-128-967-931; 106-795-240-074-523; 109-693-812-275-868; 110-264-881-190-972; 111-919-922-812-274; 115-346-647-105-048; 115-593-329-395-113; 119-260-521-174-783; 120-767-750-309-125; 125-202-391-439-588; 129-021-815-959-003; 132-079-361-012-500; 133-482-855-606-276; 138-208-977-169-06X; 145-342-651-631-374; 147-542-802-261-93X; 149-079-498-302-549; 151-013-882-029-268; 158-742-323-083-537; 163-112-378-888-265; 164-057-272-725-721; 171-726-121-153-964,33
106-059-195-106-980,Open Source Software for Efficient and Transparent Reviews,2021-02-01,2021,journal article,Nature Machine Intelligence,25225839,Springer Science and Business Media LLC,,Rens van de Schoot; Jonathan de Bruin; Raoul Schram; Parisa Zahedi; Jan de Boer; Felix Weijdema; Bianca Kramer; Martijn Huijts; Maarten Hoogerwerf; Gerbrich Ferdinands; Albert Harkema; Joukje Willemsen; Yongchao Ma; Qixiang Fang; Sybren Hindriks; Lars Tummers; Daniel L. Oberski,"To help researchers conduct a systematic review or meta-analysis as efficiently and transparently as possible, we designed a tool (ASReview) to accelerate the step of screening titles and abstracts. For many tasks - including but not limited to systematic reviews and meta-analyses - the scientific literature needs to be checked systematically. Currently, scholars and practitioners screen thousands of studies by hand to determine which studies to include in their review or meta-analysis. This is error prone and inefficient because of extremely imbalanced data: only a fraction of the screened studies is relevant. The future of systematic reviewing will be an interaction with machine learning algorithms to deal with the enormous increase of available text. We therefore developed an open source machine learning-aided pipeline applying active learning: ASReview. We demonstrate by means of simulation studies that ASReview can yield far more efficient reviewing than manual reviewing, while providing high quality. Furthermore, we describe the options of the free and open source research software and present the results from user experience tests. We invite the community to contribute to open source projects such as our own that provide measurable and reproducible improvements over current practice.",3,2,125,133,Systematic review; User experience design; Data science; Quality (business); Scientific literature; Open source software; Computer science; Pipeline (software); Active learning (machine learning); Machine learning; Artificial intelligence; Systematic review; User experience design; Quality (business); Task (project management); Scientific literature; Field (computer science); Computer science; Pipeline (software); Active learning (machine learning),,,,"This project was funded by the Innovation Fund for IT in Research Projects, Utrecht University, The Netherlands.",https://ui.adsabs.harvard.edu/abs/2020arXiv200612166V/abstract https://arxiv.org/abs/2006.12166v3 http://arxiv.org/pdf/2006.12166.pdf,http://dx.doi.org/10.1038/s42256-020-00287-7,,10.1038/s42256-020-00287-7,3128349626; 3111278950,,0,000-463-164-380-216; 003-166-098-791-006; 005-705-404-325-920; 006-101-714-460-131; 013-260-671-162-16X; 015-039-274-199-380; 015-248-096-326-711; 017-560-922-552-788; 020-950-184-908-122; 021-451-489-196-939; 021-944-720-672-500; 022-679-308-814-097; 024-760-877-829-02X; 026-125-810-364-184; 026-709-908-303-899; 028-759-901-866-283; 033-288-391-845-10X; 034-533-202-512-481; 036-148-810-117-532; 046-459-409-573-25X; 049-060-995-787-676; 050-423-698-433-797; 051-184-290-913-704; 051-397-572-169-679; 052-445-958-755-232; 054-266-200-187-509; 054-305-812-360-084; 058-870-470-456-373; 061-673-321-001-469; 063-129-245-776-759; 064-264-695-662-36X; 066-290-946-609-881; 067-292-577-027-602; 068-574-374-283-990; 068-864-486-586-772; 070-714-954-312-026; 071-199-582-781-499; 072-349-030-109-159; 073-468-710-608-128; 082-550-558-186-328; 083-554-675-681-736; 083-990-059-961-049; 085-332-066-486-707; 088-510-290-446-96X; 092-442-200-314-385; 100-670-384-984-692; 103-854-878-408-148; 107-242-381-671-539; 112-211-057-792-485; 130-479-418-766-62X; 145-254-027-039-991; 154-152-264-327-427; 156-891-309-206-576; 166-220-344-943-657; 176-630-973-543-175,18
106-099-734-347-430,Kangaroo Care: Experiences and Needs of Parents in Neonatal Intensive Care: A Systematic Review ‘Parents’ Experience of Kangaroo Care’,,2015,journal article,Pediatrics and Neonatal Nursing: Open Access ( ISSN 2470-0983 ),24700983,"Sci Forschen, Inc.",,karlijn Gabriels; Annemieke J. Brouwer; Jessica maat; Agnes van den Hoogen,"Abstract This review is focusing on the experiences and needs of parents with infants within NICU regarding Kangaroo Care. Ten studies with qualitative designs were included. Kangaroo Care was overall experienced as positive; giving parents the opportunity to get to know their babies and (re-) construct their parenting role. Parents need potential barriers like communication, support, environment and physical needs to be facilitated in a way that they contribute to a positive experience. Keywords: Experiences; Kangaroo care; Needs; NICU; Parents",1,1,,,Nursing; Construct (philosophy); Kangaroo care; Intensive care; Medicine,,,,,http://www.sciforschenonline.org/journals/pediatrics-neonatal/article-data/PNNOA-1-102/PNNOA-1-102.pdf https://core.ac.uk/display/39824150 https://www.sciforschenonline.org/journals/pediatrics-neonatal/PNNOA-1-102.php https://dspace.library.uu.nl/bitstream/1874/332508/1/PNNOA_1_102.pdf https://dspace.library.uu.nl/handle/1874/332508,http://dx.doi.org/10.16966/2470-0983.102,,10.16966/2470-0983.102,2469606259,,0,000-823-095-830-346; 001-331-542-849-23X; 005-026-356-909-950; 007-870-217-150-987; 008-281-706-318-315; 010-907-565-542-703; 016-945-139-153-444; 017-016-457-482-016; 029-750-805-079-445; 029-788-914-457-840; 030-177-276-085-028; 030-683-037-347-854; 032-673-024-461-491; 035-680-602-209-699; 041-311-522-706-787; 044-952-434-597-815; 045-341-195-177-955; 047-044-176-106-547; 049-274-793-934-109; 050-451-706-357-084; 051-589-166-413-513; 053-031-606-330-421; 058-615-071-528-570; 058-881-054-094-303; 059-243-637-111-590; 059-920-659-644-828; 061-659-820-319-868; 062-606-019-483-862; 062-878-616-440-755; 063-694-599-954-753; 065-155-938-085-274; 067-295-308-239-264; 069-585-735-744-466; 070-059-213-938-162; 077-136-567-755-831; 083-275-795-865-394; 091-381-636-116-782; 095-675-691-998-473; 101-336-076-789-505; 102-730-001-029-693; 116-791-149-566-548; 117-485-574-020-846; 127-302-219-750-279; 135-829-159-113-040,2
106-199-018-669-584,Systematic search of Bayesian statistics in the field of psychotraumatology,2017-10-31,2017,journal article,European journal of psychotraumatology,20008066; 20008198,Co-Action Publishing,Sweden,Rens van de Schoot; Naomi Schalken; Miranda Olff,"In recent years there has been increased interest in Bayesian analysis in many disciplines; for example, see the systematic reviews in the fields of educational science (Konig & van de Schoot, 2017...",8,sup1,1375339,1375339,Bayesian statistics; Bayesian probability; Field (geography); Systematic review; Data science; Educational science; Systematic search; Computer science,,,,Netherlands Organisation for Scientific Research,https://core.ac.uk/display/141649526 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F361108 https://europepmc.org/article/MED/29152158 http://dspace.library.uu.nl/handle/1874/361108 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678372 https://psycnet.apa.org/doi/10.1080/20008198.2017.1375339 https://www.tandfonline.com/doi/full/10.1080/20008198.2017.1375339 https://tandfonline.com/doi/pdf/10.1080/20008198.2017.1375339,http://dx.doi.org/10.1080/20008198.2017.1375339,29152158,10.1080/20008198.2017.1375339,2766109474,PMC5678372,0,002-409-714-971-367; 004-332-003-552-211; 005-736-552-003-159; 006-831-769-668-604; 008-481-424-830-405; 008-697-289-662-455; 015-352-272-257-373; 015-427-422-699-665; 016-297-173-095-513; 023-256-615-405-287; 030-878-809-976-483; 032-759-450-866-165; 033-606-614-443-345; 037-231-598-517-099; 038-175-718-961-470; 045-030-631-060-764; 051-440-617-728-202; 054-936-279-720-598; 063-505-764-411-846; 067-205-678-006-263; 067-868-825-689-023; 068-762-528-291-079; 074-482-194-706-473; 078-356-833-161-368; 081-963-771-132-758; 085-185-269-631-17X; 086-068-985-829-236; 086-619-979-639-143; 087-972-815-939-696; 089-237-913-569-459; 096-939-894-863-854; 099-304-018-066-45X; 099-517-833-147-829; 106-476-737-190-783; 107-991-507-106-251; 112-604-849-327-87X; 133-857-027-019-322; 139-986-893-605-01X; 142-361-974-470-493; 142-664-881-139-249; 154-538-694-877-332; 177-347-237-584-078,11
106-444-558-554-442,"The association between neighbourhoods and educational achievement, a systematic review and meta-analysis",2015-07-24,2015,journal article,Journal of housing and the built environment : HBE,15737772; 15664910,Springer Netherlands,Netherlands,Jaap Nieuwenhuis; Pieter Hooimeijer,"Many studies have examined the effects of neighbourhoods on educational out-comes. The results of these studies are often conflicting, even if the same independ-ent variables (such as poverty, educational climate, social disorganisation, or ethnic composition) are used. A systematic meta-analysis may help to resolve this lack of external validity. We identified 5,516 articles from which we selected 88 that met all of the inclusion criteria. Using meta-regression, we found that the relation between neighbourhoods and individual educational outcomes is a function of neighbourhood poverty, the neighbourhood’s educational climate, the proportion of ethnic/migrant groups, and social disorganisation in the neighbourhood. The variance in the findings from different studies can partly be explained by the sampling design and the type of model used in each study. More important is the use of control variables (school, family SES, and parenting variables) in explaining the variation in the strength of neighbourhood effects.",31,2,321,347,Ethnic group; Inclusion (education); Psychology; Neighbourhood (mathematics); External validity; Poverty; Variance (accounting); Sampling design; Social psychology; Meta-analysis,Education; Gender; Meta-analysis; Neighbourhood effects; Parental characteristics; Schools; Systematic review,,,European Research Council,https://pubmed.ncbi.nlm.nih.gov/29355196/ https://www.narcis.nl/publication/RecordID/oai%3Atudelft.nl%3Auuid%3Ae0653ebe-91f7-421f-b6f7-b4fcd652d6ba https://link.springer.com/content/pdf/10.1007%2Fs10901-015-9460-7.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748572 https://www.ncbi.nlm.nih.gov/pubmed/29355196 https://repository.tudelft.nl/islandora/object/uuid%3Afb869b9e-4de1-4eda-8da1-61053d7b7063/datastream/OBJ/download http://repository.tudelft.nl/assets/uuid:fb869b9e-4de1-4eda-8da1-61053d7b7063/Nieuwenhuis_2015.pdf https://europepmc.org/article/MED/29355196 https://repository.tudelft.nl/islandora/object/uuid%3Afb869b9e-4de1-4eda-8da1-61053d7b7063 https://core.ac.uk/display/79324876 https://link.springer.com/article/10.1007/s10901-015-9460-7/fulltext.html http://resolver.tudelft.nl/uuid:e0653ebe-91f7-421f-b6f7-b4fcd652d6ba https://link.springer.com/article/10.1007/s10901-015-9460-7,http://dx.doi.org/10.1007/s10901-015-9460-7,29355196,10.1007/s10901-015-9460-7,1044055445,PMC5748572,0,001-855-538-851-414; 002-346-906-361-584; 002-914-909-966-012; 004-447-402-568-149; 006-528-491-894-890; 008-293-689-957-964; 008-496-913-551-492; 009-012-506-417-117; 009-060-214-653-966; 010-942-518-166-200; 012-921-230-978-314; 012-992-707-228-923; 013-929-789-066-087; 014-146-316-956-27X; 014-874-052-252-169; 015-377-203-789-238; 015-785-956-427-832; 016-841-886-824-639; 016-954-981-724-549; 017-126-223-057-065; 017-695-441-495-696; 018-245-592-398-904; 018-585-592-096-974; 018-601-857-892-827; 018-886-280-892-284; 019-677-025-997-607; 020-598-039-783-642; 020-854-708-362-758; 021-179-363-957-691; 021-393-960-002-153; 021-842-776-349-318; 025-563-661-886-061; 025-756-138-362-184; 028-139-803-459-978; 030-396-741-885-865; 030-901-231-180-405; 031-673-964-906-343; 032-075-005-166-534; 032-090-240-885-489; 032-307-657-058-782; 034-174-070-263-919; 035-721-036-747-756; 035-947-921-965-512; 036-221-269-149-904; 036-312-830-160-505; 037-929-185-173-608; 040-066-685-397-031; 040-636-843-604-22X; 043-817-931-131-209; 044-866-727-876-85X; 049-454-882-591-249; 050-342-174-041-587; 050-343-937-124-175; 051-716-226-504-249; 051-960-568-225-80X; 053-341-025-819-53X; 055-429-334-021-547; 055-604-951-644-972; 056-532-957-911-02X; 057-059-738-975-889; 057-132-128-614-355; 059-264-721-708-413; 059-413-948-067-83X; 060-519-128-225-303; 060-688-165-878-984; 060-907-042-286-759; 061-447-720-946-755; 061-576-755-487-22X; 062-101-123-371-998; 062-328-813-890-134; 062-469-035-573-632; 063-425-348-628-19X; 063-685-839-200-746; 063-823-047-801-044; 065-475-424-259-946; 066-579-798-078-843; 069-880-664-047-090; 070-172-249-458-907; 072-499-453-646-873; 073-998-513-008-404; 074-006-145-859-871; 075-690-492-842-281; 077-747-862-832-927; 077-847-471-934-73X; 078-893-901-894-39X; 080-280-782-287-983; 080-367-994-235-247; 081-088-010-961-102; 081-124-020-861-741; 081-516-257-722-89X; 082-051-664-874-427; 082-599-527-110-15X; 086-188-091-505-589; 086-465-855-882-185; 089-267-101-594-162; 091-282-432-658-260; 091-392-358-953-014; 092-438-596-141-051; 093-187-440-980-265; 096-210-153-766-655; 097-558-544-093-72X; 099-403-445-776-521; 100-211-019-481-410; 101-669-398-745-412; 102-390-207-533-555; 102-566-941-655-043; 102-696-444-981-660; 102-711-137-804-341; 104-474-053-238-457; 107-186-276-653-693; 109-317-982-077-101; 113-272-078-308-408; 116-518-677-990-097; 121-529-989-780-384; 121-718-467-734-930; 123-914-727-956-988; 124-345-525-155-372; 128-239-642-464-568; 134-935-110-624-993; 136-387-519-503-490; 138-966-202-416-187; 141-831-385-867-959; 142-242-653-967-288; 143-729-687-068-732; 144-818-577-079-060; 145-898-871-932-287; 147-750-148-560-711; 152-137-367-408-475; 153-166-468-409-572; 158-211-977-561-662; 161-231-097-776-506; 161-811-516-254-851; 162-236-742-917-981; 164-979-246-230-785; 165-955-252-300-874; 169-430-522-826-846; 171-214-257-698-315; 171-637-186-657-261; 172-115-983-943-664; 172-301-736-266-466; 175-664-767-683-619; 176-939-933-828-569; 177-651-895-195-230; 181-189-816-778-41X; 181-909-510-604-006; 190-527-773-829-277; 191-093-464-200-169; 193-726-850-838-689,77
107-603-985-611-757,Trends in blood pressure-related outcomes after adrenalectomy in patients with primary aldosteronism: A systematic review.,2020-12-03,2020,journal article,American journal of surgery,18791883; 00029610,Elsevier Inc.,Netherlands,Diederik P. D. Suurd; Wessel M. C. M. Vorselaars; Dirk-Jan van Beek; Wilko Spiering; Inne H.M. Borel Rinkes; Gerlof D. Valk; Menno R. Vriens,"Abstract Background Decrease in blood pressure (BP) is the major goal of adrenalectomy for primary aldosteronism. Nevertheless, the optimal timing to assess these outcomes and the needed duration of follow-up are uncertain. We systematically reviewed the literature regarding trends in BP-related outcomes during follow-up after adrenalectomy. Methods A systematic literature search of medical literature from PubMed, Embase and the Cochrane Library regarding BP-related outcomes (i.e. cure of hypertension rates, BP and antihypertensives) was performed. The Quality In Prognosis Studies risk of bias tool was used. Results Of the 2057 identified records, 13 articles met the inclusion criteria. Overall study quality was low. In multiple studies, the biggest decrease in BP was shown within the first month(s) after adrenalectomy and afterwards BP often remained stable during long-term follow-up. Conclusions Based on the available studies one might suggest that long follow-up is unnecessary, since outcomes seem to stabilize within the first months.",222,2,297,304,Pediatrics; Cochrane Library; Medical literature; Adrenalectomy; Primary aldosteronism; Systematic search; In patient; Study quality; Medicine; Blood pressure,Adrenalectomy; Blood pressure; Follow-up; Hypertension; Primary aldosteronism,Adrenalectomy; Antihypertensive Agents/therapeutic use; Blood Pressure; Humans; Hyperaldosteronism/complications; Hypertension/diagnosis; Treatment Outcome,Antihypertensive Agents,,https://pubmed.ncbi.nlm.nih.gov/33298320 https://www.sciencedirect.com/science/article/abs/pii/S0002961020307819 https://www.sciencedirect.com/science/article/pii/S0002961020307819 https://www.ncbi.nlm.nih.gov/pubmed/33298320,http://dx.doi.org/10.1016/j.amjsurg.2020.12.003,33298320,10.1016/j.amjsurg.2020.12.003,3108845217,,0,001-787-373-259-874; 003-944-593-255-831; 005-039-010-557-225; 010-780-930-913-125; 012-008-712-200-476; 012-009-080-530-593; 013-518-648-485-804; 013-541-969-076-695; 017-300-737-144-757; 019-886-042-738-077; 020-543-710-084-111; 024-405-102-934-32X; 028-297-231-960-006; 034-026-381-551-032; 036-122-104-375-66X; 040-298-203-529-39X; 041-049-441-892-345; 046-905-066-489-378; 049-725-599-445-846; 054-034-085-537-311; 056-628-504-510-318; 058-870-470-456-373; 060-295-971-093-666; 063-232-343-564-165; 073-436-587-681-963; 081-256-963-281-018; 094-233-165-540-572; 098-399-566-373-088; 101-198-862-385-791; 101-240-945-483-756; 101-806-621-454-051; 104-466-883-821-094; 117-847-857-173-119; 126-374-550-051-351; 127-710-618-524-183; 137-928-638-445-874; 170-337-923-389-391,3
107-910-977-697-204,The effect of intra-arterial angiotensin II on the hepatic tumor to non-tumor blood flow ratio for radioembolization: a systematic review.,2014-01-17,2014,journal article,PloS one,19326203,Public Library of Science,United States,Andor F. van den Hoven; Maarten L. J. Smits; Charlotte E.N.M. Rosenbaum; Helena M. Verkooijen; Maurice A.A.J. van den Bosch; Marnix G.E.H. Lam,"Purpose ; Treatment efficacy of intra-arterial radioembolization for liver tumors depends on the selective targeting of tumorous tissue. Recent investigations have demonstrated that tumors may receive inadequate doses of radioactivity after radioembolization, due to unfavorable tumor to non-tumor (T/N) uptake ratios of radioactive microspheres. Hepatic arterial infusion of the vasoconstrictor angiotensin II (AT-II) is reported to increase the T/N blood flow ratio. The purpose of this systematic review was to provide a comprehensive overview of the effect of hepatic arterial AT-II on T/N blood flow ratio in patients with hepatic malignancies, and determine its clinical value for radioembolization.; Methods ; This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A structured search was performed in the PubMed, EMBASE and Cochrane databases. Only studies that presented data on T/N ratios before and after infusion of AT-II into the hepatic artery, in human patients with hepatic malignancies, were selected. Median T/N ratios before, during and after AT-II infusion, and the median T/N ratio improvement factor were extracted from the selected articles. All data on systemic blood pressure measurements and clinical symptoms were also extracted.; Results ; The search identified 524 titles of which 5 studies, including a total of 71 patients were considered relevant. Median T/N ratios before infusion of AT-II ranged from 0.4 to 3.4. All studies observed a substantial improvement of the T/N ratio after AT-II infusion, with median improvement factors ranging from 1.8 to 3.1. A transitory increase of systemic blood pressure was observed during AT-II infusion.; Conclusions ; Infusion of AT-II into the hepatic artery leads to an increase of the tumor to non-tumor blood flow ratio, as measured by T/N uptake ratios. Clinical trials are warranted to assess safety aspects, optimal administration strategy and impact on treatment efficacy during radioembolization.",9,1,e86394,,Urology; Surgery; Blood flow; Embolization; Artery; Hepatocellular carcinoma; Hepatic arterial infusion; Angiotensin II; Clinical trial; Medicine; Blood pressure,,"Angiotensin II/administration & dosage; Embolization, Therapeutic/adverse effects; Humans; Infusions, Intra-Arterial; Liver Neoplasms/blood supply; Radioisotopes/therapeutic use; Regional Blood Flow/drug effects",Radioisotopes; Angiotensin II,,https://pubmed.ncbi.nlm.nih.gov/24466071/ http://europepmc.org/articles/PMC3895031 https://paperity.org/p/60617451/the-effect-of-intra-arterial-angiotensin-ii-on-the-hepatic-tumor-to-non-tumor-blood-flow http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086394 http://ui.adsabs.harvard.edu/abs/2014PLoSO...986394V/abstract https://dx.plos.org/10.1371/journal.pone.0086394 http://www.ncbi.nlm.nih.gov/pubmed/24466071,http://dx.doi.org/10.1371/journal.pone.0086394,24466071,10.1371/journal.pone.0086394,2032561214,PMC3895031,0,000-985-308-086-058; 002-769-580-836-74X; 003-686-670-067-457; 004-144-168-815-819; 004-633-443-611-042; 005-607-095-502-751; 006-990-703-221-074; 010-119-858-685-161; 010-499-737-307-647; 011-535-497-425-258; 013-370-339-687-412; 014-721-906-647-088; 015-159-192-503-429; 015-830-214-744-396; 015-930-702-044-979; 016-669-024-621-609; 017-056-707-517-303; 017-300-737-144-757; 018-214-181-956-316; 022-110-917-160-002; 023-199-868-110-585; 023-775-028-209-833; 024-107-114-174-908; 024-829-201-902-779; 026-012-522-878-841; 026-262-742-117-034; 026-449-568-486-44X; 027-959-413-771-533; 028-809-364-724-732; 030-312-796-606-594; 030-560-135-852-790; 031-842-417-460-877; 032-010-030-190-133; 036-840-586-500-860; 037-574-729-260-612; 039-404-099-270-218; 040-028-473-022-775; 049-548-376-891-190; 054-912-922-553-746; 058-098-219-203-498; 066-160-150-659-984; 070-040-498-689-613; 073-139-619-577-650; 074-970-169-429-761; 075-883-051-051-901; 077-805-189-682-967; 081-100-945-583-513; 083-275-795-865-394; 089-167-867-747-515; 089-790-309-245-101; 090-490-516-019-829; 097-775-126-117-670; 108-515-844-456-809; 119-031-148-413-15X; 120-702-090-607-188; 125-004-624-922-54X; 136-648-411-856-131; 151-142-894-402-171; 171-288-147-881-196,12
110-708-179-315-768,Maternal lipid profile and the relation with spontaneous preterm delivery: a systematic review,2016-11-02,2016,journal article,Archives of gynecology and obstetrics,14320711; 09320067,Springer Verlag,Germany,Maryam Moayeri; Karst Y. Heida; Arie Franx; Wilko Spiering; Monique W. M. de Laat; Martijn A. Oudijk,"It is unknown whether an unfavorable (atherogenic) lipid profile and homocysteine level, which could supersede clinical cardiovascular disease, is also associated with an increased risk of spontaneous preterm delivery (sPTD). A systematic review of studies assessing the lipid profile and homocysteine value of women with sPTD compared to women with term delivery in pre-pregnancy and during pregnancy. A systematic search of peer-reviewed articles published between January 1980 and May 2014 was performed using MEDLINE, EMBASE and the Cochrane database. We included case–control and cohort studies that examined triglycerides, high/low density lipoprotein cholesterol, total cholesterol and homocysteine in women with sPTD. Articles were subdivided in pre-pregnancy, first, second and third trimester. Of 708 articles reviewed for eligibility, 14 met our inclusion criteria. Nine cohort studies and five case–control studies were analyzed, reporting on 1466 cases with sPTD and 11296 controls with term delivery. The studies suggest a possible elevated risk of sPTD in woman with high TG levels, no association of high and low density lipoprotein cholesterol with the risk of sPTD was found. High homocysteine levels are associated with sPTD in the second trimester. The role of triglycerides and homocysteine in sPTD should be explored further.",295,2,313,323,Obstetrics and gynaecology; Obstetrics; Cohort study; Homocysteine; Cholesterol; Lipid profile; Disease; Pregnancy; MEDLINE; Medicine,Cholesterol; Homocysteine; Lipids; Preterm birth; Preterm delivery; Triglycerides,Adult; Case-Control Studies; Cohort Studies; Female; Humans; Lipids/blood; Pregnancy; Premature Birth/blood; Risk,Lipids,,https://researchinformation.amsterdamumc.org/en/publications/maternal-lipid-profile-and-the-relation-with-spontaneous-preterm- https://link.springer.com/article/10.1007/s00404-016-4216-5 https://link.springer.com/content/pdf/10.1007%2Fs00404-016-4216-5.pdf http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281656 https://paperity.org/p/78124699/maternal-lipid-profile-and-the-relation-with-spontaneous-preterm-delivery-a-systematic https://pubmed.ncbi.nlm.nih.gov/27807624/ http://dspace.library.uu.nl/handle/1874/350299 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281656 https://cyberleninka.org/article/n/1446720 https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F350299 https://europepmc.org/article/MED/27807624,http://dx.doi.org/10.1007/s00404-016-4216-5,27807624,10.1007/s00404-016-4216-5,2547924006,PMC5281656,0,001-028-662-655-753; 004-415-634-692-265; 005-269-168-862-485; 008-165-633-424-548; 008-271-279-257-503; 008-594-891-759-311; 009-081-316-132-320; 009-297-850-036-446; 010-108-101-597-334; 010-525-300-950-257; 011-650-250-081-530; 012-945-638-678-899; 014-818-108-397-118; 014-851-042-113-999; 015-595-988-007-237; 016-704-354-109-684; 018-636-460-138-754; 022-428-495-778-047; 022-491-123-118-787; 026-592-236-887-142; 030-087-018-866-164; 033-121-522-388-072; 037-931-945-283-336; 042-028-993-845-33X; 046-538-350-237-344; 048-176-199-679-082; 049-542-752-309-276; 053-366-501-574-627; 062-273-359-747-251; 063-243-302-222-680; 063-678-423-595-101; 067-061-831-649-549; 069-601-896-283-952; 091-254-002-783-880; 110-779-257-042-338; 111-065-610-143-976; 123-899-597-636-114; 128-300-800-755-142; 131-816-337-969-530; 133-945-713-246-023; 138-450-117-697-423,18
111-137-868-258-025,"Teacher leadership: A systematic review, methodological quality assessment and conceptual framework",,2020,journal article,Educational Research Review,1747938x,Elsevier BV,Netherlands,Carina Schott; Henrico van Roekel; Lars Tummers,"Abstract This article systematically reviews 93 theoretical and empirical articles and books on the topic of teacher leadership. The included studies are analyzed on the basis of the following themes: (1) definitions of teacher leadership, (2) antecedents of teacher leadership, (3) outcomes of teacher leadership, and (4) methodological quality of studies on teacher leadership. Based on our analysis we develop a conceptual framework unifying the current knowledge about teacher leadership, its definitions, and its antecedents and outcomes at different levels of analysis. We highlight the current methodological limitations of the included studies and point out avenues for further development of the field of teacher leadership. In particular, we call for more (1) conceptual clarity, (2) cross-country research designs, (3) research designs eliminating endogeneity problems, and (4) attention for the potential ‘dark sides’ of teacher leadership.",31,,100352,,Conceptual framework; Psychology; Pedagogy; Teacher leadership; Methodological quality; Conceptual clarity; Endogeneity,,,,Nederlandse Organisatie voor Wetenschappelijk Onderzoek; National Research Foundation of Korea; Nationaal Regieorgaan Onderwijsonderzoek,https://www.sciencedirect.com/science/article/abs/pii/S1747938X20302086 https://www.sciencedirect.com/science/article/pii/S1747938X20302086,http://dx.doi.org/10.1016/j.edurev.2020.100352,,10.1016/j.edurev.2020.100352,3039918624,,0,000-102-760-220-135; 000-838-722-143-919; 001-429-887-764-27X; 002-666-533-129-979; 004-223-469-112-688; 005-516-268-917-741; 005-591-807-906-815; 006-741-690-893-156; 007-802-085-798-241; 008-944-521-697-94X; 008-956-552-001-624; 010-369-554-360-036; 010-666-427-508-166; 010-677-395-160-604; 011-288-216-866-853; 011-626-095-158-699; 013-024-792-219-623; 013-541-969-076-695; 014-405-036-411-842; 016-265-156-516-105; 017-092-774-871-124; 019-590-442-238-044; 020-950-184-908-122; 023-752-750-091-308; 024-995-992-742-591; 026-792-477-999-686; 027-201-516-862-383; 027-907-562-013-790; 028-561-720-008-542; 028-831-770-967-335; 029-579-405-997-987; 030-142-025-425-614; 030-191-161-247-892; 030-452-673-265-122; 032-759-850-381-298; 033-000-348-413-728; 034-250-973-491-471; 034-516-426-342-501; 035-234-758-356-716; 036-314-191-263-768; 037-023-229-903-799; 037-438-694-746-199; 040-422-172-225-961; 041-165-705-905-882; 041-421-760-065-839; 042-255-632-899-797; 042-919-564-986-424; 047-320-676-864-14X; 050-927-665-936-549; 051-845-671-836-12X; 053-455-661-603-655; 053-866-209-801-619; 057-644-800-122-746; 058-811-187-147-065; 060-329-994-312-457; 062-753-483-386-839; 066-126-631-150-987; 066-251-604-572-407; 067-029-742-481-027; 068-066-169-789-190; 068-154-810-269-052; 070-003-236-953-83X; 077-638-695-551-139; 078-458-213-924-317; 078-529-510-367-524; 079-137-205-009-441; 079-268-601-567-613; 081-348-542-297-490; 083-275-795-865-394; 084-434-391-248-172; 085-707-570-333-476; 090-011-027-623-741; 095-519-491-582-313; 096-458-200-320-373; 100-465-869-927-896; 100-552-120-279-626; 102-036-790-521-786; 104-671-067-681-225; 106-376-235-280-852; 107-711-306-615-595; 110-324-580-273-960; 111-739-829-854-076; 112-021-303-553-766; 112-628-817-731-33X; 112-857-537-985-510; 112-908-094-415-558; 114-978-630-130-051; 117-214-663-830-387; 118-065-190-627-054; 120-288-126-558-525; 121-936-892-650-223; 126-908-412-285-305; 127-140-595-785-564; 127-164-922-129-182; 127-424-131-162-048; 128-661-116-788-777; 129-846-311-856-55X; 133-027-307-973-126; 135-356-634-191-981; 136-482-400-901-446; 137-117-805-617-524; 144-796-201-159-033; 146-845-229-315-916; 148-819-874-566-447; 150-316-037-626-083; 153-056-992-962-895; 154-127-854-872-367; 154-803-264-053-08X; 155-346-187-918-179; 164-885-635-844-96X; 170-574-185-866-860; 175-658-759-454-460; 177-561-814-145-84X; 184-251-655-972-652; 187-976-981-006-73X; 188-878-785-854-640,7
114-677-627-752-678,Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis,2020-04-28,2020,journal article,European journal of pharmacology,18790712; 00142999,Elsevier,Netherlands,Guilherme S. Ferreira; Désirée H. Veening-Griffioen; Wouter Boon; Carlijn R. Hooijmans; Ellen H.M. Moors; Huub Schellekens; Peter J.K. van Meer,"Previous qualitative research has suggested there are only minor differences between the db/db mouse and the Zucker Diabetic Fatty (ZDF) rat, both animal models of type 2 diabetes. However, it is not known whether these models are also comparable regarding drug response in quantitative terms (effect size). To investigate the extent of these differences, we conducted a systematic review and meta-analysis of approved drugs in these models. We searched on PubMed and Embase on July 3, 2019 for studies including either model, a monotherapy arm with an EMA/FDA approved drug for the treatment of type 2 diabetes, HbA1c assessment and a control group. Studies aimed at diabetes prevention or with surgical interventions were excluded. We calculated the Standardised Mean Difference (SMD) to compare effect sizes (HbA1c reduction) per drug and drug class across models. We included a risk of bias assessment for all included publications. A total of 121 publications met our inclusion criteria. For drugs with more than two comparisons, both models predicted the direction of the effect regarding HbA1c levels. There were no differences between the db/db mouse and ZDF rat, except for exenatide (P = 0.02) and GLP-1 agonists (P = 0.03) in which a larger effect size was calculated in the ZDF rat. Our results indicate the differences between the db/db mouse and ZDF rat are not relevant for preliminary efficacy testing. This methodology can be used to further differentiate between animal models used for the same indication, facilitating the selection of models more likely to predict human response.",879,,173153,173153,Internal medicine; Oncology; Efficacy; Type 2 diabetes; Drug class; Drug; Exenatide; Diabetes mellitus; Drug development; Medicine; Meta-analysis,Drug development; Systematic review; Translational research; Type 2 diabetes; animal model; meta-Analysis,"Animals; Diabetes Mellitus, Type 2/drug therapy; Disease Models, Animal; Hypoglycemic Agents/therapeutic use; Mice; Rats, Zucker; Treatment Outcome",Hypoglycemic Agents,"Ministerie van Landbouw, Natuur en Voedselkwaliteit; Ministerie van Volksgezondheid, Welzijn en Sport; College ter Beoordeling van Geneesmiddelen; ZonMw",http://dspace.library.uu.nl/handle/1874/396353 https://repository.ubn.ru.nl/handle/2066/220893 https://www.sciencedirect.com/science/article/abs/pii/S0014299920302454 https://pubmed.ncbi.nlm.nih.gov/32360835/ https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F396353 https://www.ncbi.nlm.nih.gov/pubmed/32360835 https://europepmc.org/article/MED/32360835 https://www.sciencedirect.com/science/article/pii/S0014299920302454,http://dx.doi.org/10.1016/j.ejphar.2020.173153,32360835,10.1016/j.ejphar.2020.173153,3021023466,,0,002-241-788-027-305; 003-156-019-488-019; 004-571-965-869-525; 005-039-563-179-05X; 010-844-288-010-534; 015-526-070-621-402; 015-567-817-927-719; 017-269-034-719-603; 017-396-356-826-083; 018-013-701-887-617; 020-981-619-496-844; 023-930-206-039-96X; 035-770-290-939-033; 036-634-800-701-659; 041-449-264-602-10X; 045-416-413-742-937; 045-924-197-676-939; 051-384-557-306-767; 058-870-470-456-373; 059-276-745-883-10X; 060-523-844-350-895; 064-017-171-849-301; 072-293-418-299-18X; 073-614-753-122-278; 104-898-529-211-33X; 115-350-648-150-731; 117-089-924-906-563; 140-554-723-431-690,4
115-085-829-498-863,Current Evidence for Continuous Vital Signs Monitoring by Wearable Wireless Devices in Hospitalized Adults: Systematic Review,2020-06-17,2020,journal article,Journal of medical Internet research,14388871,Journal of medical Internet Research,Canada,Jobbe P L Leenen; Crista Leerentveld; Joris D van Dijk; Henderik L. van Westreenen; Lisette Schoonhoven; Gijsbert A. Patijn,"Background: Continuous monitoring of vital signs by using wearable wireless devices may allow for timely detection of clinical deterioration in patients in general wards in comparison to detection by standard intermittent vital signs measurements. A large number of studies on many different wearable devices have been reported in recent years, but a systematic review is not yet available to date.; Objective: The aim of this study was to provide a systematic review for health care professionals regarding the current evidence about the validation, feasibility, clinical outcomes, and costs of wearable wireless devices for continuous monitoring of vital signs.; Methods: A systematic and comprehensive search was performed using PubMed/MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from January 2009 to September 2019 for studies that evaluated wearable wireless devices for continuous monitoring of vital signs in adults. Outcomes were structured by validation, feasibility, clinical outcomes, and costs. Risk of bias was determined by using the Mixed Methods Appraisal Tool, quality assessment of diagnostic accuracy studies 2nd edition, or quality of health economic studies tool.; Results: In this review, 27 studies evaluating 13 different wearable wireless devices were included. These studies predominantly evaluated the validation or the feasibility outcomes of these devices. Only a few studies reported the clinical outcomes with these devices and they did not report a significantly better clinical outcome than the standard tools used for measuring vital signs. Cost outcomes were not reported in any study. The quality of the included studies was predominantly rated as low or moderate.; Conclusions: Wearable wireless continuous monitoring devices are mostly still in the clinical validation and feasibility testing phases. To date, there are no high quality large well-controlled studies of wearable wireless devices available that show a significant clinical benefit or cost-effectiveness. Such studies are needed to help health care professionals and administrators in their decision making regarding implementation of these devices on a large scale in clinical practice or in-home monitoring.",22,6,e18636,,Wearable computer; Health care; Remote patient monitoring; Vital signs; Continuous monitoring; MEDLINE; Vital Signs Measurement; Wearable technology; Medical emergency; Medicine,clinical deterioration; continuous monitoring; early deterioration; monitoring; patient monitoring; systematic review; vital signs; wearable wireless device,"Adult; Humans; Longitudinal Studies; Monitoring, Physiologic/methods; Vital Signs/physiology; Wearable Electronic Devices/trends; Young Adult",,,https://dx.doi.org/10.2196/18636 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351263 https://pubmed.ncbi.nlm.nih.gov/32469323/ https://www.jmir.org/2020/6/e18636 http://europepmc.org/article/MED/32469323 https://doaj.org/article/1c4a8faa80a245aaa05ce5005b226b6c,http://dx.doi.org/10.2196/18636,32469323,10.2196/18636,3030319168,PMC7351263,0,000-197-180-880-916; 000-402-508-620-350; 000-691-746-060-890; 003-091-373-280-208; 003-919-372-772-654; 005-043-457-954-747; 007-803-236-486-830; 008-330-624-771-990; 009-439-805-142-11X; 010-183-602-458-682; 010-445-560-643-851; 012-209-091-190-121; 013-532-299-475-886; 015-951-149-224-837; 020-572-352-910-155; 021-944-720-672-500; 024-149-549-703-384; 025-038-601-790-740; 025-956-108-490-19X; 028-015-749-931-72X; 028-024-676-412-527; 028-790-279-539-607; 029-983-710-972-019; 032-017-593-851-03X; 032-783-802-369-155; 033-951-685-058-601; 035-356-452-967-130; 035-447-434-184-742; 035-783-050-814-584; 037-333-058-203-563; 037-712-724-604-511; 038-434-697-009-205; 043-143-508-664-384; 044-197-716-323-066; 044-622-716-127-641; 044-968-282-116-221; 045-937-117-695-391; 046-021-224-851-464; 047-960-938-689-229; 048-139-243-454-639; 048-563-950-552-441; 050-766-741-697-697; 050-821-313-844-805; 051-193-403-590-396; 051-682-344-618-893; 052-547-519-377-337; 054-459-396-853-809; 054-876-925-064-344; 057-075-056-237-870; 059-179-593-373-615; 060-468-315-603-210; 060-687-654-080-901; 061-066-254-662-974; 061-501-379-970-376; 063-531-664-892-848; 063-750-899-819-514; 068-513-326-661-580; 069-319-556-256-414; 071-723-293-359-951; 072-860-797-714-256; 073-771-869-468-552; 079-404-793-587-419; 081-085-252-512-007; 084-292-393-143-832; 087-738-418-568-179; 087-932-898-921-419; 088-563-031-391-086; 088-676-578-145-365; 090-443-461-307-011; 093-921-038-596-023; 099-573-590-976-118; 099-993-498-730-415; 100-078-764-629-446; 103-467-204-986-080; 107-475-301-247-058; 107-674-563-483-300; 110-773-127-260-946; 110-933-217-053-65X; 111-657-492-510-147; 113-406-499-758-854; 114-909-063-744-559; 116-563-035-816-428; 128-243-745-384-976; 143-817-036-925-200; 147-113-481-451-912; 147-787-104-452-443; 171-763-844-294-114,35
123-690-681-435-297,MR imaging in discriminating between benign and malignant paediatric ovarian masses: a systematic review.,2019-09-16,2019,journal article,European radiology,14321084; 09387994,Springer Verlag,Germany,Lotte W. E. van Nimwegen; Annelies M. C. Mavinkurve-Groothuis; Ronald R. de Krijger; Caroline C. C. Hulsker; Angelique J. Goverde; Jozsef Zsiros; Annemieke S. Littooij,"The use of magnetic resonance (MR) imaging in differentiation between benign and malignant adnexal masses in children and adolescents might be of great value in the diagnostic workup of sonographically indeterminate masses, since preserving fertility is of particular importance in this population. This systematic review evaluates the diagnostic value of MR imaging in children with an ovarian mass. The review was made according to the PRISMA Statement. PubMed and EMBASE were systematically searched for studies on the use of MR imaging in differential diagnosis of ovarian masses in both adult women and children from 2008 to 2018. Sixteen paediatric and 18 adult studies were included. In the included studies, MR imaging has shown good diagnostic performance in differentiating between benign and malignant ovarian masses. MR imaging techniques including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging seem to further improve the diagnostic performance. The addition of DWI with apparent diffusion coefficient (ADC) values measured in enhancing components of solid lesions and DCE imaging may further increase the good diagnostic performance of MR imaging in the pre-operative differentiation between benign and malignant ovarian masses by increasing specificity. Prospective age-specific studies are needed to confirm the high diagnostic performance of MR imaging in children and adolescents with a sonographically indeterminate ovarian mass. • MR imaging, based on several morphological features, is of good diagnostic performance in differentiating between benign and malignant ovarian masses. Sensitivity and specificity varied between 84.8 to 100% and 20.0 to 98.4%, respectively.;  • MR imaging techniques like diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging seem to improve the diagnostic performance.;  • Specific studies in children and adolescents with ovarian masses are required to confirm the suggested increased diagnostic performance of DWI and DCE in this population.",30,2,1166,1181,Radiology; Magnetic resonance imaging; Ultrasound; Neuroradiology; Differential diagnosis; Population; Mr imaging; Interventional radiology; Effective diffusion coefficient; Medicine,Magnetic resonance imaging; Ovarian neoplasms; Systematic review,"Adolescent; Adult; Child; Contrast Media; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging/methods; Female; Humans; Magnetic Resonance Imaging/methods; Ovarian Neoplasms/diagnostic imaging; Prospective Studies; Sensitivity and Specificity; Ultrasonography",Contrast Media,University Medical Center Utrecht,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957553 https://pubmed.ncbi.nlm.nih.gov/31529256/ https://www.ncbi.nlm.nih.gov/pubmed/31529256 http://dspace.library.uu.nl/handle/1874/392538 https://link.springer.com/content/pdf/10.1007/s00330-019-06420-4.pdf https://europepmc.org/article/MED/31529256 https://link.springer.com/article/10.1007/s00330-019-06420-4,http://dx.doi.org/10.1007/s00330-019-06420-4,31529256,10.1007/s00330-019-06420-4,2974397550,PMC6957553,0,002-250-828-003-805; 003-422-059-812-927; 003-972-810-971-067; 008-674-389-678-25X; 010-477-638-512-12X; 011-180-716-961-078; 011-457-090-214-79X; 012-227-939-357-056; 012-475-774-062-825; 014-856-091-309-413; 015-679-948-684-75X; 016-214-453-044-060; 017-300-737-144-757; 017-930-276-325-825; 018-619-081-951-951; 018-935-949-017-480; 020-160-140-225-868; 020-594-911-902-459; 021-157-129-285-762; 021-674-371-549-354; 022-328-029-335-080; 022-465-705-679-980; 023-639-815-159-496; 023-834-486-795-195; 024-872-598-015-302; 024-946-512-373-176; 027-940-585-256-917; 029-276-132-176-105; 035-386-537-400-173; 036-459-130-353-425; 037-327-913-127-135; 041-237-599-421-971; 042-070-200-740-319; 043-169-425-432-110; 044-188-691-291-971; 045-525-668-578-123; 047-910-828-267-601; 048-544-870-018-181; 048-675-302-706-760; 055-444-839-610-107; 056-185-107-731-686; 058-625-246-222-688; 059-874-503-970-075; 061-273-249-970-704; 061-442-570-773-744; 061-689-184-277-464; 063-097-366-537-54X; 072-564-744-482-061; 074-541-676-505-962; 074-762-737-200-169; 074-781-406-329-543; 083-275-795-865-394; 083-935-945-734-56X; 084-328-352-542-644; 085-215-371-147-952; 086-238-728-772-055; 099-835-899-668-065; 107-526-527-851-60X; 133-101-455-286-902; 135-560-718-296-99X; 142-043-303-355-247; 173-922-547-538-82X,7
124-199-562-183-783,Non-Invasive Continuous Respiratory Monitoring on General Hospital Wards: A Systematic Review.,2015-12-14,2015,journal article,PloS one,19326203,Public Library of Science,United States,Kim van Loon; Bas van Zaane; Els J. Bosch; Cor J. Kalkman; Linda M. Peelen,"Background Failure to recognize acute deterioration in hospitalized patients may contribute to cardiopulmonary arrest, unscheduled intensive care unit admission and increased mortality. Purpose In this systematic review we aimed to determine whether continuous non-invasive respiratory monitoring improves early diagnosis of patient deterioration and reduces critical incidents on hospital wards. Data Sources Studies were retrieved from Medline, Embase, CINAHL, and the Cochrane library, searched from 1970 till October 25, 2014. Study Selection Electronic databases were searched using keywords and corresponding synonyms ‘ward’, ‘continuous’, ‘monitoring’ and ‘respiration’. Pediatric, fetal and animal studies were excluded. Data Extraction Since no validated tool is currently available for diagnostic or intervention studies with continuous monitoring, methodological quality was assessed with a modified tool based on modified STARD, CONSORT, and TREND statements. Data Synthesis Six intervention and five diagnostic studies were included, evaluating the use of eight different devices for continuous respiratory monitoring. Quantitative data synthesis was not possible because intervention, study design and outcomes differed considerably between studies. Outcomes estimates for the intervention studies ranged from RR 0.14 (0.03, 0.64) for cardiopulmonary resuscitation to RR 1.00 (0.41, 2.35) for unplanned ICU admission after introduction of continuous respiratory monitoring, Limitations The methodological quality of most studies was moderate, e.g. ‘before-after’ designs, incomplete reporting of primary outcomes, and incomplete clinical implementation of the monitoring system. Conclusions Based on the findings of this systematic review, implementation of routine continuous non-invasive respiratory monitoring on general hospital wards cannot yet be advocated as results are inconclusive, and methodological quality of the studies needs improvement. Future research in this area should focus on technology explicitly suitable for low care settings and tailored alarm and treatment algorithms.",10,12,e0144626,,Intensive care medicine; Systematic review; Intensive care unit; Cochrane Library; Cardiopulmonary resuscitation; Data extraction; Respiratory monitoring; MEDLINE; CINAHL; Medicine,,"Heart Arrest/diagnosis; Humans; Monitoring, Physiologic/methods; Patients' Rooms; Respiration",,,https://dx.plos.org/10.1371/journal.pone.0144626 http://ui.adsabs.harvard.edu/abs/2015PLoSO..1044626V/abstract https://pubmed.ncbi.nlm.nih.gov/26658343/ http://dspace.library.uu.nl/handle/1874/332793 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684230/ https://europepmc.org/article/MED/26658343 https://core.ac.uk/display/150032266 https://paperity.org/p/74748243/non-invasive-continuous-respiratory-monitoring-on-general-hospital-wards-a-systematic https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0144626,http://dx.doi.org/10.1371/journal.pone.0144626,26658343,10.1371/journal.pone.0144626,2254215305,PMC4684230,0,003-544-781-088-134; 006-112-345-038-886; 010-786-596-074-377; 011-426-531-681-878; 011-479-043-571-011; 014-650-818-417-703; 017-076-537-242-578; 018-052-504-808-053; 018-340-710-176-217; 021-318-655-077-730; 022-164-734-668-392; 022-246-166-716-358; 022-375-132-071-003; 022-904-183-127-004; 023-920-449-228-969; 024-236-857-052-611; 024-995-840-370-936; 032-156-933-989-765; 038-511-758-527-994; 038-598-252-709-074; 041-226-803-399-625; 049-177-887-730-348; 049-672-565-838-290; 052-140-288-132-505; 053-926-194-539-137; 054-831-179-345-208; 058-184-282-111-984; 058-888-995-052-617; 061-729-959-606-838; 062-198-556-178-214; 063-474-833-773-666; 067-894-989-798-110; 083-866-999-854-261; 093-543-902-427-113; 097-010-797-373-398; 097-442-924-536-751; 099-519-445-381-612; 110-240-263-607-615; 114-136-670-685-026; 120-837-766-061-620; 122-694-179-993-834; 144-452-451-055-465,28
124-288-972-301-994,PTSD treatment in times of COVID-19: A systematic review of the effects of online EMDR.,2020-08-31,2020,journal article,Psychiatry research,18727123; 01651781,Elsevier Ireland Ltd,Netherlands,Lonneke I. M. Lenferink; K. Meyerbröker; Paul A. Boelen,"COVID-19 affects many societies by measures as ""social distancing"", forcing mental health care professionals to deliver treatments online or via telephone. In this context, online Eye Movement Desensitization and Reprocessing (EMDR) is an emerging treatment for patients with Posttraumatic Stress Disorder (PTSD). We performed a systematic review of studies investigating online EMDR for PTSD. Only one trial was identified. That uncontrolled open trial showed promising results. There is an urgent need to further examine the effects of online EMDR for PTSD, before its wider dissemination is warranted. Remotely delivered cognitive behavioural therapy seems the preferred PTSD-treatment in times of COVID-19.",293,,113438,,Psychology; Cognition; Social distance; Eye movement desensitization and reprocessing; Context (language use); Posttraumatic stress; Mental health care; Coronavirus disease 2019 (COVID-19); Ptsd treatment; Psychotherapist,Emdr; Internet; Ptsd,"Betacoronavirus; COVID-19; Cognitive Behavioral Therapy/methods; Coronavirus Infections; Eye Movement Desensitization Reprocessing/methods; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Social Isolation/psychology; Stress Disorders, Post-Traumatic/psychology; Telemedicine/methods",,,https://www.ncbi.nlm.nih.gov/pubmed/32905864 https://www.rug.nl/research/portal/publications/ptsd-treatment-in-times-of-covid19(705f4423-43bd-42e2-91e8-d17d37f31544).html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458053 https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F705f4423-43bd-42e2-91e8-d17d37f31544 https://www.sciencedirect.com/science/article/pii/S0165178120314591 https://www.sciencedirect.com/science/article/abs/pii/S0165178120314591,http://dx.doi.org/10.1016/j.psychres.2020.113438,32905864,10.1016/j.psychres.2020.113438,3082966463,PMC7458053,0,010-984-709-794-846; 019-970-247-675-091; 023-837-116-346-089; 031-343-692-268-111; 038-490-877-460-032; 047-109-695-660-982; 076-344-553-326-139; 093-035-138-791-321; 123-669-150-828-781; 164-711-107-841-546; 179-211-688-036-169; 179-411-648-804-473,10
141-249-349-237-884,A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients.,2020-03-30,2020,journal article,Journal of clinical epidemiology,18785921; 08954356,Elsevier USA,Netherlands,Ype de Jong; Chava L Ramspek; Vera H.W. van der Endt; Maarten B. Rookmaaker; Peter J. Blankestijn; Robin W.M. Vernooij; Marianne C. Verhaar; Willem Jan W Bos; Friedo W. Dekker; Gurbey Ocak; Merel van Diepen,"Abstract Objectives The objective of this study was to systematically review and externally assess the predictive performance of models for ischemic stroke in incident dialysis patients. Study Design and Setting Two reviewers systematically searched and selected ischemic stroke models. Risk of bias was assessed with the PROBAST. Predictive performance was evaluated within The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), a large prospective multicenter cohort of incident dialysis patients. For discrimination, c-statistics were calculated; calibration was assessed by plotting predicted and observed probabilities for stroke, and calibration-in-the-large. Results Seventy-seven prediction models for stroke were identified, of which 15 were validated. Risk of bias was high, with all of these models scoring high risk in one or more domains. In NECOSAD, of the 1,955 patients, 127 (6.5%) suffered an ischemic stroke during the follow-up of 2.5 years. Compared with the original studies, most models performed worse with all models showing poor calibration and discriminative abilities (c-statistics ranging from 0.49 to 0.66). The Framingham showed reasonable calibration; however, with a c-statistic of 0.57 (95% CI 0.50–0.63), the discrimination was poor. Conclusion This external validation demonstrates the weak predictive performance of ischemic stroke models in incident dialysis patients. Instead of using these models in this fragile population, either existing models should be updated, or novel models should be developed and validated.",123,,69,79,Framingham Risk Score; Calibration (statistics); Emergency medicine; Dialysis; Population; Predictive modelling; Stroke; Medicine; Cohort; Discriminative model,Calibration; Discrimination; External validation; Incident dialysis; Ischemic stroke; Prediction model; Predictive performance; Systematic review,Humans; Incidence; Netherlands/epidemiology; Prospective Studies; Renal Dialysis/statistics & numerical data; Reproducibility of Results; Stroke/epidemiology,,,https://www.ncbi.nlm.nih.gov/pubmed/32240769 https://www.sciencedirect.com/science/article/pii/S089543562030072X https://pubmed.ncbi.nlm.nih.gov/32240769/ http://www.ncbi.nlm.nih.gov/pubmed/32240769,http://dx.doi.org/10.1016/j.jclinepi.2020.03.015,32240769,10.1016/j.jclinepi.2020.03.015,3014195257,,0,003-316-487-930-998; 004-845-436-137-500; 004-878-619-772-962; 005-235-202-378-430; 006-613-405-816-148; 007-113-337-348-164; 009-303-516-952-658; 009-883-903-565-096; 015-769-012-346-883; 016-868-995-697-632; 018-408-232-589-807; 018-945-146-233-875; 019-051-942-507-594; 023-171-734-710-29X; 023-792-615-005-696; 024-767-817-463-494; 025-567-957-787-917; 027-972-214-596-222; 030-229-748-246-398; 030-722-414-483-915; 032-097-318-433-063; 034-026-658-998-460; 036-298-620-109-279; 037-447-989-715-87X; 037-449-707-943-145; 037-898-005-926-387; 039-106-868-432-328; 040-226-310-980-845; 040-281-684-911-870; 042-233-280-190-751; 042-591-034-583-189; 044-001-256-651-730; 045-183-959-586-396; 045-300-793-059-157; 045-760-229-466-664; 045-924-104-270-877; 049-268-098-102-49X; 052-938-076-438-37X; 053-349-867-482-773; 056-288-154-367-890; 062-039-735-404-004; 062-451-257-491-143; 063-483-162-008-06X; 064-309-833-728-053; 064-398-274-056-808; 066-137-439-241-25X; 073-718-280-349-785; 074-485-430-231-478; 076-369-964-500-067; 081-882-851-732-353; 083-838-912-823-668; 093-722-753-317-247; 099-391-913-318-017; 104-968-920-382-300; 109-682-515-181-108; 125-171-268-225-454; 126-585-164-101-111; 129-171-126-831-710; 148-362-576-416-339,7
152-434-819-130-920,The effect of intra-arterial angiotensin II on the hepatic tumor to non-tumor blood flow ratio for radioembolization: a systematic review,,2014,journal article,Journal of Vascular and Interventional Radiology,10510443; 15357732,Elsevier BV,United States,null van den Hoven; Maarten L. J. Smits; Charlotte E.N.M. Rosenbaum; L. Verkooijen; M. A. A. J. van den Bosch; Marnix G.E.H. Lam,"Treatment efficacy of intra-arterial radioembolization for liver tumors depends on the selective targeting of tumorous tissue. Recent investigations have demonstrated that tumors may receive inadequate doses of radioactivity after radioembolization, due to unfavorable tumor to non-tumor (T/N) uptake ratios of radioactive microspheres. Hepatic arterial infusion of the vasoconstrictor angiotensin II (AT-II) is reported to increase the T/N blood flow ratio. The purpose of this systematic review was to provide a comprehensive overview of the effect of hepatic arterial AT-II on T/N blood flow ratio in patients with hepatic malignancies, and determine its clinical value for radioembolization.This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A structured search was performed in the PubMed, EMBASE and Cochrane databases. Only studies that presented data on T/N ratios before and after infusion of AT-II into the hepatic artery, in human patients with hepatic malignancies, were selected. Median T/N ratios before, during and after AT-II infusion, and the median T/N ratio improvement factor were extracted from the selected articles. All data on systemic blood pressure measurements and clinical symptoms were also extracted.The search identified 524 titles of which 5 studies, including a total of 71 patients were considered relevant. Median T/N ratios before infusion of AT-II ranged from 0.4 to 3.4. All studies observed a substantial improvement of the T/N ratio after AT-II infusion, with median improvement factors ranging from 1.8 to 3.1. A transitory increase of systemic blood pressure was observed during AT-II infusion.Infusion of AT-II into the hepatic artery leads to an increase of the tumor to non-tumor blood flow ratio, as measured by T/N uptake ratios. Clinical trials are warranted to assess safety aspects, optimal administration strategy and impact on treatment efficacy during radioembolization",25,3,S105,,Internal medicine; Urology; Endocrinology; Blood flow; Angiotensin II; Hepatic tumor; Intra arterial; Medicine,,,,,https://www.sciencedirect.com/science/article/pii/S1051044313020757,http://dx.doi.org/10.1016/j.jvir.2013.12.293,,10.1016/j.jvir.2013.12.293,2067775654,,0,,0
